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I. Abstract 
Wnts are secreted morphogens that play pivotal roles in embryonic development, 
stem cell biology and a number of disease states including cancer.  Most Wnts signal 
through a pathway that results in the stabilisation of an intracellular signalling 
molecule called β-catenin.  In melanoma cells, Wnt/β-catenin signalling has been 
implicated as a key regulator of cellular invasion and metastasis.  
Using both transient and stable enhancement of Wnt/β-catenin signalling, I have 
found that mutation–based dysregulation of PI3K signalling dictates the invasive 
capacity of melanoma cell lines in response to Wnt3a stimulation.  I demonstrate by 
confocal imaging that WNT3A facilitates perinuclear localisation of mitochondria 
with higher levels of mitochondrial networking and they show significant changes in 
the proteins of mitochondrial dynamics.  Observed changes in mitochondrial fusion 
and fission proteins including MFN1, MFN2, OPA1 and DNM1L suggest that activation 
of Wnt/β-catenin signalling can increase mitochondrial fusion and decrease 
mitochondrial fission in melanoma cells.  Cellular metabolic analysis using the 
Seahorse Bioscience XFe96 Analyzer suggests that Wnt/β-catenin mediated 
mitochondrial fusion may cause a global down-regulation of cellular energy 
metabolism in melanoma cells.  This is supported by biochemical analysis of citrate 
synthase and lactate dehydrogenase activity. 
Knockout of -catenin removes the mitochondrial fusion effect in these cells and 
reverses any Wnt driven reduction in migration and metabolism suggesting that -
catenin is able to control mitochondrial function and dynamics.  We show that -
catenin binds to the mitochondrial regulatory protein PARK2 in melanoma cells and 
subsequently blocks the autophagy dependency of melanoma cells. 
In summary, we demonstrate that activation of Wnt/β-catenin signalling in 
melanoma cells can lead to reduced cellular metabolism coupled with highly altered 
mitochondrial dynamics.  This novel finding, controlled by -catenin, has potentially 
wide implications for understanding how certain context-dependent effects of 
Wnt/β-catenin signalling may be secondary to the regulation of mitochondrial 
dynamics and global cellular metabolism. 
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mtSSB - Mitochondrial-specific single-stranded DNA binding protein  
NAD+ - Nicotinamide adenine dinucleotide-oxidase 
NADH - Nicotinamide adenine dinucleotide-reduced 
NADP+ - Nicotinamide adenine dinucleotide phosphate-oxidase 
NADPH - Nicotinamide adenine dinucleotide phosphate-reduced 
NCC – Neural Crest Cells 
ND - NADH dehydrogenase  
NF-κB - Nuclear factor kappa-light-chain-enhancer of activated B cells  
NLK - Nemo-like kinase  
NRAS - neuroblastoma RAS viral (v-ras) oncogene homolog 
NOD-SCID - Non-Obese Diabetic - Severe combined immunodeficiency 
ns – not significant 
OCR - Oxygen Consumption Rate 
OMM - Outer Mitochondrial Memebrane 
OPA - optic atrophy type 1 
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OXPHOS - Oxidative Phosphorylation 
P- Phosphorylated 
PAGE - Polyacrylamide Gel Electrophoresis 
PBS - Phosphate buffered saline 
PCP - Planar Cell Polarity 
PCR - Polymerase Chain Reaction 
PDE6 - phosphodiesterase 6  
PDL - Poly-D-Lysine 
Pen/Strep - 100 U/mL penicillin and 100 μg/mL streptomycin (pen/strep)  
PFA - Paraformaldehyde 
PI3K - Phosphoinositide 3-kinase 
PIP2 - phosphatidylinositol 4,5-biphosphate  
PIP3 - phosphatidylinositol (3,4,5)-trisphosphate  
PKC – Protein kinase C 
PLC - phospholipase C  
POLG - DNA polymerase  
PolyHEMA - Poly(2-hydroxyethyl methacrylate).  
PP2A – Protein Phosphatase 2A  
PTEN - Phosphatase and tensin homolog 
qPCR - Quantitative polymerase chain reaction  
r - Recombinant 
Rac – Sub family of the Rho family of GTPases 
Ras – Rat sarcoma superfamily of proteins 
Rho – Sub Family of GTPases, sub family of Ras superfamily of proteins 
RNA - Ribonucleic acid 
ROCK - Rho-associated kinase  
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ROR2 - receptor tyrosine kinase-like orphan receptor 2 
ROS - Reactive oxygen species 
RPMI - Roswell Park Memorial Institute medium  
rRNA – ribosomal RNA 
RT - Room temperature 
RTK - receptor-like tyrosine kinase 
RT-PCR - Reverse Transcriptase Polymerase Chain Reaction 
si - Small Interfering 
SDS - Sodium dodecyl sulfate 
SFRPs - soluble frizzled-related proteins 
SNHL - non-syndromic sensorineural hearing loss  
SNPs - single poly nucleotide  
STA - stabilized constitutively active 
TAE – Tris Acetate EDTA 
TAK1 - TGFβ activated kinase  
TRP - Tautomerse  
TBS - Tris Buffered Saline 
TBST - Tris Buffered Saline Tween 
TCA cycle - tricarboxylic acid cycle 
TCF4 - Transcription factor 4 
TE – Tris-EDTA 
TEMED - Tetramethylethylenediamine  
TIM - Translocase of inner mitochondrial membrane 
TMRM - Tetramethylrhodamine, methyl ester 
TOM - Translocase of outer mitochondrial membrane 
tRNA – transfer RNA 
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UV - Ultraviolet 
UVR – Ultraviolet Radiation 
VDAC - voltage-dependent anion channel 
WIF – Wnt inhibitory factor 
Wnt – Wingless Int genes 
2D - Two Dimensional 
3D - Three Dimensional 
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 Melanoma 
Cancer is the uncontrolled, abnormal, growth of cells that initiates due to a DNA 
mutation (1).  There are over 200 different types of cancer that vary in their causes 
and symptoms, but they all have increased cell proliferation.  The current statistics 
from Cancer Research UK state that one in two people will develop cancer, at some 
point throughout their lifetime and results in more than one in four deaths in the UK 
(2).  Due to lifestyle, certain cancers have increased over the past 50 years.  These 
include lung cancer due to smoking, liver and kidney cancers due to alcohol 
consumption and melanoma due to ultraviolet radiation (2).  However, over the past 
few decades, due to increased awareness and routine screening, there has also been 
a dramatic reduction in some cancers, including cervical and lung cancer but, 
conversely, the national screening programme actually led to an increase in the 
number of breast cancer diagnoses (2).  As well as cancer being caused by external 
carcinogens, there is a hereditary link to a number of cancers, including the BRCA1 
gene in breast cancer and the CDKN2A mutation in melanoma (3-5).  These 
predispositions have lead an increase in early diagnosis, as well as increased research 
leading to better therapies and longer life expectancies have all contributed to an 
overall decrease in cancer related deaths, in both the UK and the US (2, 6).  
Cancer research is a very broad topic, given the number of different types of cancer 
and the different causes.  Some main areas of research focus on factors that affect 
most, if not all, cancers.  Tumours will initiate from one cell type but, as they grow, 
they will form a body that encompasses a variety of cells.  Tumours will evade the 
immune system as they develop from our own cells and, therefore, are not 
recognised as foreign bodies.  Current research into the tumour microenvironment, 
especially regulatory T cells, how these contribute to tumour growth and how they 
could be targeted in cancer treatments is on going (7).  Another main area of cancer 
research focuses on angiogenesis, the process by which tumours will develop their 
own blood supply to provide oxygen and nutrients for growth.  The blockade of the 
signals that initiate angiogenesis or the formation of new blood vessels is currently 
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under investigation (8).  Another area of cancer research is that of metabolism as 
described in detail in section 1.3.2.  The altered metabolism of cancer cells has been 
known since it was first described by Otto Warburg in 1924 (9).  However, research 
into this aspect of cancer biology has grown more recently as we investigate the 
mechanisms that control cancer cell metabolism and, potentially, how to target it in 
treatments. 
 
This research focuses on metastatic melanoma (MM), the worst form of skin cancer 
as described in detail in the following sections.  Other non-melanoma skin cancers 
(NMSC) are more common including squamous cell carcinoma (SCC) and basal cell 
carcinoma (BCC) but these cause relatively few deaths, compared to those caused by 
MM (10-12).  Melanoma is a cancer of melanocytes, the pigment producing cells 
predominantly found in the basal layer of the epidermis of the skin, but also, located 
in the hair follicle, the iris of the eye, and the inner ear (13-15).  Skin is the largest 
organ of the body.  It protects the major organs, acts as a barrier to pathogens and 
aids homeostasis of the body by retaining water and releasing sweat.  It also acts as 
the best protection against ultraviolet radiation (1).  The skin consists of three main 
layers; Figure 1.1 shows a cross section of the skin structure.  The top layer is the 
epidermis, which is broken down into four sub-layers.  The stratum corneum is the 
top layer, made mainly of dead skin cells, is highly hydrophobic and roughly 10-20 
μm thick (16).  The second layer is the stratum granulosum, formed of granular 
keratinocytes and the third layer is the stratum spinosum, formed of polyhedral 
keratinocytes (17).  Within these layers, there will also be Langerhans cells (16).   The 
fourth layer is the stratum germinativum.  It is within this basal layer that the 
melanocytes reside with merkel cells (17).  The second main layer of the skin is the 
dermis and the connection between the dermis and the epidermis is known as the 
basement membrane.  The main body of the dermis is called the dermal matrix, 
which is full of collagen allowing the flexibility of the skin.  The dermis also consists 
of fibroblasts, dendritic cells and a variety of immune cells, including T-cells.  This 
thick layer of the skin will also have blood vessels, hair follicles, and sebaceous and   
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Figure 1.1: The Structure of the Skin 
The skin is divided into three layers, the Epidermis is the top layer covered by the Stratum 
Corneum, which contains Langerhans cells.  It is through the epidermis that sweat is secreted, 
and hairs protrude.  The epidermis is primarily made up of keratinocytes and at the bottom 
is the basement membrane consisting of melanocytes and merkel cells.  The second layer is 
the Dermis.  Within the dermal matrix are the all other aspects of skin biology, it contains 
hair bulbs, sebaceous glands, sweat glands, and many cells types including, mast cells, T-cells, 
neutrophils, eosinophils, dermal fibroblasts and dendritic cells.  Smaller branches of blood 
vessels will also protrude into the dermis from the hypodermis, the bottom layer of the skin 
structure.  Made primarily of adipocytes the hypodermis houses the blood vessels including 
veins, arteries and lymph vessels. Image adapted from (1).  
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sweat glands.  The final layer of the skin is often not, actually, considered to be part 
of the skin structure.  The hypodermis is primarily made of adipocytes and houses 
the larger blood and lymphatic vessels (16).  
 
Melanocytes derive from neural crest cells (18) from the ectoderm of developing 
embryos (17, 19, 20).  The neuroectoderm forms the neural plate, which folds into 
the neural tube to become elements of the central nervous system.   NCC arise from 
the neural plate boarder created by levels of bone morphogenetic proteins, Wnt and 
fibroblast growth factor secreted from the underlying paraxial mesoderm, as well as 
Wnt signals from the non-neural ectoderm (19, 21, 22).  This leads to the expression 
of neural plate boarder specifiers including; Pax3/7, Zic, Msx1/2 and Dlx5 (23), which 
are precursors to the neural crest markers; Slug/Snail, FoxD3, Sox10, Sox9, AP-2 and 
c-Myc (17, 19, 24, 25).  These genes signify the specification of the NCC as they 
regulate the expression of genes controlling cell cycle, epithelial to mesenchymal 
transition (EMT) and migration (23).  Once the neural tube is formed, NCC cells form 
the roof plate and undergo EMT, the transcription of Slug/Snail repress expression of 
E-cadherin and, under non-canonical Wnt signalling, cause the progenitor cells to 
migrate along the dorsolateral route beneath the ectoderm to their final destination 
(17, 20, 22, 26).  There are typically four groups of NCC, cranial, vagal, trunk and 
sacral, where melanocytes originate from the trunk and cranial populations and 
reside, mainly, in the epithelium (17, 20).  As well as melanocytes, the NCC are 
responsible for the production of other cell lineages through the SoxE family of 
proteins.  These include cartilage mesectoderm, neurons and glial cells.  The lineage 
specification of NCC is dependent on their location and multiple signalling pathways.  
Notch and canonical Wnt signalling are both implicated in the specification of neural 
crest progenitor cells such as the melanocyte precursors, melanoblasts (19, 21, 25).  
It has been shown that melanoblasts actually have their cell lineage defined before 
they leave the neural tube (27), but the development of a melanoblast is controlled 
by Microphthalmia-associated transcription factor (MITF), together with Pax3 and 
Sox10 (28).  As both Pax3 and Sox10 are involved in the lineage specification of other 
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NCC, it is MITF that is known as the master regulator of melanogenesis (29).  
Following their lineage determination, melanocyte survival and migration is 
controlled by endothelin 3 (Edn3) and its receptor Ednrb, c-KIT and MITF (19, 25), 
leading to the activation of the Protein kinase C (PKC) and mitogen-activated protein 
kinase (MAPK) pathways (30).  As stated previously, MITF is the master regulator of 
melanocyte development and it is especially vital in melanogenesis (29, 31).  MITF 
activates pigment producing genes such as dct and tyrosinase (32) and plays a role in 
melanoblast survival by upregulating the anti-apoptotic gene bcl2 (19, 33).  Adult 
melanocyte stem cells develop through the same process and reside primarily in the 
hair bulge, although it is debated as to whether they are also present in the dermis 
(17, 34).  In the hair bulge melanocyte stem cells are activated during the 
regeneration of a new hair and, then, migrate to the basal layer of the epidermis 
where they become mature melanocytes (17).  
Melanocytes produce melanin in a biochemical process termed melanogenesis (17, 
35).  Melanin has many beneficial properties including absorption and scattering of 
ultraviolet (UV) light, scavenging of free radicals, ion storage and is used in coupled 
oxidation-reduction reactions (36, 37).  Melanin is produced in cytoplasmic 
organelles called melanosomes (37, 38) in response to ultraviolet radiation (UVR) (17, 
35-37).  These double membrane, intracellular, organelles are formed in four stages 
(39, 40).  Firstly, intraluminal proteinaceous fibrils start to form and, in stage two, 
this continues and melanin synthesis begins (as described later).  As melanin is 
produced, it is deposited on to the fibrils which causes them to thicken and darken.  
This stage is often referred to as maturation (39, 40).  The final stage sees a loss of 
the fibril structure as the melanin encompasses the internal structure.  Upon 
stimulation by sunlight, surrounding keratinocytes in the skin activate p53 by UVR, 
causing transcription of proopiomelanocortin and an increase in α-melanocyte 
stimulating hormone (α-MSH), adrenocorticotropic hormones and pro-pigment 
activities (41).  When α-MSH binds to the melanocortin-1 receptor (MC1R), it 
activates the cAMP/protein kinase A (42)/CREB signalling pathway and increases the 
levels of MITF and subsequent melanin synthesis and pigmentation (43-45).  The 
number of melanocytes in the epidermis is fairly constant at 1200/mm2 independent 
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of skin colour (17, 37) but numbers increase following UVR (46).  Melanocyte 
proliferation is controlled by factors released by the surrounding keratinocytes such 
as α-MSH, Edn3, granulocyte-macrophage colony-stimulating factor, steel factor, 
leukemia inhibitory factor, basic fibroblast growth factor, and hepatocyte growth 
factor (47), leading to the activation of the MAPK/extracellular regulated kinase (ERK) 
and phosphoinositide 3-kinase (PI3K)/AKT signalling pathways (48).  Following 
melanogenesis, melanocytes distribute the melanin to 30-40 nearby keratinocytes 
(17, 20, 49).  Melanocytes have dendritic formations that allow for the transfer of 
melanin, where it sits above the nucleus to protect the DNA from ionising radiation 
(17, 49, 50).  Figure 1.2 shows a schematic of the melanin scattering. 
Melanin comes in two different forms, the dark black/brown eumelanin and a 
red/yellow pheomelanin (13, 51), produced according to the availability of substrates 
such as cysteine and tyrosine (17).  Tyrosinase converts tyrosine to 3,4-
dihydroxyphenylalanine (DOPA) by hydroxylation and DOPA is then oxidised to 
DOPAquinone (52).  If cysteine is present, it will react with DOPAquinone to produce 
cysteinylDOPA, oxidation of which then produces the yellow/red pheomelanin (35, 
53).  If cysteine is not available DOPAquinone is converted to DOPAchrome by 
cyclisation (53).  DOPAchrome loses its carboxylic acid, becoming DHI, which, when 
oxidized, forms the insoluble dark brown/black DHI-melanin.  DOPAchrome can, 
however, also be converted to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) in the 
presence of tautomerse (TRP) 2 which is catalyzed by TRP1 to form the light brown 
DHICA-melanin (35, 53).  Figure 1.3 shows a simple schematic of this process.  There 
is always a mixture of melanins in human skin, but it is, typically, the levels of 
eumelanin that determine skin colour differences between ethnic groups (17).  
Eumelanin has better photoprotecting properties, including an ability to neutralise 
reactive oxygen species (ROS) and resistance to degradation (54).  Due to its higher 
photoprotection there is a 30-40% decrease in risk of developing skin cancer in darker 
skin (53). 
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Figure 1.2: Melanin Scattering From Melanocytes to Nearby Keratinocyte Cells 
Melanocytes sit at the base of the epidermis and dendritic formations extend around the 
keratinocytes to allow for transfer of melanin.  Melanosomes sit atop the nucleus of cells to 
protect the DNA from UVR. Image adapted from (17). 
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Figure 1.3: Melanogeneis production of Pheomelanin and Eumelanin 
Melanin formation initiates from Tyrosine. Tyrosinase converts it to 3,4-
dihydroxyphenylalanine (DOPA) by hydroxylation, DOPA is then oxidised to DOPAquinone.  
If cysteine is present it will react with DOPAquinone to produce cysteinylDOPA, oxidation of 
which then produces the yellow/red pheomelanin. If cysteine is not available DOPAquinone 
is converted to DOPAchrome by cyclisation.  DOPAchrome loses its carboxylic acid becoming 
DHI, which when oxidized forms the insoluble dark brown/black DHI-melanin.  DOPAchrome 
can however also be converted to 5,6-dihydroxyindole-2-carboxylic acid (DHICA) in the 
presence of tautomerse (TRP) 2 which is catalyzed by TRP1 to form the light brown DHICA-
melanin. Image adapted from (17). 
  
  
 
 
 
29 
 
Melanoma can occur anywhere in the body.  Melanocytes can proliferate and 
aggregate to form benign hyperplastic lesions called nevi (20).  However, these are 
not necessarily precursors to malignant melanoma as direct transformation of 
melanocytes can also occur (20).  Most often, nevi do not progress to malignant 
disease due to cellular senescence (55, 56), but melanomas acquire alterations, 
causing excessive proliferation and a survival benefit (19, 25).  Both the MAPK/ERK, 
and PI3K/Akt pathways are linked to melanocyte proliferation.  Therefore, it is 
unsurprising that the majority of mutations initiating melanomas are within these 
pathways (57), as described further in section 1.1.4.   
Melanomas typically start progressing with a horizontal or radial growth phase (RGP) 
during which they can be easily excised (19).  In the RGP, the tumour grows through 
the epidermis, but does not invade through the basement membrane, which 
separates the epidermal and dermal layers of skin.  This is followed by a vertical 
growth phase where melanoma cells will invade through the basement membrane 
into the dermis and hypodermis.  As melanoma progresses into a metastatic phase, 
it will eventually invade through the endothelium and into the vascular system by 
intravasation and travel to distant sites before extravasation and secondary tumour 
formation (19, 25, 58).  
When checking nevi, the rule of ABCDE helps aid identification of a potential 
malignant melanoma.  A stands for Asymmetry, B = Boarder, C = Colour, D = Diameter 
and E = Evolving (59).  Normal benign nevi will be uniform in shape and colour, and 
will typically be round with a smooth border and should be no wider than the end of 
a pencil (6 mm).  However, diversion from any of these factors can occur without 
diagnosis of melanoma.  The indication that something is wrong with a pre-existing 
nevi is evolution, whether the nevi changes in size, shape or colour (60).  There are 
alternative views to these descriptions, given the role of MITF in the pigmentation of 
melanoma (31), D can sometimes stand for Dark (61).  
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Metastatic melanoma is the 5th most common cancer in the UK.  It is one of the most 
aggressive malignancies in humans and is responsible for 60% of all deaths associated 
with skin cancer (49).  Melanoma accounts for less than 5% of new cancer cases in 
the US and the UK (1, 10, 62), accounting for around 20 new cases for every 100,000 
people (10, 62).  However, incidence of the disease has been on the rise for the past 
two decades (63, 64) and it is estimated that numbers have quadrupled since the 
1970s (10, 49, 65).  More recently, between 1992 and 2004, melanoma incidence 
increased 45%, or 3.1% annually (66).  This is primarily thought to be due to increased 
sun exposure from more frequent holidays, long-term increased sun exposure and, 
recently, due to the increased trend of tanning-beds (65, 67, 68).  Due to this, 
melanoma has an unusual pattern of incidence although, as with other cancers, the 
majority (45%) of cases are in the over 65s, there has been an increase in cases in the 
under 50s population (10).  The disease is more frequent in men in the over 50s age 
range (6) but, actually, has a ratio of 4:10, men to women, in the 20-24 age range 
(10).  Currently, it is the most common form of cancer among adults 25-29 and the 
second most common amongst 15-29 year olds (69).  About 65% of melanoma cases 
can now be attributed to UVR from the sun or sunbed use and this rises to 85% in the 
UK alone (70, 71).  Between 1980 and 2004, the annual incidence of melanoma 
among young women increased by 50%, from 9.4 cases to 13.9 cases per 100,000 
women (72), and this is attributed to around 100 deaths in the UK (73).  UVR is a 
proven human carcinogen (74).  Frequent tanners using new high-pressure sunlamps 
may receive as much as 12 times the annual UVA dose compared to the dose that 
they receive from sun exposure (73).  The International Agency for Research on 
Cancer, an affiliate of the World Health Organization, includes UV tanning devices in 
its Group 1, a list of the most dangerous cancer-causing substances, a group that also 
includes agents such as plutonium, cigarettes, and solar UVR (74).  A public 
awareness campaign, ‘Sun Smart’, has been running in the Australian State of Victoria 
since 1988 (75).  Incidence rates in this region are starting to now slow and the 
education on sun damage is starting to take a positive effect (76).  Due to this 
campaign, as of the beginning of this year, commercial sunbeds are now banned in 
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the State of Victoria. In the UK, as a result of the campaigning of famous skin type 1 
individuals, the Sunbeds (Regulation) Act came into effect in 2010 to ban the use of 
sunbeds for under-18s.  Unfortunately, despite the campaign, prevalence in 
Australasia is increasing rapidly, due to UVR but, it is believed, this is due to climatic 
change and the reduction in the ozone layer (70, 77-79).   
Incidences rates in non-Caucasian populations are low (80).  However, Asian 
American and African American melanoma patients have a greater tendency than 
Caucasians to present with advanced disease at time of diagnosis.  While melanoma 
is uncommon in African Americans, Latinos, and Asians, it is frequently fatal for these 
populations (81).  As few as 48% of melanomas in African Americans are diagnosed 
at an early stage, compared to 74% in Hispanics and 84% in Caucasians (82, 83).  
Melanomas in African Americans, Asians, Filipinos, Indonesians and native Hawaiians 
most often occur on non-exposed skin with less pigment, with 60-75% of tumours 
arising on the palms, soles, mucous membranes and nail regions (83). 
 
Staging of melanoma in the UK and U.S. is currently carried out according to the 
American Joint Commission on Cancer (AJCC) TNM system the details of which are in 
Table 1.1.  T stands for Tumour and determines tumour growth within the skin and 
is defined by a number 0-4, depending on depth or thickness of the tumour as 
measured by the Breslow measurement.  This classification will also be given a rating 
of a or b depending on the presence of ulceration (a-without/b-with), and/or mitotic 
cells.   N stands for Nodes and this classification determines if the cancer has spread 
to the lymph nodes or the lymphatic system and is rated on a scale of 0-3 determined 
by spread and number.  In addition, a, b or c will determine the size of metastatic 
lesion, a- for microscopic, b- for macroscopic and c- spread only to the local skin or 
lymphatic channels but has not reached the lymph nodes.  M stands for 
Metastasised.  It is based on either yes or no represented as 0 or 1.  Letters a, b and 
c determine the location of the metastases and the levels of lactate dehydrogenase   
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Table 1.1: TNM classification 
The table shows the TNM classification of melanoma.  Table adapted from AJCC Melanoma 
Staging and Classification (84). 
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(LDH) in the blood (84).  Table 1.2a shows how the TNM classification fits into the 
pathologic staging of a melanoma at diagnosis.  
 
Despite the rise in incidence, the number of associated deaths has fallen and it is now 
the least common cause of cancer-related deaths in the UK (10).  This is partly due to 
the ageing population extending survival rates but, mainly, due to increased 
awareness leading to earlier diagnosis (49).  The survival rate for patients whose 
melanoma is detected early, before the tumour has penetrated the epidermis, is 
about 97% (6).  The survival rate falls to 10% for those with advanced disease (6).  As 
stated previously, the often late diagnosis in African Americans results in their overall 
survival rate being only 77%, compared with 91% for Caucasians (80).  A detailed 
breakdown of survival rates defined by melanoma stage is shown in Table 1.2b. 
 
The primary treatment for melanoma is surgery, followed by lymph node mapping to 
test for metastasis.  Sentinel nodes are lymph nodes that are predicted to be the 
likely first sites of metastasis, due to their proximity to the tumour.  Sentinel node 
biopsies, with the use of radioactive tracers, allow the identification and removal of 
metastatic lymph nodes (84).  However, this can cause lymphedema, a swelling due 
to the lack of fluid removal that would have been carried out by the lymph node.  This 
is especially common if the nodes are removed from the groin and under the arm 
(85, 86).  It can be a lifelong problem and cause subsequent skin problems and be 
very painful so, therefore, a full lymph node dissection is only carried out if necessary.  
Following this surgery, adjuvant therapy is recommended to prevent reoccurrence.  
Typically, high dose interferon α2b is the initial treatment although the benefits of 
this have been questioned and, if it does prevent reoccurrence, the effect is minimal 
(87, 88).  If a tumour is inoperable, regional chemotherapy may be undertaken.  
However, if the tumour is in a limb, hyperthermic isolated limb perfusion has been 
shown to extend the time of reoccurrence by up to 37 months  
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Table 1.2: Pathalogic Staging of Melanoma 
a) Table represents the pathalogical staging of melanoma according to the TNM 
classification.  b) 5 year and 10 year survival rates according to stage at time of diagnosis. 
Tables adapted from AJCC Melanoma Staging and Classification (84).    
 
        a)           
            
              b)   
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 (89).  Chemotherapy agents such as dacarbazine have minimal effects in advanced 
disease, with a response seen in 5% of patients extending progression free survival 
by only 1.6 months (90).  Temozolomide is an oral analogue of dacarbazine that has 
the added benefit of penetrating the central nervous system and, therefore, has 
beneficial effects on brain metastasis (91).  Other single chemotherapeutic agents 
include anti-microtubular agent, paclitaxel which has around a 20% response rate but 
causes toxic side effects including alopecia, neuropathy and myelosupression (91).  
Chemotherapeutic agents with limited beneficial effects, when used in combination 
therapies have increased response rates.  Agents that are typically not used for the 
treatment of melanoma such as cisplatin and tamoxifen, when combined with 
dacarbazine and carmustine in a treatment called the Dartmouth regimen, had a 
response rate of 55%.  However, they had little effect on overall survival (91, 92).  
Once a melanoma has reached stage III or is a recurrent melanoma, treatments 
become more targeted (93).  Biological treatments can include IL-2 and INF-α that 
can be used alone or in combination with chemotherapeutic agents.  However, they 
are associated with high toxicity so their treatment is limited to advanced disease 
(87, 91, 94, 95).   
Another biological treatment is the cytotoxic T-lymphocyte-associated antigen 
(CTLA-4) monoclonal antibody, ipilimumab that extended overall survival from 4 to 
36 months in melanoma patients that responded to treatment (96, 97).  The blockade 
of immune checkpoints is the most promising treatment for cancer, in general and, 
specifically, in melanoma, in the last decade.  Immune checkpoints are necessary in 
normal cellular function to prevent autoimmunity and to protect tissues from 
excessive immune responses (98).  In normal THelper cells, CTLA-4 downregulates T-
cell activation, by counteracting CD28 which, following antigen recognition activates 
T-cells (98).  Tumour cells dysregulate immune checkpoint proteins as a form of 
immune resistance.  The IgG monoclonal antibody, ipilimumab inhibits CTLA4 
thereby enabling the CD28 mediated immune response and increasing the 
autoimmunity of tumours (99-102).  Initially developed by Bristol-Myers-Sqibb, the 
phase III clinical trial in 2010 showed an increased median survival of 10 months, one 
year survival to 46% and two year survival to 18% in advanced melanoma patients 
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(99).  This trial caused controversy as, instead of using a placebo control, they 
measured the drug against a trial vaccine that some claimed caused toxicity therefore 
making ipilimumab appear better by comparison.  Despite this, ipilimumab was 
approved by the US in 2010 and by the UK in 2014 for the treatment of advanced 
melanoma.  One of the major benefits of this treatment is its durability and lack of 
acquired resistance (97) which, as described later, is a major obstacle in melanoma 
treatments.  To improve the response to ipilimumab, it can be used in co-
immunotherapy.  Nivolumab is an antibody against programme death 1 (PD-1) 
receptor, another immune-checkpoint receptor (99).  Nivolumab compliments the 
effects of ipilimumab, by limiting the activity of T-cells in periphery tissues during an 
immune response, in trials of stage III melanoma a significant increase to patient 
outcomes (97, 98, 103, 104).  In addition, a current phase I trial is taking place, 
combining the treatment of ipilimumab with bavituximab, a phosphatidylserine 
antibody, that is predicted to enhance the effects of ipilimumab (105).  
Phosphatidylserine is intracellular in normal cell but is expressed on the surface of 
tumour cells allowing for a very targeted treatment (106).  Once bound, this will 
attract the immune system to target the tumour cells.  Therefore, used in 
combination with ipilimumab will enhance this effect. 
As explained in the next section, mutations within the RAS/RAF/MEK/ERK and 
PI3K/AKT pathways are the most common in melanoma and they pose as good 
targets for the treatment of melanoma (107).  Treatments targeted to the BRAF 
mutation have proven to be very successful, including debrafenib (108) and 
vemurafenib (109).  Response to vemurafenib is seen in 40-80% of patients with 
extended progression-free survival of 5.3 months (90).  However, melanoma is 
notoriously resistant to conventional therapies and can rapidly (less than 1 year) 
acquire resistance to novel, promising treatments, as has been highlighted in BRAF 
inhibitor trials (57, 110).  There are a number of mechanisms by which cancer cells 
can become resistance to treatments.  The classic method is the removal of cytostatic 
substances from the cell by P-glycoprotein through a transmembrane protein.  
However, this is not the case in melanoma (111).  Another transmembrane 
glycoprotein, that aids in the export of therapies from the cells, is a member of the 
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ABC transporter family (112), the multidrug resistance-related protein (MRP) which 
has been shown to be upregulated in melanoma (111).  However, this upregulation 
has not been seen in response to chemotherapy (113, 114).  Resistance to MEK 
inhibitors has been seen in melanoma cells due to the increased expression of the 
ubiquitin ligase SMURF2.  This overcomes the TGFβ signalling induced by the MEK 
inhibitor.  In addition, the increased expression of SMURF2 subsequently increased 
levels of MITF which also contributed to the cells resistance to cytotoxicity (57).  The 
mechanism that led to the resistance of the BRAF inhibitor vemurafenib was the re-
activation of MAPK signalling via EGFR (115).  In total, there have been 22 different 
modes of acquired resistance described for BRAF and MEK inhibitors (57).  This 
demonstrates that there is no one mechanism causing multi-drug resistance in 
patients and new therapies need to be designed with this in mind.  Due to this, 
combination therapies targeting BRAF, along with other pathways, such as MEK (116, 
117) and mTOR/PI3K (116) are utilised.  However, resistance can still occur (118).  To 
help overcome this, research into the benefits of nanoparticle-assisted treatments 
have led to increased response rates of 27% and reduced side effects with drugs such 
as paclitaxel (91).  Nanoparticle-aided therapy will also allow for directly targeted 
treatments by endocytosis of nanoparticle encapsulated drugs and active targeting, 
using the overexpression of surface markers specific to each cancer type, such as 
MC1R on melanoma cells (119). 
Most conventional anti-cancer treatments work on the assumption that cancer cells 
are equal in their ability to form tumours.  Therefore, most therapies aim to eradicate 
all the cancer cells within the tumour (120, 121).  However, accumulating evidence 
over the last decade suggests that there are subsets of cancer cells in most tumour 
types which are particularly effective at forming tumours and resisting conventional 
therapies possibly due to the upregulation of ABC transporters on melanoma cells 
(112).  It is now believed that most relapses following initial therapeutic remission 
can be attributed to these subpopulations of cancer cells (122).  It is, therefore, 
becoming increasingly apparent that effective cancer treatments of the future should 
target those subpopulations of cancer cells capable of initiating and maintaining the 
tumour mass.  However, before this can be achieved, scientists must first obtain a 
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detailed understanding of the biological properties of these cells in order to identify 
suitable targeting strategies for their eradication.  
 
UV radiation typically causes C – T prymidine dimer formations (123).  However, 
there are a number of genetic backgrounds associated with metastatic melanoma 
that are distinct from UV radiation.  Table 1.3 summarises some currently known 
mutations and states the pathway in which they function, the frequency of the 
mutation and potential treatment options.  The MAPK/ERK pathway and 
PI3K/PTEN/Akt pathways are highly implicated in melanoma progression regulated 
by cytokines and receptor tyrosine kinases (124), Figure 1.4 shows how these 
pathways interact.   
The MAPK/ERK pathway is also known as the RAS/RAF/MEK/ERK pathway and 
initiates with the small G protein RAS at the plasma membrane that becomes 
activated by exchanging a GDP for GTP (125).  RAS then binds to the serine/threonine 
kinase, RAF, which translocates to the plasma membrane and becomes activated.  
The RAF family of kinases consists of three members, A-RAF, B-RAF and C-RAF, B-RAF 
becomes activated directly by the binding of RAS but other molecules are needed to 
activate A-RAF and C-RAF (107).  Activated RAF phosphorylates, both MEK1 and 
MEK2, on the serine residues, leading to the activation of ERK1/2 (also known as 
MAPK) by phosphorylation of a Thr-Glu-Tyr motif in the activation loop (107).  
Phospho-ERK then translocates to the nucleus and increases the transcription of 
genes, regulating proliferation and cell survival (126).   
The PI3K/PTEN/Akt pathway activated via a receptor protein tyrosine kinases (Class 
1A), causing autophosphorylation of the tyrosine residues (107).  PI3K will translocate 
to the membrane and bind to the receptor by its adaptor subunit, causing activation 
of the catalytic subunit and production of phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3) from phosphatidylinositol (4,5)-bisphosphate (PIP2).  
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Table 1.3: Selected known mutations in Melanoma 
Known mutations in melanoma with their associated pathways, co-mutations, frequency and 
potential therapeutic treatments.  Table adapted from (57). NB not all known mutations are 
listed. 
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Figure 1.4: Connections of the RAS/RAF/ERK and PI3K/PTEN/AKT pathways in melanoma. 
A schematic showing the binding of a ligand to the receptor tyrosine kinase (RTK) activating 
the RAS/RAF/ERK and PI3K/PTEN/AKT signalling pathways.  The binding of a ligand activates 
RAS by swapping GDP to GTP.  This leads to the activation of RAF, which phosphorylates MEK, 
leading to the activation of ERK (also known as MAPK).  Activation of this pathway leads to 
the transcription of genes involved in growth and division.  RAF and ERK can also lead to the 
translocation of NF-κB to the nucleus by displacing the inhibitory I-κB, at the nucleus NF-κB 
turns on genes regulating the invasion, survival and angiogenesis.  Ras can also lead to the 
activation of PI3K.  This then switches PIP2 to PIP3, which can be reversed by PTEN thereby 
blocking the PI3K pathway.  PIP3 can bind to AKT, which can negatively regulate NF-κB but 
can also phosphorylate MDM2 to antagonises p53-mediated apoptosis or can activate mTOR 
via phosphorylation of TSC and leads to the activation of transcription of genes such as S6K.  
Image adapted from (125).   
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Active PIP3 will then recruit molecules with a pleckstrin homology domain such as Akt 
and PDK1 (107, 127).  The binding of PIP3 to Akt allows PDK1 to phosphorylate Akt at 
T308.  Fully active Akt is also phosphorylated at S437 but the mechanism by which 
this occurs is still unknown.  Akt, itself, can enter the nucleus and activate genes 
regulating proliferation and survival, but it can also phosphorylate mouse double 
minutes 2 homolog (MDM2) to degrade p53 and increase apoptosis (128).  
Phosphatase and tensin homolog (PTEN) is a PIP3 phosphatase and negatively 
regulates the Akt recruitment and can reverse PIP3 to PIP2.  Inactivating mutations in 
PTEN activate PIP3, causing the phosphorylation of AKT.  This increases cell survival 
proliferation and anti-apoptotic signals via mTOR though the phosphorylation of TSC 
leading to transcription of genes such as S6K (129).  
These pathways can however, interact.  RAS can activate PI3K, thereby increasing 
AKT activity (130).  Both pathways can regulate nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) via RAF and ERK from the RAS/RAF/MEK/ERK 
pathway by displacing the inhibitory I-κB and via direct Akt inhibition.  This will lead 
to the transcription of cancer associated genes (131).  It is within members of these 
pathways that we see the most frequent mutations in melanoma.   The most 
common is the BRAF mutation (123, 132-136), common in up to 53-66% of melanoma 
patients which causes constitutive activation of the MAPK/ERK signalling pathway 
(137).  Of these patients, 80% have the specific mutation BRAFV600E, whereas, 16% 
have BRAFV600K, and 4% have either BRAFV600D or R mutation (138).  The BRAFV600E 
mutation causes a 500-fold increase in BRAF kinase activity leading to increased cell 
division and survival (25).  Less common, but with the same subsequent effect of 
hyperactive MAPK signalling, are mutations within NRAS.  This is seen in 
approximately 9-29% of patients and is most often mutually exclusive to the BRAF 
mutation (134, 135, 137).  Both BRAF and NRAS are activated by Ras with BRAF having 
the highest RAS activation, as well as the highest basal activity levels, causing it to be 
one of the most common mutations in cancer (139-141).   
Other mutations are also known in melanoma, such as mutations within PTEN (142-
145) seen in around 30-50% of melanoma cases (146).  Mutations within the tumour 
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supressor PTEN are typically inactivating and cause hyperactve PI3K signalling via the 
Akt/PKB pathway (127), leading to loss of control over the cell growth, metabolism 
and survival (146, 147).  Mutations within PTEN are often seen alongside BRAF 
mutations (142).  However, they are less common in NRAS mediated melanomas 
(145).  Other less common mutations in melanoma patients include those within Akt 
(148-150), the overexpression of which can switch a melanoma from its radial growth 
phase to the vertical growth phase (151).  Inherited forms of melanoma tend to carry 
mutations within CDKN2A causing destabilisation of p53 (3, 49, 152, 153), whereas 
sun-damaged skin is more prone to mutations within C-kit (154-156).  Melanocortin 
1 Receptor (MC1R) gene variants can also cause a predisposition to melanoma 
independent from MC1Rs effects on skin tone and hair colour (157, 158).  Mutations 
within MITF are not that common, seen in around 20% of melanoma cases (159).  
Typically, they are gene amplifications and they cause the constituative transcription 
of a number of different genes, including those involved in the cell cycle such as CDK2 
(19, 160), tumour survival such as HIF1α (161), and melanocytic markers, such as 
SOX10 (25, 162).  These muations likely infer differing effects on melanoma 
progression (142, 150, 163).  Due to this diversity, it is important to compare how 
diverse mutational backgrounds affect the various characteristics of tumour cells, 
such as the differences between wildtype (WT) and BRAFV600E.   
An additional signalling pathway that has to be considered when discussing the 
genetics of melanoma is the Wnt signalling pathway.  As shown in section 1.1.2, the 
Wnt signalling pathways are involved in the development of melanocytes and section 
4.1.1 will show the roles that they play in melanoma initiation and progression.  
Although Wnts and β-catenin are rarely mutated in melanoma (164), aberrant Wnt 
signalling is common in melanoma (20, 165, 166).  The following section will describe 
the Wnt signalling pathways. 
 WNT SIGNALLING 
The Wnt signalling pathways are highly conserved regulatory pathways that play a 
role in embryonic development, as well as cell fate, migration and polarity (25, 167).  
The name Wnt comes from a combination of the Drosophila wingless (wg) gene 
  
 
 
 
44 
controlling segment polarity and the vertebrate homolog Int-1 (166-169).  The Wnt 
family consists of, at least, 19 lipid-modified, cysteine-rich, secreted glycoproteins, 
defined by a sequence homology (22, 25, 167).  Wnts are considered unconventional 
morphogens as they can act in an autocrine manner over short distances or in a 
paracrine manner over long distances (169, 170).  They all have typical features of a 
secreted growth factor, including the lack of a transmembrane domain, hydrophobic 
signal sequence and an N-glycosylation site (22).   
It was stated previously that Wnts are lipid-modified secreted glycoproteins.  The 
lipid modification is the addition of a palmitate moiety on the first cystine residue 
and is necessary for their protein function.  This causes the protein to be hydrophobic 
and allows them to target lipid-dense regions, such as the membrane or lipid rafts 
and allows the N-linked glycosylation of the Wnt protein (171).  These post-
translational modifications occur at the ER, which is where the protein Porcipine 
resides and is thought to play an important role in these lipidations (172).  The 
secretion of Wnts from the cell that produces them is regulated by wntless (wls) and 
evenness interrupted (evi).  These encode a 7-pass transmembrane located on the 
Golgi and are thought to physically interact with Wnts to shuttle them to the cell 
surface (169, 172). 
There have been three Wnt signalling pathways characterised so far; the canonical 
Wnt/β-catenin-dependent pathway, and two β-catenin-independent pathways, the 
noncanonical Wnt/calcium pathway and the noncanonical planar cell polarity (PCP) 
pathway (22, 25, 166-169).  The canonical Wnt pathway works at the transcriptional 
level to control proliferation and differentiation, whereas the non-canonical 
pathways are linked to cell motility and cytoskeletal rearrangements (22, 25, 166).  A 
summary of these three pathways is shown in Figure 1.5.  All the pathways are 
activated through Frizzled (FZD) receptors although other receptors can also activate 
these pathways, as discussed below.  In humans, there are ten FZD 7-transmembrane 
receptors (22, 25, 167, 173), which share topological similarities with G-protein 
coupled receptors (174) and, also have a number of differences (22).  FZD receptors   
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Figure 1.5: Schematic of Wnt/β-catenin and β-catenin-independent Wnt Signalling 
A schematic of the β-catenin-dependent (175) and -independent (right) Wnt signalling 
pathways.  The far left shows the β-catenin-dependent pathway in the absence of a Wnt 
ligand.  The destruction complex formed of Axin, APC and GSK3 causes the phosphorylation 
of β-catenin in the cytoplasm, this leads to β-catenin ubiquitination and subsequent 
destruction by the proteasome.  The binding of a Wnt ligand to the FZD receptor and the LRP 
5/6 co-receptor causes the recruitment of Dvl, and inhibits the destruction complex.  This 
allows β-catenin to accumulate in the cytoplasm and translocate to the nucleus where it 
activates transcription of Wnt-target genes via the TCF/LEF transcription factors.  This 
pathway can be inhibited by DKK competitively binding to the LRP5/6 co-receptor; blocking 
the binding of Wnt ligands by SFRPs or WIF can also inhibit this pathway. The two branches 
of the β-catenin-independent signalling pathway are activated by the binding a Wnt ligand 
to the FZD receptor and a variety of co-receptors including ROR2.  The Wnt/Ca2+ pathway 
can alter intracellular Ca2+ levels.  This can block the β-catenin-dependent pathway through 
inhibition of TCF gene transcription but also can lead to NFAT mediated gene activation. 
Activation of the Wnt/PCP pathway can cause the activation of small GTPases Rho and Rac 
to cause cytoskeletal changes and subsequently affect cell motility. Image adapted from 
(173).  
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have sites for glycosylation and phosphorylation for PKA, PKC and CK2, as well as an 
N-terminus that contains a cysteine rich domain (CRD) for direct Wnt ligand binding 
(22, 168, 169, 174).  The crystal structure of FZD8 bound to Wnt8 has already been 
shown by Janda et al. 2012 (176).  The Wnt8 ligand is described as forming a hand 
shape with the thumb and index finger extended to grab the CRD binding site of the 
FZD receptor.  The activation of the FZD receptor causes the recruitment of the 
cytosolic phosphoprotein dishevelled (Dvl) to the plasma membrane and initiates a 
series of intracellular signalling events (25). 
As stated in section 1.1.1, Wnt signalling is intrinsically involved in embryogenesis in 
the formation of the neural tube, the determination of cell lineage, migration and 
EMT.  Therefore, it is unsurprising that Wnt signalling has been linked to stem cells 
and self-renewal properties.  Due to this, Wnt/β-catenin signalling is found in the 
adult tissues associated with self renewal, including the epithelium of the small 
intestines, hair follicles, bones, hematopoietic stem cells and, crucially, in 
melanocytes (168).  Due to their wide-ranging effects, Wnt proteins have 
subsequently been linked to a number of diseases, including cancer (166, 177, 178).    
Mutations within low-density lipoprotein receptor-related protein (LRP) LRP5 and -6 
(LRP5/6) have a number of effects including; reduced bone density in osteoporosis, 
familial coronary disease and late-onset Alzheimer’s disease (179-181).  Mutations 
within the non-canonical Wnt signalling pathway have also been linked to type II 
diabetes through Wnt5B, Wnt10B and TCF7L2 (182-184) and to end-stage polycystic 
kidney disease (185, 186), whereas upregulation of Wnt5a has been linked to 
Alzheimer’s disease (187).  More recent work has now started to link Wnt signalling 
to the control of the mitochondria and energy cell metabolism (188-196). 
Almost all Wnts have been implicated in cancer.  In breast, esophageal and colorectal 
cancers, nuclear β-catenin predicts lower patient survival and adenomatosis 
polyposis coli (APC) is found to be mutated in 80% of colorectal carcinomas, causing 
constitutive activation of the Wnt/β-catenin pathway (166, 168).  Non-canonical 
Wnts are linked to multiple cancer types including gastric, lung and melanoma (197, 
198) and are shown to increase cancer cell invasion and metastasis, specifically in 
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breast cancer metastasis to the brain (198, 199).  However, as this research will show, 
along with the research of others, Wnt signalling is not always oncogenic in its nature 
(166, 200-203), especially as the β-catenin-independent pathway can inhibit Wnt/β-
catenin signalling (166, 173).  Instead, Wnt signalling, both canonical and non-
canonical, is highly context-dependent in differing tumours (177, 204, 205).  Due to 
this, it is important to investigate the roles of the differing Wnt pathways in different 
tumour types and in different genetic backgrounds of the same tumour. 
 
There are three commonly canonical Wnts; Wnt-1, 3a and 8 (20, 25).  However, their 
downstream activity is determined by which of the 10 FZD receptors they bind (206).  
In the absence of a Wnt ligand, Glycogen Synthase Kinase 3 (GSK3β), which forms 
part of a destruction complex, phosphorylates cytoplasmic β-catenin (173), which is, 
subsequently, ubiquitinated by the E3 ubiquitin ligase β-Trcp, leading to its 
proteasomal degradation (25, 167, 177, 200, 201, 207-214).  Along with GSK3β, the 
destruction complex consists of the tumour suppressor APC, Protein phosphatase 2A 
(PP2A), and Casein Kinase 1α (CK1α), as well as the scaffolding protein Axin (20, 22, 
25, 173).  In a Wnt ‘on’ situation, a Wnt ligand will bind to the CRD of a FZD receptor 
that couples to single pass transmembrane molecule, LRP5/6 (20, 22, 166-169, 174).  
These, also have the ability to bind Wnt proteins and are required to mediate the 
canonical Wnt signal (167).  LRP5/6 is phosphorylated, causing deactivation of the 
destruction complex by translocating Axin (a negative Wnt regulator) to the plasma 
membrane, thereby inhibiting its interaction with GSK3β.  The binding of a Wnt ligand 
to a FZD receptor also causes the recruitment of Dvl to the plasma membrane, where 
it, also is phosphorylated and interacts directly with Axin (20, 25).  Once at the plasma 
membrane, Axin is de-phosphorylated (215), releasing β-catenin to accumulate in the 
cytoplasm and, subsequently, translocates to nucleus.  This translocation process is 
poorly understood as β-catenin has no nuclear localisation sequence and the nucleus 
does not require importin machinery (25, 168, 216).  Once at the nucleus, β-catenin 
binds to transcription factors TCF/LEF, displacing Groucho and activating 
transcription of an estimated 70-Wnt target genes (20, 168).  In order to do this, other 
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factors are needed.  Legless and Pygopus both bind to the TCF-β-catenin complex via 
the N-terminus of β-catenin (217).  In addition, transcription has been shown to occur 
independently of TCF, as this becomes altered by TAK1 and Nemo signalling (218) 
through activation of the MAPK pathway (described in section 1.1.4) and β-catenin 
binds to Pitx2 (219) or Prop1 (220).  The Wnt/β-catenin pathway self-regulates both 
positively and negatively as the expression of LRP, Axin2, TCF/LEF and FZD are all 
controlled by the β-catenin/TCF complex (168).  The Wnt/β-catenin pathway can also 
be activated independently of a Wnt ligand through the binding of Norrin and R-
Spondin2 to the LRP5/6 receptors (167, 173).   
 
There are two non-canonical pathways activated by Wnt ligands (see Figure 1.5).  The 
archetypal β-catenin-independent Wnts are Wnt5a, Wnt5b and Wnt11 (198).  As 
stated previously, the β-catenin-independent Wnts can inhibit Wnt/β-catenin 
signalling.  However, it has been shown in melanoma cells that Wnt5a can actually 
increase Wnt/β-catenin signalling by activating ARF6 via FZD4 and LRP6 receptors 
(221).  These pathways are implicated in embryogenesis including gastrulation, 
neural tube closure and EMT of neural crest cells (22).  
 
The planar cell polarity pathway (PCP) regulates actin cytoskeletal structures and cell 
movement (22, 198).  Cell polarity is very important to normal cell function.  PCP is 
the polarisation of cells along the plane of the epithelial layer at right angles to the 
apical-basal axis (22).  The pathway uses FZD receptors previously described, 
specifically FZD3 or 6.  It also utilises co-receptors including the receptor tyrosine 
kinase-like orphan receptor 2 (ROR2), receptor-like tyrosine kinase (RTK) and protein 
tyrosine kinase 7 (25).  Following activation of the FZD and co-receptor, Dvl is 
recruited forming a complex with the Dishevelled-associated activator of 
morphopgenesis 1 (Daam1) which, subsequently, activates the small G-protein Rho-
associated kinase (ROCK) and myosin (22, 25, 167).  This pathway ultimately regulates 
cytoskeletal dynamics (198).  However, another pathway can be activated 
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independent of Daam1.  Instead this branch of the PCP pathway uses a separate 
domain of Dvl and activates small Rac GTPase which, subsequently, stimulates Jun 
kinase (JNK), which regulates actin rearrangement (22, 25, 198).   
Due to its upregulation in a number of cancers, it has been suggested that levels of 
PCP/Wnt could be used for cancer prognostics (198).  It has also been shown that 
Wnt5a inhibitors block melanoma cell invasion, indicating that they could be used as 
potential future treatments for melanoma or, potentially, other cancers (222).  This 
is especially beneficial as levels of Wnt5a increase resistance to BRAF targeted 
treatments (223).  In gastric cancer, single poly nucleotide (SNPs) mutations occur 
with molecules of the Wnt/PCP pathway.  Therefore, sequencing for these could be 
used to screen for a predisposition to gastric cancer (198).  
 
The Wnt/Ca2+ pathway is dependent on G-proteins and regulates the levels of 
intracellular calcium from the endoplasmic reticulum (ER) stores and, via PKC, also 
regulates cytoskeletal organisation and cell motility (22, 167).  PKC in this pathway 
acts in a positive feedback loop with Wnt5a, as Wnt activation of this pathway leads 
to activated PKC but, subsequent activated PKC, leads to increased Wnt5a (22).  
When a Wnt ligand binds in this pathway, the FZD receptor directly interacts with a 
G-protein which leads to the activation of phospholipase C (PLC) that translocates to 
the plasma membrane (22, 167, 224, 225).  This causes the hydrolysation of 
phosphatidylinositol 4,5-biphosphate (PIP2) into inositol 1,4,5-triphosphate (IP3) and 
di-acyl glycerol (22).  IP3 interacts with calcium channels on the ER and causes the 
release of calcium ions.  The increase in calcium activates a number of calcium-
dependent proteins, including calcium-calmodulin-dependent kinase (CamKII), in 
addition to PKC which is known to regulate processes during gastrulation (167).  Both 
of these calcium sensitive molecules activate nuclear transcription factors NFκB and 
CREB (22, 224).  In addition, CamKII can activate downstream effectors, including 
TGFβ activated kinase (TAK1) and Nemo-like kinase (NLK) which antagonise β-
catenin/TCF signalling (167).  The activation of the Wnt/Ca2+ pathway can also 
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activate phosphodiesterase 6 (PDE6) leading to a decrease in cyclic guanosine 
monophosphate (25, 224, 225). 
As with the previous pathways, the Wnt/Ca2+ pathway is implicated in embryonic 
development and cancer (226-229) but, also, it is implicated in inflammatory diseases 
through its upregulation of NFκB (224, 230).  Inhibition of this pathway can reduce 
both myocardial and Alzheimer’s disease (187, 231). 
 
There are natural inhibitors of the Wnt signalling pathways (see Figure 1.5).  This first 
group are extracellular secreted antagonists of the Wnt pathways.  The Wnt-inhibitor 
protein (WIF) has been shown to bind to Wnts 3a, 4, 5a, 7a, 9a and 11.  They bind 
through their WIF domain and block the binding of Wnts to the FZD receptors and 
prevent downstream signalling (232).  Soluble frizzled-related proteins (SFRP) also 
block the Wnt pathways by mimicking the cysteine-rich binding sequences on FZD 
receptors or the receptor tyrosine kinases (169, 233, 234).  They bind to the Wnt 
ligands, preventing Wnt from binding to the FZD receptor.  In normal cells, SFRPs act 
as tumour suppressor genes and both WIF1 and SFRPs are commonly downregulated 
in cancers (173, 178, 235).  Other extracellular antagonists of the pathways are 
Cerberus and its homolog Coco, that also bind to Wnts and block the downstream 
signalling (234).  These inhibitors have been shown to bind to Wnt ligands associated 
with both the β-catenin-dependent and –independent pathways.  The second group 
of inhibitors all work by competitively binding to LRP5/6 co-receptor to block 
signalling (20, 168, 169, 234, 236).  The family of Dickkopf (DKK) proteins (236), Wise, 
SOST and Insulin-like growth factor binding protein (IGFBP-4) predominantly bind to 
LRP6 but DKK proteins have also been shown to bind to Kremem1 and Wise has been 
shown to bind to LRP4 (237).  The final group of Wnt signalling inhibitors are 
transmembrane molecules that work at the plasma membrane.  These include Shisa, 
Waif1, APCDD1 and Tiki1.  They are classed as one family as they are all 
transmembrane molecules.  However, this family do not all function in the same 
manner.  For example, Waif1 binds to the LRP6 receptor, whereas APCDD1 binds to 
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Wnt ligands and LRP5 and Tiki1 modifies Wnt ligands to remove 8 amino residues 
and inhibit its function (237). 
 THE MITOCHONDRION AND ITs FUNCTION 
This project investigates the effects of the Wnt/β-catenin signalling pathway on 
melanoma cell metabolism.  Therefore, it is necessary to understand the 
mitochondria and the processes of energy metabolism that they carry out. 
Mitochondria are semi-autonomous organelles that produce the majority of the 
required energy of eukaryotic cells through the processes of adenosine triphosphate 
(ATP) synthesis by oxidative phosphorylation (OXPHOS) and the tricarboxylic acid 
(TCA) cycle (238-241).  However, they are also involved in a number of other cellular 
processes, including intracellular calcium homeostasis and are vital for cell growth, 
division and apoptosis (239).  Mitochondria play a central role in the sensing and 
production of cellular energy levels and, along with transcription factors, hormones 
and kinases, they measure ratios of (nicotinamide adenine dinucleotide) NAD+ to 
NADH, ADP to ATP and levels of acetyl CoA and adjust their response accordingly 
(242).   The number, size and location of mitochondria are tightly controlled and can 
vary between cell types (240, 243, 244), but can also vary according to the metabolic 
function of the cell (245).  Specifically, cells such as hepatocytes have a high-energy 
demand and, therefore, have many mitochondria (246), whereas erythrocytes 
produce all their energy through glycolysis and, therefore, have no need for 
mitochondria and, through evolution, have lost them (238, 247, 248).  It has been 
shown that mitochondria do not increase their numbers according to the energy 
demand but, instead, increase their mass in order to induce OXPHOS and ATP 
production (242).  It has also been shown that mitochondria can exist in a number of 
formations: individual, heterogeneous or as interconnected networks (239, 245, 
249).   
 
Mitochondria are semi-autonomous, double membrane, organelles, the structure of 
which is shown in Figure 1.6.  Mitochondria vary in shape from punctate structures  
  
 
 
 
52 
 
 
Figure 1.6: The Structure of Mitochondria 
The semi-autonomous organelle encased by a double phospho-lipid membrane, the inner 
membrane forms the inner boundary and is convoluted into cristae connected together by 
thin tubular junctions, the space in between the membranes is the intermembrane space 
and the internal space is the matrix.  Mitochondria contain their own mtDNA contained in 
nucleoids, mitoribosomes for replication and translation, ATP synthase or complex V of the 
ETC, and iron containing granules.  Image adapted from (250). 
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to intricate networks.  Two opposing processes control this process of mitochondrial 
morphology; fusion and fission (239, 245, 251) and the balance between these is 
necessary to maintain cellular and mitochondrial functions described above (239, 
252).  The shape of mitochondria is linked to Ca2+ signalling, the generation of ROS, 
movement and the cells energy requirements (239, 249, 252).  It has been shown 
that slowly proliferating or quiescent cells have lower energy requirements and will, 
often, form larger mitochondrial networks whereas, where there is a demand for 
higher energy production within the cell, smaller mitochondria will move along 
microtubules of the cytoskeleton and accumulate where needed (239, 244, 249, 
252).  However, during the process of mitochondrial dynamics, the basic architecture 
of a mitochondria remains constant (244).  The two membranes encapsulating the 
mitochondria are functionally different (242).  The outer mitochondrial membrane 
(OMM) is a phospholipid bilayer that contains porins such as the voltage-dependent 
anion channel (VDAC), these are channels spanning the membrane that allow the 
passage of metabolites (253).  Whereas, larger proteins pass through the membrane 
via translocase of the outer membrane (TOM) complexes (254).  The inner 
mitochondrial membrane (IMM) is also a phospholipid bilayer that, not only forms 
the inner boundary but, also is convoluted to form cristae that are connected to the 
inner boundary by small tubular junctions (249, 255).  The IMM has a much higher 
protein:lipid mass ratio than a traditional phospholipid membrane at 75:25% (256).  
There are transport ports through the IMM called the translocase of the inner 
membrane (TIM) complexes that allow the transport of proteins into the inner space 
of the cristae to the mitochondrial matrix, the site of the TCA cycle, which is described 
in detail in section 1.3.3.2 (254).  The space in between the two membranes is the 
intermembrane space which, along with the electron transport chain (ETC) within the 
IMM, is the site of OXPHOS, also described in section 1.3.3.4 (242, 257).  The 
mitochondrial cristae are dynamic structures, changing shape to adapt to different 
cellular processes, as the ETC is integrated into the IMM.  One of these processes is 
mitochondrial respiration (256).  Identified in isolated mitochondria, the cristae 
become condensed during ADP stimulated respiration, thereby decreasing the 
mitochondrial matrix volume.  This is referred to as State III Respiration (258).  
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Whereas during state IV, following the phosphorylation of ADP to ATP or in ADP 
limiting conditions, the mitochondria are in the orthodox formation as shown in 
Figure 1.6 where the matrix is larger and the intermembrane space is small (256).  
The mitochondrial cristae will fluctuate between these states as the availability of 
metabolites changes (259).  Another change in the cristae shape occurs during 
apoptosis when the cristae become disorganised, enabling the release of cytochrome 
c (256, 260).   
 
As stated previously, mitochondria are semi-autonomous, contain their own circular 
DNA and have their own transcription, translation and protein assembly machinery 
(240).  Mitochondrial DNA (mtDNA) is maternally inherited, with paternal mtDNA 
destroyed after fertilisation (240, 242).  The mtDNA is organised into nucleoids 
located within the mitochondrial matrix (242).  The supercoiled, doubled-stranded, 
circular, molecule encodes for 37 genes (see Table 1.4) within 16.6 kbp of DNA (240, 
261, 262).  mtDNA contains no introns, genes are encoded back-to-back and, 
therefore, render the mtDNA more vulnerable to mutations than nuclear DNA and, 
as they are in the coding region, these mutations tend to cause mitochondrial 
diseases, as discussed in section 1.3.4 (240).  The number of mtDNA mutations are 
accentuated by the nearby production of DNA-damaging ROS from the ETC 
(discussed in section 1.3.4.1) and the lack of histone protection or DNA repair 
mechanisms in the mitochondria (240).  mtDNA encodes for 13 of the proteins 
necessary for OXPHOS, with the remaining 74 proteins being encoded by nuclear 
DNA and actively imported into the mitochondria and sorted into compartments 
(240, 242, 261, 262).  In addition, mtDNA encodes the 12S, and 16S rRNAs and 22 
tRNAs necessary for protein synthesis within the mitochondria (240, 261-263).  The 
replication of mtDNA is independent of nuclear DNA replication and is not synced to 
the cell cycle (240, 261).  Factors unique to mtDNA replication include a DNA 
polymerase (POLG), helicase (Twinkle) and mitochondrial-specific single-stranded 
DNA binding protein (mtSSB) but, as with nuclear DNA replication, the process 
involves RNase H1 and DNA ligase III (261, 262).  mtDNA has two strands, the light 
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Table 1.4: List of 37 Genes Encoded for by mtDNA 
Mitochondrial DNA encodes 37 genes, these include 13 polypeptide proteins, 22 tRNAs and 
the two subunits of rRNA.  28 genes are encoded by the heavy strand and 9 genes are 
encoded by the light strand.  Table adapted from (240). 
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strand with low guanine levels with a single promoter region (LSP) and the heavy 
strand, which has high guanine levels and two promoter regions (HSP1 and HSP2) 
that are responsible for the production of specific transcripts (240, 262).  The HSP1 
promoter leads to the production of rRNAs for mitochondrial ribosomes 
(mitoribosomes), HSP2 produces 10 mRNAs and 14 tRNAs and the LSP leads to 8 
tRNAs and the transcript to encode the ND6 protein (261).  Fully processed mRNAs 
are produced from the tRNAs following cleavage of their 5’ and 3’ ends by RNase P 
and RNase Z respectively and the subsequent polyadenylation and stabilisation by 
PPR-containing proteins (261, 262).  Following this, mRNAs are translated in the 
mitoribosomes.  Mitochondrial translation requires a number of components 
encoded by nuclear DNA and imported into the mitochondria, including ribosomal 
proteins, and initiation, elongation and termination factors (261).  During initiation, 
the mitoribosome is separated by an initiation factor (IF3mt) into its 39S and 28S 
subunits.  The 28S subunit then forms a complex with the initiation factor and, 
following the presence of a 5’ start codon, adds the first residue (formylmethionyl-
tRNA) to the mitochondrial polypeptide chain (264).  The 39S subunit then binds to 
the complex along with a second initiation factor (IF2mt).  This hydrolyses GTP to GDP 
and releases the reformed mitoribosome from the initiation factors, allowing 
elongation to start (261, 264).  During elongation, a complex forms, consisting of a 
GTP bound, active elongation factor Tu (EF-Tumt) and aminoacyl-tRNAs.  This complex 
enters the A site of the mitoribosome and coordinates codon:anti-codon-specific 
paring which, if successful, leads to GTP hydrolysis.  Ribosomal enzymes then drive 
the transfer of residues from the P site to the A site of the mitoribosome, extending 
the polypeptide chain.  This process repeats until a stop codon is reached (261, 264).  
Mitochondrial termination release factor (mtRF1a) recognises the stop codon and 
binds to the GTP bound ribosome inducing hydrolysis and causing the release of the 
mature polypeptide.  Mitochondrial recycling factors then coordinate the release of 
the tRNA, mRNA and the mitoribosomal subunits ready for another round of 
synthesis (261, 264).   
 
  
 
 
 
57 
 
The mitochondria are the site of energy sensing and production in the cell.  However, 
they also function in a number of other processes in the cell, including apoptosis, 
(discussed further in section 4.5.2) through the release of cytochrome c, Ca2+ 
homeostasis (discussed in section 6.1.1) through the proximity to the ER and iron 
metabolism through the synthesis of iron-sulphur clusters.  At the start of the 
apoptosis process, the outer mitochondrial membrane will depolarise, regulated by 
the Bcl-2 family members, Bax and Bak, causing the release of cytochrome c from the 
inter-mitochondrial-membrane space (265-267).  However, at this stage a cell can 
still overcome this and survive.  If full apoptosis occurs there is a conformational 
change of the mitochondrial cristae regulated by other Bcl-2 family members Bid and 
Bim, which causes the release of cytochrome c from within their convoluted structure 
(268-271).  For the process of calcium homeostasis, the mitochondria are situated 
near to the ER where Ca2+ is produced.  The mitochondria regulate levels, through a 
uniporter, by taking up calcium from intra-mitochondrial ER stores (242, 249) and 
releasing it when necessary.  This process, that is also linked to the mitochondrial 
shape (249) as the juxtapositioning of the ER to the mitochondria, is also, a site of 
mitochondrial fission and, again, the Bcl-2 family member, Bak plays an important 
role in the initiation of this process (272, 273).  The mitochondria are responsible for 
the synthesis of iron-sulphur clusters which are used by proteins, in many areas of 
the cell, to support enzymatic and structural functions (274).  As explained in section 
1.3.4 neurological diseases are often associated with dysfunctional mitochondria, 
and an accumulation of iron.  It is still unknown if the iron accumulation is a symptom 
or a cause, as dysregulated iron metabolism will, subsequently, cause mitochondrial 
dysfunction (274). 
 
As stated previously, mitochondria are responsible for the sensing and production of 
cellular energy through the process of cellular respiration, a combination of three 
processes; glycolysis, the TCA cycle and OXPHOS.  These processes combine to break 
down calorie intake into cellular energy in the form of ATP, discarding carbon dioxide 
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and water as waste.  A schematic of how these processes combine with each other 
is shown in Figure 1.7. 
 
Glycolysis is the first process in cellular respiration and, in brief, it is the conversion 
of glucose to pyruvate (see Figure 1.8) which, subsequently, enters the 
mitochondrial-localised TCA cycle, as discussed in section 1.3.3.2.  In detail, glycolysis 
is a series of 10 reactions (as shown in Figure 1.9) that break down glucose and other 
organic molecules to produce two molecules of ATP, two molecules of pyruvate and 
two molecules of NADH.  This process is not dependent on the presence of oxygen.  
The first reaction is the phosphorylation of glucose by hexokinase. The phosphate is 
taken from an ATP molecule and results in the formation of α-glucose 6-phosphate, 
which is then converted into its isomer β-fructose 6-phosphate by phosphoglucose 
isomerase in the second reaction (275).  The third reaction of glycolysis uses a 
phosphate from ATP to phosphorylate β-fructose 6-phosphate into β-fructose 1,6-
bisphosphate, using the enzyme phosphofructokinase.  This is subsequently broken 
down into two isomers; dihydroxyacetone phosphate and glyceraldehyde 3-
phosphate, using the enzyme fructose bisphosphate aldolase in reaction four.  These 
compounds are rapidly turned over by triosephosphate isomerase in reaction five 
and the glyceraldehyde 3-phosphate is then used in reaction six (275).  As there have 
been two molecules of glyceraldehyde 3-phosphate formed, from this stage onwards 
there are two molecules at each step.  In reaction six, glyceraldehyde phosphate 
dehydrogenase adds a hydrogen, converting NAD+ to form NADH and adds a 
phosphate to each glyceraldehyde 3-phosphate to form 1,3-bisphosphoglycerate 
(275).  In reaction seven, phosphoglycerate kinase removes the phosphate from both 
1,3-bisphosphoglycerate and uses them in the conversion of ADP to ATP generating 
two molecules of ATP and two molecules of 3-phosphoglycerate (275).  Reaction 
eight uses the enzyme phosphoglycerate mutase to transfer a phosphate group from 
the third carbon of 3-phosphoglycerate to the second carbon, forming 2- 
phosphoglycerate from which water is removed by enolase to form 
phosphoenolpryuvate in reaction nine (275).  In the final, tenth, reaction pyruvate   
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Figure 1.7: Cellular Respiration  
The combination of glycolysis, the TCA cycle and the ETC make up the processes of normal 
cellular respiration to produce 36 molecules of ATP.  Cancer cells rely on glycolysis for ATP 
production leading to increased lactate secretion.  Connecting into glycolysis, the pentose 
phosphate pathway produces NADPH and Ribose-5-phosphate.  Connecting into the TCA 
cycle, glutaminolysis can drive the TCA cycle from α-ketoglutarate to drive amino acid 
synthesis or reverse the TCA cycle for lipid synthesis.  Image adapted from (276). 
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Figure 1.8: Simplified Model of Glycolysis 
The overall reaction of glycolysis converts glucose to pyruvate also produces two molecules 
of ATP, two molecules of water, two molecules of NADH and two molecules of Hydrogen. 
 
 
 
 
Figure 1.9: Detailed schematic of Glycolysis 
Glycolysis is a series of 10 reactions that break down glucose to pyruvate and produces 2 
molecules of ATP, 2 molecules of H20 and 2 molecules of NADH.  All of the reactions take 
place in the cytosol of cells and are independent of Oxygen.  The reactions are driven by the 
break down of ATP and each reaction uses a different enzyme.  The end product of pyruvate 
is subsequently used in the TCA cycle in the mitochondria.  The image is adapted from (277), 
the black labels indicate the compound formed, red labels indicate the enzyme utilised at 
each stage.  Further details are found in the text. 
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kinase takes a phosphate from phosphoenolpryuvate and uses it in the conversion of 
ADP to ATP, resulting in pyruvate as the end product which, subsequently, enters the 
mitochondria to be processed in the TCA cycle (275).   
When oxygen is not present, pyruvate does not enter the TCA cycle and is, instead, 
converted to lactate by LDH (278).  In total, the reaction produces four molecules of 
ATP but it uses two of these and, therefore, yields a total of 2 molecules of ATP for 
every molecule of glucose.  Consequently, it is an inefficient form of energy 
production, compared to OXPHOS.  However, if OXPHOS is impaired, it is a 
compensatory mechanism that cells can employ (240).   
A second pathway links into glycolysis called the Pentose Phosphate Pathway (PPP) 
as shown in detail in Figure 1.10.  The anabolic PPP pathway initiates from glucose 6-
phosphate, from glycolysis, and produces NADPH, the metabolite ribose-5-
phosphate, which makes nucleic acids and glyceraldehyde-3-phosphate, which feed 
back into glycolysis (279).  Glucose 6-phosphate is oxidised by the enzyme glucose 6-
phosphate dehydrogenase and NADP+ to produce 6-phosphogluconolactone and 
NADPH.  6-phosphogluconolactone is very unstable and glutconolactonase catalyses 
the hydrolysis of the ester link, opening the ring resulting in 6-phosphogluconate.  
This is subsequently oxidized by NADP+ with the enzyme 6-phosphogluconate 
dehydrogenase producing ribose-5-phosphate and NADPH (275, 279).  Ribulose-5-
phosphate can then, either be converted to ribose-5-phosphate by isomerase or, 
once the cells requirements are reached, is instead converted to xylulose-5-
phosphate by ribulose 5-phosphate 3-epimerase (275, 279).  These two products can 
then be converted to many different length carbon chains, depending on the enzyme.  
Transketolase cleaves a two-carbon unit from xylulose-5-phosphate creating 
glyceraldehyde-3-phosphate and adds it onto either ribose-5-phosphate resulting in 
the formation of sedoheptulose-7-phosphate, or on to erythrose-4-phosphate 
resulting in fructose-6-phosphate (275, 279).  Transaldolase then transfers a three-
carbon unit from sedoheptulose-7-phosphate on to glyceraldehyde-3-phosophate 
resulting in erythrose-4-phosphate and fructose-6- phosphate, which leads back into 
the glycolysis process, along with any excess glyceraldehyde-3-phosphate (275, 279).   
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Figure 1.10: Pentose Phosphate Pathway  
The pentose phosphate pathway takes place in the cytosol and initiates from Glucose-6-
phosphate from glycolysis.  It is a series of reactions that produces NADPH for fatty acid 
synthesis and ribose-5-phosphate for nucleic acid synthesis and also feeds back into 
glycolysis.  Black labels indicate the compound formed, red labels indicate the enzyme 
utilised at each stage.  Schematic adapted from (279), further details can be found in the 
main text. 
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The TCA cycle is a series of 8 chemical reactions that occurs in the mitochondrial 
matrix following the conversion of glucose to pyruvate in glycolysis (see section 
1.3.3.1, Figures 1.7 and 1.11).  The TCA cycle produces three molecules of NADH, one 
(flavin adenine dinucleotide) FADH2 and one molecule of ATP for every molecule of 
acetyl-CoA (277).  Before entering the TCA cycle, pyruvate is transformed by pyruvate 
dehydrogenase with the help of coenzyme A and NAD into acetyl-coenzyme A 
(acetyl-CoA), the starting product of the TCA cycle (275).  Acetyl Co-A is formed of an 
acetyl group attached to a coenzyme A molecule, which contains an ADP molecule 
so when it is broken down, large amounts of energy are released to drive the TCA 
cycle.  The first reaction joins acetyl-CoA with oxaloacetate to form citric acid using 
the enzyme citrate synthase; water then breaks the bonds connecting the acetyl and 
coenzyme A releasing it from the complex (275).  Acontinase then transfers the -OH 
group from position 3’ to 4’ of citric acid forming isocitrate.  Step three of the TCA 
cycle has two reactions, firstly isocitrate dehydrogenase and NAD+ drive the oxidation 
of the –OH group in the 4’ position of isocitate, the second reaction then removes 
CO2 to produce α-ketoglutarate (275).  Step four removes another CO2 molecule from 
α-ketoglutarate and replaces it with coenzyme A to produce succinyl-coA, this 
reaction uses NAD+ and α-ketoglutarate dehydrogenase.  The fifth reaction of the 
TCA cycle is catalysed by succinyl-CoA synthase, it drives the release of CoA from 
succinyl-CoA to produce succinate and phosphorylation of GDP to GTP, molecules 
very similar in structure and function to ADP and ATP.  In reaction six, FAD+ is reduced 
to FADH2 by removing two hydrogen ions from succinate to produce fumarate under 
the enzyme of succinate dehydrogenase (275).  The penultimate reaction uses 
fumarase to change fumarate to malate with the addition of water.  In the final 
reaction, oxaloacetate is generated by the oxidation of malate using malate 
dehydrogenase and NAD+ as an oxidizing agent, this is now available to be used in 
the first stage of the next cycle (275).   
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Figure 1.11: The TCA cycle  
The tricarboxylic acid cycle is driven by the energy from broken down coenzyme A, it is a 
series of 10 reactions from pyruvate (as a product of glycolysis) to citrate.  It produces CO2, 
ATP, NADH and FADH2, which subsequently feeds into the electron transport chain.  The 
process starts with the conversion pyruvate to acetyl-CoA, this occurs outside of the 
mitochondria and acetyl-CoA is shuttled into the mitochondria using a transport protein.  The 
cycle can be driven by glutamine from α-ketoglutarate to citrate in a process called 
glutaminolysis.  Alternatively glutamine can drive the cycle in reverse to increase fatty acid 
synthesis.  Image adapted from (277, 280), further details can be found in the main text. 
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Glutaminolysis is an alternative pathway that can drive the TCA cycle from α-
ketoglutarate to citrate.  Driven by glutamine instead of glucose, cells will undertake 
glutaminolysis when levels of glucose are low or when levels of enzymes in the TCA 
cycle are sparse halting its progression.  During this process, glutamine is taken into 
the cells and hydrolysed by glutaminase to produce glutamate and ammonium as a 
waste product.  Glutamate dehydrogenase then converts glutamate to α-
ketoglutarate (281, 282).  It has also been shown in some cancers, that glutamine can 
cause a reversal in the TCA cycle to drive fatty acid synthesis using isocitrate 
dehydrogenase to carboxylate oxoglutarate to isocitrate (241, 281, 283, 284).  
 
OXPHOS is a series of redox reactions via five complexes situated in the IMM known 
as the ETC as shown in Figures 1.7 and 1.12.  The reaction catalyses the oxidation of 
ingested calories into energy in the form of ATP and as a result produces water from 
the reduction of oxygen (261).  The generation of NADH and FADH2 from the TCA 
cycle (described in section 1.3.3.2) provides the electrons to drive the ETC (242, 276).  
As previously explained the complexes in the ETC are encoded for by a mixture of 
both nuclear and mtDNA (240, 242, 261, 262).  Specifically, the mtDNA encodes 7 
NADH dehydrogenase units of complex I, the largest complex comprising of 45 
subunits (242).  mtDNA also encodes for 1 cytochrome b in complex III, 3 cytochrome 
c oxidase subunits in complex IV and 2 ATPase in complex V (240).  Nuclear DNA 
encodes for 36 subunits of complex I, the whole of complex II, which comprises of 4 
subunits, 10 subunits of complex III and complex IV and 14 subunits of complex V 
(240).  In Complex I two electrons are taken from NADH and transferred to 
ubiquinone (285).  Complex II does not contribute to the proton gradient as it does 
not span the whole IMM, it connects the TCA cycle and the ETC as it is the oxidation 
of succinate to fumarate (see section 1.3.3.2) via FAD+ producing electrons that 
contribute to the quinone pool (286).  Complex III acts in the Q cycle, oxidising 
ubiquinol and reducing two molecules of cytochrome c and subsequently produces 
four hydrogens that are pumped across the IMM adding to the proton gradient (287).    
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Figure 1.12: ETC  
The electron transport chain consists of five complexes (288) situated in the inner 
mitochondrial membrane of the mitochondria.  Driven by the oxidation of NAD the ions pass 
through the complexes creating a membrane potential and eventually are used in the 
conversion of ADP to ATP by complex V also known as ATP synthase.  Image adapted from 
(240, 275).  
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Complex IV produces two molecules of water by taking four molecules of hydrogen 
from cytochrome c and transferring them to molecular oxygen, in this process four 
protons are transferred across the IMM (289).  The functions of Complex I, III and IV 
results in protons being pumped across the IMM creating a proton gradient 
otherwise known as the mitochondrial membrane potential (261).  The proton 
gradient subsequently drives the conversion of ADP to ATP through the rotary 
turbine-like complex V also called ATP synthase, generating 34 molecules of ATP per 
molecule of glucose (242).  Complex V is formed of two subunits, the lower Fo 
subunit, called such due to its interaction with oligomycin, which is located within 
the IMM.  The larger F1 subunit is located in the intermembrane space (as seen in 
Figure 1.6 labelled ATP synthase particles); it is comprised of 5 subunits named alpha, 
beta, gamma, delta and epsilon (175, 290).   
As the proton gradient drives the activity of ATP synthase, converting ADP to ATP 
(175, 290), it is essential for efficient OXPHOS but is also vital for other mitochondrial 
functions including mitochondrial protein import (242) and mitochondrial fusion 
which can still occur in the absence of ATP or a functional respiratory chain but 
cannot occur if the membrane potential is removed (245, 291).   
Reactive oxygen species (ROS) in the form of oxygen radicals and hydrogen peroxide 
are generated by complexes I and III of the ETC (242) this is due to electron that leak 
from the ETC and react with molecular oxygen.  ROS can be used as secondary 
messengers in the cell and can help cells to adapt to stress such as hypoxia (242).  
However, ROS can also be toxic causing apoptosis (249) and due to their close 
proximity to the mtDNA replication machinery, are a common cause of mutations in 
mtDNA (292), as well as nuclear DNA.  Mutations within mtDNA can also change the 
formation of ETC complexes and increase the escape of electrons (240).  This is 
specifically linked to various cancer types as discussed in section 1.3.4.2.  
 
Mitochondrial diseases are defined as disorders caused by alterations in 
mitochondrial proteins encoded for by either, mtDNA, or the nuclear DNA that cause 
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mitochondrial dysfunction (293).  However, as will be explained further in section 
1.3.4.3, cancer has an altered metabolism and, therefore, can be defined as a 
mitochondrial disease (294, 295).   
 
As explained previously (see section 1.3.1.1), mutations within mtDNA are frequent, 
due to their lack of introns (240).  However, as there are between 2-10 copies of the 
genome in each mitochondrion and multiple mitochondria within each cell, this 
results in hundreds to thousands of copies of mtDNA in each cell.  Therefore, a certain 
number of mutations can be tolerated until a threshold is reached and the mutations 
have causative effects (240, 261-263, 293).  This can vary, depending on the mutation 
and the cell type (296).  In addition to this, during mitosis, the division of mtDNA is 
not necessarily equal and, therefore, the amount of mutant mtDNA can accumulate 
in certain cells, changing their phenotype in a process called mitotic segregation (240, 
293, 296, 297).  There are currently no curative treatments of mitochondrial diseases 
(261).  Mitochondrial DNA mutations can occur in tRNA, rRNA, or within the factors 
of mtDNA translation.  Some examples of mitochondrial diseases are; mitochondrial 
encephalopathy, lactic acidosis and stroke-like episode (MELAS) syndrome, caused 
by a tRNA mutation, non-syndromic sensorineural hearing loss (SNHL), caused by an 
rRNA mutation incited following treatment with aminoglycoside antibiotics and 
Leber’s hereditary optic neuropathy (LHON), an inherited disease affecting Complex 
I of the ETC (293, 296, 297).   Neurological disorders, including Parkinson’s and 
Alzheimer’s disease, are also linked to mitochondrial dysfunction (298-300). 
 
There are also multiple cases of cancer caused by somatic mutations within mtDNA.   
These include breast, ovarian, colorectal, gastric, hepatic, eosphageal, and pancreatic 
cancers where the common sites, containing mutations are the non-coding D-loop 
regions, the NADH dehydrogenase (ND) genes and the cytochrome b gene (240).  
Mutations, within the mtDNA encoding the metabolism machinery, are also known 
to cause various types of cancer.  Mutations within Complex I have been shown to 
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cause thyroid, colorectal, head and neck, medulloblastoma, bladder and prostate 
cancers (240, 301).  Mutations found within Complex III have been shown to cause 
thyroid, breast, colorectal, bladder and ovarian cancers (301) whereas, mutations 
with Complex IV are less common and are only seen in ovarian and prostate cancer 
(301).  Complex V mutations are seen in renal, prostate, thyroid and pancreatic 
cancers (240, 301).  There are also mutations within the enzymes of the TCA cycle 
linked to various types of cancer.  The TCA cycle is encoded by nuclear DNA but, as 
explained in section 1.3.2.2, is a vital aspect of cellular respiration and, therefore, 
mutations can have metabolic and oncogenic effects.  Citrate synthase has been 
linked to pancreatic, cervical and renal cancers (302-304).  Mutations within 
aconitase have been found in gastric and prostate cancers (305, 306).  Isocitrate 
dehydrogenase mutations are found in a number of cancers including, AML, prostate, 
and glioblastoma (307-309).  Hereditary forms of renal, breast and GI cancers have 
been found to have mutations within succinate dehydrogenase (310-312).  
Alterations in fumarase are linked to glioblastoma and neuroblastoma, as well as 
hereditary renal cancers (313-315).  Mutations within the final enzyme of the TCA 
cycle, malate dehydrogenase, have been linked to cases of hematologic malignancies 
(316, 317). 
 
It was stated previously that mitochondrial diseases are those that cause 
mitochondrial dysfunction, changes to metabolism that lead to, or progress, cancer 
are becoming better understood and, therefore, cancer is considered as a 
mitochondrial diseases (294, 295).  In 1924, Otto Warburg found that cancer cells had 
altered metabolism and would preferentially metabolise glucose, even in the 
presence of oxygen, a process termed the Warburg effect (9, 276, 318).  This effect 
was wrongly attributed to dysfunctional mitochondria (seen in only rare cases; (241) 
but, now, there are generally two accepted phenotypes of cellular metabolism, the 
respiratory phenotype and the glycolytic phenotype (257, 319, 320).  In the 
respiratory phenotype (described in sections 1.3.3.1-1.3.3.4), glucose is taken into 
the cell and converted to pyruvate by the process of glycolysis.  Pyruvate then enters 
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the mitochondria and initiates the TCA cycle where it produces free ions.  These pass 
though the ETC, creating a membrane potential, which is used to convert ADP to ATP, 
creating 34 molecules per glucose molecule (276).  The mitochondria in this 
phenotype are described as being elongated with well-formed cristae for good gas 
exchange (265, 318).  The glycolytic phenotype, that is typical of cancer cells, has a 
larger intake of glucose (321).  Any ATP produced is through the process of glycolysis, 
producing just 2 molecules of ATP per molecule of glucose (276).  Glycolysis is the 
primary production of ATP in malignant cells, therefore requiring a high level of 
glucose intake to keep up with the demand for cellular energy of highly proliferative 
cells (240).  The pyruvate created from glycolysis does not enter the TCA cycle but, 
instead, is converted to lactic acid by LDH, creating an acidic environment around the 
cells, even in the presence of oxygen and, therefore, is termed aerobic glycolysis 
(276, 318).  The TCA cycle is still often active in the glycolytic phenotype but, instead 
of being driven by glucose, it is driven by glutamine (277).  Tumour cells often use 
glutaminolysis preferentially as glutamine tends to be in excess in tumour cells and 
it leads to an increase in amino acid synthesis (277, 322, 323).  The mitochondria in 
the glycolytic phenotype are described as small, rounded, structures where the 
cristae are poorly defined (265).   
The PPP pathway and the subsequent fatty acid synthesis are also altered in cancer 
cells.  In cancer cells with altered PI3K/Akt signalling, mTOR can upregulate the 
oxidative portion of the PPP pathway to increase NAHPH for fatty acid synthesis (324, 
325).  In addition, levels of the enzyme G6PDH are often upregulated in cancer.  This 
enzyme is responsible for the production of the first molecule of NADPH in the 
pathway, as cancer cells require large levels of NADPH and, therefore, the activity of 
the enzyme is upregulated (324).  It has also been shown that the increased NADPH 
has been linked to the ability of cancer cells to resist oxidative stress and some 
therapeutic agents (318).  Conversely, RAS activated cancers increase the non-
oxidative portion of the PPP pathway by upregulating the enzymes ribulose-5-
phosphate isomerase and ribulose-5-phosphate epimerase (326).  This requires a 
large increase in glucose and, subsequently, increases the amount of 5-carbon sugars 
available for nucleotide synthesis (324).  Likewise, there is a substantial increase in 
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lipid metabolism in cancer and it has been shown that the PI3K/Akt pathway and 
oncogenic RAS are, once again, involved in the regulation of this process (327).  Fatty 
acids and phosphoglycerides are required for energy storage and the production of 
new biological membrane and, therefore, are required for the increased proliferation 
of cancer cells.   
It would now appear that the definitions of a respiratory and glycolytic phenotype 
are too strict, and that cellular metabolism can alter and adapt to meet the specific 
requirements of the cells or tissues, as necessary (276).  These more recent findings 
indicate that targeting the altered metabolism of cancer cells could provide potential 
new treatments for cancer but it is necessary to understand the differences between 
normal and malignant cells (295, 328, 329). 
 Aims 
The purpose of this study is to investigate a panel of 29 melanoma cell lines.  The cell 
lines will be characterised in terms of their 3D Matrigel growth, proliferation, 
apoptosis, their ability to grow in a non-adherent environment, and the expression 
of markers associated with models of melanoma progression and tumour initiation. 
Using a selection of melanoma backgrounds, the effects of Wnt/β-catenin signalling 
on cancer cell characteristics will then be investigated, measuring cell migration, 
invasion and the afore-mentioned proliferation and apoptosis.  This will help 
determine if there are any distinct phenotypes that can be identified within different 
melanoma cells.   
I will then investigate the effects of Wnt/β-catenin signalling on the mitochondria of 
melanoma cells and any subsequent effects on melanoma cell metabolism.  It has 
previously been shown that Wnt/β-catenin signalling plays a vital role in melanoma 
and that the dysregulated metabolism of cancer cells has been well established.  New 
data is emerging to suggest that Wnt can play a role in the alterations of melanoma 
cell metabolism.  However, the mechanism by which this occurs is not well 
understood.  This research aims to investigate these mechanisms and bridge the 
knowledge gap that currently exists. 
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 Materials 
Product Supplier Catalog No. 
0.4% Trypan Blue in PBS Fisher HYC-044-010D 
10 cm dishes Tissue Culture (TC) Grade Fisher 10508921 
10 ml strippette Fisher FB55484 
10 µl tips Fisher FB78000 
12-well plates TC Grade Fisher TKT-190-070N 
15 ml falcon tubes Fisher FB55951 
1 ml tips Fisher FB78076 
200 µl tips Fisher FB78036 
24-well companion plate BD 734-0067 
25 cm flasks TC Grade Fisher TKT-130-250H 
50 ml falcon tubes Fisher FB55959 
5 ml strippette Fisher FB55483 
6 well plates TC Grade Fisher TKT-190-110E 
8.0 µm pore Cell Culture Inserts BD 353097 
96 well plates TC Grade Fisher 1056-7131 
Acrylamide/bis-aceylamide 40% Sigma A7168-100ml 
Agarose Fisher BPE1356-100 
Ampicillin Sigma A5354 
Apop-TRACE Sigma Cs1110 
APS Ammonium Persulfate Sigma A3678 
ATP determination Kit Invitrogen A22066 
BCA Protein Assay Kit Pierce 23225 
BSA Fisher BPE9702-100 
Cell Scrapers Fisher 11597692 
Cell Strainers VWR 734-0003 
Citrate Synthase Assay Kit Sigma CS0720-1KT 
Competent E.coli Top10 cells Fisher FH01006A 
cOmplete mini Tablets protease 
inhibitor cocktail 
Roche 4693124001 
ConA Sepharose 4B BioWorld 20182001-1 
Crystal Violet Fisher SDS102-2 
DCFDA Cellular Ros Detection Assay Kit abcam ab113851 
DMSO Fisher D/4121/PB08 
DNA polymerase NEB  M0530G 
dNTPs Sigma DNTP10 
Dual Luciferase Reporter assay Promega E1910 
Dynabeads Protein G Novex 10003D 
ECL Prime Western Blotting Detection GE Healthcare RPN2232 
EDTA Sigma E9884 
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Eppendorfs Fisher FB74031 
EZ-PCR Mycoplasma Test Kit GeneFlow K1-0210 
FBS (Lot # RVJ35882) Hyclone SV30160 
Fermentas spectra multicolour broad 
range protein ladder 
Fisher SM1841 
Filter paper Fisher CJF-500-150K 
Gel Red nucleic acid stain VWR BT41003 
GeneJet RNA purification Kit Thermo Scientific K0731 
GFP-Parkin Construct  pEGFP-parkin WT  Addgene 45875 
Glucose (HK) Assay Kit Sigma GAHK20-1KT 
Lactate Assay BioVision K607-100 
LC3 construct pQCXI Neo DsRed-LC3-
GFP Addgene 31183 
L-Glutamine TC Grade Sigma G7513 
LightCycler FastStart DNA Master SYBR 
Green I Roche 3515869001 
LightCycler® 480 Multiwell Plate 96 Roche 04729692001 
LightCycler® 480 sealing foil Roche 04729757001 
Lipofectamine 2000 Invitrogen 11668-027 
Lipofectamine RNAi Max Invitrogen 13778-075 
Loading buffer 3X BioLabs B7703s 
Magic Marker Novex LC5602 
Marvel Milk Powder Marvel 00183932773 
Matrigel basement membrane matrix BD 356234 
Melanocyte media Fisher M-254-500 
Mitochondrial isolation Kit for 
Mammalian Cells 
Thermo Scientific 89874 
Nitrocellulose 0.45um 300mmx3.5m Fisher 1077-3485 
NovaQUANT Human mitochondrial to 
nuclear DNA Ratio Kit Novagen 72620-1KIT 
Parafilm Fisher SEL-400-060G 
Paraformaldehyde Sigma 158127 
PBS tablets Fisher BPE9739-1 
Pen/Strep TC Grade Sigma P0781-100ml 
PhosSTOP phosphatase inhibitor 
cocktail tablet 
Roche 4906837001 
Propidium Iodide (PI)/RNase Staining 
solution 
Cell signalling 4087s 
Poly-D-Lysine Sigma P7280 
PolyHEMA Sigma P3932-10G 
Protein G Sepharose Fast Flow Beads Sigma P3296-5ML 
Proteinase K Sigma P6556 
PVDF Thermo Scientific 88518 
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Qiaquick gel purification Qiagen 28704 
Quick load 100bp DNA ladder NEB  H04675 
Quick load 1Kb DNA ladder NEB  N0468 
Rat Tail Collagen Type I  BD Bioscience 354236 
Recombinant Human DKK-1 (rDKK1) R&D  5439-DK-010 
Recombinant Human Wnt3a protein 
(rWnt3a) 
R&D  5036-wn 
RPMI-1640 Hyclone SH30096.01 
SeeBlue Pre-stained standard Novex LC5625 
Sequence Grade Modified Trypsin  Promega V511c 
Silencer Select Validated siRNA CTNNB1 Ambion 4390824 #s437 
Silencer Select validated siRNA negative 
control #1 Ambion 4390843 
Silencer Validated siRNA PTEN Ambion 114050 
Silencer validated siRNA negative 
control #1 Ambion AM4611 
Taq DNA polymerase Bioline BIO-21085 
TEMED NNNN-
Tetramethylethylenediamine Sigma T9281-50ML 
Trizma HCl Sigma T5941-500g 
Trypsin-EDTA 0.5% Fisher FF01058J 
Vectashield Vector laboratories H1000 
Waters Sep Pack Vac 1cc (50mg) c18 
cartridge Waters Wat054955 
Wizard Genomic DNA extraction Kit  Promega A1120 
XF Cell Mito Stress Test Kit Seahorse 
Bioscience 
102308-400 
 
Antibodies and Cell Stains   
ABCB5 PAb Abgent AP6122a 
AF488 phalloidin Invitrogen A12379 
AF633 anti-mouse Invitrogen A21050 
Akt (pan) (C67E7) Rabbit mAb Cell Signalling 4691P 
Anti p75 NGF receptor Ab Abcam ab8874 
Anti Rabbit IgG HRP NEB 7074s 
Anti-CD146 rabbit mAb Abcam ab75769 
Anti-CD44 rabbit mAb Abcam ab51037 
Anti-Drp1 Abcam ab56788 
Anti-LEF Rabbit Mab  NEB 2230s 
Anti-Mitofusin 1 Abcam ab57602 
Anti-Mitofusin 2 Abcam ab56889 
Anti-mouse IgG HRP Cell Signalling 7076s 
Anti-Nanog rabbit pAb Abcam ab80892 
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Anti-OPA1 Abcam ab55772 
Anti-Parkin (PRK8) Mouse mAb Abcam ab15954 
Anti-Sox2 rabbit pAb Abcam ab97959 
Anti-TCF4 Rabbit Mab NEB 2569s 
Anti-TOMM20  Sigma HPA011562 
β-catenin Antibody rabbit Cell signalling 9562 
CD20 mAB Abgent AJ1155a 
Chicken anti-goat IgG HRP R&D Systems HAF019 
Cytochrome C AbD Serotec MCA2740 
Donkey anti-rabbit AF488 Invitrogen A-21206 
E-cadherin (32A8) Cell Signalling 5296s 
GFP (4B10) Mouse mAb Cell signalling 2955 
Goat anti-Rat IgG HRP R&D Systems HAF005 
Hoechst 33342 Invitrogen H1399 
Human MITF Pab R&D Systems AF5769 
Human/Mouse Wnt5a Mab R&D Systems MAB645 
JC-1 ebioscience 65-0851-38 
Lamin A/C Rabbit Ab Cell Signalling 2032 
LC3 Sigma L7543 
MitoTracker Deep Red FM Invitrogen M22426 
MitoTracker Green FM Invitrogen 7514 
MitoTracker Red Fm Invitrogen M22425 
N-cadherin  Cell Signalling 4061s 
P-Akt (s473) (D9E) XE Rabbit mAb  Cell Signalling 4060P 
p62 Abcam ab91526 
pAb anti-PINK1 Novus Biologicals BC100-494 
Parkin (Prk8) mouse Mab Cell Signalling 4211 
Phopho-DRP1 (Ser616) Antibody rabbit cell signalling 3455 
PROM1 Pab Abnova PAB12663 
PTEN (A2B1) Santa Cruz 
Biotechnology 
sc-7974 
Rhodamine 123 Invitrogen R302 
Snail (C15D3) Rabbit mAb Cell Signalling 3879P 
TMRM Fisher VXT668 
Vimentin (D21H3) XP Rabbit mAb Cell Signalling 5741 
Wnt3a Mouse mAb R&D Systems MAB1324 
α-tubulin mouse Mab Cell Signalling 3873s 
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 Recipes  
 
1 Tablet in 100 mls dH2O 
Autoclave 
 
Formation: 
Sodium Chloride 137 mM 
Phosphate Buffer 10 mM 
Potassium Chloride 2.7 mM 
(pH 7.4) 
 
 
10 mM Tris-HCL 
1 mM EDTA 
(pH 8.0) 
 
 
121 g Tris Base 
28.55 mls acetic acid 
50 mls 0.5M EDTA (9.3 g in 50mls) 
(pH 8.0) 
H20 to 500mls 
 
 
150 mls PBS 
8 g PFA (in fume hood) 
 
Stir in a beaker of water heated to 60°C to disolve 
pH 7.3 with NaOH 
Fill to total volume of 200 mls with PBS 
 
Cool to room temperature 
Store at 4°C 
 
 
50 mM Tris-HCL  
1% Triton-X 
10 mM MgCl2 
20% Glycerol 
(pH 7.4) 
Store at 4°C  
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0.5 M TrisHCL (19.7 g) 
(pH 6.8) 
200 mls H20 
 
 
1.5 M Tris HCL (36.4 g) 
(pH 8.8) 
200 mls H20 
 
 
20 g SDS  
up to 200 mL water 
 
 
25 mM TrisBase (30.2 g) 
190 mM Glycine (144 g) 
0.1% SDS 
(pH 8.3) 
 
 
25 mM TrisBase (30.2 g) 
192 mM Glycine (144 g) 
(20% methanol to be added to 1X solution) 
Store at 4°C 
 
 
5ml glacial acetic acid  
0.2 g Ponceau S  
up to 100 ml with water  
Store at 4°C 
 
 
1.5 g Glycine 
0.1 g SDS 
1 ml Tween 20 
(pH 2.2) 
Store at 4°C 
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24.23 g TrisHCL 
80.6 g NaCl 
800 mls ddH2O 
(pH 7.6) 
ddH2O to 1 L 
(Tween to be added to 1X solution to make TBST) 
 
 
Sigma P3932-10G, Poly(2-hydroxyethyl methacrylate).  Make a 2.5% 
solution in 95% ethanol dissolve by heating to 95°C.  
 
 
0.5 g EDTA  
150 mls H20 
pH 8.9 with NaOH 
Total volume 250 mls 
Autoclave 
 
 
50 ml PBS 
0.5 ml EDTA (40mM) 
 
 
0.5% FBS in PBS 
Store at 4°C 
 
 
1X Sodium Pryuvate 
DMEM + Glucose 
 
 
4 ml 1 M NaCl 
40 µl 1 M Tris-HCL pH7.4 
40 µl 0.1 M EDTA 
1.6 µl Hoechst 33342 10 mg/ml in H20 
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5% formaldehyde at 37% = 26.8 ml 
2% sucrose at 50% = 8 ml 
40 mg of sodium azide 
165.2 ml PBS 
 
 
198 ml PBS 
2 ml serum 
40 mg sodium azide 
 
 
1 ml Triton-X 
20 g sucrose 
2 ml serum 
40 mg sodium azide 
197 ml PBS 
 
 
198 ml PBS 
2 ml serum 
4 g sucrose 
40 mg sodium azide  
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 Methods 
 
All cell culture methods are adapted from protocols outlined in a manual of basic 
technique for the culture of animal cells (330), unless otherwise stated.  Human cells 
were cultured in sterile, tissue culture grade plastic flasks of 25 or 175 cm2 in surface 
area, or dishes 100 mm in diameter.  All manipulations were carried out in a class II 
safety cabinet (LabGard).  Unless otherwise stated, cells were grown in RPMI-1640, 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), 2 mM L-
Glutamine, 100 U/ml penicillin and 100 ug/ml streptomycin.  This media is referred 
to as growth media throughout the text.  Incubation was carried out in a humidified 
incubator at 37°C with 5% CO2.  Once opened, all medium was used within 1 month 
and all cultures checked visually using an inverted microscope at least three times a 
week.  FBS (HyClone), batch number RVJ35882 was used throughout the project to 
limit variability. Cells were subcultured every 4 days.  For a 100 mm diameter Petri 
dish, the medium was removed and discarded; cells were washed once with 3 ml 1X 
PBS (see section 2.2.1) and incubated with 1 ml 0.05% trypsin (Gibco) at 37°C for 1-5 
minutes depending on the cell line.  Once cells had become unattached they were 
resuspended in 5 ml of medium containing 10% FBS and centrifuged at 180g for 5 
minutes to remove the trypsin.  Cells were then diluted as desired and plated in new 
tissue culture flasks/dishes, with appropriate reagent volumes. 
 
The melanoma cells were gifted by Prof. A. Ribas (UCLA; M285, M296 and M375) and 
Prof. A. Chien and Prof. R. T. Moon (University of Washington; A2058, A375, Colo829, 
HMB2, HTB63, M202, M207, M229, M308, Malme3M, Mel501, Mel624, SkMel5, 
Skmel24, SkMel28 and UACC1273). 
 
Human Epidermal Melanocytes Neonatal (HEMa-LP; Invitrogen) are primary human 
melanocytes that are a mixed population, extracted from lightly pigmented forskins.  
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These cells were cultured in Medium 254 (Invitrogen) supplemented with Human 
Melanocyte Growth Supplement (HMGS; Invitrogen) in the absence of antibiotics 
and antimycotics.  The media was changed every 2-3 days.  Subculturing of these cells 
was carried out at 5X103 cell/cm2.  4 ml of Trypsin/EDTA solution was added to the 
flask and immediately 3 ml was removed.  The flask was incubated at room 
temperature for approximately 1-3 minutes until the cells have become nearly 
completely round with a few small processes remaining.  The flask was then gently 
knocked to dislodge the cells and 3 mls of Trypsin Neutralizer solution was added to 
the flask, the cell suspension was then transferred to a sterile 15 ml conical tube.  An 
additional 3 mls of Trypsin Neutralizer solution was added to the flask and pipetted 
over the flask surface several times to remove any remaining cells. This solution was 
also added to the 15 ml conical tube and it was centrifuged at 180g for 7 minutes.  
The cell pellet was resuspended in 4 mls supplemented Medium 254 and the cell 
concentration determined by trypan blue exclusion count (see section 2.3.5).  The 
cells were diluted in supplemented Medium 254 to 5X103 cells/cm2 and added to a 
new culture flask. 
 
The Moon group at the University of Washington have developed cell lines to 
overexpress Wnt3a as well as encode GFP expression.  The sequences for human 
WNT3A was amplified by PCR and cloned into third-generation lentiviral vectors.  The 
Wnt3a and control cells were sorted by FACS to obtain populations expressing equal 
levels of GFP (203).  Cells were cultured in the same media as described in section 
2.3.1 with the exception that 5% FBS was used (203).  Cells were serum starved for 
48 hours prior to all assays unless otherwise stated.  
 
Seed stocks of all cell lines were stored in sterile cryovials in liquid N2.  Cells were 
frozen at a concentration of approximately 0.75X106 cells/ml in a solution of FBS with 
10% dimethyl sulfoxide (DMSO).  Freezing was carried out at a controlled rate of 1°C 
per minute using a Mr Frosty (Nalgene) apparatus containing 100% Isopropanol.  At 
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-70°C the cells were placed in liquid N2 for long-term storage.  Resuscitation of the 
cells was carried out rapidly by thawing in a 37°C water bath, and the cell stock 
resuspended gently in 5 ml of the appropriate growth medium, to dilute the DMSO 
concentration.  Once all the seeded cells had adhered to the tissue culture flask, 
approximately 12-24 hours after resuscitation, the growth media was changed.  
Alternatively, in hypersensitive DMSO cells (M375, M296, Malme3M and Mel624) 
cells were thawed as described above and after were centrifuged at 180g for 5 
minutes to remove the DMSO and the cell pellet was resuspended and seeded.  
 
Mycoplasmas are a potential source of tissue culture contamination that do not 
reveal themselves by alterations to the cells growth medium.  Many mycoplasma 
species grow slowly in continuous cell lines and do not destroy the host cells.  
Therefore, it was essential to routinely screen for Mycoplasma contamination.  
Testing for Mycoplasma was carried out using the EZ-PCR Mycoplasma Test Kit 
according to the manufacture’s instructions.  Analysis of the PCR results was done 
using a 2% agarose gel (see section 2.3.4).  Screening was also carried out using the 
PCR primers and method shown below (331, 332): 
Forward Primer (GPO-3): 5’-gggagcaaacaggattagataccct -3’ 
Reverse Primer (MGSO): 5’-tgcaccatctgtcactctgttaacctc -3’ 
The sample preparation and PCR protocol was adapted from (332), briefly, the cells 
were centrifuged in the media they had grown in, at 180g.  1 ml of supernatant was 
removed from the cells; this had to have been on the cells for a minimum of 48 hours 
with the cells at least 50% confluent. A positive control (Mycoplasma hominis DNA) 
was included in the PCR reaction.  A positive result produces a band of 270 bp when 
resolved on a 2% agarose gel (see section 2.3.4). 
 
Unless otherwise stated a 1% (w/v) agarose solution was made up in 1X TAE (see 
section 2.2.3) and boiled to dissolve the powder.  The solution was cooled down to 
touch and 2 µl of Gel-Red was added.  A gel-casting tray was prepared by sealing the 
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edges with tape and inserting a comb.  The agarose solution was poured into the 
casting tray and left to set at room temperature.  Before use, the tape and comb 
were removed and the samples loaded with 5 µl Quick load 100 bp DNA ladder.  A 50 
ml gel was run at 90 V for 30 minutes and visualised under UV light on the BioRad 
Molecular Imager ChemiDoc XRS. 
 
Cell suspension concentrations were determined using an Improved Neubauer cell 
counter (Marienfeld).  Cells were diluted 1:1 in 0.4% trypan blue solution (333) before 
transferring to the counting chamber.  Viable cells excluded the dye, while dead cells 
stained blue.  Viable cell concentration could then be calculated using the defined 
area of known depth within the counting chamber.   
 
Cells were counted, seeded and left to adhere overnight.  The growth media was 
removed and 1X PBS (see section 2.2.1) was added to wash the cells and then 
discarded.  Stimulants or a carrier control were then added to the cells in serum free 
media for a period of 48 hours, unless otherwise stated.  Recombinant Human Wnt3a 
(rWnt3a) and Recombinant Human DKK1 (rDKK1) were used at 50 ng/ml unless 
stated otherwise.   
 
The protocol was adapted from (334) briefly, matrigel basement membrane matrix 
was pre-aliquoted in 1 ml vials and kept at -20°C, vials were defrosted on ice 
overnight before use.  Matrigel was coated at a volume of 100 µl/cm2 in a 48-well 
plate ensuring no air bubbles remained and left to solidify at 37°C until use.  Plates 
could be pre-coated and re-frozen but were not freeze-thawed more than once.  
4X104 cells were seeded (see section 2.3.5) per well in 400 µl of growth media and 
left at 37°C for 48 hours before analysis.  Analysis was done at 10X magnification on 
an inverted light microscope.  For stimulated experiments (see section 2.3.6) cells 
were counted and seeded onto Matrigel following 48 hours of stimulation. 
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Cells were counted as previously described (see section 2.3.5), and seeded in 
triplicate onto 12-well plates at a concentration of 4X104 cells/well.  After 24, 48 and 
72 hours a viable cell count was carried out (333, 335).  For stimulated experiments, 
the cells were stimulated as previously described (see section 2.3.6), for 48 hours 
before being seeded into the assay plates.  They were then analysed after 48 and 96 
hours of growth.   
Population doublings of overexpression cells were calculated over a longer period of 
time (336).  Cells were seeded in triplicate into a 6-well plate at a concentration of 
2X104 cells/well and left to proliferate to confluency. They were then counted and 
passaged at an appropriate ratio and seeded back into the same plate and left to 
proliferate.  The number of cells counted, the number of days taken to reach 
confluency and ratio of the split were all recorded.  The number of population 
doublings that had occurred was calculated using the following LOG2 formula: 
Number of population doublings = Log (average cell count/number of cells seeded, 
2) 
Using the above results, the population doubling times were then calculated: 
Time taken for population doubling = ((Day of count - Day of 
seeding)*24hours)/number of          population doublings 
The average population doubling time for the cells could then be calculated over the 
course of the experiment.   
 
Cells were serum starved for 48 hours before the assay.  Matrigel basement 
membrane matrix was treated according to the manufacturer’s instructions and 
coated onto cell culture inserts with 8.0 µm pores placed inside a 24-well companion 
plate.  Matrigel was coated at a volume of 50 µl/cm2 of growth surface making sure 
no air bubbles remained and left to solidify (30 minutes) at 37°C until use.  The 
coating was thin enough so that the cells, when seeded, were in the same plane of 
vision as the pores of the insert.  Cells were seeded onto the matrigel coated inserts 
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(see section 2.3.5) at 4X104 cells/well in 0.4 ml of serum free media.  Complete 
growth media was then added to the bottom of the well and the cells were left for 
48 hours at 37°C.  After 48 hours the invaded cells were fixed, stained and counted 
as previously described (337).  For stimulated experiments (see section 2.3.6) the 
cells were seeded on to Matrigel following 48 hours of stimulation and the assay 
carried out as described above. 
 
Cells were lysed in protein lysis buffer (222) centrifuged at 10,000g for 10 minutes at 
4°C and the supernatant transferred to a fresh tube unless otherwise stated.  A BCA 
assay (see section 2.3.11) was carried out to calculate total protein to allow for equal 
loading on the gel. 
 
The assay was carried out according to the manufacturer’s protocol 
(ThermoScientific #23225 Pierce BCA Protein Assay Kit).  Briefly, a standard curve was 
diluted according to the method for a microplate procedure and total protein was 
calculated from the standard curve.  If necessary, samples were diluted in lysis buffer 
to fit them into the standard curve (this dilution was then taken into account when 
protein concentrations were calculated).  The assay was analysed using the 
POLARstar Optima microplate reader (BMG Labtech). 
 
The gel-casting apparatus was set up according to the manufacturer’s instructions 
(Bio-Rad, mini PROTEAN II, 165-2940).  A 12% resolving polyacrylamide gel solution 
was prepared (see Table 2.1), poured and overlaid with a 5% stacking gel (see Table 
2.1).  Once the gels were set, the gel-tank was filled with 1X running buffer (see 
section 2.2.9) and equal amounts of protein were loaded in each well.  10 µl of pre-
stained SDS-PAGE standard low or high range protein marker were run 
simultaneously with the samples to determine protein size.  Gel electrophoresis was 
carried out at 90 V until stacking of the samples had occurred and then increased to 
120 V until the samples had reached the bottom of the gel. 
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Table 2.1: Formulation of Resolving and Stacking Gel for SDS-Polyacrylamide Gel 
Electrophoresis 
 Resolving Gel Stacking Gel 
 12% 5% 
dH2O 3.45 ml 2.9 ml 
40% acrylamide mix 2.4 ml 0.75 ml 
1.5M tris pH 8.8 2 ml - 
0.5M Tris pH 6.8 - 1.75 ml 
10% SDS 0.08 ml 0.05 ml 
10% APS 0.08 ml 0.05 ml 
TEMED 0.008ml 0.005ml 
Total 8ml 5.5ml 
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The following apparatus was set up as shown in Figure 2.1.  The transfer tank (Bio-
Rad Mini PROTEAN II) was filled to the brim with 1X transfer buffer (see section 
2.2.10).  The transfer was carried out at room temperature with an ice pack at 250 
mA for 2 hours.  Transfer efficiency was checked with Ponceau S (see section 2.2.11) 
stain before being rinsed in dH2O and the membrane was imaged on the BioRad 
Molecular Imager ChemiDoc XRS. 
The following steps were undertaken in a falcon tube on a roller (338).  The 
membrane was blocked for at least 1 hour in 5% blocking buffer at room 
temperature.  The blocking buffer used was dependant on the antibody, either 5% 
BSA or 5% Marvel milk.  It was then incubated for overnight at 4°C in the primary 
antibody diluted accordingly in 5% blocking buffer.  The membrane was washed 3 x 
10 minutes in TBST (see section 2.2.13) followed by a 1 hour incubation in the 
secondary antibody conjugated to horseradish peroxidase in a 1:10,000 dilution for 
the mouse IgG or a 1:5,000 dilution for rabbit IgG.  The blot was then washed 3 x 10 
minutes in TBST.  The ECL (Enhanced Chemi-Luminescence) method was used to 
detect the antibody.  The blot was incubated with the ECL solution for 5 minutes, 
before imaging on the BioRad Molecular Imager ChemiDoc XRS.   
 
Protocol adapted from (339, 340), briefly 12-well plates were coated 3 times in 
Poly(2-hydroxyethyl methacrylate), this is referred to as polyHEMA throughout the 
text (see section 2.2.14).  After each coating the plates were put onto a rocker for 5 
minutes and then left to dry in a sterile hood.  Before cells were seeded the wells 
were washed twice with 1X PBS, if the PBS turned cloudy the polyHEMA had 
degraded and the plate discarded.  Cells were counted as previously described (see 
section 2.3.5).  1X104 cells were seeded/well in 1 ml growth media.  Cells were left 
for 7 days at 37°C with a very gentle top-up of media every three days.  Images were 
captured using an inverted light microscope, Zeiss camera and AxioVision software 
at 10X magnification.  The first 20 objects to be seen in the images were measured   
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Figure 2.1:  Set up of Protein Transfer Equipment 
Set-up of the BioRad Mini PROTEAN II transfer system, to transfer proteins from SDS-
Polyacrylamide gel onto nitrocellulose membrane. 
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whether they were single cells or clusters.  Melanospheres were measured in μm 
using Image J software.  For stimulated experiments the cells were stimulated as 
previously described (see section 2.3.6) for 48 hours before seeding into the 
polyHEMA coated plates. 
 
 
Cells were washed once in PBS, and detached using PBS-EDTA (see section 2.2.16).  
Cells were counted (see section 2.3.5) and 2X105 cells were centrifuged at 180g for 5 
minutes and resuspended in FACS buffer (see section 2.2.17).  Samples were 
incubated at 4°C for 1 hour as a blocking step.  Cells were centrifuged at 180g for 5 
minutes, and the supernatant removed.  Primary antibodies were added directly to 
cell pellets (Table 2.2) and to the unstained control and secondary antibody only 
samples, 300 µl of FACS buffer was added.  Samples were incubated at 4°C for 1 hour.  
1 ml FACS buffer was added to each sample and centrifuged at 180g for 5 minutes; 
the supernatant was tipped off the pellet.  The same secondary antibody was used 
for each of the samples, Donkey anti-rabbit AF488 (Invitrogen).  This was added 
directly to the cell pellet at 1:400 (40 µl per sample).  Samples were incubated in the 
dark at 4°C for 1 hour.  1 ml FACS buffer was added to each sample and centrifuged 
at 180g for 5 minutes and the supernatant was removed.  350 µl of FACS buffer was 
added to all samples and analysed using an Accuri C6 bench top flow cytometer and 
C-Flow Plus software (BD).  Mean levels of the FL2 channel were recorded and 
compared to unstained and secondary antibody only staining. 
 
The cells were cultured and stimulated as normal in cell culture plates; they were 
then trypsinized and put into an eppendorfs before the fixation step.  Cells were 
centrifuged at 180g for 3 minutes between each stage.  Cells were fixed and 
permeablised as described (see section 2.3.26.1) before primary antibodies were 
added at a working concentration for 1 hour (337).  Species relevant secondary 
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Table 2.2: Antibodies used in Flow Cytometry of cell Surface markers. 
Antibody Catalogue Number Recommended Dilution 
CD271 Abcam #ab8874 1:100 from stock in 1X PBS 
CD133 Abnova #PAB12663 15 µg per 106 cells, stock is 0.5 µg/µl 
CD20 Abgent #AJ1155a 1:20 from stock in 1X PBS 
ABCB5 Abgent #AP6122a 10 µg/ml per 106 cells, stock 250 µg/ml 
  
  
 
 
 
92 
antibodies conjugated to fluorophores were diluted 1:400 to 5 µg/ml and 100 μl put 
onto the cells for 1 hour in the dark.  Cells were resuspended in FACS buffer (see 
section 2.2.17) and analysed immediately on a BD Accuri C6. 
 
Protocol adapted from (341), briefly cells were pelleted and resuspended in ice cold 
70% ethanol.  The cell suspension was stored at 4°C for at least 24 hours.  Pellet the 
cells by centrifugation at 180g for 5 minutes and wash once in PBS.  Resuspend the 
pellet in 300 µl of PI/RNase A solution and incubated for 30-45 minutes.  Analysis was 
carried out on the accuri C6 flow cytometer firstly gating on the live population in a 
forward scatter/side scatter plot and then exclude any doublets in a forward scatter-
area/forward scatter-height plot.  Following this gating, analysis of the FL2 channel 
on a linear scale was carried out. 
 
Live cells were stained with Mitotracker Green diluted in phenol-red free media to 
10 nM (Invitrogen) as previously described (342), JC1 at 2 µM or TMRM at 20 µM.  
Following staining, the cells were washed with phenol-red free media, trypsinized 
and put into eppendorfs.  Cells were resuspended in FACS buffer (see section 2.2.17) 
and analysed immediately on a BD Accuri C6. 
 
Protocol adapted from (203), briefly cells were counted as previously described (see 
section 2.3.5), and seeded on to 24-well plates at a concentration of 4X104 cells/well.  
The following day, cells were transfected with the Super8TOPFlash or 
Super8FOPFlash reporter constructs (343, 344).  DNA was mixed in eppendorfs for 5 
minutes as described below:   
 
Positive Control: 300 ng PGL3, 150 ng Renilla  
TOPFlash: 300 ng TopFlash, 150 ng Renilla 
FOPFlash Negative control: 300 ng Fop Flash, 150 ng Renilla 
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1 µl/per well of Lipofectamine was mixed with 100 µl transfection media (RPMI with 
no FBS, no antibiotics and no L-Glutamine) for 5 minutes.  The DNA and the 
lipofectamine were then combined for 30 minutes.  The cells were washed twice in 
the transfection media before 100 µl of the lipofectamine/DNA mixture was added 
to the cells and incubated at 37°C for 6 hours.  The transfection media was then 
replaced with normal growth media.  For melanocytes the transfection process was 
carried out in normal melanocyte growth media and the transfection mix was only 
incubated on the cells for three hours.  The following day the melanoma cells were 
stimulated as described in section 2.3.6.  Melanocytes were stimulated with rWnt3a 
at the same concentration (see section 2.3.6) in melanocyte growth media.  Wnt3a-
overexpression cells were not stimulated with rWnt3a but fresh media was added to 
the cells following the transfection. 
The dual luciferase kit (Promega ♯E1910) was used according to the manufacturer’s 
instructions and the luciferase readings were carried out on PerkinElmer Envision 
plate reader.  The LaII and Stop&Glow readings were calculated as a ratio to analyse 
the Wnt3a stimulated response. 
 
Protocol adapted from (345), briefly overexpression cells were counted as previously 
described (see section 2.3.5), and seeded on to 24-well plates at 6X104 cells/well.  
After 48 hours of serum starvation the assay was carried out according to the 
manufacturer’s instructions (Sigma #CS1110).  Fluorescent readings were normalised 
to protein concentration analysed by BCA from the two wells left without Apo-TRACE. 
 
Protocol adapted from (337), briefly cells were counted as previously described (see 
section 2.3.5), and seeded on to 6-well plates at a concentration of 4X105 cells/well.  
After the cells had adhered overnight the monolayer was scratched three times with 
a pipette tip in a long strip, the media was changed and 10X images were taken of 
the scratch.  The media was then changed and images taken at 24 and 48 hours in 
the same region along the scratch.  The images were analysed using Image J to 
  
 
 
 
94 
measure the open area of cells and the data represented as fold-change compared 
to control. 
 
Protocol adapted from (346), this work was carried out at the University of 
Washington by Peggy Yang (all mouse work), Rima Kulikauskas (cell preparation).  All 
animal studies were performed using Institutional Animal Care and Use Committee 
protocols as approved by a review board at the University of Washington.   
Cultured control and Wnt3a overexpression cells were removed from the culture 
surface using PBS-EDTA (see section 2.2.16) and were washed in 1X PBS three times 
before 1X106 cells were counted and resuspended in 1 ml sterile saline.  The cells 
were injected using a 26 G needle into the tail vein of NOD-SCID mice, 6 mice per cell 
line.  The mice were monitored for 4 weeks checking for any significant weight loss, 
change in behaviour or death.  After 4 weeks the mice were sacrificed and the lungs 
removed, these were initially imaged under fluorescent light on a Nikon SMZ1500 
microscope.  The samples were then fixed in 10% neutral buffered formalin (Thermo 
Scientific). 
 
This work was carried out at the University of Washington by Brian Johnson 
(HIC/Comparative Pathology Program).  Paraffin embedded tissue is hydrated on an 
ice bath for 30 minutes and placed on a Rotary Microtome (Leica RM2265, Leica 
Microsystems Inc.) for sectioning.  The paraffin block is cut to approximately 100 µm 
to “face in” and ensure maximum tissue area per section.  The block is then cut at 4 
µm and sections are placed on a glass slide.  The first section is stained for H&E, 30 
serial sections are cut (4 µm) and the 30th section is again stained for H&E. 
Immunohistochemical staining was performed on the Leica Bond Automated 
Immunostainer.  Sections were deparaffinized in Leica Bond Dewax Solution (Leica) 
and rehydrated through 100% ETOH.  After antigen retrieval with EDTA buffer pH 9.0 
(Lieca Bond Epitope Retrieval Solution 2) at 100C for 20 minutes and blocking 
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endogenous peroxidase activity with 3.0 % H2O2 for 5 minutes and blocking with 10% 
Normal Goat Serum in TBS for 20 minutes the sections were incubated with Rabbit 
polyclonal S-100 antibody, (Invitrogen) 46.8 mg/mL or Normal Rabbit IgG, isotype 
control, (Invitrogen) at (1:1000 dilution, 1 µg/ml) both in Bond Primary Antibody 
Diluent (Leica) for 30 minutes at room temperature.  Sections were then incubated 
with Goat anti Rabbit Poly-HRP polymer secondary detection (Leica) for 8 minutes at 
room temperature.  Sections were then incubated with Leica Bond Mixed Refine DAB 
substrate detection for 10 minutes at room temperature. (Leica). After washing with 
DIH2O the sections were counter stained with Hematoxylin solution (Leica Bond 
Refine Kit) dehydrated through 100% ETOH, cleared in Xylene and mounted with 
synthetic resin mounting medium and 1.5 coverslip. 
Slides were scanned in Brightfield at 20X objective using a Nanozoomer Digital 
Pathology slide scanner (Olympus America).  The digital images were then imported 
into Visiopharm software (Hoersholm, Denmark) for analysis.  Using the Visiomorph 
Digital Pathology module, regions of interest (ROIs) were applied around relevant 
areas using a tissue detect protocol and manual clean-up.  The software was then 
programmed to label positively stained areas versus normal tissue areas, using 
project-specific configurations created for each staining set.  Images were processed 
in batch using these configurations to generate the desired output calculations.  
 
Seahorse XF96 Cell Culture Plates were coated in Poly-D-Lysine (347) at 0.1 mg/ml 
for 1 hour in a cell culture hood.  The plate was then washed twice in 1X PBS and left 
to dry in the hood for an hour.  Overexpression cells were counted as before (see 
section 2.3.5) and seeded on to the plates at 8X103 cells/well in 80 µl culture media 
(see section 2.2.18).  The plate preparation and running of the Mito Stress Assay was 
carried out according to manufacturer’s instructions (Seahorse Bioscience) (348).  
The compounds were diluted in seahorse media as stated below (349); please note 
the concentrations are adjusted to allow for the change in volume after each 
injection as shown in Table 2.3: 
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Port A: Media 
Port B: Oligomycin 2.5 µM 
Port C: FCCP 1 µM 
Port D: Antimycin and Rotenone both at 2.5 µM 
To normalise the Seahorse data to cell number a Hoechst stain assay was carried out 
on each plate.  Ensuring the Seahorse XF96 Cell Culture Plate was at room 
temperature; 40 µl/well of 0.01% SDS (diluted in water) was added and the plate 
stored at -80°C for 30 minutes.  The plate was then thawed and 40 µl/well of staining 
solution (see section 2.2.19) was added, the plate was then incubated at 37°C for 1 
hour on a nutator before the fluorescence was read at excitation 355, emission 460 
(349). 
 
The seahorse Gylcolysis Stress test was carried out according to manufacturer’s 
instructions (Seahorse Bioscience).  All other aspects of the assay were kept the same 
as for the Mito Stress Assay (see section 2.3.20).  The compounds were diluted in 
seahorse media as shown in Table 2.4, please note the concentrations are adjusted 
to allow for the change in volume after each injection, Table 2.4 shows the highest 
concentration of Glucose, the dose range was 0, 2.5, 5, 7.5 and 10 mM: 
Port A: Glucose 0-10 mM 
Port B: Glucose 0-10 mM 
Port C: Oligomycin 2.5 µM 
Port D: 2-DG 100 mM 
The plates were stored at -20 °C until cell number normalisation could be carried out 
as explained in section 2.3.20. 
 
The Citrate Synthase Assay Kit (Sigma) was used according to the manufacturer’s 
instructions and a positive control was used at 1 µl.  Briefly, cells were seeded on to 
6-well plates at 2X105 cells/well.  After 48 hours of stimulation as previously 
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 Table 2.3: Mito Stress Test Compound Dilutions  
Compound Stock Conc. Preparation 
Conc. 
Final Conc. Volume needed 
for 1.7mls 
Oligomycin 5 mM 15 µM 2.5 µM 5.1 µl 
FCCP 2.5 mM 7 µM 1 µM 4.76 µl 
Antimycin and 
Rotenone 
2.5 mM 20 µM 2.5 µM 13.6 µl each 
 
 
Table 2.4: Glucose Stress Test Compound Dilutions 
Compound Stock Conc. Preparation 
Conc. 
Final Conc. Volume 
needed for 
1.7mls 
Glucose 350 mM 50 mM 10 mM 242.86 µl 
Glucose 350 mM 60 mM 10 mM 291.60 µl 
Oligomycin 5 mM 17.5 µM 2.5 µM 4 µl 
2-DG 1 M 800 mM 100mM 800 µl 
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described (see section 2.3.6), the cells were lysed in 100 µl lysis buffer (see section 
2.2.5) and centrifuged at 20,000g for 15 minutes at 4°C.  A BCA was carried out (see 
section 2.3.11) and the volume of lysate required for 8 µg of protein was calculated.  
The absorbance was read at 412 nm before and after addition of Oxaloacetate (OAA) 
using the POLARstar Optima microplate reader (BMG Labtech).  Citrate Synthase 
Activity was then calculated using the manufacturer’s guidelines and represented as 
the fold change compared to control.   
 
The lactate Assay was carried out according to the manufacture’s (BioVision) protocol 
for the colorimetric assay.  Briefly, cells were seeded onto 6-well plates at 2X105 
cells/well.  After 48 hours of stimulation, as previously described (see section 2.3.6).  
The cell supernatant was removed and stored at -80°C for at least 24 hours, to stop 
Lactate dehydrogenase activity.  The cells were lysed and the total protein measured 
using a Peirce BCA assay Kit (see section 2.3.11).  The standard curve of lactate was 
extended to include a 12 and 14 nmol/well measurement and 1 µl of sample was 
used.  The absorbance was analysed using the POLARstar Optima microplate reader 
(BMG Labtech) and the results were calculated as the fold change compared to 
control. 
 
The ROS Assay was carried out according to the manufacturer’s instructions (Abcam).  
96-well plates were coated for 1 hour in 50 µg/ml collagen in 0.02 M acetic acid.  
Wnt3a overexpression cells were seeded at 1X104 cells/well and serum starved for 
48 hours.  A positive control of 0.01% Triton X and a negative control of serum free 
media only were included.  DCFDA was used at 25 µM, for 45 minutes.  The plate was 
read on a POLARstar Optima microplate reader (BMG Labtech) at ex 485nm em 
535nm, results were analysed after the subtraction of background from the negative 
control. 
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The Glucose assay was carried out according to the manufacturer’s instructions 
(Sigma).  Briefly, Wnt3a-overexpression cells were seeded on to 6-well plates at 
2X105 cells/well.  After 48 hours of serum starvation, the cells were lysed in 100 µl of 
lysis buffer (supplied with assay kit) and centrifuged at 20,000g for 15 minutes at 4°C.  
Three controls were used, a sample blank which contained sample but no reagent, a 
reagent blank that contained regent and no sample and a positive standard sample.  
Equal volumes of each sample were used and the assay was measured using the 
POLARstar Optima microplate reader (BMG Labtech) and results normalised back to 
protein concentration determined by BCA analysis (see section 2.3.11). 
 
 
Sterile cover slips were placed into 12-well plates.  Cells were counted as previously 
described (see section 2.3.5) and 2X104 cells seeded into the wells ensuring no air 
bubbles were under the cover slips.  The cells were left to adhere and stimulated with 
rWnt3a or serum starved as required.   
Live cells were stained with Mitotracker Deep Red, diluted in phenol-red free media 
to 250 nM (Invitrogen) as previously described (342).  Cells were the fixed and stained 
with counter-stains; Phalloidin 488 (6nM) and Hoechst 33342 (10 nM).  Briefly, cells 
were fixed (see section 2.2.20) using PBS with 5% formaldehyde, 2% sucrose and 
permeabilized (see section 2.2.22) with 1% Triton-X, 10% sucrose and 1% calf serum.  
Cells were incubated for 20 minutes with Phalloidin 488 and counterstained with 
Hoechst before being mounted onto slides with mounting medium (337).  They were 
left at 4°C overnight before the edges were sealed with nail varnish.  Slides were then 
imaged on a Zeiss LSM510 confocal microscope. 
 
Sterile cover slips were placed into 12-well plates.  Cells were counted as previously 
described (see section 2.3.5) and 2X104 cells seeded into the wells making sure no air 
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bubbles were under the cover slips.  The cells were left to adhere and stimulated or 
serum starved as required.   
Cells were fixed and permeablised as previously described (see section 2.3.29.1) 
before primary antibodies were added at working concentration for 1 hour in a damp 
environment (337).  Secondary antibodies conjugated to fluorophores were diluted 
(see section 2.2.23) 1:400 to 5 µg/ml and 100 μl put onto the cells for 1 hour in a 
dark, damp environment, followed by counterstaining with Phalloidin and Hoechst 
stains and mounting as previously described (see section 2.3.26.1).  Slides were 
imaged on a Zeiss LSM510 confocal microscope. 
 
 
The protocol was carried out according to the manufacturer’s instructions 
(NovaQUANT) for whole cell lysis.  Briefly, cells were counted and diluted to allow for 
50 cells per well, and resuspended in DNase/RNase free water to a volume of 10 µl 
per well.  2X RT2 Fast SYBR Green Mastermix was added to the cells and mixed gently 
by pipetting.  Three controls were used in each run, a no template control (NTC) was 
included by replacing the cell suspension with PCR grade water.  A positive and 
negative control for mitochondrial targets were used; human wildtype and human 
rho zero DNA controls were provided in the kit, these are used to verify the primers 
work effectively and the plate run was successful.  A fast SYBR protocol was run with 
an extended denaturing step at 95 °C for 10 minutes.  Data analysis was carried out 
using the relative copy number method.  The Ct values for each of the four genes are 
used to determine mtDNA copy numbers as described in the manufacturer’s 
protocol. 
 
RNA was extracted from cells using the GeneJet RNA purification kit, according to the 
manufactuer’s instructions for the Mammalian Cultured Cells Total RNA Purification 
Protocol.  RNA was eluted in 50 µl of nuclease free water and the elution was 
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repeated to increase RNA concentration.  RNA samples were then quantified on a 
NanoDrop ND-100 Spectrophotometer. 
 
2 µg of RNA was diluted with DEPC-H2O to total volume of 10 µl this was then 
converted to cDNA by adding; 1 µl oligo(dT)18 primer (0.5 µg/µl), 1 µl random 
hexamer primer (0.2 µg/µl), 4 µl 5X reaction buffer, 2 µl 10 mM dNTPs, 1 µl RiboLock 
Ribonuclease Inhibitor (20 U/µl), 1 µl RevertAid M-MuLV Reverse Transcriptase (200 
U/µl).  The 20 µl reaction mix was then put into a PTC-100 thermocycler (BioRad) and 
incubated for 25°C for 10 minutes, 42°C for 60 minutes, 70°C for 10 minutes, samples 
were then held at 4°C until use in qRT-PCR reactions (350). 
 
10 µM primer pairs (see Table 2.5) were checked for their specificity using a standard 
Tm melting point assay following the manufacturer’s instructions (Roche), good 
primer pairs are seen as one single peak on the melting curve.  PCR was carried out 
using 1× of 10×Taq Buffer, 1 mM MgCl, 0.1 mM dNTPs, 0.3 µM primers, 1 unit Taq 
DNA polymerase enzyme and 5 µl cDNA in 50 µl reactions for 35 cycles.  PCR products 
were run on a 1.5% agarose gel (see section 2.3.4), and purified using QIAquick gel 
extraction kit according to the manufactures protocol (Qiagen).  DNA was eluted in 
30 µl 10 mM Tris and quantified on a NanoDrop ND-100 Spectrophotometer.  The 
DNA copy number was then calculated using the equation below: 
1 mol = MW x g  
1 mol = 6X1023 molecules = copies 
Copies/µl =    (6x1023 copies/mol) X (concentration g/µl) 
         (MW g/mol) 
 
Using the value of copies/µl a standard curve was generated starting at 1X1010 down 
to 1X101, for experimental use only use 6 points of the curve, usually starting at 
1X106. 
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Table 2.5: qRT-PCR Primer Sequences 
  
Gene Forward Primer Reverse Primer Reference 
AXIN2  CTCCCACCTTGAATGAAGA  TGGCTGGTGCAAAGACATAG (350) 
MFN1  CTCTCCGCCTTTACTTCTC  TCTGCCATTATGCTAAGTCTCC Self  
Designed 
MNF2  CTCAAGACTATAAGCTGCGA  TCAAGCCATCTATCATGTCC Self 
Designed 
OPA1  TATGACAGAACCGAAAGGGA  GAATAACCCTCAAGCTGTCCT Self 
Designed 
DRP1 GAAATGCTACTGGTCCTCGT  ACGAAGAAGACAAGTCACCA Self 
Designed 
UBC CTGCTCATAAGACTCGGCCT AAGATCTGCATTGTCAAGTGACG (337) 
-actin AGAGCAAGAGAGGCATCCTC  CTCAAACATGATCTGGGTCA (351) 
YWHAZ ACTTTTGGTACATTGTGGCTTCAA  CCGCCAGGACAAACCAGTAT (337) 
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cDNA from samples and standards were diluted 1:10 in H20 and 2 µl were added to a 
8 µl reaction mix including 5 µl SYBR Green, 1 µl primer pair mix at 10 mM, 2 µl H20.  
Samples were loaded into 96-well qPCR plate, sealed with qPCR plate sealer and 
centrifuged to ensure all contents are at the bottom of the well.  A standard TM 
meting point assay was then run and the Δct values of the samples compared to that 
of the standard curve (352). 
 
A reverse transfection protocol was used (203).  The following siRNA mixes were 
made: 
 Lipofectamine RNAi Max: 3 µl/well in 100 µl/well of optimum media. 
 Gene of interest siRNA: 20 nM in 100 µl/well of optimum media. 
 Negative control: 20 nM in 100 µl/well of optimum media. 
These were incubated for 5 minutes at room temperature before the lipofectamine 
mix was added to each of the siRNA mixes and incubated for 30 minutes at room 
temperature.  The cells were then prepared to be 30% confluent in a 12 well plate.  1 
ml of cell suspension was put into the plate with 200 µl siRNA/lipofectamine mixture.  
The cells were then incubated for 72 hours before analysis of the knockdown.  The 
following siRNAs were used: 
β-catenin siRNA 5’-3’: GGAUGUUCACAACCGAAUUtt (353) 
PTEN siRNA 5’-3’: CGAACUGGUGUAAUGAUAUtt (Ambion, Validated) 
 
The protocol was carried out according to the manufacturer’s instructions 
(ThermoScientific) for the Mitochondrial Isolation Kit from Cultured Cells using 
Reagent Based Method.  The samples were centrifuged at 12,000g.  If multiple 
samples preps were carried out for one sample they were combined to increase the 
overall protein yield.  The pellets were resuspended in 1X loading buffer consisting 
of 3X SDS, 30X DTT and lysis buffer (+ protease and phosphatase inhibitors).  An 
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appropriate volume was used according to how many samples preps had been 
carried out per sample and how many western blot samples were subsequently 
needed. 
 
Protocol adapted from (354-356). Cells were lysed for 30 minutes on ice in lysis buffer 
with added protease and phosphatase inhibitors (see section 2.2.5), and a BCA 
carried out (see section 2.3.11).  20 µl of Con-A beads per sample were washed twice 
in lysis buffer and centrifugation was used to remove the supernatant at 90g for 2 
minutes.  2 mg of cell lysate was diluted to 1 ml in lysis buffer added to the beads 
(ensuring to keep some total cell lysate for western blotting) and incubated at 4°C on 
a rotator.  50 µl of Dynabeads G were used per sample and washed twice in PBS using 
a magnetic rack for separation.  200 µl of Rabbit IgG was diluted to 1 µg/ml in PSBT 
(0.02% Tween), 200 µl and incubated with the beads at room temperature for 30 
minutes, vortexing every 5 minutes.  IgG was removed, and lysates previously 
incubated with the Con-A beads were added and incubated at 4°C on a rotator for 30 
minutes. 
A second washed aliquot of Dynabeads G were resuspended using β-catenin 
antibody diluted in PBST 1:100, and incubated at room temperature for 30 minutes, 
vortexing every 5 minutes.  The antibody was removed and the beads resuspended 
in the cell lysate samples from the IgG coated beads, and incubated at 4°C overnight 
on a rotator.  The IgG coated beads were washed 3X in PBS and resuspended in 20 µl 
1X SDS sample buffer with 0.1 M DTT, heated to 98°C for 10 minutes.  The pre-cleared 
fraction sample was removed from the beads and stored at -20°C until the western 
blot was performed. 
The unbound cell lysates were transferred from the β-catenin coated beads to a fresh 
eppendorf.  The beads were washed 5X in PBS and resuspended in 30 µl 1X SDS 
sample buffer with 0.1 M DTT, heated to 98°C for 10 minutes.  Then the IP sample 
was removed to a fresh tube and stored until analysis.  Samples were analysed either 
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by western blot (see section 2.3.13) or prepared for mass spectrometry (MS) analysis 
as described below.   
 
Immunoprecipitated proteins were solubilized in 1 M urea, 50 mM ammonium 
bicarbonate, pH 7.8, and heated to 50C for 20 minutes.  Proteins were reduced with 
2mM DTT, alkylated with 15 mM iodoacetamide, and digested overnight with a 1:50 
ratio of trypsin to total protein.  The resulting peptides were desalted on Waters Sep-
Pak C18 cartridges.   
 
The running of the MS samples was carried out at The University of Washington by 
Dr Aaron Robitaille.  Peptides were measured by nano-LC-MS/MS on a Thermo 
Scientific Q Exactive (QE).  Peptides were separated online by reverse phase 
chromatography using a heated 50C 30cm C18 columns (75 mm ID packed with 
Magic C18 AQ 3 M /100  beads) in a 180 minute gradient (1% to 45% acetonitrile 
with 0.1% formic acid) separated at 250 nL/min. The QE was operated in data-
dependent mode with the following settings: 70000 resolution, 400-1600 m/z full 
scan, Top 10, and an 1.8 m/z isolation window. 
 
Identification and label free quantification of peptides was done with MaxQuant 1.5 
(355), using a 1% false discovery rate (FDR) against the human Swiss-Prot/TrEMB 
database.  The databases contained forward and reverse mouse sequences as well 
as common contaminants.  Three replicates per condition were analysed.  Peptides 
were searched using a 5 ppm mass error and a match between run window of 2 
minutes.  Proteins that were significantly regulated between conditions were 
identified using a permutation-based t-test (S1, FDR 5%) in Perseus 1.4.1.3. GO-terms 
were analyzed using Protein ANalysis THrough Evolutionary Relationships (PANTHER) 
9.0.  
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All data was normalised to control and analysed using a student’s two-tailed paired 
t-test unless otherwise stated.  Imaris data was analysed from the whole data set 
(not data represented as % of a whole) and analysed using a two-way ANOVA test.  
Seahorse data was analysed using an unpaired t-test with Welch’s correction.  S100 
staining on mouse lung tissue was analysed using an unpaired t-test with Welch’s 
correction.  Significance was defined as a P value of ns (not significant) = >0.05.  * = 
<0.05, ** = <0.01, *** = <0.001, **** = <0.0001.  
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 PHENOTYPIC CHARACTERISATION OF A 
GENETICALLY DIVERSE MELANOMA CELL 
LINE PANEL 
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 Introduction 
Metastatic melanoma is one of the most aggressive malignancies in humans and is 
responsible for 60% of all deaths associated with skin cancer (49).  As explained in 
detail in Chapter 1, there are a number of different genetic backgrounds associated 
with metastatic melanoma, most noteably the BRAFV600E mutation (123, 132-136).  
Less common, but having the same subsequent effect of hyperactive MAPK 
signalling, are mutations within NRAS (134, 135, 137) and other mutations also 
known in melanoma, such as PTEN (142-145), Akt (148-150), CDKN2A (3, 49, 152, 
153) and C-kit (154, 155).  These muations likely infer differing effects on melanoma 
progression (142, 150, 163).  Due to this diversity, it is important to compare how 
different mutational backgrounds affect the various characteristics of tumour cells, 
such as the alterations between wildtype (WT)C and BRAFV600E.  It is also important 
for us to understand the cellular mechanisms that result in tumour heterogeneity, 
forming distinct subpopulations of cells capable of different levels of proliferation, 
invasion and therapeutic resistance (357, 358). 
 
There are two current theories that exist within the field to explain establishment of 
the rapid and, typically, lethal metastasis that occur as the disease progresses (121, 
334, 359-370).  The first is the phenotype switching model that defines two 
phenotypes, proliferative and invasive.  The model suggests that microenvironmental 
factors cause the phenotypes of melanoma cells to switch, driving progression 
between a tumour expansion phase with highly proliferative cells and a metastatic 
phase where the cells are more invasive (365) see Figure 3.1.  This model can lead to 
drug resistance by creating subpopulations with variable levels of chemo-resistance 
(359) and has recently been shown to act as a treatment itself by forcing the cells 
towards one phenotype and targeting them specifically in a lineage-specific therapy 
(371).  The second theory is that of a ‘stem-like’, or tumour initiating, cell population 
capable of disseminating and are responsible for initiating secondary tumours, which 
may also be responsible for the high levels of   
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Figure 3.1: Schematic of the phenotype switching model  
Model schematic adapted from (365) Hoek, K. S., O. M. Eichhoff, et al. (2008). "In vivo 
Switching of Human Melanoma Cells between Proliferative and Invasive States." Cancer 
Research 68(3): 650-656.  Melanoma cells initially proliferate into the primary tumour.  
Changes in microenvironmental conditions alter the gene expression prolife from high LEF1 
and MITF to high TCF4 and WNT5A causing the cells to switch and become more invasive, 
breaking away from the primary tumour and initiating metastasis.  Expression profiles switch 
again turning the cells back to a proliferative phenotype and the process continues to 
progress tumour formation. 
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drug resistance in melanoma (359).  These cells can sit dormant and, therefore, avoid 
traditional chemotherapeutic treatments that target dividing cells (372) and after, 
many years, can initiate growth of genetically resistant tumours.    Cancer stem cells 
were first identified in acute myeloid leukaemia (373) but have now been identified 
in a number of other solid tumours, including breast cancer (374, 375) and some 
would argue, also, in malignant melanoma (364).  Cancer stem cells are defined as 
self-sustaining cancer cells that are able to divide and expand the cancer stem cell 
pool, as well as differentiate into heterogeneous non-tumourigenic cancer cells that 
constitute the bulk of the tumour (376).  Therefore, they have the properties of a 
stem cell in their ability to self-renew and give rise to other cell types but with the 
underlying tumourigenic properties of a cancer cell.  It is possible that the phenotype 
switching model and the cancer stem cell model could be linked and that it is the 
cancer stem cell’s tumourigenic properties that could be responsible for the 
switching between the two cell phenotypes.   
 
The phenotype switching model in melanoma has been described as two phenotypes 
- proliferative and invasive which switch back and forth to drive melanoma 
progression (359).  The phenotypes draw on two of the original hallmarks of cancer 
(377), limitless replicative potential and increased invasiveness and can be 
distinguished by a number of factors.  These factors include their growth in 2D cell 
culture and 3D culture, the expression patterns of certain molecular markers and by 
comparisons in proliferation and invasion assays (334, 361, 365).  In 2D cell culture 
on untreated tissue culture plastic, proliferative phenotype cells appear smaller, 
more rounded and have dendritic processes, whereas the invasive phenotype cells 
are flatter, larger and fibroblastic in shape (361).  When grown on a 3D growth 
medium such as Matrigel basement membrane matrix, proliferative phenotype cells 
form small individual clusters.  However, invasive cells form connected networks 
within the matrix as shown in Figure 3.2 (334).  The phenotypes also differ in their 
molecular expression profiles; proliferative cells show higher expression of the 
transcription factors, MITF and LEF1, whereas   
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Figure 3.2: 3D Matrigel growth defines melanoma phenotype 
Image taken from (334) Zipser, M. C., O. M. Eichhoff, et al. (378). "A proliferative melanoma 
cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status." 
Pigment Cell & Melanoma Research 24(2): 326-333.  Melanoma cells grown on Matrigel form 
different patterns.  Proliferative (175) form small, individual colonies whereas Invasive cells 
(right) form connected networks with in the Matrigel. 
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invasive cells have higher expression of Wnt5a and TCF4 (361).  Finally, the 
phenotypes differ in their proliferative and invasive potentials, giving the phenotypes 
their respective names.  The proliferative cell lines have a much faster population 
doubling time and the invasive phenotypes have higher levels of cellular invasion 
(361).  Characterising melanoma cells in their 2D and 3D growth patterns, molecular 
expression markers of proliferative and invasive phenotypes, along with their 
proliferative and invasive potentials helps to verify this model.   
 
As stated previously, there is a second theory to explain establishment of metastasis 
in melanoma which is the ‘stem-cell’ or tumour initiating model.  The topic of cancer 
stem cells has been widely discussed by references (121, 360, 366, 376, 379, 380).  
The idea of cancer stem cells is controversial, with many arguments for and against 
their existance.  This is especially true in melanoma, whereas in other cancers, such 
as hematopoietic-derived tumours, they have been very well defined (374).  It has 
been shown that tumours are heterogeneous in their formation.  They consist of 
distinct genotypes and phenotypes and many believe that cancer stem cells are 
responsible for giving rise to this heterogeneity.  However, it has yet to be 
indisputably proven that these cells exist in melanoma.  It has been hypothesised 
that, as part of the phenotype switching model, it is the invasive phenotype stage 
that is responsible for metastasis and, therefore, it is within the invasive cell 
population when they arise, that a sub-population of tumour initiating cells could 
exist (121, 359).  Various groups have tried to distinguish a distinct ‘stem-like’ 
population using cell surface markers due to this and a number of potential markers 
have been suggested, including ABCB5, CD271 and CD133.  A more recent suggestion 
is that expression of multiple markers might be required in combination to 
distinguish the cancer stem cells from the general bulk tumour cell population (381).  
There are a number of techniques used to detect tumour initiating populations of 
cells.  Most commonly, cells are detected and isolated using flow cytometry using 
defined markers.  These cells are then often tested for their tumour initiating 
capabilities in growth assays such as soft agar colony formation, the growth of non-
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adherent spheroids and in immunodeficient mouse xenotransplantation 
experiments.  It has been argued that the use of traditional cell culture methods 
creates an unnatural environment to investigate solid tumours and, instead, 3D 
culture techniques provide a more appropriate in vitro model for investigations 
(382).  As quiescent cancer stem cells are thought to be resistant to current 
therapeutic treatments, identifying and isolating cells with tumour initiating 
potential could lead to new targeted therapies for treating melanoma and preventing 
metastatic spread.  This could be especially effective if they are found to have 
characteristics that can be specifically targeted, without effecting normal cells such 
has been identified in leukemia (383). 
 
As explained in detail in Chapter 1, Wnt plays an important role in melanoma and the 
basis of this research is to understand those effects.  Understanding more about the 
models of melanoma can help in such investigations.  Wnt has been shown to have 
an effect on both the proliferation and invasion of melanoma cells (203, 384), 
therefore potentially implicating it in the phenotype switching model.  This model 
also highlights that there are changes in the expression levels of different Wnt 
signalling genes that can be used to define the phenotypes; Proliferative lines highly 
express MITF and TCF4 whereas invasive lines express higher levels of LEF1 and 
WNT5A (361, 385).  The expression of these genes and the inter-play between them 
in the two phenotypes implicate Wnt as being heavily involved in the establishment 
of melanoma cell phenotype switching.   
Proliferative cells highly express genes associated with the differentiation of 
melanocytes, such as MITF and MLANA which are controlled in a β-catenin-
dependent manner through LEF1 (20).  MITF-M isoform controls the development 
and function of melanocytes and subsequent melanin production (29).  Therefore, 
MITF is inherently linked to melanoma but, also, to Wnt signalling as Wnt has been 
shown to up-regulate the expression of MITF-M by increasing recruitment of β-
catenin and LEF-1 to the MITF promoter to drive transcription (386).  LEF1 and TCF4 
are a vital part of the Wnt/β-catenin signalling pathway.  They are located in the 
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nucleus and, when a Wnt ligand binds, β-catenin will translocate to the nucleus and 
bind to LEF1 and TCF4 transcription factors, displacing Groucho and activating 
transcription of Wnt target genes (387).  Independently of β-catenin, LEF1 down-
regulates TCF4 and WNT5A expression.  Changes in the microenvironment, such as 
hypoxia, induce the expression of genes, such as TGFβ, causing the increased 
expression of WNT5A (388).  This, in turn, acts in an autocrine manner, binding to 
Frizzled or ROR2 receptors, and causes the phosphorylation of PKC and subsequent 
suppression of the melanocytic markers LEF1 and MITF.  With lower expression of 
LEF1, the down-regulation of TCF4 and WNT5A is relieved and, therefore, drives 
invasion (361).  This is represented in Figure 3.3. 
Wnt has also been implicated in the stem cell/tumour initiating model.  Wnt 
signalling has been highly conserved throughout evolution, as a part of the 
embryonic development process and is vital for the regulation of somatic stem cell 
production (389).  It has, also, been shown to be involved in regulation of 
haematopoietic stem cells in both an autocrine and paracrine manner, along with 
Hedgehog and Notch signalling, which are also often dysregulated in cancer (357, 
390-392).  The Wnt pathway is linked to tumour initiating cells as many markers 
associated with identifying cancer stem cells are direct targets of activated Wnt such 
as CD44 or CD24 (389, 393).  Expression levels of MITF and DKK1 have also been 
linked to the ability of melanoma cells to form melanospheres and self-renewing 
capacity (394).  Activation of the Wnt/β-catenin pathway could, therefore, control 
cancer stem cell formation and, therefore, change tumour progression in melanoma 
models. 
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Figure 3.3: Gene expression patterns in melanoma phenotype switching model 
Model schematic adapted from (361) Eichhoff, O. M., A. Weeraratna, et al. (378). 
"Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching." 
Pigment Cell & Melanoma Research 24(4): 631-642.  Proliferative cells express high levels of 
LEF1 and MITF driven by the Wnt/LEF1/β-catenin signalling pathway and supress TCF4 and 
WNT5A in a β-catenin independent manner.  Changes to external signals such as TGFβ cause 
increases in TCF4 and WNT5A which in turn signals through frizzled to phosphorylate PKC 
and supress LEF1 therefore removing its suppressive effects on TCF4 and WNT5A increasing 
their expression further to drive the invasive phenotype. 
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The aim of this first chapter is to characterise a panel of 19 human melanoma cell 
lines.  Firstly, the cells will be defined in terms of their phenotype according to their 
growth in 3D Matrigel, looking for individual cells as a proliferative phenotype and 
connected networks as an invasive phenotype comparing them to Figure 1 (334).  A 
selection of cells will then be further characterised with respect to their melanoma 
and cancer cell properties by measuring their proliferative and invasive potentials 
and their expression of markers associated with the different melanoma phenotypes.  
The cells will also be analysed in terms of their tumour initiating properties and 
cancer stem cell populations by assessing their ability to form melanospheres and 
the expression of selected cell surface markers.  This data will provide an 
understanding of the basic characteristics of these cells, including how they grow and 
behave in these assays.  This will then allow effective comparison, in future work, of 
the effects of activating the Wnt/β-catenin signalling pathway. 
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 Characterizing growth in 2D and 3D Culture 
 
We had access to a large cohort of genetically-diverse melanoma that we wanted to 
characterise, prior to our future work investigating the role of the Wnt/β-catenin 
signalling pathway in melanoma.  These lines were gifted from Prof. R. Moon and Dr. 
A. Chien (University of Washington) and Prof. A. Ribas (UCLA).  Firstly, we wanted to 
characterize them as either proliferative or invasive according to the phenotype 
switching model.  To do this, we grew the lines in a 3D cell culture system.  It has 
previously been described that 3D growth on Matrigel basement membrane matrix 
(see section 2.3.10), can define melanoma cells into two different phenotypes, 
proliferative and invasive (365).  Proliferative phenotype cells will form small 
individual clusters in 3D, whereas invasive cells will form connected networks within 
the matrix (334).  The panel could be divided into the two phenotypes (proliferative 
and invasive) according to their growth characteristics in 3D, as shown in Table 3.1.  
7 cell lines (A375, HMB2, M285, M296, M308, Mel501, and SkMel28) produced inter-
connected networks within the matrigel.  This formation has previoulsy been 
described as being indicative of the invasive cell phenotype.  12 cell lines (A2058, 
Colo829, HTB63, M202, M207, M229, M375, Malme3M, Mel624, SkMel5, SkMel24 
and UACC1273) formed either small clusters of cells or stayed individual.  This 
formation was previoulsy described as representing the proliferative phenotype 
(334).  From the initial 19 cell lines, 4 of each phenotype were chosen to carry through 
for further characterisation where their mutation status was well understood.   
In total,  8 cell lines (shown in Table 3.2), representing a mix of wildtype BRAF or a 
V600E mutation and wildtype or mutant N-Ras (395), were characterised in more 
depth.  There is both an invasive and a proliferative cell line with a PTEN mutation 
(146) and one line each with MITF amplification (29, 396), as well as a variety of other 
mutations including Akt, CCND1 and EGFR amplification, deletions of CDKN2A and 
mutations of MC1R.  These mutations have previoulsy all shown to cross talk with 
Wnt signalling pathways and are important in the progression of malignant   
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Table 3.1:The Molecular Characterisation of 19 Melanoma Cell Lines: 
3D growth on matrigel over 48 hours was captured at 10X magnification.  7 cell lines 
produced connected networks within the matrigel, this formation has previoulsy been 
described as being indicative of an invasive cell phenotype.  12 cell lines formed either small 
clusters of cells or remained individual, this formation was previously described as 
representing a proliferative phenotype  
WT – Wildtype, Amp – Amplification, Het – Heterozygous, Homo – Homozygous, Pro – 
Proliferative, Inv – Invasive. 
Cell  
Line 
BRAF 
Status N-Ras PTEN PI3K 
MITF 
Amp 
AKT 
Amp 
EGFR 
Amp CDKN2A MC1R 
PRO/ 
INV 
3D 
growth 
A2058  
(144) 
Het 
V600E WT Het Del         
 Homo 
del  PRO 
 
A375 
(163, 397) 
Homo 
V600E WT INTACT WT No No    
 Homo 
del R151C=R INV 
Colo829 
(223, 397) 
Het 
V600E WT NULL WT No  No No  
Homo  
del  V92M=r PRO 
HMB2 
(398)  V600E  WT              INV 
HTB63 
(163) V600E WT              PRO 
M202     
(397, 399) WT Q61L INTACT WT No No Yes 
Homo  
del WT PRO 
M207 
(397, 399) WT Q61L Het Del WT Yes No 
L747_P
753>s WT V60L=r PRO 
M229 
(397, 399) 
Homo 
V600E WT Het Del WT No AKT 1 No WT R151C=R PRO 
M285 
(400) WT WT INTACT WT No No No   INV 
M296 
(397, 400) WT Q61R INTACT WT No No No  WT INV 
M375 
(400) WT WT INTACT WT No No No   PRO 
M308 
(397, 399) 
Het 
V600E WT INTACT WT Yes AKT 2 Yes Het del WT INV 
Malme3M
(397, 401) 
Het 
V600E WT INTACT WT Yes     
 Homo 
del WT PRO 
Mel501 
(402) V600E WT  Null            INV 
Mel624 
(223) V600E WT              PRO 
SKmel5 
(397, 403) 
Het 
V600E WT INTACT WT No No     WT V92M=r PRO 
SKmel24 
(144, 397)  
Het 
V600E WT NULL WT No     
 Homo 
del R163Q=r PRO 
SKmel28 
(397, 399) 
Homo 
V600E WT Het Del WT Yes No P753s Het del I155T=r INV 
UACC 
1273 (223)  V600E  WT              PRO 
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melanoma (20, 165, 173, 404).   Therefore, these mutations could play an important 
role in the way cells respond to Wnt signalling later in our investigations.  The chosen 
8 lines were; A375, M285, M296 and SkMel28 representing the invasive phenotype, 
and M202, M229, M375 and SkMel5 representing the proliferative phenotype (see 
Table 3.2 and Figure 3.4).  Using the 3D matrigel, defines melanoma cells into two 
different cohorts, those that form connected networks and those that do not.  The 
selected panel of 8 cell lines will now be further analysed in terms of their melanoma 
and cancer cell characteristics.   
 
Following the initial 3D Matrigel growth assay we decided to test the time the cells 
took to form their respective patterns in a time trial with images taken at 1, 2, 4, 6, 
24, 48, 72 and 96 hours, Figure 3.5.  It is noteworthy that there is variation in the time 
different cell lines took to form their respective clusters or networks.  Some lines 
(M296 and M375) formed networks within the first hour following seeding, whereas 
the A375 and M285 cells took over 24 hours before the phenotype was 
distinguishable.  The reason for this is unknown but could potentially be due many 
factors such as age of the cells, proliferation rate or strength of the specific 
phenotype.  In 3D culture, the A375, M296, M285 and SkMel28 cells all formed 
connected networks with the Matrigel typical of the invasive phenotype (Figures 
3.5a-d).  Likewise, the proliferative lines M202, M229 and Skmel5 (Figures 3.5e-g) all 
remain as individual clusters in 3D culture.  However, not all cell lines behaved as 
expected.  The M375 cells (Figure 3.5f) formed an invasive phenotype pattern within 
the first hour of the time course; this is the different phenotype to that which was 
observed in the initial 3D growth assay, indicating that phenotypes could switch 
spontaneously.   
It has also been previously noted that the two phenotypes (proliferative and invasive) 
can be distinguished by their appearance in 2D cell culture as well as in 3D (334, 361).  
In 2D cell culture on untreated tissue culture plastic, proliferative phenotype cells are 
smaller, more rounded and have dendritic processes, whereas the invasive 
phenotype cells are flatter, larger and fibroblastic in shape (361).    
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Table 3.2: 8 cell lines chosen for further characterisation with 3D growth images 
Invasive cell lines A375, M285, M296 and SkMel28 form connected networks in a 3D Matrigel 
growth assay and proliferative cell lines M202, M229, M375 and SkMel5 stay individual or 
form small clusters.  Scale bar, 200 μm. 
Cell Line 
BRAF 
Status N-Ras PTEN PI3K 
MITF 
Amp 
AKT 
Amp 
EGFR 
Amp CDKN2A MC1R 
PRO
/INV 
A375 Homo 
V600E WT 
INTA
CT WT No No    
 Homo 
del 
R151C=
R INV 
M202 
WT Q61L 
INTA
CT WT No No Yes 
Homo  
del WT PRO 
M229 Homo 
V600E WT 
Het 
Del WT No AKT 1 No WT 
R151C=
R PRO 
M285 
WT WT 
INTA
CT WT No No No   INV 
M296 
WT Q61R 
INTA
CT WT No No No  WT INV 
M375 
WT WT 
INTA
CT WT No No No   PRO 
SkMel5 Het 
V600E WT 
INTA
CT WT No No     WT 
V92M=
r PRO 
SkMel28 Homo 
V600E WT 
Het 
Del WT Yes No P753s Het del I155T=r INV 
 
 
Figure 3.4: 3D Matrigel growth of 8 selected cell lines 
3D culture growth, eight cell lines seeded onto matrigel basement membrane at 4x104 
cells/well and images were captured at 48 hours at 10X magnification.    
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Therefore, images were captured of the cells under normal 2D cell culture conditions 
to see if differences could be identified as shown in Figure 3.5i.  The A375, M296, 
M375, M202, M229, and SkMel5 appear in 2D culture as expected, defined by their 
previous appearance in 3D phenotypes.  However, not all cells are as uniform.  The 
M285 cells appear invasive in 3D culture but have the appearance of a proliferative 
phenotype in 2D culture, looking small and rounded while the SkMel28 cells had a 
mixture of large, flat, fibroblastic cells and small rounded cells, therefore making it 
hard to define phenotype through this method.   
It is clear that there are distinctions between the cells in the patterns that they form 
within the Matrigel membrane and their appearance in 2D culture, but not all cell 
lines tested correlated to the previous description in both assays.  It also appears that 
cells are capable of switching without any pre-emptive signals, an observation that 
has not previously been reported before, making phenotype analysis hard to 
interpret consistently. 
 Investigation of the Proliferative and Invasive Potential of the 
Melanoma Cell Line Panel 
 
It was expected that the proliferation of melanoma cells would represent the distinct 
phenotype observed in the 3D cell culture conditions, according to previous findings 
(361).  This was investigated and 3D cell culture assays were set up, at the same time 
as cell proliferation and invasion analysis, to verify the 3D cell culture phenotype at 
the time of seeding (See Figure 3.6a).  The proliferation assays were carried out as 
population doubling times (see section 2.3.11) over a time period of 72 hours (Figure 
3.6b).  The cell lines Skmel28 and M202 appeared to have mixed phenotypes, areas 
of connected networks and areas of individual cells as shown in Figure 3.6a.  There 
were areas of joined up matrix associated with invasive phenotypes and areas of 
smaller individual clusters, which is commonly associated with a proliferative 
phenotype.  The other cell lines produced uniform patterns in the 3D Matrigel 
growth. 
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a) 
b) 
c) 
d) 
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e) 
f) 
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Figure 3.5: Time Course Analysis of Melanoma Cell Lines Panel Growth in 3D with 2D Cell 
Culture Conditions:  
3D culture growth, eight cell lines seeded onto matrigel basement membrane at 4x104 
cells/well and images were captured at 1, 2, 4, 6, 24, 48, 72 and 96 hours at 10X 
magnification.  Images were captured at the same XY location for each image and compared 
to the original 3D growth assay as shown in Table 2, a) A375, b) M296, c) M285, d) SkMel28, 
e) M202, f) M229, g) SkMel5, h) M375. All cells were cultured on non-treated tissue culture 
plastic under normal culture conditions to capture 2D cell growth at 10X magnification, i) 2D 
culture.  Scale bar, 200 µm. 
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The population doubling shown in Figure 3.6b does not seem to follow the expected 
patterns of the phenotypes.  All lines show a steady rate of growth over the course 
of the assay.  The A375 cell line is the fastest growing line, doubling nearly 25 times 
in 72 hours.  M202 is the next fastest at 22 population doublings in 72 hours.  M285 
doubled 16 times while SkMel28 carried out 11 population doublings in 72 hours.  
SkMel5 doubled 9 times and the remaining lines M2296, M375 and M229 doubled 
around 5 times over 72 hours.  Therefore, these population doubling times varied 
irrespective of the phenotypes indicated in 3D cell culture conditions.  Thus, the 
melanoma panel cannot be distinguished, based on population doublings between 
high and low proliferative cell types. 
 
It was also expected that the invasion of melanoma cells would represent the distinct 
phenotype observed in the 3D cell culture conditions, according to previous findings 
(361).  The invasion assay (see section 2.3.12) was adapted from a previously 
published method, which involves coating a membrane based insert with a thin layer 
of Matrigel.  Due to the method of this assay studying the invasion of the cells 
through a Matrigel layer, it is possible to simultaneously use this assay to analyse the 
cell lines 3D Matrigel growth patterns for phenotype analysis.  Cells are serum 
starved and seeded into the top of the insert and complete media is used in the lower 
well as a chemoattractant to draw the cells through the membrane.  Cells were then 
fixed, stained and counted (361).  The cells were seeded at (4x104) equal cell numbers 
across the lines, rather than adjusted for growth rates and the assay was left to run 
for 48 hours.  Figure 3.6c shows the results of the invasion assay.  On average, over 
500 cells were seen for the A375 cell line and around 200 cells moved through the 
membrane for both M285 and M296 cell lines.  These are the lines that appear 
invasive in 3D culture.  The fourth invasive line, SkMel28 had an average of 50 cells.  
Approximately 100 cells for the M202 cells were stained with Crystal Violet, the M229 
and SkMel5 cells had around 50 cells pass through the membrane and M375 had 
around 10 cells in each assay.  These were previously tested to be proliferative lines 
by the 3D culture assay.  The overall trend for each phenotype  
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a) 
 
b) 
 
c) 
 
 
Figure 3.6: Proliferation and Invasion with Matched 3D matrigel Growth Assay 
a) Matrigel 3D growth assay at 10X magnification seeded simultaneously using same method 
as previously described.  Two images were captured for M202 and SkMel28 as they had areas 
of individual clusters and areas of joined up matrix, all other cell lines produced a uniform 
pattern.  Scale bar, 200 µm. b) 4x104 cells seeded and population doubling counts carried out 
at 24, 48 and 72 hours using trypan blue exclusion. N=3.  3D growth in figure a shows two 
lines (M202 and SkMel28) are both proliferative and invasive, so the distinction is based on 
earlier data (figure 3.4) c) Average (n=2) number of cells invaded through matrigel coated 
membrane after 48 hours plotted with SEM.  4x104 cells were serum starved in 3% serum for 
48 hours before seeding into serum free media.  10% serum media was used as an attractant 
to draw the cells through the membrane.  Matrigel was coated onto 8 µm pore inserts at 50 
µl/cm2.  Cells that had passed though the membrane after 48 hours were stained with Crystal 
Violet and counted.  
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shows increased invasion in the invasive phenotype and lower levels of invasion for 
the proliferative phenotype.  However, this is not true for all cells lines as the 
SkMel28 cells had particularly low invasion compared to that of the other ‘invasive’ 
cell lines.  Therefore, like the proliferation assay (Figure 3.5b), the invasion assay also 
corresponded poorly to 3D phenotype analysis.  
 
As shown in section 3.1.4 and Figure 3.3, the phenotypes switching model suggests 
that the expression of particular markers can also be used to identify the different 
phenotypes.  Higher expression of MITF and LEF1 have been described as defining 
the proliferative phenotype and higher expression of TCF4 and Wnt5a are associated 
with an invasive phenotype (361).  Therefore, using western blotting (see sections 
2.3.13 – 2.3.16), the expression of these markers were analysed in the eight cell lines 
and the results shown in Figure 3.7.  It is clear that the pattern of expression does 
not fit the previously published data (361).  All samples have very different levels of 
expression of all four markers.  For example, M375 (a proliferative cell line) has 
particularly high expression of TCF4, a marker associated with the invasive 
phenotype, yet it has low expression of Wnt5a another marker of invasion.  Whereas, 
the proliferative line M229 has very high expression of LEF1 but low expression of 
MITF, the two markers of the proliferative phenotype (361).  The panel of four 
invasive lines all have higher expression of MITF, a marker of the proliferation 
phenotype, but their expression levels of LEF1 are lower.  Overall, these markers do 
not correlate with the phenotypes as analysed by 3D cell growth in these cell lines.  
Nor do the proliferative and invasive assays correlate with each other.  The A375 cell 
line has the highest rate of proliferation and invasion.  Likewise, the M375 cell line 
has the lowest rate in both assays.  Therefore, it is hard to use these assays to define 
distinctive phenotype characteristics.    
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Figure 3.7: Expression of proteins associated with different phenotypes 
Cell lysates were separated by SDS-PAGE and transferred onto nitrocellulose membrane.  
Expression of markers TCF4 and Wnt5a, described as markers of the invasive phenotype and 
MITF and LEF1 as markers of the proliferative phenotype were analysed and β-actin was used 
as a loading control.  The cell line phenotypes were defined using the 3D culture assay shown 
in Figure 3.4. 
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 Identification of Tumour Initiating Cells in the Melanoma Cell 
Line Panel 
 
Now the growth patterns have been analysed and it was found that the proliferative 
and invasive potential correlate poorly with markers of the phenotype switching 
model, it was decided to assess if, instead, it correlated with the other model of 
melanoma, the tumour initiating potential/cancer stem cell model (359).  The ability 
to form spheroids (see section 2.3.17) has been suggested to be indicative of tumour 
initiating properties, such as self-renewing ability and surface marker expressions 
(120, 382, 405).  In order to allow melanospheres to form, the cells were seeded on 
plates coated with polyHEMA which produces a non-adherent surface (336).  Cells 
were seeded on polyHEMA coated plates and images captured after 1 week of 
culture.  The first 20 objects in the images were measured using Image J software.  
Figure 3.8a shows the typical formations seen in invasive and proliferative cell lines 
and Figure 3.8b shows the average and the range of sizes of melanospheres seen in 
the eight cell lines.  The invasive phenotype (as defined by their growth in 3D culture) 
form large, rounded, solid clusters of cells called melanospheres.  In contrast, the 
proliferative cell lines are only able to form smaller spheres, but the majority of the 
cells remained individual.  This ability may be indicative of tumour initiating 
properties within the invasive phenotype.  All of the ‘invasive’ lines formed 
spheroids.  A375 formed the largest spheres at 900 μm.  Of the ‘proliferative’ lines, 
M229 and SkMel5 did not form any spheroids and remained as individual cells.  
However, M375 and M202 cells did form smaller spheres but were all less than 400 
μm.  The overall trends shown in Figures 3.8a and 3.8b indicate that, on average, the 
invasive phenotypes have the ability to form much larger spheroids and, therefore, 
may have potential tumour initiating properties.   
 
It has been suggested that the expression of various cell surface markers could allow 
for the detection of cancer stem cells or tumour initiating cells in cancer and,   
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a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
Figure 3.8: Non-adherent melanosphere formation  
a) Images of Melanospheres in culture after 7 days on polyHEMA coated plates at 10X 
magnification. Scale Bar, 200 µm. The phenotypes were defined using the 3D culture assay 
shown in Figure 3.4.  b) Analysis of the size distribution of melanospheres formed by eight 
different cell lines with SEM plotted.  Pink indicated invasive phenotypes and purple 
represents proliferative phenotypes as determined by the matrigel 3D growth patterns.  N=3.  
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therefore, enable the isolation of these cells from a heterogeneous multicellular 
tumour (362, 364, 367-370, 406-417).  Table 3.3 shows some of the previously 
suggested markers able to identify melanoma initiating cells.   Based on the 
previously published literature using patient derived tumour cells in 
xenotransplatation experiments, the expression of cell surface markers; ABCB5, 
CD271, CD20 and CD133 were analysed by flow cytometry (see section 2.3.18.1).  
Marker CD133, currently, has unknown function but has been found to be expressed 
on both normal and cancer stem cells, especially breast cancer stem cells (406, 407, 
417).  Marker CD271 is expressed on neural crest stem cells and is involved in 
development, survival and differentiation of cells (408, 409).  Marker CD20 is typically 
associated with B-cell immune response but has also been found to be expressed on 
cancer stem cells (409).  Finally, marker ABCB5 regulates skin progenitor cell fusion 
and mediates chemotherapeutic drug resistance in stem-like tumour cell 
subpopulations in human malignant melanoma and is over-expressed on circulating 
melanoma tumour cells in patients, suggesting potential role in metastasis (364, 
407).  The initial analysis was done individually, in order to determine expression 
levels of each of the markers in the cell line panel.  All antibodies were designed to 
be compatible with the same secondary conjugated antibody; this would allow 
relative intensities to be estimated.  Figure 3.9a shows an example of the live cell 
gating for cell line M285.  Figure 3.9b shows an example of the expression of CD271 
(red) and secondary only control (418) in M285 cells.  Figure 3.9c summarises the 
flow cytometry data for all cell lines, which was consistent across multiple 
experiments.   The unstained results show that there are high levels of 
autofluorescence in these cells and high variability between the cell lines.  For 
example, the fluorescence of M296 is especially high compared to the other cell lines.  
This could be due to high levels of the autofluorescent polymer melanin in these cells 
(419).  The secondary antibody alone, shows that there are also high levels of non-
specific binding in all the cell lines.  In five out of the eight cell lines, ABCB5 showed 
high expression levels and CD20 was expressed above background in four of the eight 
lines.  Overall, four of the lines showed above background expression of all four of 
the markers.  These were SkMel28, A375,  
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Table 3.3: Melanoma Tumour Initiating Cell Surface Expression Markers: 
All markers have previously been identified in melanoma cell lines and have a variety of 
secondary assays carried out to confirm the stem-like phenotypes of the cells. 
  
Marker Cancer Stem Cell Assays 
ABCB5 
(364)  
Primary-patient-derived tumour cells in serial human-to-NOD/SCID mouse 
xenotransplantation experiments 
CD133 (406) 
Primary-patient-derived tumour cells in serial human-to-NOD/SCID mouse 
xenotransplantation experiments 
 
CD271 (408) 
Intradermal injection in 30% matrigel into B-, T- and NK cell deficient 
Rag2−/− γc−/− (130) mice 
ALDH (410) 
Cell suspensions were xenografted subcutaneously into NOD/SCID mice 
and NSG mice 
CD20 (370) Sphere formation followed by s.c. injection in SCID mice 
CD146 
(MCAM/ 
MUC18) 
(411) 
Male athymic nude mice (BALB/c background 
Melanosphere formation 
CD40 (412) Tumour cell proliferation 
CD44 (368) 
S.c. flank injection into C57BL/6 mice 
Soft agar colony formation 
MDR1 (414) Melanosphere formation 
ABCG2 
(406) 
Primary-patient-derived tumour cells in serial human-to-NOD/SCID mouse 
xenotransplantation experiments 
JARID1B 
(369) 
Melanosphere and soft agar  formation, Single cell growth assays 
s.c. injection into NOD/LtSscidIL2Rγ null mice 
CD49F (362) 
Single cell tumour formation 
NOD/SCID mouse xenotransplantation experiments 
CD166 (367) None carried out, expression analysis only. 
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SkMel5 and M229 cells.  To verify these results, two proliferative and two invasive 
lines were chosen.  These were; A375 (I), M285 (I), SkMel5 (P) and M229 (P), for their 
relatively low background autofluorescence levels.  The antibodies were tested again 
using their respective isotype controls to remove any background from non-specific 
binding.  Figure 3.9d shows an example of M285 cells with CD271 expression shown 
in red and the isotype control shown in blue.  As each antibody is different in terms 
of the species that it was produced in and the immunoglobulin type, it was important 
that each antibody was compared to its cognate isotype.  Figure 3.9e summarises the 
data from the four cell lines and shows the isotype controls abated any previously 
seen differences.  In only four of the sixteen samples was the antibody intensity 
higher than that of the isotype control.  Three of these were with the CD20 antibody 
in the A375, M285 and M229 cell lines.  The SkMel5 cells only showed increased 
expression over the isotype control with the ABCB5 antibody.  The increases seen 
were very small and the results were inconsistent.  In repeated experiments, the 
expression levels shown here could not be matched and there was variation between 
cell lines and antibodies (data not shown).  There was no consistency to the 
expression levels, no pattern in expression levels to identify proliferative verses 
invasive phenotypes and no outstanding marker of melanoma cells.  Therefore, in 
this panel of melanoma lines with the markers tested, it is not possible to identify a 
cancer stem cell marker that can delineate proliferative against invasive melanoma 
cell types.    
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c) 
 
  
Figure 3.9: Flow Cytometry of Cell Surface Marker Expression: 
a) Example of live gating on flow cytometry analysis for M285 cell line. b) expression of 
CD271 (red) and secondary only antibody staining (418), c) expression of CD271 (red) and 
isotype control (333), c)  Mean FL1-A fluorescence values for each sample.  Shading (red) 
represents fluorescence levels seen above background of secondary antibody only.  d) 
expression of CD271 (red) in the M285 cell line with isotype control (333) e) Mean FL1-A 
fluorescence values for each sample.  Shading (red) represents fluorescence levels seen 
above isotype control.  (I)-Invasive Line, (P)-Proliferative Line. 
  
 
M285 
(I) 
SkMel28 
(I) 
A375 
(I) 
M296 
(I) 
M375 
(P) 
M202 
(P) 
SkMel5 
(P) 
M229 
(P) 
un-
stained 3356 7139 3718 13079 7508 4665 4707 3848 
2° only 21313 9742 8551 27433 31680 30131 6737 23395 
CD271 72397 37833 17113 37845 32725 40836 22932 45465 
CD20 11808 12392 9865 25091 9145 19642 8648 23578 
CD133 30463 18304 19877 40372 31873 32500 11396 70032 
ABCB5 22393 10006 12562 23861 22257 10411 10692 37434 
a) b) 
d) e) 
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 Discussion 
In order to help further investigations into the effects of Wnt/β-catenin signalling on 
melanoma cells, a selection of cell lines have been characterised in terms of the 
phenotypic switching model (334, 361, 365) and the cancer stem cell model (121, 
360, 366).  However, the melanoma lines tested did not fit either of the published 
models.  In an attempt to distinguish different types of melanoma cells based on their 
phenotypes, the basal rates of proliferation and invasion were measured.  The cells 
also did not express the suggested markers to define phenotypes, thereby not 
providing any significant features with which to delineate different phenotypes.  The 
cells were distinctive in their 3D Matrigel growth, but spontaneous switching 
provides an unstable characteristic upon which to base future investigations.  Finally, 
the cells were assessed for their cell surface markers and tumour initiating 
properties.  No cell surface marker could be identified in this group of cells that could 
isolate potential cancer stem cells.  However, some lines did show tumour initiating 
potential through the formation of melanospheres.  Given that Wnt has been 
implicated in both of these models of melanoma, future work will go on to investigate 
if activating the Wnt/β-catenin signalling pathway changes any of these findings. 
Deciding to choose eight cell lines based on their 3D Matrigel growth and previously 
described mutations (397) has limited the cell lines available for further 
characterisation.  However, it was necessary to match cell lines based on their 
mutational background in case these differences affected how the cells behave in 
these assays and in future assays, in response to Wnt/β-catenin signalling.  It is 
worthy to note that the data previously published on the phenotype switching model 
was on 6 lines chosen from an original panel of 86 (385).   Generally, the data 
produced that was able to match to the published phenotype descriptions was all 
measured by visual interpretation as shown by 3D and 2D cell culture growth 
patterns, shown in Table 3.1 and Figure 3.5.  As this is qualitative and not quantitative 
it is obviously left open to a degree of subjectivity.  However, the 3D Matrigel does 
represent a difference between the two phenotypes but, given the additional data, 
it is difficult to conclude that it corresponds to proliferative verses invasive 
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phenotypes.  The 3D Matrigel time course assay showed that the different cell lines 
not only produce very different patterns within the Matrigel, but they also vary 
hugely in the time taken to do so.  The most interesting observation was the M375 
cells, as they appeared to switch phenotypes from proliferative, in the initial analysis, 
to invasive throughout the time course - an observation that was again later seen in 
SkMel28 and M202 cells.  In contrary to Hoek’s published statement that; ‘in vitro, 
spontaneous phenotypes changes are not observed because intra-tumoural 
microenvironmental changes are absent, and their differences are maintained by 
epigenetic mechanisms (361)’, we have seen a number of these cell lines change in 
their 3D growth patterns, suggesting phenotype switching is potentially capable in 
these melanoma cells.  The fact that the cells can switch in culture could cause 
problems interpreting data from our assays.  This also raises questions as to the 
differences in our cell culture methods and the culture environment, compared to 
that of Hoek’s laboratory that enable us to observe spontaneous switches in 
melanoma cell phenotypes, in vitro.  It has previously been suggested that it is 
changes to cellular conditions during inflammation or hypoxia that can induce these 
switches in tumours (365, 385, 388).  The final characteristic analysed to determine 
phenotype was expression molecular markers (361, 385).  All cell lines tested showed 
expression of MITF, TCF4, LEF1 and WNT5A.  However, none of the cells showed 
distinct patterns that could help define their phenotype.  Despite this, all of these 
markers are components of the Wnt signalling network and investigating if activation 
of the Wnt/β-catenin signalling pathway induces any changes could give insight into 
Wnt driven melanoma progression.  
It has been suggested that there are tumour initiating cells within the heterogeneous 
cell population of melanomas (363, 364, 393, 408).  It has also been suggested that 
these tumour initiating cells would be defined within the invasive cell phenotype 
population (121, 359).  The best method to test if a population of cells are capable of 
initiating tumour formation would be to inject these cells into immunocompromised 
mice (362, 364, 368-370, 406, 408, 410), as this gives an accurate representation of 
the size and number of tumours formed from patient derived cells in vivo.  In the 
interest of the 3R’s (340), an in vitro method seemed more appropriate, initially, to 
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explore if there was a difference between the phenotype’s abilities to form tumours.  
Following a week of culture in a non-adherent environment, the invasive cells 
produce melanospheres more easily.  This ability may be indicative of tumour 
initiating properties within the invasive phenotype.  The invasive phenotype form 
large, rounded melanospheres and it appears that they not only recruit cells to these 
structures but, also, continue to grow in this formation.  It would be interesting to 
stain these clusters for proliferative markers such as PI or EdU to test if the 
melanospheres are actively proliferating or, simply recruiting cells to the outside of 
the sphere, as previously suggested for other cancer spheroid models (420, 421).  In 
contrast, the proliferative cell lines seem unable to form these structures, although 
they can form smaller clusters, the majority of the cells remain individual.  If Wnt/β-
catenin signalling can change the size or formation of the melanospheres, it could 
again have implications in melanoma initiation and metastasis.  
The cancer stem cell topic in melanoma is highly debated in the literature and there 
are many experiments that could be carried out to further assess tumour initiating 
ability and cancer stem cells marker expression, such as assays looking at tumour 
formation in soft agar and the cell autonomous ability to form spheroids from 
individual cells (408).   
It has been suggested by others that individual markers could be used to identify the 
tumour initiating cells from the rest of the population (362, 364, 367-370, 406, 408, 
410-412, 414).  Using flow cytometry, cell surface markers that have previously been 
shown in the literature to have tumour initiating properties were assessed.  Initial 
findings showed that CD133 and CD271 are expressed on all of the cell lines.  CD20 
and ABCB5 are expressed on half of the lines.  However, upon further investigation 
with more stringent controls, it seemed unlikely that any of these markers were 
expressed above the isotype control on these cell lines and, therefore, none were 
able to identify and isolate tumour initiating cells.  However, it is possible that it 
would take a combination of these markers to identify subpopulations responsible 
for tumour initiation and it is tempting to speculate that when looking at multiple 
markers, cells would show a comprehensive spectrum of expression combinations 
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(381).  It has also been debated as to how large the population of cancer stem cells 
would be in the total cell population of the tumour.  This seem to vary not only 
between tumour type but, also, within tumours of the same type (357).  For example, 
in melanoma, ABCB5 expression has been shown to vary between 2-20% of the total 
tumour cell population (357, 360, 364).  Likewise, CD133 expression has also been 
shown to vary to as low as 1% of the melanoma cell population (360, 364, 370, 406, 
417).  Therefore, it is likely that if such low populations of these cancer stem cells 
exist in these melanoma cell lines, they could have easily have been missed in the 
flow cytometry analysis.  To overcome such problems, it is possible to enrich for the 
cancer stem cells expressing particular markers (409).  It is also likely that growing 
cells in 3D melanospheres could produce differences in the expression of cell surface 
markers, compared to expression levels of cells grown in 2D (394) and the use of a 
stem cell media to generate the spheroid population, rather than an engineered 
polymer, may also alter any expression results (422, 423).  It has also been suggested 
that cancer stem cells could, instead, express markers associated with normal stem 
cells (120-122, 417, 422), such as nestin, E-cadherin, N-cadherin, NANOG and SOX2, 
as a number of these markers stem from the neural crest, they have merit as 
potential markers in melanoma which, again, could have their expression changed 
by Wnt/β-catenin signalling.  Such markers should be investigated in future studies. 
 
It has been hard to define specific melanoma phenotypes using these cells with high 
levels of proliferation and invasion seen in all cell lines.  However, the cells do differ 
in their 3D Matrigel growth patterns and investigating which factors determine these 
differences could give important information about melanoma progression.  The 
tumour initiating properties to facilitate melanosphere formation also vary across 
the panel of cells but, as yet, an expression pattern capable of identifying and 
isolating them has not been found.  This work has given important information about 
the growth of these cells and it will now be interesting to investigate if the activation 
of the Wnt/β-catenin signalling pathway has any effect on the features that have 
been analysed within this chapter.  
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 Introduction 
The roles of Wnt signalling in cancer are complex given that there are different Wnt 
pathways that are often antagonistic of each other (167, 424), their function is 
commonly context dependent (425-427) and Wnts are morphogens (170).  The β-
catenin-dependent (canonical) and -independent (non-canonical) pathways are 
already known to have opposing effects in different cancer types, including 
melanoma (165, 428, 429).  It is generally accepted that β-catenin-dependent Wnt 
signalling promotes melanocyte differentiation and tumour development, whereas 
β-catenin-independent Wnts are responsible for melanoma progression and 
induction of melanoma metastasis (165).  This research focuses on the β-catenin-
dependent pathway but, as the data shows, it is not necessarily as simple as which 
Wnt pathway is activated but, rather, that the mutational background of melanoma 
plays an important role in how the cells respond to Wnt. 
 
Melanoma is a cancer of melanocyte cells - melanin-producing cells derived from the 
neural crest (17, 19, 25).  As explained in Chapter 1, Wnt signalling is highly involved 
in embryogenesis and the formation of the neural crest (22) but Wnt signalling also 
controls neural crest cell fate and melanocyte specification (22, 430).  Neural crest 
cells gradually lose their pluripotency during development as cells differentiate into 
their specific cell types.  This is usually determined by their anatomical location in the 
neural crest (19).  Melanocytes are formed and migrate along the dorso-lateral 
pathway (20).  Initially lineage specification forms melanoblasts which proliferate, 
migrate and eventually differentiate into melanocytes (17).  Wnt-1 and Wnt-3 (β-
catenin-dependent Wnts) are implicated in the neural crest cell specification, as 
double knockout mice do not have any melanoblasts (19, 20, 25).  Overexpression of 
Wnt-1 caused an increase in melanoblast number and differentiation into pigmented 
melanocytes (25) and Wnt3a conditioned media caused differentiation of neural 
crest cells into melanoblasts (431).  MITF, a known transcriptional target of the Wnt 
signalling pathway, is expressed in melanoblasts and regulates melanogenesis 
(production of pigment) in melanocytes (22).  This is upregulated by Wnt3a and 
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removal of MITF results in the development of no melanocytes (432).  β-catenin also 
has control over melanoblast differentiation, overexpression in the neural crest cells 
of zebrafish, increased pigmented melanocytes and a loss of β-catenin in mice 
removed all melanoblasts (19, 20, 25).  It was also found that melanoblasts have very 
low levels of the Wnt signalling inhibitor Frzb-1, a finding not common to all neural 
crest derived cells, as neuroblasts and glioblasts have higher levels (431).  Another 
Wnt signalling inhibitor DKK1, inhibits melanocyte differentiation and melanogenesis 
(433), also implicated in melanocyte differentiation, are Trpm1, Met, SOX9 and Kit, 
all known to interact with the Wnt/β-catenin signalling pathway (203).  This data 
shows that canonical Wnt signalling is very important in the location and 
differentiation of melanoblasts. 
As described by Larue et al. as well as others, β-catenin leads to the immortalisation 
of melanocytes, bypassing senescence due to the inactivation of p16 (20, 165, 430, 
434, 435) therefore, leading to melanomagenesis but its continued expression 
inhibits metastasis formation and promotes differentiation.  Therefore, the roles of 
β-catenin and the β-catenin-dependent-Wnts in melanoma are controversial.  Some 
groups show nuclear accumulation of β-catenin in over 30% of melanoma cell lines 
(164, 436), leading to increased melanoma proliferation (177, 437) and reduced 
patient survival (436).  Likewise, other groups show increased transcriptional activity 
of β-catenin during melanoma progression and downregulation of β-catenin 
increased apoptosis in melanoma cell lines (430).  Linking the increase of β-catenin 
to the reduction in E-cadherin expression (438), it is suggested that reduced cell 
adhesion can lead to the increased cell migration and invasion that has been 
recorded (404, 430, 439-441).  These studies have also shown that, in mouse models 
of melanoma, Wnt-β-catenin increased proliferation and tumour growth through 
MITF (437) and Ras signalling (435). 
However, there are alternative views on the effects of Wnt/β-catenin pathway in 
melanoma and, in contrast, to some of the studies described above, several other 
groups report that higher levels of nuclear β-catenin in patient samples prolongs 
survival (20, 166, 203, 442-444).  In addition to this data, it is known that most benign 
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nevi are positive for nuclear β-catenin which is subsequently lost in melanoma 
progression (443).  Chien et al. show that activation of the Wnt/β-catenin pathway 
decreased proliferation in both patient samples and a murine model of melanoma 
(203).  An increase in β-catenin caused by inhibiting GSK3β, which normally degrades 
β-catenin, has been seen to also cause reduction in proliferation in mouse B16 cells 
and melanocytes (445).  Whereas, downregulation of β-catenin has been shown to 
cause poor survival rates in melanoma patients (442, 443) and, in B16 cells, caused 
increased metastasis (446).  Likewise, other studies have shown stabilisation of β-
catenin reduced cellular invasion (384) and increased apoptosis (350).  Genome Wide 
Association Studies have shown transcriptional upregulation of genes such as Trpm1 
and MelanA in B16–F1 melanoma cells treated with Wnt3a (203).  These genes are 
associated with melanocyte differentiation, but are shown to be lost in melanoma 
progression (154).   
In support of this view of the effects of Wnt/β-catenin signalling in melanoma is the 
knowledge that β-catenin independent Wnts are known to be antagonistic of the 
Wnt/β-catenin-dependent pathway (167, 424).  The β-catenin-independent 
signalling pathway is also implicated in the development of melanocytes, driving EMT 
from the neural plate and migration of neural crest cells (22).  It has been shown that 
blocking the Wnt inhibitor DKK1, the FZD7 receptor, or activity of β-catenin-
independent Wnt11 or Wnt5a will halt neural crest cell migration, proliferation and 
melanogenesis (26, 447).  As described in Chapter 1, β-catenin independent Wnts can 
be divided into two separate pathways - the Wnt/planar cell polarity (PCP) and the 
Wnt/Ca2+ pathway.  The PCP pathway is activated by non-canonical Wnt ligands and 
signals through the small GTPases, Rho and Rac to promote changes in the actin 
cytoskeleton but has not yet been shown to play a role in melanoma (22, 165). 
The Wnt/Ca2+ pathway promotes intracellular Ca2+ signalling and negatively regulates 
the Wnt/β-catenin pathway (22, 404, 448).  Wnt5a can antagonise β-catenin 
signalling and increase metastasis but is not involved in tumour formation (165).  
Wnt5a expression is not measured in melanocytes, nor in benign nevi, but is highly 
expressed in advanced, aggressive melanoma, indicating that it is turned on during 
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melanoma progression (449).  This is correlated with decreased patient survival 
(450).  Once melanocytes transform, Wnt5a activation can decrease β-catenin 
signalling through activation of SIAH2 (451, 452) but has also been shown to signal 
through FZD receptors 2 and 5 and increase β-catenin signalling in the presence of 
LRP6 (221, 453).  More commonly, Wnt5a can interact with the ROR2 receptor (453-
456) which is highly expressed in melanoma and this interaction mediates 
downstream signalling to alter melanoma metastasis and degrade β-catenin (25, 165, 
454).  Therefore, Wnt5a signalling is context and receptor-dependent.  Wnt5a has 
also been shown to increase cell motility and invasion (228, 449, 450, 453, 457-461) 
through its upregulation of the transcriptional repressor Snail and Vimentin and 
downregulation of E-cadherin (228), thereby changing cell shape, increasing motility 
and progressing melanoma (462).  Wnt5a can also increase cell adhesion (453) which 
is known to be less favourable for melanoma patient outcome (463). 
Therefore, it is clear that depending on the stage of development from melanocyte 
to benign nevi to advanced melanoma, Wnt signalling can vary and it is important to 
look at the context of the cells and the receptors available to understand the 
oncogenic and tumour suppressor roles of Wnt signalling in cancer (22, 165, 166, 173, 
404).   
 
Having previously analysed the merits of the melanoma models of phenotype 
switching and cancer stem cells and found that they correlate poorly with the 
behaviour of our panel of melanoma cell lines, the question was raised if any of these 
parameters would be affected by the activation of the Wnt/β-catenin signalling 
pathway?  The aim of this chapter was to use a selection of melanoma cell lines to 
assess the effects of active Wnt/β-catenin signalling on the previously investigated 
models of melanoma progression.  Four cell lines of each phenotype (invasive and 
proliferative) have had their growth in 3D Matrigel assessed following activation of 
the Wnt/β-catenin pathway with recombinant Wnt3a protein (rWnt3a), to assess if 
Wnt/β-catenin signalling could force the cell lines to switch their phenotype.  The 
same panel of cells was also analysed for changes in the growth of melanospheres as 
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an indication of Wnt/β-catenin signalling in being able to regulate tumour-initiating 
properties.  Following this, both short and long term growth was assessed, as well as 
changes to apoptosis, cell cycle, invasion, migration and metastatic burden, all with 
the use of either rWnt3a or stably transfected overexpression cells that secrete 
Wnt3a to activate the Wnt/β-catenin signalling pathway.  
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 Recombinant Wnt3a Activates the Wnt/β-catenin Signalling 
Pathway 
It was necessary to ensure that the cell lines used had the ability to respond to 
recombinant Wnt3a (rWnt3a) protein stimulation by checking for activated β-catenin 
induced transcription.  The binding of a Wnt ligand to the frizzled receptor and co-
recptor LRP5/6 activates a series of signalling events that eventually lead to the the 
stabilisation of β-catenin (see Chapter 1 for details), allowing it to translocate to the 
nucleus and activate transcription of Wnt target genes (20, 169, 207).  The 
SuperTOPFlash dual reporter assay (see section 2.3.19) was developed in order to do 
this (429).  Adapted from the TOPFlash transcription-based luciferase designed by 
Korinek et al. (344), the SuperTOPFlash reporter contains eight TCF response 
elements (CCTTTGATC) upstream of Clontech’s minimal TA promoter (464).  A control 
construct has also been developed called SuperFOPFlash which, instead, contains 
eight mutant TCF response elements with the sequence CCTTTGGCC (343).   
The cells were co-transfected with a Renilla control and stimulated with rWnt3a at 
50 ng/ml or carrier control for 24 hours before the dual luciferase assay was carried 
out.  To analyse the results, the TOP and FOPFlash readings were first normalised to 
Renilla transfection levels.  FOPFlash was then subtracted from the TOPFlash to give 
the final results.  Figure 4.1 shows the normalised data for 10 cell lines stimulated 
with rWnt3a protein or carrier control.  All cells show a higher response to rWnt3a 
compared to their respective controls.  The A375 have the highest response at over 
50,000 ALU.  Other cell lines, such as Mel501 and SkMel28, also have high responses 
at over 15,000 ALU.  However they also have the highest control responses, indicating 
that the cell lines A2058, M202, M229 and SkMel5 may have a higher response as 
their relative background levels are lower.  However, not all cell lines have such a 
high luciferase response.  M285, M296 and M375 all show a response above their 
controls but are much lower with under 200 ALU.  All cells respond to rWnt3a 
stimulation, leading to active β-catenin transcription. 
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Figure 4.1: Analysis of Wnt/β-catenin signalling using the TOPFlash reporter assay.   
Cell lines were co-transfected with Renilla and either TOPFlash or FOPFlash for 6 hours.  
Following this, cells were stimulated with either carrier control or rWnt3a (50 ng/ml) for 24 
hours.  Dual luciferase reporter analysis was carried out and results were firstly normalised 
to Renilla as a transfection control and then to FOPFlash. 10 melanoma cell lines were used 
and show all lines respond to rWnt3a stimulation. N=4.   
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 rWnt3a has no Effect of the Phenotype Switching Model 
The cell lines have already had their growth in 3D matrigel basement membrane 
assessed (see section 3.2.1), allowing their phenotypes to be defined.  Cells that form 
connected networks within the matrigel are defined as the invasive phenotype and 
those that remain individual are defined as the proliferative phenotype (334).  As 
explained in detail in section 3.1.4 Wnt signalling is intrinsically linked to the 
phenotype switching model through the expression of MITF, LEF1, TCF4 and WNT5A 
(364, 385).  Figure 3.3 shows the interaction of these genes and, if, the Wnt/β-catenin 
signalling pathway was to be activated, this should drive the proliferative pathway, 
as it would stabilise β-catenin, driving the expression of the proliferative genes MITF 
and LEF1 which would, in turn, inhibit the expression of the invasive genes TCF4 and 
Wnt5a.  Therefore, in order to see if the 3D growth patterns within the matrigel were 
affected by the activation of Wnt/β-catenin signalling, the panel of eight cell lines 
were treated as described in section 2.3.6 and seeded into the assay, as previoulsy 
described (see section 2.3.10).  Images were captured after 48 hours and Figure 4.2 
shows representative images which demonstrate that there were no changes to the 
3D matrigel phenotype growth patterns of these cells following rWnt3a treatment.  
The A375 and SkMel28 cell lines form connected networks within Matrigel and the 
M202 and M229 cell lines are small, individual, clusters (see Figure 4.2).  The upper 
panel shows cells treated with control and the lower panel are the cells treated with 
rWnt3a.  There are no differences in the 3D Matrigel growth patterns of these cells 
in response to rWnt3a treatment. 
 rWnt3a Has no Effect on Melanosphere Formation 
As previoulsy described in section 3.1.4, the cancer stem cell model/tumour-initating 
model is also linked to Wnt/β-catenin signalling (389-393).  The formation of 
melanospheres is an indication of tumour initating properties (120, 382) and, 
therefore, to determine if the sizes of the melanospheres formed were affected by 
the activation of Wnt/β-catenin signalling, the cells were treated for 48 hours with   
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Figure 4.2: The Effects of rWnt3a on 3D Melanoma Cell Culture 
Cells were stimulated for 48 hours with either carrier control or rWnt3a (50 ng/ml), they 
were then seeded onto matrigel coated plates at 4x104 cells/well for 48 hours.  Images were 
captured at 10X magnification.  Arrows highlight connected cell clusters typical of an invasive 
phenotype. Scale bar = 200μm. 
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rWnt3a before being counted and seeded into the polyHEMA plates, as previously 
described in section 2.3.14 (339, 340).  Figure 4.3a shows representative images of 
the melanospheres with, and without, treatment with rWnt3a and Figure 4.3b shows 
the size of melanospheres (above 50 μm in diameter) formed after one week, 
cultured in media treated with either carrier control or rWnt3a.  As stated previously 
in section 3.5.1, the different cell lines showed differing abilities to form 
melanospheres under general growth conditions (Figure 3.4a), but there was no 
affect of Wnt/β-catenin signalling on melanosphere size. 
 Wnt/β-catenin Signalling Reduces Proliferation and Increased 
Apoptosis of Melanoma Cells 
 
 
It has already been shown that Wnt/β-catenin signalling can affect melanoma cell 
proliferation (203).  To check this, a selection of melanoma cells were stimulated (see 
section 2.3.6) with rWnt3a for 48 hours, then proliferation measured over 48 (Figure 
4.4a) and 96 (Figure 4.4b) hours (see section 2.3.11).  All three cell lines used (A375, 
M202 and SkMel28) showed a small, yet significant, increase in proliferation at 48 
hours post-treatment.  This is contrary to what has previously been published, where 
a reduction in proliferation was measured over 3 and 6 days in stable overexpression 
B16-F1 mouse melnaoma cells (203).  Not all data was measured to a significant level 
for the 96-hour data.  M202 show a small, but significant, increase, but the increase 
seen in A375 and SkMel28 cells are not significant.   These results suggest that there 
may be an initital signalling event activated by Wnt3a that increases melanoma cell 
proliferation which, for some lines may be transient. 
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    a) 
 
 
b) 
 
Figure 4.3: The Effects of rWnt3a on Melanosphere Growth. 
a) Cells were stimulated for 48 hours with either rWnt3a at 50 ng/ml or carrier control, they 
were then seeded onto polyHEMA coated plates at 4x104 cells/well for 7 days before images 
were captured at 10X magnification. b) Image J was used to measure melanosphere size, 
anything smaller than 50 µm was discounted. Ns. 
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         a) 
 
            b) 
 
Figure 4.4: rWnt3a increases melanoma cell population doublings over 48 and 96 hours. 
A375, M202 and SkMel28 cells were stimulated for 48 hours with either rWnt3a at 50 ng/ml 
or carrier control, they were then seeded in triplicate at 4x104 cells/well and viable cell 
counts carried out after 48 (a) and 96 (b) hours. N=3. Mean shown ± SD. p = <0.05* or 
<0.01**. 
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A375 and A2058 cells have been transfected to overexpress a Wnt3a or control 
backbone vector (see section 2.3.1.3).  These cells were chosen as they are well-
characterised melanoma lines and differ in their genetic backgrounds.  Figure 4.5a 
shows western blot analysis of Wnt3a overexpression and Figure 4.5b the normalised 
TOPFlash analysis (see section 2.3.19) of the β-catenin stabilisation, compared to 
controls.  These results suggest that the cells can secrete Wnt3a and activate the 
Wnt/β-catenin pathway.  Using the overexpression cell lines (see section 2.3.4), it is 
possible to monitor the growth of the cells for longer periods of time without the use 
of recombinant protein.  rWnt3a stimulation is carried out in serum free media, 
making long-term assays hard to carry out using this method.  The overexpression 
cells were kept in culture for 36 (A375) and 21 (A2058) days to monitor their growth 
patterns.  The A2058 cells were only cultured for 21 days as the difference in 
population doubling time between the cells was bigger and, therefore, a significant 
difference in total cell number could be detected more quickly.  This allowed the 
calculation of the average population doubling times shown in Table 4.1 (see section 
2.3.11).  A375 cells take an average of 21.9 hours to double their population.  This is 
increased in the Wnt overexpression cells to 22.4 hours.  The A2058 cells proliferate 
a little quicker, taking 18.7 hours to double their population but this is, again, reduced 
in the Wnt3a overexpression cells to 19.7 hours.  The longer time taken for the Wnt3a 
overexpressing cells to double their population, compared to the control cells, is 
represented in their overall lower total cell counts as shown in Figures 4.6a and 4.6b.  
This long-term data is supported by the previoulsy published study (203), which 
showed that activation of the Wnt/β-catenin signalling pathway reduces melanoma 
cell proliferation.  
 
As a reduction in cell number was seen in these cells and one of the hallmarks of 
cancer cells is their ability to evade programmed cell death or apoptosis (377, 465), 
it was necessary to analyse the effects of Wnt/β-catenin signalling on apoptosis.  
ApoTRACE (see section 2.3.20) was used to measure alterations in plasma   
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a)                                                            b) 
      
 
Figure 4.5: Overexpression of Wnt3a in melanoma lines A375 and A2058 with control.  
a) 10 μg of cell lysates were separated by SDS-PAGE and transferred on to nitrocellulose 
membrane.  The Odyssey system was used for blocking, antibody dilution, washing and 
developing.  Antibody dilutions used were 1:2000 for anti-Wnt3a and 1:10,000 for anti-
Hsp90. Carried out by R. Kulikauskas at UW. b) TOPFlash analysis of stabilised β-catenin.  
A375 and A2058 Wnt3a overexpression cells secret Wnt3a activating the β-catenin pathway, 
the GFP control cells show no activation. N=4. ALU = Arbitrary Light Unit, measurement of 
luminescence. 
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Table 4.1: Cell population doubling times, A375 and A2058-Wnt3a overexpression cells and 
controls 
Cells were cultured over 36 (A375) and 21 (A2058) days, the average time taken for the cell 
population to double was calculated in hours. 
 
Cell Line Population Doubling Time 
(hours) 
A375 21.9 
A375-Wnt3a 22.4 
A2058 18.7 
A2058-Wnt3a 19.7 
 
a) 
 
b) 
 
Figure 4.6: Long-term proliferation of Overexpression Cells 
Wnt3a Overexpression cells and control cells were seeded in triplicate at 2x104 cells/well.  
When confluent a viable cell count was carried out, the population was split at a known ratio 
and reseeded, this continued for 36 days (A375) and 21 days (A2058).  From this a total cell 
number could be plotted and a population doubling time calculated. a) A375 b) A2058. N=3. 
Mean shown ± SD. T-test of total cell number over entire time course p = <0.05*.   
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membrane potential and phospholipid scrambling (466).  The levels of fluorescence 
measured was normalized to total protein concentration and the data shown in 
Figure 4.7 shows both cell types (A375 and A2058) having a significant 1.4 fold 
increase in apoptosis in response to Wnt/β-catenin signalling.   
Cytochrome c is an essential component of the electron transport chain (ETC).  A 
protein found loosely associated to the inner mitochondrial membrane, it transfers 
electrons between complexes III and IV (268).  It is also a component of the apoptosis 
pathway being released from the mitochondria during apoptosis.  Therefore, levels 
can be measured as an indication of apoptosis in the cell (269-271).  Using flow 
cytometry (see section 2.3.18.2), the levels of cytochrome c in the Wnt3a 
overexpressing cells was measured.  Figure 4.8 shows that both the A375 and the 
A2058 cells have a significant 1.3 fold increase in cytochrome c levels, again indicating 
an increase in apoptosis in response to Wnt-β-catenin signalling and confirming the 
results from the apoTRACE assay in Figure 4.7.   
As increases in apoptosis (Figure 4.7 and 4.8) and a reduction in cell proliferation 
(Figure 4.6) are often a result of cell cycle arrest and often observed in cancer cells 
(467), it is necessary to check if Wnt/β-catenin signalling caused cell cycle arrest in 
melanoma cells (see section 2.3.18.3).  By measuring the amount of propidium iodide 
(PI) staining it is possible to measure the DNA content of cells, making sure that no 
RNA will be stained with the use of RNase A and cell doublets excluded.  A typical cell 
cycle will produce a pattern where cells in the G0/G1 phase of the cell cycle will be 
diploid (2n DNA).  Cells in S phase are in the process of duplicating their DNA so will 
be a mixture of diploid and tetraploid and cells in G2/M will be tetraploid (4n DNA).  
The relative fluorescence of cells in G2/M will, therefore, be twice as high as those in 
G0/G1 (468).  Figure 4.9 shows the cell cycles of the A375 and A2058 cells.  There is 
no difference between them nor any difference from a standard cell cycle pattern, 
suggesting that Wnt/β-catenin signalling does not cause a cell cycle arrest in 
melanoma cells. 
The increase in apoptosis that has already be shown in Figures 4.7 and 4.8 can also 
be seen in the cell cycle profiles (See Figure 4.9).  The cell cycles of the Wnt3a   
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Figure 4.7: Increase in fold change in apoTRACE (FLU/μg of protein) in A375 and A2058 Wnt3a 
overexpression cells. 
Cells were seeded at 6x104 cells/well then stimulated for 48 hours with serum free media.  
ApoTRACE was added to the cells for 1 hour in the dark before the cells were lysed and analysed 
for fluorescence at ex 328 nm em 563 nm.  A BCA was carried out to determine total protein 
concentration for normalisation and fold change over control was then calculated. N=3 Mean 
shown ± SD. p = <0.05* or <0.01**. FLU = Fluorescence Light Unit. 
 
Figure 4.8:  Increase in fold change in Cytochrome C measured by flow cytometry in A375 and 
A2058 Wnt3a overexpression cells. 
Cells were fixed, permeablised and incubated with cytochrome c antibody at 20 µg/ml for 1 hour.  
An anti-mouse secondary antibody conjugated to AF633 was used and live events were measured 
on the C6 Accuri flow analyser in far-red channel FL4.  Fold change in FLU was calculated. N=3. 
Mean shown ± SD. p = <0.05* or <0.01**. 
 
            
 
Figure 4.9: Cell cycle analysis of Wnt3a overexpression cell lines. 
Cells were fixed overnight in 70% EtOH before incubation for 45 minutes with PI/RNase.  Live 
events were measured, excluding doublets on the C6 Accuri flow analyser in channel FL2. 
Representative % of cells in different stages of the cell cycle are displayed.  N=3. Mean shown. p 
= <0.05*.  
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samples shift to the right of their controls, thereby showing a significant increase in 
the sub G1 measurement which is a sign of DNA fragmentation associated with 
apoptosis (469).  Taken together, this data showed that activation of Wnt/β-catenin 
signalling increase apoptosis in melanoma cells. 
 Wnt/β-catenin Signalling Alters Invasion, Migration and 
Metastasis in a PTEN Context-Dependent Manner 
 
The effects of Wnt/β-catenin signalling on reducing melanoma cell invasion has 
already been published (384) and it is known that Wnt5a signalling in a non-canonical 
manner increases invasion in melanoma cells (453).  Therefore, it was expected that 
Wnt3a would inhibit melanoma cell invasion.  To confirm this in our panel of cells, 
the invasion through a Matrigel coated transwell was analysed over 48 hours (see 
section 2.3.12).  Across a panel of 6 cell lines stimulated with rWnt3a and the two 
sets of overexpression cells we observed a significant difference in invasion.  As 
shown in Figure 4.10a, the cell lines A375, M202 and Mel501 showed up to a 0.3 fold 
reduction in invasion in response to rWnt3a, whereas the A2058, M229 and SkMel28 
cells showed up to a 10 fold increase.  This pattern was replicated in the A375 and 
A2058 Wnt3a overexpression cells where A375 cells showed a 0.4 fold significant 
decrease in invasion, whereas the A2058 cells measured nearly a 2 fold increase in 
cell invasion.  The difference in the number of cells stained on the transwell chamber 
was clearly visable as shown by representative images in Figure 4.10b. 
Upon further investigation of Table 3.1 (chapter 3), it was noted that the cells with 
reduced invasion had wild-type PTEN (PTENWT) and those that showed increased 
invasion had a mutation within PTEN (PTENMut).  PTEN expression was confirmed by 
western blot analysis in the panel of 6 lines in Figure 4.11, where lower or no PTEN 
expression is seen in the cells with PTENMut status depending on their homozygous   
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a) 
 
b)    
   
 
 
 
Figure 4.10: Reduced invasion in PTEN intact melanoma cells and increased invasion in 
PTEN null melanoma cells in response to Wnt3a signalling. 
a) Cells were stimulated for 48 hours with either rWnt3a (50 ng/ml), carrier control or just 
serum free media for the overexpression cells, and then seeded on to matrigel coated 
transwells at 4x104 cells/well in serum free media, using 10% media as a chemoattractant in 
the lower well.  After 48 hours the cells that had invaded through the membrane were fixed, 
stained and counted with fold change compared to control calculated. b) Representative 
images of stained cells on transwell membranes for the Wnt3a overexpression cells.  Arrows 
indicate cells fixed to the membrane following invasion. 10X magnification. N=4. Mean 
shown ± SD. p = <0.05*, <0.01** or <0.001***. Scale bar = 200μm.  
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Figure 4.11: PTEN Expression analysis by Western Blot 
10 μg of cell lysates were separated by SDS-PAGE and transferred on to nitrocellulose 
membrane.  Antibody dilutions used were 1:500 for anti-PTEN and 1:10,000 for anti-α-
tubulin.  Cell lines A375, M202 and Mel501 are PTENWT.  A2058 have a homozygous deletion 
of PTEN, lines M229 and SkMel28 have a heterozygous deletion for PTEN.    
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(A2058) or heterozygous (M229 and SkMel28) mutation.  Interestingly, these data 
show that hyper-activated Wnt/β-catenin signalling increases invasion in PTENMut 
cells but reduces invasion in PTENWT cells.    
 
It was predicted that, given the previous result in cellular invasion, a similar effect 
would be seen in cellular migration as the two are often indicative of each other 
(470).  Using a standard scratch assay (471), the monolayer of the Wnt3a 
overexpression and control melanoma cells was disturbed and an image of the 
scratch was captured.  After 24 hours, the same site was imaged again and the 
difference in area calculated (see section 2.3.21).  Figure 4.12a shows the results 
were as predicted and match the invasion assay data.  The PTENWT cells show a 0.5 
fold reduction in migration and the PTENMut cells measure a 0.5 fold increase in 
response to hyper active Wnt/β-catenin signalling. Figure 4.12b shows 
representative images of the wound 24 hours after insult.  The A375 (PTENWT) 
overexpression cells showed a reduced migratory effect after 24 hours and the A2058 
(PTENMut) overexpression cells showed the opposite in response to Wnt3a.  This 
matches the invasion capacity of these cells, indicating that activation of the Wnt/β-
catenin pathway affects how melanoma cells migrate, which is dependent on PTEN 
expression to determine whether this effect is promoted or inhibited.  This shows 
that in melanoma cells, activated Wnt/β-catenin signalling increases migration in 
PTENMut cells but reduces migration in PTENWT cells.    
 Wnt/β-catenin Signalling Reduces Metastasis of PTENWT 
Melanoma Cells in an In Vivo Model 
In vitro, the PTENWT cells showed a reduction in cellular invasion and the PTENMut cells 
showed an increase (see Figure 4.10).  To see if this is translated in an in vivo model 
of metastasis, a tail vein injection study was carried out (see section 2.3.22).  This 
model analyses if the cells form tumours in organs as an indication of   
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                            a) 
 
                        b)   
 
 
 
Figure 4.12 Reduced migration in PTEN intact melanoma cells and increased migration in 
PTEN null melanoma cells. 
a) Cells were stimulated for 48 hours with serum free media, and then seeded at 4x105 
cells/well.  After 24 hours the monolayer of cells was disturbed with a pipette tip and the 
assault was marked and imaged.  The cells were left for 24 hours when the damaged area 
was imaged again and the area calculated as a % of the original was calculated, fold change 
over control was then calculated. b) Representative images of migration assay 24 hours after 
assault. 10X magnification. N=3. Mean shown ± SD. p = <0.0001****. Scale bar = 100μm. 
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metastasis and if there are differences in the size and number of tumours formed by 
the different cell types (472).  The Wnt3a overexpression cells and their respective 
control lines were injected into the tail vein of NOD-SCID mice and left for four weeks.  
The cells were prepared and labelled as groups A-D by one researcher before 
injection by another, to allow for the analysis to be unbiased.  This work was carried 
out at the University of Washingon with help from Dr. Peggy Yang and Rima 
Kulikauskas.  The groups were as follows: 
A = A2058-Wnt3a 
B = A2058 
C = A375-Wnt3a 
D = A375 
Each group consisted of 6 mice, one mouse from group C and D died at week three, 
the remaining mice were culled at week four and the lungs were extracted for further 
analysis.  In addition to Wnt3a, the overexpression cells encode GFP allowing them 
to be easily visualised under a fluorescent microscope (203). 
The images shown in Figure 4.13a and 4.13b show a reduction in metastasis between 
the A375 control and Wnt3a overexpression cells through the reduction of 
fluorescent tissue in the A375-Wnt3a samples.  However, initial analysis showed the 
same is true for the A2058 cells shown in Figure 4.13c and 4.13d.  The in vitro invasion 
assay would have predicted an increase in metastasis but the images show a 
reduction in the A2058-Wnt3a samples, compared to control.  
Further analysis was carried out on the extracted lung tissue samples.  
Representative images are shown in Figure 4.14 of S100 staining, a commonly used 
marker for melanoma cells in vivo (473).  The reduction in metastasis in the Wnt3a 
samples is clear in both cell lines A375 (Figure 4.14a) and A2058 (Figure 4.14b).  This 
staining was scored independently and the reduction is shown to be significant in 
both the A375 cells (Figure 4.15a) and the A2058 cells (Figure 4.15b) However, it is 
clear from the IHC images in Figure 4.14 that the types of tumours formed by the   
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a)                b)
   
c)               d) 
   
Figure 4.13: Fluorescent images of Mouse Lungs Following In Vivo Tail Vein Model of 
Metastasis 
0.75X GFP fluorescence images of mouse lungs following tail vein metastasis model, a) A375 
b) A375-Wnt3a c) A2058 d) A2058-Wnt3a. Star indicates a metastasis free lobe.  
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         a) 
 
         b) 
 
Figure 4.14: S100 staining of Lung samples  
Representitive images of IHC S100 staining a) 4X and 10X images A375 and A375-Wnt3a 
sections b) 10X images of A2058 and A2058-Wnt3a sections. Metastasis and lung boundary 
are circled by dash lines. Magnified areas are marked by squares. Scale bar = 100 µM. 
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      a)                     b) 
 
Figure 4.15: In Vivo model of metastasis.  
Statistical analysis of IHC staining of S100 melanoma specific marker on mouse lung sections 
n=15 a) A375 cells b) A2058 cells. Mean shown ± SD. p = <0.0001****. 
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A375 cells are very different to those formed by the A2058 cells.  In the A2058 
samples, there appears to be a considerable number micro-metastasis, rather than 
fewer large metastatic tumours.  Using the Image J point selector tool, the number 
of micro-metastasis in the A2058 samples were counted.  There were roughly three 
times more micro-metastasis in the A2058-Wnt3a samples, compared to the control.  
Figure 4.16 shows a 40X zoomed section of the IHC staining with crosses marking 
each micro-metastasis.  The A2058 control sample has 28, whereas the A2058-Wnt3a 
sample has 78.  This indicated that, although, the S100 scoring showed a decrease, 
the number of micro-metastasis increased in the A2058-Wnt3a samples and could 
indicate increased in metastatic burden.  In Vivo, Wnt/β-catenin signalling causes a 
reduction in metastasis to the lungs in PTENWT cells but an increase in PTENMut cells. 
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Figure 4.16: 40X zoomed IHC 
Image J analysis of micro-metastasis in A2058 IHC samples, crosses represent visible micro-
metastasis with S100 staining A2058 has 28 micro-metastasis, A2058-Wnt3a has 78 micro-
metastasis. Scale bar = 400 µM. 
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 Discussion 
Despite the fact that the cell line panel used within this research did not correlate 
well with either the phenotype switching model nor the tumour initiation model, as 
shown in Chapter 3, it was interesting to investigate if Wnt/β-catenin signalling had 
any effects on these models of melanoma progression.  As has already been 
explained, Wnt/β-catenin signalling has been implicated in both models of 
melanoma progression and therefore it was reasonable to assume it might change 
the cellular characteristics associated with the two models.  However, no effects 
were seen in either the 3D Matrigel growth nor melanosphere formation with active 
Wnt/β-catenin signalling.  Conversely, other melanoma characteristics such as 
proliferation, invasion and metastasis were significantly affected by activation of the 
Wnt/β-catenin pathway.  Wnt/β-catenin signalling has been implicated in both the 
progression (164, 177, 404, 430, 436, 437, 439-441) and regression of melanoma (20, 
165, 166, 203, 350, 384, 442-444).  This research shows that the effect of Wnt/β-
catenin signalling in melanoma is context dependent and that the mutational status 
of PTEN is playing an important role in dictating the cellular response to active 
canonical Wnt signalling.  
The growth of melanoma cells in 3D Matrigel basement membrane (see Figure 3.1) 
provided the best distinction of different melanoma cells but it was hard to link these 
findings to the previously described melanoma phenotypes (334).  Despite Wnt/β-
catenin signalling being highly relevant in this model of melanoma (364, 385), there 
was no effect of hyperactive Wnt/β-catenin signalling on switching the 
invasive/proliferative phenotypes on any of the cell lines tested (see Figure 4.2).  
Previously, Wnt/β-catenin signalling was linked to this model of melanoma through 
the phenotype specific expression of genes involved in Wnt signalling which switched 
between the proliferative expression of MITF and TCF4 and the invasive expression 
of LEF1 and Wnt5a in a process driven by microenvironmental factors, such as 
hypoxia and inflammation (361, 365, 385).  However, as no switching was seen here 
(see Figure 4.2), Wnt/β-catenin signalling is not capable of inducing a switch in 
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melanoma cell phenotype as described by the phenotype switching model (334, 361, 
365).    
Wnt signalling has also been linked to cancer stem cells with tumour initiation 
properties (394) but there was no effect of Wnt/β-catenin signalling on the cells’ 
ability to form melanospheres (see Figure 4.4) contrary to previous work (435).  It has 
been suggested that melanosphere formation is an indication of a cancer stem cells’ 
ability to regenerate a growing tumour (474).  As stated in Chapter 3, the 
identification of cancer stem cells from their expression profiles could offer another 
way of isolating them.  However, as yet, a distinct set of markers for melanoma has 
not been found (367, 392, 415, 416) and we were unable to find consistent data using 
the previously described markers (see Figure 3.7).  It is currently viewed that the most 
reliable indication of cancer stem cell presence is the ability to form tumours in a 
xenotransplantation assay, followed by serial in vivo xenotransplantation assays 
(474).  Using such models will identify tumour initiating properties within cancer 
cells.  It has previously been suggested that using cells isolated from melanosphere 
cultures will enhance in vivo tumour formation (370, 406, 414) but it has, in fact, been 
shown by Perego et al. that the ability to form tumours in xenotransplantation assays 
showed no difference in cells from melanospheres or adherent cultures (363).  
Instead, this assay showed that both cultures contained cells with tumour forming 
abilities and, therefore, contained cancer stem cells.  As there was no effect of Wnt 
signalling on the formation of melanospheres in these cells, it was unnecessary to 
continue with serial passages in immunocompromised mice.  In summary, Wnt/β-
catenin signalling does not increase the growth of melanospheres and does not 
appear to enhance the number of melanoma cancer stem cells within the cell lines 
tested. 
When testing the effects of the Wnt/β-catenin pathway on cellular characteristics, it 
was possible to validate a number of already published findings.  We also found a 
distinct pattern in the cells’ ability to move and invade, based on their PTEN status.  
It has previously been shown that Wnt/β-catenin signalling can reduce melanoma 
cell proliferation and increase melanoma cell apoptosis (203, 344, 353), effects that 
we were able to replicate (see Figures 4.6 - 4.9).  The proliferation was measured 
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over long periods of growth, gradually decreasing the population doubling rate in 
cells with active Wnt/β-catenin signalling, over time confirming work by Chien et al 
(203).  An increase in apoptosis was measured by an increase in cytochrome c release 
and by an increase in apoTRACE indicating changes to the plasma membrane, a 
finding supported by other groups (353).  As it is known that the Wnt signalling 
pathways can be opposing of each other (167, 424), the increase in apoptosis in 
response to Wnt3a is supported by the reduction in apoptosis seen in response to 
Wnt5a in melanoma and other cancers (42, 223).  However, these results are in 
contrary to previous studies showing that inhibition of Wnt/β-catenin signalling can 
induce apoptosis in lung, breast and colorectal cancers (475-477).  An increase in 
apoptosis could be explained by a cell cycle arrest (467).  Cells that have damaged 
DNA will sense that they are no longer functional and target themselves for 
destruction, a process that is often perturbed in cancer (478).  However, as was clear 
from our analysis, there is no cell cycle arrest in these cells (see Figure 4.10) as there 
is no expansion of any individual phase of the cell cycle in response to active Wnt/β-
catenin, nor are there any differences between the two cells types with the 
percentages of cells at each stage remaining consistent.  Thus Wnt/β-catenin 
signalling decreases proliferation and initiates apoptosis in melanoma cells. 
Throughout the proliferation, apoptosis and cell cycle analysis, all melanoma cells 
were responding to rWnt3a stimulation or Wnt3a overexpression in the same way.  
However, it was when the cells were assessed on their ability to migrate and invade 
that we detected significant differences between them, based on PTEN expression.  
In a standard scratch assay and a transwell invasion assay through Matrigel, the same 
pattern was seen across the whole panel of cells, with the PTENWT cells showing 
significant decreases in cell motility and PTENMut lines measuring significant increases 
in response to active Wnt/β-catenin signalling.  A reduction in migration and invasion 
could be due to changes in cell adhesion (463).  This seems especially possible as 
Wnt5a has been shown to increase cell adhesion and subsequent invasion and 
metastasis in melanoma (222, 460).  Decreased melanoma cell invasion and 
metastasis due to active Wnt/β-catenin signalling has been published by other 
groups (142, 143, 165, 384).  Bosenberg’s genetically engineered mouse model uses 
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a variety of genetic backgrounds common to human melanoma to investigate the 
role of Wnt/β-catenin signalling in melanoma initiation and progression.  When β-
catenin signalling was constitutively active in a model of mutated Braf and PTEN 
(PTEN/Braf/βcat-STA), there were high levels of metastasis to the lungs, spleen and 
bowel, the mice had shorter life expectancy and tumours were large and pigmented 
(143).  Linking this to the fact that the majority of melanoma related deaths are due 
to distant metastasis (479), these findings indicate that this genetic phenotype 
(PTEN/Braf/βcat-STA) exhibits poor prognosis and led to the lowest survival rate in 
these animals.  This is comparable to the increased invasion we observed in the 
A2058-Wnt3a cells (see Figure 4.10).  It has previously been shown that the 
aggressiveness of breast cancers can be determined by its PTEN status (480) and that 
the role of β-catenin is highly context dependent (481).  This research corroborates 
these previous findings in a melanoma model.   However, this study focused on the 
increased aggressiveness of tumours with a PTEN/Braf background.  PTEN mutations 
are seen in 30-50% of melanoma patients (146), whereas Braf mutations are seen in 
nearly 70% of melanomas (142), indicating that there are other models of aggressive 
melanoma still to be studied.  Bosenberg’s model also only focused on Braf mutations 
but there are other mutations of the MAPK pathway, including those of Nras seen in 
the M202 cells, and up to 29% of melanoma patients (137).  Therefore this too has 
clinical relevance and models of Nras interaction with β-catenin (435) and PTEN (145) 
also show high rates of melanoma formation in transgenic mouse models.  Based on 
this, it is important to see if the differences measured in vitro were also seen in vivo. 
In order to investigate if the PTENWT and PTENMut cells responded to activated Wnt/β-
catenin signalling in vivo in the same manner as in vitro, the Wnt3a overexpression 
cells and their controls were injected into the tail vein of NOD-SCID mice and the lung 
metastasis were analysed after 4 weeks growth (see Figure 4.13-4.16).  In vivo, the 
PTENWT A375 cells match the in vitro cell invasion assay; Wnt3a causes a reduction in 
metastasis to the lungs compared to the control cells.  However, the PTENMut A2058 
cells did not initially produce the expected result with the Wnt3a cells also causing 
reduced metastasis to the lungs as measured by S100 staining, contradicting the in 
vitro invasion assay results.  However, upon further analysis, the tumour formation 
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between the two cell lines was vastly different.  The PTENWT cells form large tumours 
that are clearly visible, whereas the PTENMut cells form much smaller punctate 
tumours.  Due to this, an alternative form of analysis was undertaken and the number 
of micrometastasis in the tumour samples was recorded.  The PTENMut cells with 
activated Wnt/β-catenin showed substantial increase in the number of 
micrometastasis, potentially indicating an increase in tumour burden. 
The differences in tumour formation between the two cell types could be due to the 
changes in relative cell growth and apoptosis.  The PTENMut cells have a lower 
population doubling rate that the PTENWT cells (see Table 4.1) and this could suggest 
the smaller tumour size.  An alternative reason for this could be described by Paget’s 
theory of Seed and Soil (482, 483) as they are different cells from different patients 
and, therefore, differences between them should be expected.  Using Paget’s theory, 
it is possible the PTENMut cells metastasise to different organs better than the lungs, 
due to other factors such as the environment or genetics.  Therefore, comparing 
metastasis of both cell lines to just the lungs might not be sufficient.  As shown by 
Bosenberg’s model, metastasis was seen to the lymph nodes, lungs, spleen and 
bowel at varying levels (143), indicating other organs should be considered in future 
analysis.  One future possible approach in order to investigate the effects of the 
genetic background on melanoma metastasis, would be ideal to alter the PTEN status 
of the cells.  To do this, a PTEN knockout would be needed in the A375 cells and to 
knock-in PTEN in the A2058 cells, comparing each to their own controls.  This would 
strongly confirm that the effects of canonical Wnt signalling on metastasis were 
dependent on PTEN. 
These findings show that, in advanced melanoma, the activation of the Wnt/β-
catenin pathway can have both beneficial and detrimental effects on the progression 
of the disease.  If patients could be stratified, based on their PTEN status, potentially 
those patients with both an activating BRAF mutation and an inactivating PTEN 
mutation could be treated with Wnt inhibitors to reduce invasion and metastasis.  
Currently, in clinical trials for prostate cancer (484), small molecular inhibitors 
targeting Porcupine blocking the palmitoylation of Wnt ligands and their subsequent 
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secretion have proved beneficial in breast and head and neck cancer (485-487) and, 
in this specific genetic context, could be beneficial for melanoma patients.   
 
Activation of the Wnt/β-catenin pathway had little effect on the phenotype switching 
or tumour-initiation models of melanoma.  However, there were significant effects 
on cell growth and cell death, which were similar across the cell lines tested.  The 
cells differed dramatically in their ability to migrate, invade and metastasise, which 
was dependent upon their PTEN status.  PTENWT cell lines showed reduced invasion, 
migration and metastasis, whereas PTENMut cell lines showed an increase in response 
to active Wnt/β-catenin signalling.  This novel finding could be exploitable in the 
treatment of metastatic melanoma.  It would now be interesting to investigate how 
these genetic differences affect other aspects of cancer cell behaviour, such as 
tumour metabolism and the mechanism that controls the changes in cellular 
invasion.  
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 THE EFFECTS OF THE WNT/β-CATENIN 
SIGNALLING PATHWAY ON THE 
METABOLISM AND MITOCHONDRIA OF 
MELANOMA CELLS 
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 Introduction 
Altered cellular metabolism in cancer cells has been known since it was first 
described by Otto Warburg in 1924, when he showed the switch to aerobic glycolysis 
from aerobic respiration, where the production of ATP occurs through glycolysis 
rather than the TCA cycle (9).  However, initially this was wrongly attributed to the 
dysfunction of the mitochondria.  The study of cellular metabolism has since 
discovered that the mitochondria of cancer cells are not non-functioning but, 
instead, have altered metabolism to increase fatty acid synthesis and glutamine 
driven metabolism (242, 281, 318).  Using the findings from Chapter 4 showing 
Wnt3a has differing effects on genetically diverse melanoma cell types, the 
hypothesis was suggested that; Wnt3a would have differing effects on melanoma 
metabolism, depending on their specific mutational backgrounds.   
 
In cells, processes such as proliferation, apoptosis, differentiation and growth arrest 
are intrinsically linked to changes in metabolism.  Increased proliferation associated 
with cancer growth requires a shift in metabolism to produce the extra energy 
required for rapid cell division (319).  This shift, typically seen in cancer cells, is 
termed the Warburg effect and involves metabolism changes from oxidative 
phosphorylation (OXPHOS) to glycolysis, even in the presence of oxygen known as 
aerobic glycolysis (276).  This shifts the way energy is produced by the cells, but also 
increases the amount of macromolecules and lipid biosynthesis which is needed for 
biomass production for accelerated cell proliferation (488).  Many oncoproteins not 
only activate proliferative and anti-apoptotic pathways, but also trigger metabolic 
changes in order to transform cells (489).  For example, changes in cancer 
metabolism cause increased lipogenesis of signalling lipids such as 
phosphatidylinositol, phosphatidylserine or phosphatidylcholine, which 
subsequently regulate proliferation and apoptosis through signalling pathways such 
as PI3K/Akt, RAS and Wnt (490).  In addition to this, the structure of Wnt proteins 
themselves can also be modified by fatty acids from increased lipogenesis and 
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therefore, Wnt oncogene properties can be activated in response to changes in fatty 
acid metabolism (489-491).   
There are a number of different pathways that connect apoptosis to metabolism and 
the mitochondria (492) and many of these have links to the Wnt/β-catenin signalling 
pathway.  Section 4.5.2 showed the Wnt/β-catenin pathway increased cell death in 
melanoma cells.  This included increases to cytochrome c, a component of the 
apoptosis pathway (269-271), and metabolism via the ETC (268).  It has been shown 
that both Wnt3a (193) and Wnt1 (493), another commonly β-catenin-dependent 
Wnt ligand, suppress cytochrome c oxidase in breast cancer.  Other connections of 
the Wnt pathway to the mitochondria include mutated APC proteins accumulating at 
the mitochondria preventing apoptosis (494). APC mutations are common in 
colorectal cancer (428, 429), it is known that the Wnt/β-catenin pathway often has 
opposing effects in both colorectal and breast cancer compared to those seen in 
melanoma. 
It has already been shown that Wnt ligands alter cancer metabolism (191, 195, 495).  
Wnt5a, a commonly non-canonical Wnt ligand, effects both melanoma and breast 
cancer cell metabolism (448) where, unsurprisingly, given its known role as either a 
tumour suppressor, as in breast cancer tumours or oncogene, as in melanocytic 
tumours (496), its effects on metabolism vary between tumour types.  Specifically, β-
catenin-independent Wnt signalling increased aerobic glycolysis in malignant 
melanoma cells through elevated Akt signalling and lactate dehydrogenase (LDH) 
activity whereas, in breast cancer cells, Wnt5a increased OXPHOS (448).  As it is 
already well established that the canonical and non-canonical pathways oppose each 
other (428), it suggests that Wnt3a, a predominantly canonical Wnt ligand, could also 
affect melanoma cell metabolism (potentially in an opposite way to that of Wnt5a).  
It has been shown that C2C12 cells, a murine muscle cell line, responded to Wnt3a 
signalling with an increase in OXPHOS and mitochondrial mass.  Increased oxygen 
consumption was also seen in adipocytes, along with enhanced mitochondrial gene 
expression in response to active β-catenin signalling (235).  It has also been shown in 
hepatocytes that activation of the Wnt/β-catenin pathway up-regulated genes 
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involved in glutamine metabolism (190).  Interestingly, the Wnt/β-catenin pathway 
is further implicated in the control of metabolism as a number of metabolism genes 
contain TCF/LEF response elements in their promoters (497).  Collectively this 
research suggests that the Wnt signalling network is a regulator of cancer cell 
metabolism. 
 
The function and structure of mitochondria are described in detail in Chapter 1 but, 
briefly, they are the main source of energy for eukaryotic cells.  A cell’s mitochondrial 
content is directly regulated by the metabolic requirements of the cell (498).  As 
highly dynamic organelles, they are capable of changing size, shape and location.  
Typically described as rod shaped structures, they can range in size from 1-10 µm in 
length, depending on the processes of fusion and fission which occur primarily to 
regulate the health of cells (499).  In 2010, Yoon et al. showed that Wnt3a could affect 
mitochondrial shape and function in C2C12 cells (495).  Wnt5a signalling in a Ca2+-
dependent manner has also been shown to play a role in mitochondrial fusion and 
fission in rat neurons (500) and, through the Wnt/PKC pathway, has been shown to 
regulate mitochondrial distribution and dynamics by degradation of Alex3 protein, 
part of the KIF5/Miro/Trak2 protein complex (501).  It is known that the shape of the 
mitochondria is linked to cell death (249, 502) and, as explained, above (see section 
5.1.1) the Wnt pathway can directly affect apoptosis in cells, cancer and specifically, 
in melanoma (350, 503), therefore potentially linking Wnt to mitochondrial shape.  
For example, the Bcl-2 family are regarded as regulators of apoptosis but have 
recently been linked to mitochondrial dynamics (504).  This family of genes are 
intrinsically linked to the Wnt pathway (494, 505, 506) and provide a direct link 
between the processes.  Currently, we do not know how the Wnt/β-catenin pathway 
regulates mitochondrial shape and whether this is controlled through manipulations 
of mitochondrial dynamics.  Furthermore, it is currently unknown if the Wnt/β-
catenin pathway regulates mitochondrial shape and function in cancer cells.  These 
are all important questions that require further investigation. 
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The aims of this chapter are to assess the effects of active Wnt/β-catenin signalling 
on melanoma cell metabolism and their mitochondria, specifically comparing the 
effects upon melanoma cells with PTENWT to those with a deletion within the PTEN 
gene (PTENMut).  Cellular metabolism will be investigated through live cell flux analysis 
as well as biochemical analysis of the cells.  This will include analysis of basal 
metabolism, the response to Wnt/β-catenin signalling and their function in low 
glucose.  Confocal imaging with the use of a mitochondrial specific dye will be used 
to carry out investigations into the mitochondrial structure and any changes due to 
Wnt/β-catenin signalling.  Comparisons will also be made between mitochondria of 
melanoma cells and non-cancerous melanocytes.  To assess if there is any effect on 
the mitochondrial content of the cells, qPCR and flow cytometry will analyse 
mitochondrial number.  Finally, this chapter will determine if any effects are 
dependent on activation of the Wnt/β-catenin signalling pathway or on β-catenin 
itself and if the differences seen can be reversed with the PTEN status of the cells. 
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 Wnt/β-catenin Signalling Changes Melanoma Cell Metabolism 
 
In order to analyse the cellular metabolism of the melanoma cells including their 
aerobic respiration and glycolytic capacity the PTENWT and PTENMut cells were 
analysed on the Seahorse XFe96 Extracellular Flux Analyzer.  This 96-well plate-reader 
is capable of analysing the Oxygen Consumption Rate (507) and Extracellular 
Acidification Rate (507) of live cells, thereby analysing mitochondrial respiration and 
glycolysis simultaneously.  Following the standard protocol for the Mito Stress Test 
Kit (see section 2.3.23), at known time points, compounds are injected on to the cells 
and the changes in OCR and ECAR can be measured, allowing the calculation of a 
number of different metabolic parameters.  Indicated in Figure 5.1a, the following 
compounds are injected through the built-in compound injection ports, A = 
Oligomycin, B= FCCP, C = Antimycin A and Rotenone.  Oligomycin is an ATP synthesis 
inhibitor.  It blocks the proton channel necessary for oxidative phosphorylation of 
ADP to ATP and will cause a reduction in the flow of electrons through the electron 
transport chain (ETC) (508).  Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
(509) is a mitochondrial uncoupler that causes ETC acceleration by dissipating the 
proton gradient and causing an increase in the flux of electrons (510), leading to a 
subsequent depolarisation of the mitochondrial membrane and inhibition of 
OXPHOS (511).  Antimycin A and Rotenone are inhibitors of complex III and complex 
I of the ETC, respectively.  Antimycin A binds to the quinone reduction site of the 
cytochrome bc1 complex, whereas Rotenone inhibits the transfer of electrons from 
iron-sulfur centers in complex I to ubiquinone. This prevents NADH from being 
converted into ATP (508, 512).  Following the assay, the data was normalised to cell 
number calculated from a Hoechst stain (see section 2.2.23) and the following 
readings were calculated (511) - Basal Respiration is the steady OCR reading before 
any injections; ATP Production was calculated as the change in OCR before and after 
oligomycin injection (injection A).  Maximal Respiratory Capacity is the OCR reading 
following FCCP injection (injection B) subtracting non-mitochondrial respiration.  
Non-mitochondrial respiration is the final OCR reading following injection of 
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Antimycin A and Rotenone (injection C).  Protein leak is the OCR reading following 
Oligomycin injection (injection A), subtracting non-mitochondrial respiration.  Basal 
ECAR is the steady ECAR reading before any injections.  This is shown in graphical 
form in Figure 5.1a.   
The raw data shown in Figure 5.1b+c are representative traces of OCR and ECAR 
readings using the A375 and A2058 Wnt3a overexpression and control cells.  It is 
clear that the A375 cells (Figure 5.1b) show the opposite pattern to the A2058 cells 
(Figure 5.1c) in response to increased Wnt3a expression.  Wnt3a overexpression in 
A375 cells causes lower OCR and ECAR readings, compared to their cognate control 
cells.  This is in contrast to the higher OCR and ECAR levels observed in the A2058 
cells in response to Wnt3a overexpression. Figure 5.2 shows the data following these 
calculations.  The A375 Wnt3a overexpression cells showed a significant reduction, 
compared to control cells, in every metabolism parameter measured; basal 
respiration, ATP production, maximal respiratory capacity, non-mitochondrial 
respiration, proton leak and basal ECAR.  Conversely, the results from the A2058 cells 
indicated that every parameter was possibly increased in the Wnt3a overexpression 
cells compared to control cells, but not significantly.  Thus, activating the Wnt/β-
catenin signalling pathway causes a global downregulation of cellular metabolism in 
PTENWT melanoma cells, which is not observed in PTENMut melanoma lines. 
The Seahorse XFe96 Extracellular Flux Analyzer is also capable of analysing ECAR 
response in no glucose conditions using the Glycolysis Stress Test Kit (see section 
2.3.24).  Using media with added L-Glutamine, instead of glucose, the basal ECAR 
shows the minimum glycolysis activity, gradually increasing the amount of glucose in 
the media through two subsequent injections will increase the glycolysis levels.  The 
injection of oligomycin will have the same effect, as seen in the cell mito stress test 
kit, inhibiting ATP synthesis and causing the ECAR to increase.  Finally 2-DG, a 
glycolysis inhibitor (348), is injected, causing the ECAR reading to fall back to their 
minimum levels, allowing any non-glycolytic ECAR to be analysed.  2-DG does this by 
competitively inhibiting the production of glucose-6-PO4 from glucose at the   
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a) 
 
 
 
   b)                 c) 
 
 
Figure 5.1: Seahorse Mito Stress analysis of A375 and A2058 cells. 
a) Using the changes in OCR readings due to compound injections various metabolic 
parameters can be calculated. Image Adapted from http://www.seahorsebio.com b) 
Representative traces of OCR and ECAR from PTENWT A375 overexpression cells. c) 
Representative traces of OCR and ECAR from PTENMut A2058 Wnt3a overexpression cells. 
Arrows indicate point of compound injections; A=oligomycin, B=FCCP, C=Antimycin A and 
Rotenone.  
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a) 
 
 
Figure 5.2: Seahorse Mito Stress Analysis of A375 and A2058 cells. 
a) A375 and b) A5058 Wnt3a overexpression and control cells were seeded at 8x103 
cells/well into PDL coated Seahorse 96 well plates.  Compounds were diluted as described 
and loaded into the companion plate.  The assay was run as described (section 2.3.23) and 
data was normalised to cell number before the following calculations were done: Basal 
Respiration is the steady OCR reading before any injections.  ATP Production was calculated 
as the change in OCR before and after oligomycin injection (injection A).  Maximal 
Respiratory Capacity is the OCR reading following FCCP injection (injection B) subtracting 
non-mitochondrial respiration.  Non-mitochondrial respiration is the final OCR reading 
following injection of Antimycin A and Rotenone (injection C).  Protein leak is the OCR reading 
following Oligomycin injection (injection A) subtracting non-mitochondrial respiration.  Basal 
ECAR is the steady ECAR reading before any injections.  N=8. Mean shown ± SD. p = <0.05*, 
<0.01** or <0.001***. Not significant (Ns). 
  
b) 
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phosphoglucoisomerase level as it is the same as a glucose molecule with a hydrogen 
in place of the 2-hydroxyl group (513).  An initial dose response assay was set up to 
gather the optimum amount of glucose to use in a Glycolysis Stress Test, the results 
are shown in Figure 5.3.  Both the A375 and the A2058 cells responded to the addition 
of compounds.  However, what was apparent was that the concentration of glucose 
did not seem to have an effect on the A375 cells with the reaction across the different 
doses seemingly having no effect (see Figure 5.3a+b), nor was there any difference 
between the control and the Wnt3a overexpression cells.  In the A2058 cells, 
however, there was an effect of the dose response in the control and the Wnt3a 
overexpression cells (see Figure 5.3c+d).  In both cell lines, the patterns of ECAR seen 
in the Cell Mito Stress Test are seen here; in the A375 cells, the control cells have 
higher ECAR than the Wnt3a and the reverse is seen in the A2058.  In both, the 5 mM 
concentration of glucose (which is the concentration in the standard growth media) 
gave the highest readings, implying that excessive glucose does not increase 
glycolysis in the A2058 cells.  Figure 5.4 shows that the A2058-Wnt3a cells respond 
to a statistically higher level than the A375-Wnt3a cells in the Glucose Stress Test at 
5 mM glucose.  This could indicate a preference for glutaminolysis in A375 cells, 
whereas the A2058 cells are more reliant on glycolysis.  This shows that glycolysis in 
A375 cells is not necessarily dependent on the amount of glucose present, but that 
the A2058 cells are potentially more reliant on glucose.  This data highlights that basal 
metabolism of melanoma cells in culture varies, as would be expected.  Importantly 
however, regardless of differences in basal metabolism our data shows that Wnt3a 
expression is able to dramatically alter basal metabolism of melanoma cells. 
 
Next we wanted to confirm the Seahorse OCR data.  So we decided to use 
biochemical analysis of citrate synthase levels.  As the first enzyme of the TCA cycle, 
levels of citrate synthase are a measurement of TCA cycle activity (304).  Citrate 
synthase catalyses the condensation reaction of the two-carbon acetate residue from 
acetyl coenzyme A, and a molecule of four-carbon oxaloacetate, to form the six-   
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  a)      c) 
 
Figure 5.3: Seahorse Glycolysis Analysis of A375 and A2058 Cells. 
Representative traces of ECAR from A375 and A2058 Wnt3a overexpression cells following 
the Glycolysis Stress Test. a) A375, b) A375-Wnt3a, c) A2058, d) A2058-Wnt3a. Cells were 
seeded at 8x103 cells/well into PDL coated Seahorse 96 well plates.  Glucose was added to 
the cells at various concentrations, followed by the injection of Oligomycin and 2-DG.  The 
assay was run as described and data was normalised to cell number. N=4. 
 
 
  
Figure 5.4: A2058-Wnt3a Cells have Higher ECAR in a Glycolysis Stress Test at 5 mM Glucose 
compared to A375-Wnt3a Cells 
Data extrapolated from the Glycolysis Stress Test in Figure 5.3.  The average ECAR values 
from A375-Wnt3a and A2058-Wnt3a overexpression cells were calculated following each 
compound injection.  The data was taken from the 5 mM glucose level. N=4.  
b) d) 
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carbon citrate (514).  Citrate synthase levels (see section 2.3.25) were measured in 
the whole panel of melanoma cells, normalised to total protein levels and can be 
represented as fold change compared to the control cells (see Figure 5.5).  The 
PTENWT cells (A375, M202, Mel501 and A375-Wnt3a overexpression cells) all showed 
a significant decrease (between 0.7 fold and 0.2 fold, in citrate synthase activity), 
verifying the results that OXPHOS in these cells is decreased as previously indicated 
by the Seahorse Flux analysis.  The PTENMut cells, however, showed mixed results; 
two cell lines, A2058 and M229, showed a significant 1.3 and 1.6 fold increase 
respectively, whereas SkMel28 and the A2058-Wnt3a overexpression cells showed a 
0.5 and 0.7 fold decrease to significant levels.  This suggests that in PTENMut 
melanoma cells, hyperactive Wnt3a signalling produces inconsistent effects on 
citrate synthase activity, which could be representative of differences in basal 
metabolism between the PTENMut cell lines.  Taken together, this data suggests that 
on PTENWT cells, Wnt/β-catenin activity reduces oxidative metabolism but has less 
predictable effects in PTENWT cells. 
 
In order to confirm the Seahorse ECAR data, we wanted to use biochemical analysis 
of LDH activity by measuring lactate secretion from the cells.  Lactate is secreted by 
cells following the conversion of pyruvate to lactate by lactate dehydrogenase (515).  
Measurement of lactate (see section 2.3.26) can provide an indication of the 
glycolytic activity of cells.  Cancer cells tend to have increased glycolytic respiration 
and, therefore, the lactate secretion is expected to be high (9).  Figure 5.6 shows total 
lactate secretion that was normalised to protein concentration and represented as 
fold change compared control cells.   
The panel of four PTENWT cells all showed between 0.5 and 0.8 fold significant 
decreases in lactate secretion.  The ECAR results seen in Figure 5.2 indicated a 
reduction in cellular acidification in A375 cells in response to Wnt3a overexpression 
cells so the lactate secretion data corroborates these findings (Figure 5.6).  Lactic acid 
will be one of the main components of this measurement and, therefore, supports 
the lactate secretion results shown here.  The PTENMut cells all showed between a 1.1   
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Figure 5.5: Citrate Synthase Activity is Reduced in PTENWT Cells in Response to Wnt/-
catenin   
Melanoma cells were seeded at 2x105 cells/well before being stimulated for 48 hours with 
either rWnt3a at 50 ng/ml, carrier control or (for the overexpression cells) serum free media.  
A BCA was carried out to normalise data to total protein concentration and fold change in 
citrate synthase activity compared to control was calculated.  N=4. Mean shown ± SD. p = 
<0.05*, <0.01** or <0.001***. 
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Figure 5.6: Lactate Secretion is Reduced in PTENWT Cells in Response to Wnt/-catenin 
Melanoma cells were seeded at 2x105 cells/well before being stimulated for 48 hours with 
either rWnt3a at 50 ng/ml, carrier control or (for the overexpression cells) serum free media.  
Cell supernatants were stored at -80°C overnight before the assay was carried out.  A BCA 
allowed for normalisation of data to total protein concentration and fold change compared 
to control was calculated.  N=4. Mean shown ± SD. p = <0.05*, <0.01** or <0.001***. 
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and 1.3 fold increase in lactate secretion, but only the A2058 Wnt3a overexpression 
cells were measured to a significant level.  Wnt/β-catenin signalling reduces 
glycolysis in PTENWT melanoma cells and has no effect in the PTENMut cells, albeit the 
trend indicates it may increase lactate secretion from PTENMut cells.  
 
Reactive Oxygen Species (ROS) are involved in the regulation of many different 
physiological processes and the production of ROS, to a certain level, is required for 
normal cellular homeostasis (516).  In melanoma, high ROS levels have been linked 
to increased melanin production and apoptosis via Bax, but lower levels have been 
seen to increase proliferation and reduce apoptosis (241).  One of the main sources 
of ROS is the mitochondrion.  Using the Wnt3a overexpression cells, total cellular ROS 
was measured (see section 2.3.27) and represented as fold change, compared to 
control cells.  In Figure 5.7, the A375-Wnt3a cells showed a 0.8 fold significant 
reduction in cellular ROS, whilst the A2058-Wnt3a cells showed a 1.1 fold increase, 
which was not however significant.  Taken together, these results shown that Wnt/β-
catenin signalling reduces ROS production in PTENWT melanoma cells, but has no 
significant effect on PTENMut cells.  
 
Glucose is animal cells’ main source of energy.  It is taken into the cells and used in 
the process of glycolysis in both aerobic and anaerobic respiration.  Cancer cells 
typically have higher glucose intake, as the glycolytic phenotype only produces 2 
molecules of ATP per molecule of glucose through glycolysis, but they need more 
energy to keep up with the demand for higher proliferation rates (277).  This 
enzymatic, glucose determination assay (see section 2.3.28) allows the amount of 
total cellular glucose to be measured by assessing the amount of NAD reduced to 
NADH.  NADH is fluorescent and NAD is not.  The change in the fluorescence is 
proportional to the concentration of glucose as the reaction is equal to the 
phosphorylation of Glucose to Glucose-6-phosphate and the oxidation of Glucose-6-
phosphate to 6-phospho-gluconate (517).    
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Figure 5.7: Total cellular ROS is Reduced in PTENWT Cells in Response to Wnt/-catenin 
A375 and A5058 Wnt3a overexpression and control cells were seeded at 1x104 cells/well 
onto collagen coated plates.  They were serum starved for 48 hours before the assay was 
carried out.  Results were calculated as fold change over control. N=5. Mean shown ± SD. p 
= <0.01**. 
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Using the Wnt3a overexpression cells, total cellular glucose was measured and 
represented as fold change over the control cells.  Figure 5.8 shows glucose 
consumption for both the A375 and A2058-Wnt3a cells.  Both lines show a 2.1 fold 
increase in cellular glucose.  However, only the A375 cells were measured to 
significant levels, indicating that, despite a reduction in glycolysis in the A375-Wnt3a 
cells, there is a paradoxical increase in glucose consumption.  This might potentially 
be a compensatory mechanism to provide additional energy that is not produced do 
to the low metabolism. 
 Wnt/β-catenin Changes the Mitochondria of PTENWT 
Melanoma Cells 
The mitochondria are the bioenergetic and metabolic centres of eukaryotic cells.  In 
order to study the metabolism of these cells, investigation of the mitochondria was 
necessary and may reveal differences in cell lines upon activation of the Wnt/β-
catenin pathway. 
 
To investigate the mitochondria of melanoma cells in response to Wnt/β-catenin 
signalling we first stained the cells with Mitotracker Deep Red organelle, specific 
stain.  Mitotracker dyes are mitochondrial selective stains that contain a mild thiol-
reactive chloromethyl moiety, allowing it to be retained by the cell following fixation 
(518, 519).  Mitotracker Deep Red is also retained after cell permeabilization, 
therefore making it the best option for multi-colour immunocytochemistry.  The stain 
passively diffuses across the plasma membrane, accumulating in active 
mitochondria.  It is not, however, dependant on the mitochondrial membrane 
potential.  All the cells were imaged in a three colour set up; mitochondria stained 
with Mitotracker Deep Red, cell nucleus stained with Hoechst and the cytoskeleton 
labelled with Phalloidin for F-actin (see section 2.3.29.1).  The laser power and gain 
settings for each cell type are shown in Table 5.1.  These remained consistent 
between the carrier control and Wnt3a treated samples for each cell type. 
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Figure 5.8: Total Cellular Glucose is Increased in Response to Wnt/-catenin 
A375 and A5058 Wnt3a overexpression and control cells were seeded at 2x105 cells/well.  
They were serum starved for 48 hours before the assay was carried out and a BCA was used 
to normalise results.  The results were then calculated as fold change over control. N=5. 
Mean shown ± SD. p = <0.05*. 
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Table 5.1: Laser Power Settings And Gain Adjustments For Mitotracker Tri-Colour Images 
All samples were analysed on a Zeiss 510 LSM 63X oil/1.4 DIC objective, unless otherwise 
stated. 
They all have a voxel size of 0.08 x 0.08 x 0.45 µm with 8 bits per pixel. 
The microscope was set to HFT UV/488/543/633 with the following filters: 
1 – BP385-470 
2 – LP650 
3 – BP505-550 
Each sample was analysed using 4X track sampling using two tracks, 1st for Hoechst and Deep 
Red and 2nd track for Phalloidin. 
The channels used were: 
Ch1 – 633 pinhole 124 
Ch2 – 364 pinhole 122 
Ch3 – 488 pinhole 119.9 
Cell Type Channel Power % Gain settings ABU 
A375 9 638.9 
6 632 
0.5 681 
M202 10 873.93 
2 737.00 
0.5 681.45 
Mel501 12 644 
2 614 
0.5 686.5 
A375 overexpression cells 3 585.9 
3 772.1 
0.5 566.5 
A2058 18 525 
2 604 
0.5 656.5 
M229 12 599 
2 569 
0.5 591.5 
SkMel28 10 873 
2 737 
0.5 681 
A2058 overexpression cells 12 529 
2 554 
0.5 646.5 
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The panel of PTENWT cells lines Figure 5.9a all show a relocation of the mitochondria 
(red) towards the nucleus (333) of the cell, as indicated by the arrows.  In the majority 
of the cells, a few mitochondria were still seen in the very tips of the cells but there 
were large areas of cytoplasm left with no mitochondria.  The panel of PTENMut cells 
Figure 5.9b showed no differences between carrier control and rWnt3a treated cells 
or any differences between the control or Wnt3a overexpression cells.  The 
mitochondria do not change location or shape.  It was observed that, when treated 
with or when Wnt3a is overexpressed, the mitochondria of the PTENWT cells not only 
move towards the nucleus but also appear clustered together and looked very 
elongated.  When the images were zoomed to 150X magnification, the elongation of 
the Wnt3a overexpression cells is very clearly seen Figure 5.10.  The mitochondria of 
the control cells are small, round and appear individual; the Wnt3a cells are much 
longer and thinner in shape with intense punctate staining indicating areas of overlap 
or joining.  Activating the Wnt/β-catenin signalling pathway appears to cause the 
mitochondria of PTENWT cells are located nearer towards the nucleus, become 
elongated and potentially fused into networks. 
 
In order to quantify the changes in mitochondrial shape seen in Figures 5.9-10, we 
used Imaris (Bitplane), a software package capable of visualising cells in 3D and 
analysing the interaction of subcellular structures.  Therefore, it can quantify if the 
mitochondria of the PTENWT cells are, in fact, connected in larger networks.  Using 
immunofluorescence images taken as Z-stacks to create a 3D image in Mitotracker 
stained cells, the software derives a surface, based on the fluorescent channel of the 
users’ choice.  In the case of this data, the red channel is selected to study the 
mitochondria stained with Mitotracker Deep Red.  The surface created is a computer-
generated representation of the specified region of interest. This surface object is 
visualised as an artificial solid object and allows the user to verify the accuracy of 
segmentation against the original data, in an interactive manner, by   
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a)                 b)    
  
Figure 5.9: Representative Mitotracker Images of the Whole Cell Panel 
Cells were seeded at 2x104 cells/well onto sterile coverslips, before stimulation for 48 hours 
with either rWnt3a at 50 ng/ml, carrier control or just serum free media for overexpression 
cells.  Cells were incubated with mitotracker deep red before fixation and counter staining 
with Hoechst and Phalloidin.  Cells were imaged on a Zeiss LSM510 META with a 63X oil 
objective.  Laser power and gain settings remained constant between carrier and stimulated 
but were adjusted between cell types. a) Panel of PTEN intact cell lines treated with carrier 
control or Wnt3a. Scale bar = 50μm. Arrows highlight areas of perinuclear mitochondria. b) 
Panel of PTEN null cell lines treated with carrier control or Wnt3a. Scale bar = 50μm.  
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Figure 5.10: Representative Mitotracker Images of the Whole Cell Panel 
A375 overexpression cells were seeded at 2x104 cells/well onto sterile coverslips, before 48 
hours in serum free media. Cells were incubated with mitotracker deep red before fixation.  
Cells were imaged on a Zeiss LSM510 META with a 63X oil objective, with the nucleolus in 
focus.  Laser power and gain settings remained constant between carrier and stimulated but 
were adjusted between cell types. A375 and A375-Wnt3a overexpression cells shown in 150X 
magnification.  Images were falsely coloured green during analysis. 
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sliding a scale bar, revealing the original image beneath.  It is possible to set a 
background level and, knowing the average size of a mitochondria can vary between 
0.5 – 1 µm, the background was set in these samples to 0.5 µm for all the cells in the 
interest of ‘fair’ experimentation.  Imaris is capable of measuring various aspects of 
the surface including voxel size, number of structures, and volume of structures, but 
the data presented here is a measurement of the area of the structures.  The data 
produced by the software shows that the area of all structures measured are within 
the parameters set.  The total area of all mitochondrial surfaces was calculated and 
then the area of those within defined ranges was represented as a percentage of the 
total (see Figure 5.11).  Representative images from the M202 cell line with carrier 
or rWnt3a are shown in Figure 5.11a with either individual or large networks 
highlighted in yellow.   
After analysis was carried out on the whole panel of cells it was clear that the changes 
seen in the confocal images in Figure 5.9 were quantifiable by the Imaris software.  
The PTENWT cells treated with rWnt3a or overexpressing Wnt3a all show very large 
networks of mitochondria.  They all have an additional section on their graphs above 
their respective carrier controls.  A375 control cells have a maximum network size of 
1000 µm2, whereas the A375 treated with rWnt3a have networks in the region of 
1000-10000 µm2.  The same pattern is seen in Mel501 and A375 overexpression cells.  
The M202 control cells have networks in the region of 1000-10000 µm2, but the M202 
cells stimulated with rWnt3a have increased network sizes as large as 10,000+ µm2.  
These shifts are all shown to be significant by a two-way ANOVA, as shown in Figure 
5.11b.  In addition to this, the percentages shown at the bottom of each graph 
represent the percentage of structures measured with the smallest group of 0-10 
µm2.  The PTENWT Wnt3a treated or overexpression cells have a reduction in this 
group showing that they have less fragmented individual mitochondria.  A375 cells 
reduce the percentage in this category from 11.5 to 7.9%, M202 reduce from 12.1 to 
6.7%, Mel501 show a decrease from 26.2 to 8.1% and the overexpression cells show 
the biggest reduction from 64.3 to 45.3%.  As expected from their confocal images, 
the PTENMut cells do not show any differences in the quantified data from Imaris 
shown Figure 5.11c.  None of the PTENMut cell   
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a) 
 
b) 
 
c) 
 
Figure 5.11: Representative 3D Images of Whole Cell Panel using Imaris Software  
Z-slices of confocal images were carried out at the optimum depth for each sample. a) 
Representative images of 3D reconstructions for M202 cells following Carrier or Wnt3a 
stimulation, isolated mitochondrial network are highlighted in yellow, nucleus is shown in 
blue, cytoskeleton is shown in green and mitochondria are shown in red. Data was collated 
from multiple cell images for each data set.  The area of every ‘Red channel’ object was 
calculated by the software and a total area calculated. Scale bar = 10 μm.  The total areas of 
all objects within the defined ranges were then represented as a percentage of the total. b) 
PTENWT cell lines. p = <0.05* or <0.01**. c) PTENMut cell lines. Ns. A two-way ANOVA was used 
to compare each data set compared to carrier treated cells. 
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lines produce a network above 1000+ µm2.  Only in the SkMel28 cells is there an 
increase in the percentage of cells in the largest range seen and only in the A2058 
cells did we find a reduction in the smallest range by 0.1%.  This matches the images 
captured by confocal microscopy and confirms that there is increased networking of 
mitochondria in the panel of PTENWT cells when the Wnt/β-catenin signalling 
pathway is activated, but there is no effect on the panel of PTENMut cells. 
 
A potential explanation of the changes to the mitochondria seen in the PTENWT Figure 
5.9a could be an increase in mitochondrial mass upon stimulation with Wnt3a.  In 
order to determine if there were changes to the number of mitochondria between 
the samples two different methods were utilised. 
 
In order to determine if there was an increase in mitochondrial number in the Wnt 
activated PTENWT cells, Mitotracker Green was used in live cell flow cytometry (see 
section 2.3.15.4).  Mitotracker Green has the advantage over the Mitotracker Deep 
Red in that it is non-fluorescent in aqueous solutions and only becomes fluorescent 
once in the lipid environment of the mitochondria.  It also has relatively low 
background levels making it the ideal stain for live cell imaging or flow analysis (509).  
As with Mitotracker Deep Red, the stain passively diffuses across the plasma 
membrane, accumulating in active mitochondria and, again, is not dependant on the 
mitochondrial membrane potential, therefore making it a tool for mitochondrial 
mass analysis (509).  However, as the overexpression cells also encode GFP (203), this 
does pose an additional problem of false results.  Due to this, for these cells an 
unstained sample was used to gate on the natural fluorescence and allow 
compensation to be added accordingly.  Figure 5.12 shows the flow cytometry data 
with controls shown in red and Wnt3a shown in black.  The mean FL1 readings are 
shown below each graph indicating the average intensity of Mitotracker green.  The   
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a)               b)            c) 
 
 
Figure 5.12: Mitochondrial Mass by Flow Cytometry for Mitotracker in PTENWT Cell Lines. 
Cells were seeded at 2x104 cells/well before stimulation for 48 hours with either rWnt3a at 
50 ng/ml, carrier control or just serum free media for overexpression cells.  Cells were 
incubated with mitotracker green at 10nM before being washed and analysed immediately 
on the Accuri C6 analyser.  Cells were gated on live cell population on a FFC/SSC plot before 
analysis of the FL1 channel.  a) Overexpression cells were also gated against an unstained 
control to allow for the auto-florescence of the GFP construct. b) A375 c) M202.  N=3. Ns. 
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differences are very small for all three cell lines used and inconsistent, as the FL1 
reading decreased for the Wnt3a overexpression cells but increased for the A375 and 
M202 treated cells.  This data show that there is no increase in mitochondrial mass 
as measured by this method. 
 
An alternative method to determine if there are more mitochondria in the PTENWT 
Wnt3a treated cells is to analyse the amount of mitochondrial DNA, compared to the 
amount of nuclear DNA.  Using the NovaQUANT Human Mitochondrial to Nuclear 
DNA ratio kit (see section 2.3.30.1), whole cells were lysed directly in the qPCR plate 
during the reaction.  The pre-designed plate houses four sets of primers, two genes 
encoded by mitochondrial DNA (ND1 and ND6) and two nuclear encoded genes 
(BECN1 and NEB).  ND1 encodes NADH dehydrogenase I, ND6 encodes NADH 
dehydrogenase 6, and these are both mitochondrial DNA encoded genes.  BECN1 
encodes Beclin-1 and NEB encodes Nebulin, and these are the two nuclear DNA 
encoded genes.  ND1 is paired with BECN1 and ND6 is paired to NEB.  These provide 
the ratios between mitochondrial and nuclear and then the average between the two 
is calculated for each sample, providing a relative copy number (RCN). Figure 5.13 
shows that neither the A375 (Figure 5.13a) overexpression cells, nor the A2058 
(Figure 5.13b) overexpression cells are there significant increases in relative copy 
number of mitochondrial DNA in the Wnt3a samples.  This data show that there is no 
effect of Wnt/β-catenin on mitochondrial DNA content. 
 Increased Mitochondrial Networking and Reduced Metabolism 
Are Dependent on the Wnt/β-catenin Pathway 
The effects reported so far in this chapter 5 were all as a result of Wnt3a stimulation 
or overexpression, presumably by activating the Wnt-β-catenin signalling pathway.  
Therefore, the question was posed; do these effects of reduced cellular metabolism 
and increased mitochondrial networking depend on activation of β-catenin 
signalling?  
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               a)                 b) 
     
Figure 5.13: Nuclear to Mitochondrial DNA Ratio in Wnt3a Overexpression Cells. 
Using the whole cell lysis method described by the manufacturer, the NovaQUANT Human 
Mitochondrial to Nuclear DNA ratio kit was used with 50 cells per well.  A Fast SYBR green 
programme was run with an extended 10 minute denature at 95°C.  Data was analysed 
according to the manufactures instructions for (RCN) relative copy number. a) A375 cells b) 
A2058 cells. N=3. Ns. 
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Dickkopf related protein 1 (DKK1) is a member of the Dickkopf family of genes 
composed of two cysteine rich domains.  It is a secreted protein that is known to be 
involved in embryonic development and is a specific inhibitor of the Wnt/β-catenin 
signalling pathway (520).  By forming a complex with the transmembrane protein 
Kremen, it causes internalisation of LRP6 therefore, blocking its co-receptor activity 
in Wnt ligand binding (521).  We wanted to see if DKK1 could block mitochondrial 
fusion, but before this, we first needed to check it could block the canonical Wnt 
pathway. 
To check the efficiency of the recombinant DKK1 protein at blocking the Wnt/β-
catenin signalling pathway, the TOPFlash dual reporter assay was used (see section 
2.3.19).  A375 cells were transfected with the dual luciferase reporter constructs and 
treated with carrier control or Wnt3a.  In addition, some cells were treated with DKK1 
alone or DKK1 in combination with Wnt3a.  The results shown in Figure 5.14 were as 
expected showing DKK1 could inhibit Wnt/β-catenin signalling.  Carrier control and 
rDKK1 protein have no effect on activation of the Wnt/β-catenin pathway.  rWnt3a 
protein activates the Wnt/β-catenin pathway and this effect is significantly reduced 
by the rDKK1 protein.  This confirms that rDKK1 has the expected effect of blocking 
the Wnt/β-catenin pathway. 
 
Next we investigated the effects of blocking the Wnt/β-catenin pathway by DKK1 on 
mitochondrial fusion.  The A375 cells were treated using the same conditions as for 
the TOPFlash assay described above and they were stained, as previously described, 
for the initial analysis of the mitochondria using Mitotracker (see section 2.3.29.1).  
Cells were treated with carrier, rWnt3a or rWnt3a in combination with rDKK1, as 
shown in Figure 5.15 for the TOPFlash assay, which showed that rDKK1 alone had no 
effect on the Wnt/β-catenin pathway.  The carrier control and the rWnt3a affected 
the mitochondria as previously seen in Figure 5.9a.  The carrier has   
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Figure 5.14: TOPFlash Analysis of DKK1 Treatment in A375 cells 
A375 cells were seeded at 4x104 cells/well and co-transfected with Renilla and either 
TOPFlash or FOPFlash for 6 hours.  Following this, cells were stimulated with carrier control, 
rWnt3a at 50 ng/ml, rDKK1 at 50 ng/ml or rWnt3a and rDKK1 both at 50 ng/ml for 24 hours.  
Dual luciferase reporter assay was carried out and luminescence (ALU = Arbitrary Light Units) 
results were normalised to Renilla as a transfection control and then to FOPFlash. N=3. Mean 
shown ± SD. p = <0.01** or <0.001***. 
 
 
 
 
Figure 5.15: Confocal images of A375 with rDKK1 Treatment 
A375 cells were seeded at 2x104 cells/well onto sterile coverslips, before stimulation for 48 
hours with either carrier control, rWnt3a at 50 ng/ml, rDKK1 at 50 ng/ml or rWnt3a and 
rDKK1 both at 50 ng/ml.  Cells were incubated with Mitotracker deep red before fixation and 
counter staining with Hoechst and Phalloidin.  Cells were imaged on a Zeiss LSM510 META 
with a 63X oil objective.  Laser power and gain settings remained constant between carrier 
and stimulated cells. Arrows highlight areas of perinuclear mitochondria. Scale bar = 20 μm. 
Representative images shown. 
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the mitochondria spread out throughout the cytoplasm, they are small and 
individual, but the rWnt3a treated cells have highly networked, perinuclear 
mitochondria.  When the cells are treated with rWnt3a and rDKK1 in combination, 
DKK1 inhibits the effects of the rWnt3a already described above.  The mitochondria 
are still located near the nucleus, although they are starting to spread out into the 
cytoplasm.  They are smaller in shape and size, and are very small and round and 
appear to have lost the high levels of networking. 
Imaris software was utilised to measure the amount of mitochondrial networking.  
Representative images of the 3D reconstructions are shown in Figure 5.16a, with 
representative mitochondria from the data highlighted in yellow.  The data 
generated by the software was analysed as a percentage of the whole mitochondrial 
area.  The results of the rDKK1 effect on Wnt3a-induced mitochondrial networking 
are shown in Figure 5.16b.  The control cells and the rWnt3a cells have a distribution 
similar to that previously seen in Figure 5.11a, while the rWnt3a samples have a 
higher percentage of larger networks.  In cells co-stimulated with rWnt3a and rDKK1, 
75% of the mitochondria switch from a size range of 100-1000 µm2 down to 10-100 
µm2.  This is even smaller than the networks seen in the control cells.  The data shows 
that DKK1 antagonises the Wnt/β-catenin pathway and appears to block the 
networking of mitochondria in A375 melanoma cells. 
 
To confirm these findings further, we next decided to reduce the expression of β-
catenin using siRNA transiently knocked down.   
 
To check the efficiency of the β-catenin siRNA knockdown (see section 2.3.31), two 
methods were used.  Firstly, qPCR was used to check the expression levels of Axin2 
(see section 2.3.30.2).  Axin2 plays an important role in the Wnt/β-catenin signalling 
pathway.  It causes a negative feedback loop as it is a part of the destruction complex 
responsible for the proteasomal degradation of β-catenin but, it is, itself,   
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a)  
 
 
   b) 
 
 
Figure 5.16: Imaris Images and Data from rDKK1 Treated A375 cells 
a) Z-slices were carried out at the optimum depth for each sample.  Representative images 
of 3D reconstructions for each cell type following Carrier, Wnt3a or Wnt3a+DKK1 
stimulation, isolated mitochondrial network is highlighted in yellow. Scale bar = 20 μm.  b) 
Data was collated from multiple cell images for each data set.  The area of every ‘Red 
channel’ object was calculated by the software and a total area calculated.  The total areas 
of all objects within the defined ranges were then represented as a percentage of the total. 
A two way ANOVA was carried out to compare variance of the data compared to carrier 
treated cells. p = <0.05* or <0.01**. 
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regulated by activation of the TCF promoter transcription by activation of Wnt/β-
catenin signalling (201).  Therefore if β-catenin is successfully knocked down, there 
will be reduced expression of Axin2 mRNA (351).  A control siRNA was also used as a 
negative control.  The control siRNA is a non-targeting siRNA with the same chemical 
modifications for enhanced transfection efficacy as in the siRNA of choice.  Figure 
5.17a shows that the β-catenin knockdown significantly reduces the expression of 
Axin2 in both the A375 control cells and the Wnt3a overexpression cells.  As 
expected, there are higher levels of Axin2 produced by the Wnt3a overexpression 
cells as these have constitutively active Wnt/β-catenin signalling as shown in Figure 
4.5a. 
The second method utilised to measure knockdown of β-catenin was western blot 
analysis (see section 2.3.13-16) for β-catenin protein expression, shown in Figure 
5.17b.  The protein expression of the A375-Wnt3a overexpression cells with either 
scrambled or β-catenin siRNA, were probed with an anti-β-catenin antibody and an 
α-tubulin antibody, the latter of which was used as a loading control.  The blot shows 
that β-catenin expression is knocked down using siRNA technology. 
 
The A375 and the A375-Wnt3a cells were treated with both scrambled control and 
β-catenin siRNA for 72 hours before the cells were stained as previously described 
(see section 2.3.29.1).  The cells shown in Figure 5.18a were imaged on a Nikon A1R 
confocal with a 60X oil objective.  The images show there is no effect on the 
mitochondria of cells treated with scrambled siRNA.  In the control cells, they look 
small and individual throughout the cytoplasm and in the Wnt3a overexpression 
cells, they are highly networked around the nucleus, as expected.  The cells treated 
with the β-catenin siRNA show a significant reduction of mitochondrial networking.  
In both the control and Wnt3a overexpression cells, the mitochondria are small and 
individual.  The Imaris data in Figure 5.18b quantitatively shows the mitochondrial 
networking.  The Wnt3a overexpression cells had no networks over 100 µm2 and the 
percentage of mitochondria in the smallest size range increased from 44 to 71% in 
control cells and from 24 to 88% in the Wnt3a overexpression cells upon siRNA   
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a) 
 
b) 
                                        
 
 
Figure 5.17: β-catenin siRNA Knockdown Confirmation by qPCR for Axin2 and Western Blot 
for β-catenin 
A375 cells were reverse transfected with β-catenin siRNA or a scrambled control siRNA for 
72 hours. a) RNA was extracted using GeneJetRNA purification Kit, 2 µg of RNA was 
transcribed using a Revertaid First Strand cDNA synthesis Kit.  qPCR for Axin2 was run on a 
LightCycler 480 system, mRNA expression levels were normalised based on the expression 
of YWHAZ. N=3. b) A375 overexpression cells were lysed and BCA for protein concentration 
was carried out.  10 µg of protein was run on a 12% Bis-Tris gel and transferred onto 
nitrocellulose membrane.  Blocking and antibody dilutions were carried out in a 5% BSA 
solution, β-catenin antibody was diluted 1:1000 and incubated overnight before anti-rabbit 
secondary antibody and ECL development.  α-tubulin was used as a loading control. Mean 
shown ± SD. p = <0.05*. 
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knockdown of β-catenin.  The removal of β-catenin in the A375 cells, whether treated 
with Wnt3a or not, causes mitochondrial networking to be reduced in the cells.  This 
shows that β-catenin is a necessary component of mitochondrial networking.   
 
As it seems that there are large effects upon the cells treated with β-catenin siRNA, 
it was easy to hypothesise that the knockdown would also have effect on other 
parameters previously tested.  The A375-Wnt3a cells previously showed a reduction 
in their ability to migrate, compared to their controls.  The Wnt3a overexpression 
cells treated with siRNA were seeded, as previously described, and the monolayer 
disturbed (see section 2.3.21).  After 24 hours, the ability of the cells to migrate into 
the wounded area was measured and represented as fold change over the Wnt3a 
cells treated with scrambled siRNA.  Figure 5.19a shows that there was a 1.3 fold 
increase in the migration ability of the A375-Wnt3a cells with knockdown of β-
catenin compared to the siRNA controls.   
Biochemical analysis of the Wnt3a overexpression cells showed a reduction in lactate 
secretion and citrate synthase compared to controls (see Figures 5.4-5.5).  When 
treated with the β-catenin or control siRNA and seeded into the assays (see sections 
2.3.25-2.3.26), cells treated with the β-catenin siRNA showed a 1.3 fold increase in 
lactate secretion compared to those cells treated with the scrambled control siRNA 
(Figure 5.19b).  Citrate synthase activity was also increased by 2.3 fold in β-catenin 
knockdown cells (Figure 5.19c).   
When β-catenin is reduced in the PTENWT cells the previous reduction in migration, 
lactate secretion and citrate synthase activity (shown in Figures 4.12, 5.5 and 5.6) 
were all reversed, indicating that β-catenin plays an important role in cellular 
migration and metabolism. 
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a) 
 
 
       b) 
 
Figure 5.18: β-catenin siRNA Knockdown Mitotracker Images, Imaris Images, Imaris Data 
a) β-catenin or control siRNA transfected cells were seeded at 2x104 cells/well onto sterile 
coverslips.  Cells were incubated with mitotracker green before counter staining with 
Hoechst.  Cells were imaged on a Nikon A1R confocal with a 60X oil objective, with the 
nucleolus in focus.  Laser power and gain settings remained constant between carrier and 
stimulated cells.  Scale bar = 10μm.  b) Data was collated from multiple cell images for each 
data set.  The area of every ‘Red channel’ object was calculated by the software and a total 
area calculated.  The total areas of all objects within the defined ranges were then 
represented as a percentage of the total.  A two way ANOVA was carried out to compare 
variance of the data. p = <0.05* or <0.0001****. 
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    a)               b)                c) 
 
Figure 5.19: β-catenin siRNA Knockdown Reverses Wnt3a-Mediated Effects on Cell 
Migration, Lactate Secretion, Citrate Synthase Activity 
a) Transfected cells were seeded at 4x105 cells/well.  After 24 hours the monolayer of cells 
was disturbed with a pipette tip and the assault was marked and imaged.  The cells were left 
for 24 hours when the damaged area was imaged again and the area calculated as a % of the 
original was calculated, fold change over control was then calculated. N=6.  b) Transfected 
cells were seeded at 2x105 cells/well before the cell supernatant was removed and stored at 
-80°C overnight before the assay was carried out.  A BCA allowed for normalisation of data 
to protein concentration and fold change over control was calculated.  N=6.  c) Transfected 
cells were seeded at 2x105 cells/well before the cells were lysed and the assay carried out 
according to manufacturer’s instructions.  A BCA for total protein was carried out to 
normalise data to protein concentration and fold change over control was calculated.  N=6. 
Mean shown ± SD. p = <0.05* or <0.0001****. 
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In order to determine if the effects on mitochondrial networking in the PTENWT cells 
are dependent on intact PTEN signalling, siRNA was used to transiently knock down 
PTEN.  The PTENWT A375 cells were treated with scrambled control or PTEN siRNA for 
72 hours, followed by a 48-hour stimulation with rWnt3a or carrier control.  Figure 
5.20a shows the successful but partial knockdown of PTEN expression levels, verified 
by western blotting (see section 2.3.13-16).  Cells were then stained with Mitotracker 
deep red as previously described (see section 2.3.29.1) and imaged on a Zeiss LSM510 
META confocal with a 63X oil objective.  Figure 5.20b shows representative images 
of the Mitotracker staining and the scrambled control samples.  These results show 
that, when treated with carrier control, there is no effect upon the mitochondria of 
the cells but, when treated with rWnt3a, the mitochondria form large networks 
around the nucleus, as expected.  The cells transfected with PTEN siRNA also show 
no differences when treated with carrier control.  However, when they are treated 
with rWnt3a the mitochondria do not become perinuclear and have reduced 
mitochondrial networking.  The mitochondria are not as fused together and, also, 
they are not as focused to the nucleus.  Rather they are spread out into the cytoplasm 
of the cells with individual mitochondria visible. 
Imaris data shown in Figure 5.20c quantifies the mitochondrial fusion effect in these 
cells.  It clearly shows the expected result in the scrambled control siRNA samples 
with networks over 1000 μm2 being formed in the rWnt3a treated cells corroborating 
previous findings (see Figure 5.9a).  The reduction in the smallest size range 0-10 μm2 
is reduced from 32% in the carrier cells to 12% in the rWnt3a cells.  The same pattern 
is seen in the cells transfected with PTEN siRNA.  There is an increase in the 
percentage of cells in the larger size range.  However, the rWnt3a treated cells do 
not form networks larger than their respective controls.  There is also a reduction in 
the percentage in the lower size range but only from 31% to   
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b) 
 
               c) 
 
Figure 5.20 PTEN Knockdown Reduces Mitochondrial Networking 
A375 cells were reverse transfected with PTEN siRNA or a scrambled control siRNA for 72 
hours. a) Cells were lysed and BCA for protein concentration was carried out.  10 µg of 
protein was run on a 12% Bis-Tris gel and transferred onto nitrocellulose membrane.  
Blocking and antibody dilutions were carried out in a 5% BSA solution, Anti-PTEN antibody 
was diluted 1:200 and incubated overnight before anti-rabbit secondary antibody and ECL 
development.  α-tubulin was used as a loading control.  b) PTEN or control siRNA transfected 
cells were seeded at 2x104 cells/well onto sterile coverslips.  Cells were incubated with 
Mitotracker deep red before fixation and counter staining with Hoechst and Phalloidin.  Cells 
were imaged on a Zeiss LSM510 confocal with a 63X oil objective.  Laser power and gain 
settings remained constant between carrier and stimulated cells.  Scale bar = 10μm.  c) Z-
slices were carried out at the optimum depth for each sample.  Data was collated from 
multiple cell images for each data set.  The area of every ‘Red channel’ object was calculated 
by the software and a total area calculated.  The total areas of all objects within the defined 
ranges were then represented as a percentage of the total.  A two way ANOVA was carried 
out to compare variance of the data compared to carrier treated cells. p = <0.05* or 
<0.001***.  
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25%.  These results show that the knockdown of PTEN significantly reduces the 
effects of Wnt/β-catenin on mitochondrial networking. 
 Analysis of Melanocytes Mitochondria in Response to Wnt3a 
Signalling 
Melanocytes are melanin producing primary cells that become mutated and are the 
basis of melanoma.  Therefore, it is interesting to investigate how the cell type of 
origin responds to Wnt3a in terms of their mitochondria.  Initially, it was necessary 
to make sure melanocytes had the capability to respond to rWnt3a stimulation, using 
the TOPFlash assay (see section 2.3.19).  Stabilised β-catenin and Wnt activated 
transcription via the TCF response elements was measured to a significant level, 
when melanocytes were stimulated with rWnt3a (see Figure 5.21a).   Following this, 
confocal imaging of the mitochondria in melanocytes treated with rWnt3a cells 
showed that there were no differences observed between cells treated with carrier 
control or rWnt3a (as shown in representative images in Figure 5.21b).  However, 
what is interesting in these findings is the mitochondria of melanocytes are very 
elongated as previously seen in the Wnt activated PTENWT cells.  This is especially 
clear in the yellow highlighted mitochondria by Imaris analysis in Figure 5.21c.  There 
is no change in the location of the mitochondria.  They remain distributed throughout 
the cytoplasm of the cells in both carrier control and rWnt3a stimulated samples.  
When analysed by the Imaris software, the carrier and rWnt3a treated cells have very 
comparable distribution of mitochondrial sizes, (Figure 5.21d) indicating that there is 
no obvious effect of activating the Wnt/β-catenin pathway on the mitochondria of 
melanocytes. 
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     a)                        b) 
  
c)               d) 
        
 
Figure 5.21: Confocal Images of Melanocytes with Imaris Analysis 
a) TOPFlash analysis of Melanocytes stimulated with carrier or rWnt3a normalised to Renilla 
showing activated Wnt/-catenin signalling in response to rWnt3a. Cells were seeded at 
2x104 cells/well onto sterile coverslips, before stimulation for 48 hours with either rWnt3a 
at 50 ng/ml or carrier control.  Cells were incubated with mitotracker deep red before 
fixation and counter staining with Hoechst and Phalloidin.  Cells were imaged on a Zeiss 
LSM510 META with a 63X oil objective.  Laser power and gain settings remained constant 
between carrier and stimulated. b) Representative confocal images.  Scale bar = 20 μm. c) 
Representative screen shots of Imaris analysis, individual mitochondria highlighted in yellow. 
Scale bar = 20 μm. d) Imaris data, data was collated from multiple cell images for each data 
set.  The area of every ‘Red channel’ object was calculated by the software and a total area 
calculated.  The total areas of all objects within the defined ranges were then represented as 
a percentage of the total. Mean shown ± SD. p = <0.05*. Ns. 
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 Discussion 
Here we show that activation of Wnt/β-catenin signalling reduces the global 
metabolism of PTENWT melanoma cells, shown by reduction in OCR, ECAR, lactate 
secretion and citrate synthase activity.  In the Wnt/β-catenin activated PTENWT cells, 
the mitochondria become perinuclear and highly networked.  The reduction of PTEN 
expression in these cells removed the fusion effect, indicating that the expression of 
PTEN is necessary for Wnt/β-catenin-induced mitochondrial fusion.  Reduction of β-
catenin also reduced the mitochondrial fusion effect and reversed the Wnt-mediated 
reduction in migration, lactate secretion and citrate synthase activity. This indicates 
that β-catenin is vital for mitochondrial dynamics and function, in cells with intact 
PTEN expression.  
The Seahorse Extracellular Flux Analyzer measures two basic parameters of cellular 
bioenergetics, oxygen consumption and acid secretion.  However, from these two 
readings a number of different metabolic factors can be calculated (511).  The 
readings are measured by small solid state sensor probes that sit 200 μm above the 
surface of the cells and record the changes in dissolved oxygen and free protons in 
the media approximately every 9 minutes.  This gives an accurate, real-time recording 
and any changes following the pneumatic injection of the compounds are seen in real 
time in the readings.  The data calculated for the A375 cells showed that there was a 
global down regulation of metabolism in these cells when the Wnt/β-catenin 
pathway was activated through the overexpression of Wnt3a.  Every aspect of 
cellular metabolism that can be calculated from these readings was reduced in the 
Wnt3a samples.  The Basal OCR and Basal ECAR are readings taken at the start of the 
assay before the injection of any compounds and these readings measure how the 
cells compare in their normal growth conditions.  These were both reduced by over 
50% of the control cell readings.  This shows that there are substantial differences in 
the cell’s metabolic phenotype with reduced cellular respiration and glycolysis levels 
when Wnt/β-catenin is activated.  Following injection of oligomycin (508), ATP 
synthesis is inhibited and the reduction in OCR can be used to calculate the ATP 
production from the cells.  FCCP is injected to uncouple the mitochondria, forcing the 
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cells to take in large volumes of oxygen as a compensation mechanism and allowing 
the maximal respiratory capacity of the cells to be calculated (511).  Finally, the 
inhibition of complex I of the electron transport chain by Rotenone (512) and 
complex III by Antimycin A (508) inhibits any mitochondrial respiration, allowing the 
calculation of any non-mitochondrial respiration, i.e. any oxygen consumption by 
non-mitochondrial sources and the proton leak, which is the re-entering of protons 
back into the mitochondrial matrix without contributing to ATP synthesis (522).  To 
reiterate, all of these factors were reduced in Wnt activated PTENWT cells and can 
possibly explain the reduction in proliferation, apoptosis, invasion and migration that 
has previously been seen in the PTENWT cells in response to active Wnt/β-catenin 
signalling (see Figures 4.6-4.10 and 4.12).  The experiments that followed, tested 
lactate secretion and amount of citrate synthase activity.  These, also, were 
measured as significantly reduced in the whole panel of PTENWT cell lines with active 
Wnt/β-catenin signalling.  All these measurements suggest that the activation of 
Wnt/β-catenin signalling reduces the global metabolism of PTENWT melanoma cells, 
including both OXPHOS and glycolysis.  In published data using mouse melanoma 
cells, B16 (203) and Figures 4.6, 4.10, 4.12-16 using PTENWT melanoma cells, 
activation of the Wnt/β-catenin signalling pathway reduced cell proliferation, 
invasion, migration and metastasis.  With reduced cellular metabolism, the cells will 
likely have reduced energy production needed for invasion, migration and metastasis 
(470), or macromolecule and lipid biosynthesis necessary for proliferation (257, 488, 
523).  In addition, a reduction in OXPHOS could be linked to the increase in apoptosis 
(see Figures 4.7-4.9), as the release of cytochrome c can halt the ETC and inhibit ATP 
synthesis (276, 524) and caspase 3 will reduce oxygen consumption via complex I and 
complex II (525).  
The results from the Extracellular Flux Analyzer for the PTENMut A2058 cells were not 
as uniform and could not be measured to a significant level.  There is a trend in all 
measurements that the metabolism of the Wnt3a cells is increased in both 
respiration and glycolysis, albeit this was not significant.  These results were 
somewhat verified by the lactate secretion where insignificant increases were seen 
in all cell lines and citrate synthase assays, where increases were seen in two lines 
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and decreases in two lines, showing the results are variable for the PTENMut cells but 
with a trend towards increased metabolism, which could explain the increased 
migration and invasion of the PTENMut cells.  The increased lactate secretion creates 
an acidic environment around the cells and facilitates invasion (318).  Although they 
could not be measured to a significant level the results, especially the basal OCR and 
ECAR readings, are very interesting as they trend towards the opposite in the A2058 
cells to the previously described A375 cells.  The activation of Wnt/β-catenin 
signalling causes a decrease in the metabolism of PTENWT cells, which was not seen 
in the PTENMut cell lines indicating that the presence of PTEN in melanoma cells has 
a significant effect on their response to Wnt/β-catenin signalling.  It is already known 
that glycolysis is regulated by PI3K-Akt pathway (194, 526).  Therefore, if signalling is 
disrupted by the lack of PTEN, an increase in glucose uptake, lactate secretion and 
increased proliferation would be expected (147).   These two pathways are linked by 
GSK3β as it is a downstream target of Akt and an upstream regulator of β-catenin.  
However, previous data is mixed on whether Akt-inhibition of GSK3β can lead to 
stabilised nuclear β-catenin (527-529).  It has already been shown that Wnt5a can 
alter melanoma cell metabolism in an Akt-dependent manner in A2058 PTENMut cells 
(196), increasing LDH activity and glycolysis.  Therefore, it would be expected that, in 
a PTENWT cell line, Wnt3a would reduce glycolysis and lactate secretion, as is seen in 
this data. 
The preliminary results gathered for the Glycolysis Stress Test assay show that the 
two cell lines also respond very differently in low glucose conditions.  The ability of 
the A375 cells to continue to respond independently of the glucose concentration 
implies that they are able to run their metabolism via another energy source.  As the 
media contains glutamine, this is probably the energy source in a process termed 
glutaminolysis (190, 277, 281, 322, 323).  Glutaminolysis allows tumour cells to 
partially run the TCA cycle from α-Ketoglutarate to citrate (277, 281, 323).  This 
alternative energy production is insensitive to high tumour ROS levels and does not 
use as much acetyl-coA, leaving it available for fatty acid synthesis (530).  
Glutaminolysis has already been found to be active in melanoma samples (281, 284), 
and, increases in c-Myc expression, leads to increase glutamine catabolism (284).  C-
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Myc is upregulated by Wnt/-catenin signalling (531).  Therefore, in these cells, the 
activation of the Wnt/-catenin pathway could be driving the PTENWT cells away from 
glycolysis and towards increased glutaminolysis, this could be tested by measuring 
glutamine levels.  The A2058 cells respond to different glucose concentrations, 
thereby indicating that glucose plays a more vital role in driving the metabolism of 
these cells.  It would be interesting to now assess the metabolism of both cell lines in 
the absence of glutamine. 
In the PTENWT A375 melanoma cells, there is a reduction in cellular ROS production 
in response to Wnt/β-catenin signalling.  As ROS can be associated with many 
different elements of cell biology, this could be seen as both positive and negative 
for the cancer cells.  ROS are a natural product of oxygen metabolism, but in times of 
cellular stress ROS can be produced at levels that cause damage to cellular 
components including DNA and RNA, which can lead to cell death (532).  High levels 
of ROS drive genetic instability as they are capable of diffusing to the nucleus where 
they damage DNA (533).  Therefore, a reduction in ROS could indicate that there is 
less cellular stress (516, 534-536) and be positive for cancer cells.  However, they 
have also been shown to have protective implications in wound repair mechanisms 
and immunology.  So, a reduction could be seen as detrimental for the cancer cells 
(535, 537).  They have also been implicated in the regulation of cell migration (538, 
539) and play a complex role in autophagy via a negative feedback loop (540-545).  A 
reduction in ROS could indicate an increase in autophagy that removes damaged 
mitochondria that are sources of ROS (543, 544) or a reduction of ROS induced 
autophagy (546).  In metastatic melanoma it is thought that a subset of ROS produced 
from NADPH oxidase (NOX) are increased and that they interact with reactive 
nitrogen species to drive melanomagenesis (90), indicating a reduction in total 
cellular ROS could be beneficial for melanoma prognosis.  The trend for the 
melanoma cells is the same as seen in the Seahorse data and the variations in aerobic 
glycolysis, and OXPHOS, can explain the relative changes in ROS levels, reduced in the 
PTENWT cells and increased in the PTENMut cells.  The ETC is a major source of ROS, 
therefore, a reduction in OXPHOS would result in reduced ROS and conversely (242), 
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higher levels of glycolysis leads to ROS production (547), but as with previous data, it 
is not significant and therefore could be unsubstantial as the increase is small.   
Recently, it has been shown that Wnt/β-catenin is linked to cellular redox via 
dishevelled (548, 549).  Nucleoredoxin (548) can reduce Wnt/β-catenin by binding to 
dishevelled and a knockdown of Nucleoredoxin activates TCF, increases proliferation, 
c-Myc and Cyclin D expression and lead to increased Ras-mediated tumourigenesis 
(548).  
The A375 cells overexpressing Wnt3a show a significant increase in total cellular 
glucose.  It has previously been shown that there is reduced glycolysis, reduced 
OXPHOS and ATP production.  Therefore, a significant increase in total cellular 
glucose poses the questions - are the cells taking in more glucose as a compensation 
for the low ATP production?  Where is this glucose being used if not through 
glycolysis?  In podocytes, Wnt/β-catenin signalling can lead to increased glucose and 
cellular stress (550).  Alternatively, Wnt/β-catenin signalling protects mesangial cells 
from high glucose induced stress (551).  It has also been shown that increased glucose 
can drive Wnt/β-catenin signalling in some cancers (188).  As described previously, 
the metabolism of melanoma cells has already shown to be dissociated from glucose 
and, rather, can be driven by glutamine (284).  Therefore, the only way to understand 
the role of glucose in these cells and answer these questions is to do a full 
metabolomics study, where 13C-glucose would be used in the culture media of the 
cells and mass spectrometry would analyse which metabolites contain labelled 
carbon atoms (552, 553).  This would be very useful for future work.   
Having previously seen differences between the PTENWT and PTENMut cohorts of 
melanoma cells in their metabolism, migration and invasion capacity, it was expected 
that their mitochondria and mitochondrial activity might be affected.  The main 
difference between the two cell cohorts is that there is no effect of Wnt/β-catenin 
signalling on the PTENMut cells.  In both the treated and the control cells, the 
mitochondria are individual and spread out throughout the cytoplasm and this effect 
is confirmed by the Imaris data.  There is no difference between the percentage of 
mitochondrial networks in any of the size ranges between control and treated cells 
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(see Figure 5.11c).  As there were no significant changes in the extracellular flux 
analysis either, these results indicate that Wnt/β-catenin signalling has no effect on 
the mitochondria or metabolism of PTENMut melanoma cells.  The PTENWT cells 
however, show a dramatic change in response to active Wnt/β-catenin signalling.  
The mitochondria appear perinuclear and the zoomed images show that they are 
elongated compared to control cells.  It has previously been shown that non-
canonical-Wnt5a signalling causes mitochondrial fission in rat neurons (500) and, 
through PKC, regulates mitochondrial distribution and dynamics by degradation of 
Alex3 protein (501).  Yoon et al. linked Wnt3a to altered mitochondrial physiology, 
but no mechanism was suggested for this effect in C2C12 cells (495).  Here we show 
that Wnt3a alters mitochondrial shape in melanoma cells.  The Imaris data shows 
that the mitochondria become highly networked.  The PTENWT cells lose a lot of their 
small individual mitochondria and the percentage of networks in the largest size 
range increases.  Interestingly, there is no effect of Wnt/β-catenin signalling on the 
mitochondrial remodelling of melanocytes.  The mitochondria of these cells are 
spread throughout the cytoplasm, but they are elongated.  Scott et al. have already 
studied the metabolic profile of melanocytes and shown that they have lower 
glycolysis levels and respond to hypoxia with a typical Pasture effect, with increased 
fermentation of glucose to lactate (284).  It would be interesting to see if Wnt/β-
catenin has an effect on melanocyte metabolism given that it had no effect on the 
mitochondrial structure (20). 
The movement of the mitochondria towards the nucleus in the PTENWT cells could 
explain the reduction in invasion and migration previously seen in Figures 4.10 and 
4.12.  The mitochondria are the site of cellular energy production.  Without the 
mitochondria at the leading edge of the cell, they do not have the energy to migrate 
and invade (239, 554).  This relocation was not seen in the PTENMut cells therefore 
leaving the mitochondria available at the leading edge.  Here, they will provide for 
the higher bioenergetic demands of the migrating cells, and will allow for an 
increased influx of Ca2+ to maintain cellular sensitivity to stimuli, and aid in cellular 
migration (554).  It is noteworthy that this is not the case for all cell types, as it has 
been shown that migrating lymphocytes have mitochondria to the posterior of the 
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nucleus and are seen to be pushed by uropods rather than pulled by pseudopods as 
seen in cancer cells (554).  The clustering or fusion of the mitochondria could have 
been due to increased numbers of mitochondria in the cells.  However, through both 
qPCR and mitochondrial mass, this was shown not to be the case, as there was no 
change in mitochondrial mass in the PTENWT cells and no difference in the ratio of 
nuclear to mitochondrial DNA ratio.  
Following these initial findings in the PTENWT cells, it was subsequently investigated 
if the changes to the mitochondria were dependent on the Wnt/β-catenin signalling 
pathway.  The same results were seen by blocking the pathway and by knocking down 
β-catenin.   DKK1 inhibits Wnt/β-catenin signalling by binding to the LRP5/6 receptor 
and blocks it from acting as a c0-receptor to FZD (234, 520).  Whereas, small 
interfering RNA is targeted to specifically disrupt the expression of β-catenin protein.  
Both of these methods result in incomplete Wnt/β-catenin signalling and the 
subsequent effect was that the mitochondria, which had previously become highly 
networked and perinuclear in response to Wnt3a signalling, now became smaller and 
spread throughout the cytoplasm, even in the presence of Wnt3a stimulation.  This 
was more severe in the β-catenin knock down, especially as a similar effect was seen 
in the control cells where the mitochondria were already small and individual.  Imaris 
quantified the effects caused by DKK1 blockage of the pathway and β-catenin 
knockdown.  The large networks are not formed and the percentage of small 
individual mitochondria is significantly increased.  This shows that β-catenin is a vital 
protein in the process of mitochondrial fusion and localisation.  Further investigation 
showed that β-catenin is also important in cell migration and metabolism.  The 
previously seen Wnt-induced reduction in migration, lactate secretion and citrate 
synthase assays were all reversed by β-catenin siRNA knockdown in the Wnt3a 
overexpressing A375 PTENWT cells.  However, what must be considered in these 
results are the wider ranging effects of β-catenin removal.  Stabilised β-catenin 
regulates the transcription of up to 70 genes (20, 168) including, Cyclin D1 and MYC, 
removal of which would affect progression through the cell cycle (439, 531), as well 
as CD44 which would change cell adhesion and migration (555).  In addition, it would 
remove the pool of β-catenin from the adherens junctions (439), therefore, altering 
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the cytoskeleton and subsequently cell shape.  However, the experiments blocking 
the pathway with DKK1 negate this effect.  However, despite these considerations, 
these findings indicated that β-catenin is vital for mitochondrial dynamics and 
function and activation of the Wnt/β-catenin signalling pathway has significant 
effects on the metabolism and mitochondria of PTENWT melanoma cells.  
The initial differences seen in invasion and metastasis and the subsequent 
differences in metabolism and upon the mitochondria were seen in cell cohorts with 
differences in PTEN.  When the PTEN levels are reduced in the PTENWT cells, the 
control over PI3K signalling is reduced.  It has already been shown that the PI3K/Akt 
pathway has an effect on cellular metabolism (526) and specifically that Wnt5a can 
alter melanoma metabolism in an Akt-dependent manner (196).  Therefore it would 
be expected that levels of PTEN would directly affect the mitochondria.  In addition, 
in neuronal cells (556, 557), and recent data in breast cancer cells (558, 559) shows 
PTEN can play a direct role in cellular metabolism and mitochondrial dynamics.  The 
data from this research supports this and shows that knockdown of PTEN 
subsequently removes the effects of increased fusion and localisation of 
mitochondria when the Wnt/β-catenin pathway was activated and, instead, the 
mitochondria were small and individual as in the PTENMut cells where there was no 
effect of Wnt3a signalling on the mitochondria (See Figure 5.9b).  These results 
confirm that the changes to the mitochondria were dependent on the PTEN status.   
These findings now push the investigation to understand why and how 
mitochondrion move towards the nucleus, forming the large networks and is this as 
a result of the reduced metabolism or is the cellular metabolism reduced because of 
the mitochondrial changes?   
 
The effects of the Wnt/β-catenin pathway were altered in melanoma cells based on 
the PTEN status.  PTENWT cells that previously showed a reduction in invasion, 
migration and metastasis (Chapter 4), also show a global reduction in cellular 
metabolism with effects upon both glycolysis and OXPHOS.  These changes were 
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accompanied by a change in mitochondrial shape and location, with the 
mitochondria becoming highly networked and perinuclear.  It was determined that 
these results were dependent upon the activation of the Wnt/β-catenin pathway and 
crucially on the presence of β-catenin itself.  Such changes to the mitochondria were 
not seen in the PTENMut cells.  However, reversing the PTEN status of the PTENWT cells 
did block these effects.  These results show that the PTEN status of melanoma cells 
plays a vital role in how the cells respond to Wnt/β-catenin signalling.  In addition 
they show that β-catenin is vital for mitochondrial fusion and cellular metabolism.   
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 Introduction 
Chapter 5 showed that activated Wnt/β-catenin signalling caused changes to 
mitochondrial shape and location and, also, reduced the metabolism of PTENWT 
melanoma cells.  The shape and function of the mitochondria has also been discussed 
in detail in Chapter 1.  This chapter will investigate the processes of mitochondrial 
dynamics, mitochondrial quality control, mitochondrial clearance and any currently 
known effects of the Wnt/β-catenin signalling pathway.  To date, most work 
investigating mitochondrial dynamics has been carried out in yeast as it is a system 
very similar to that of mammalian cells.  In vitro studies have typically used neuronal 
cells, as defects within these mitochondrial processes often lead to neurological 
disorders (242, 560).  However, the field of mitochondrial dynamics is starting to 
expand, especially given the realisation that metabolism plays such a vital role in 
many other disorders, including cancer.  Here we investigate how Wnt/β-catenin 
signalling effects mitochondrial dynamics in melanoma cells. 
 
Mitochondria are dynamic organelles that constantly go through the processes of 
fusion and fission (245, 499, 561-563), however these two opposing processes do not 
just control mitochondrial shape, but also play important roles in metabolism (258, 
564), cell cycle regulation (565) and apoptosis (238, 249, 504, 566).  It has already 
been shown in the previous chapters that Wnt signalling is highly involved in all of 
these processes.  Mitochondrial fusion and fission occur constantly during the cell 
cycle, where the biogenesis of mitochondria is dictated by cell proliferation levels 
(567).  Mitochondria have been seen to elongate during G1 phase to increase ATP 
levels for continued growth (265, 561), but they are seen to fragment during S-phase 
(265) to make sure each daughter cell has its required allocation of mitochondria 
(561, 568, 569).  The process of fusion allows for the exchange of mitochondrial 
matrix, proteins but also controls mitochondrial size and morphology (245).  There 
are three genes that control mitochondrial fusion; Mitofusin 1 (MFN1) and Mitofusin 
2 (MFN2) located on the outer mitochondrial membrane (OMM), and Optic Atrophy 
1 (OPA1) on the inner mitochondrial membrane (570).  Mfns are transmembrane 
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GTPase proteins that share a high percentage of primary sequence homology (560, 
564) and have the same functional domains, but it is thought that they play different 
roles in the fusion process.  Mfn1 is known to be involved in tethering of two 
neighbouring mitochondria together (571, 572).  This tethering can be achieved by 
homotypic or heterotypic activity of the two Mfn proteins; Mfn1-Mfn1 or Mfn1-Mfn2 
(560, 564).  However, it has been shown that the homotypic Mfn1 tethering is 100-
fold more efficient at fusing mitochondria than any other combination (571).  Mfn1 
directly interacts with Opa1 (249, 251) on the IMM to facilitate the fusion of 
mitochondrial contents.  Mfn2 has a more specific tissue expression pattern than that 
of Mfn1 (560, 572-574), which could be explained by the fact that as well as its role 
in fusion, Mfn1 is involved in a number of other processes, such as oxidative 
metabolism, cell cycle, cell death and in neuronal cells, mitochondrial axonal 
transport (560, 564).  Mfn2 tethers the mitochondria to the endoplasmic reticulum 
(ER) as part of intracellular calcium flux (560, 564, 575).  Mfn2 also binds to apoptosis 
proteins including Bak, Bcl-x and Bcl-2 in order to aid mitochondrial fission during 
apoptosis (249, 504, 560).   
Opa1 is a dynamin-related GTPase located on the IMM that regulates mitochondrial 
shape, fusion and cristae remodelling (249, 258, 564).  It is known that Opa1 is 
responsible for the fusion of the inner mitochondrial membrane, allowing the final 
step in fusing two mitochondria together and the mixing of the mitochondrial DNA 
(560).  Opa1 can form up to eight isoforms following post-transcriptional regulation 
(560, 564).  Dominant isoforms are isoform 1 (containing exon 4) and 7 (containing 
exon 4 and 5b).  Subject to proteolytic cleavage, the longer isoforms are often 
degraded (564), leaving up to 5 bands visible by western blot analysis (560).  Cleavage 
of Opa1 can also be induced by apoptosis and by loss of membrane potential (418).  
OPA1 knockdown experiments resulted in cells having reduced respiratory potential 
(561, 576), reduced membrane potential, disorganised cristae (258) and 
mitochondrial fragmentation (249, 564), but surprisingly, overexpression of OPA1 
can also lead to mitochondrial fragmentation and an increased rate of fission (258, 
418, 574).   
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There are two genes involved in the mitochondrial fission process - Dynamin-related 
protein (DNM1L) and Fission protein 1 homolog (FIS1) (560).  Drp1 is located in the 
cytoplasm and is recruited to the mitochondria when fission occurs (577).  It has has 
been shown that Drp1 forms a ring of beads around the mitochondria, gradually 
tightening until the organelle separates into two (520).  Fis1 is located on the 
mitochondria and is thought to be involved in the recruitment of Drp1 (517, 560, 
578).  Drp1 is also linked to ROS production, but the mechanism to explain this finding 
is currently unclear (249).  As well as in normal mitochondrial maintenance, fission 
occurs to break up severely damaged mitochondria to allow for more efficient 
removal of mitochondria from the cell (499, 579).  
The roles of these four genes are quite distinct in the fusion and fission processes.  
However, as stated previously, they are also involved in a number of other cellular 
processes.  Their roles in apoptosis are convoluted, involving Mfn2, Drp1 and Opa1.  
It was previously stated that Mfn2 tethers the mitochondria to the ER (560, 564, 567) 
and also binds apoptotic factors such as Bak, Bcl-x and Bcl-2 (249, 504, 560, 580).  In 
normal cells, these Bcl-2 proteins play a role in mitochondrial fusion (242, 266, 504) 
but, during early apoptotic signals, have the opposite effect to facilitate 
mitochondrial fission (265-267), to make mitochondria small enough for efficient 
removal from the cell (499, 581).  The juxtapositioning of the ER and the 
mitochondria is important for the up-take of Ca2+ through a uniporter from the intra-
mitochondrial ER stores, but it also makes the mitochondria vulnerable to apoptosis 
(242, 249, 564, 575).  The ER has been shown to be present at the site of 
mitochondrial fission, wrapping itself around the mitochondria in a constrictive 
manner (242, 561) and, at these sites of fission, Drp1 co-localises with the pro-
apoptotic factor Bak (272, 560) which normally regulates Mfn2 complex assembly 
but, in this situation, inhibits Mfn2 activity (266).  These findings indicate that Ca2+ 
influx increases mitochondrial fission via Drp1 and it has been shown in rat neurons 
that this can be induced specifically by Wnt5a β-catenin-independent signalling 
(500).  This is further justified by the finding that increased Ca2+ levels lead to Drp1 
related fission via PKC activation (as discussed in Chapter 1), which is also regulated 
by Wnt5a signalling (228, 582, 583).  Conversely, the Bcl-2 anti-apoptotic targets of 
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the Wnt/β-catenin signalling pathway have been shown to actually increase Ca2+ 
uptake without affecting respiration, thereby protecting the mitochondria from 
excessive Ca2+ (584, 585). 
The second apoptosis pathway linked to mitochondrial dynamics it that of 
cytochrome c release.  As already discussed in section 4.5.2, cytochrome c is located 
in the intermembrane space and in the mitochondrial cristae (265) and it is released 
into the cytosol in two steps.  The first step follows the outer membrane 
depolarisation.  The second step follows activation of the apoptosome during 
apoptosis and cytochrome c is released following the remodelling of the cristae by 
Opa1 and Parl (the Opa1 regulator) (249, 560, 561, 586).  Members of the Bcl-2 
family, Bax and Bak, control this release as they regulate mitochondrial membrane 
permeablisation (265, 266, 587) but, also, by Bid and Bim, which regulate cristae 
shape (258, 260, 588).  It has already been shown that Wnt/β-catenin signalling plays 
an important role in apoptosis, including the Bcl-2 proteins (350, 494, 503, 589, 590) 
and in cytochrome c release.  In addition, this research has already shown that 
Wnt/β-catenin signalling increases both apoptosis and cytochrome c release (see 
Figures 4.7-4.8) and therefore, could potentially play a role in Opa1 levels (193).  
 
The term mitophagy refers to the selective removal of mitochondria through the 
process of autophagy (591, 592).  Autophagy can occur for a few reasons, but all stem 
from the basis of metabolic stress (593).  It has been posed that autophagy in cancer 
is likely to be context, tissue and genetically-dependent (547, 594-596).  It can act in 
both a tumour suppressor role (597) as defects in autophagy lead to tumour 
progression (547), as well as being tumourigenic and promote resistance to anti-
cancer treatments (547).  Autophagy due to stress is linked to nutrient availability 
and energy homeostasis.  Alternatively, selective mitophagy is activated to remove 
damaged mitochondria that consume ATP to sustain the mitochondrial membrane 
potential (598).  The removal of mitochondria from the cell is a process that recycles 
their biomass for reuse to build macromolecules and prevent accumulation of toxic 
levels of mitochondrial ROS (594, 596, 599). 
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Mitochondrial fusion is a process dependent on mitochondrial membrane potential.  
Damaged mitochondria will lose their membrane potential, targeting them for 
removal, thereby disabling damaged mitochondria (245, 291).  It has been shown 
that mitochondrial fusion will occur even in the absence of a functional respiratory 
chain or after ATP depletion, but cannot occur when the mitochondrial membrane 
potential is lost (245).  Mitophagy targets mitochondria with a depolarised 
membrane, although it has been suggested that depolarised mitochondria may 
remain in the cell, unable to fuse (600).  PTEN-induced kinase 1 (Pink1), a 
mitochondrial kinase (601, 602), is taken into the mitochondria where Parl cleaves it 
at the N-terminus forming ΔN-Pink1 (602-605).  This removes Pink1 from 
constitutively activating the mitophagy pathway on healthy mitochondria (606).  
When the membrane potential is diminished, Pink1 is no longer processed and full 
length Pink1 accumulates on the surface of the mitochondria (242, 602, 607, 608).  It 
has been shown in neuronal cells that knockdown of PINK1 increased mitochondrial 
fragmentation and autophagy (601, 603, 609, 610), similar to the findings in Pink1-
muatated Parkinson disease cells.  Whereas, overexpression of PINK1 increased 
mitochondrial networking, elongation, cristae density and reduced autophagy.  
However, studies in Drosophila show the opposite findings (577, 610, 611) where 
overexpression of PINK1 caused mitochondrial fragmentation and increased 
autophagy.   
In selective mitophagy Parkin, an E3 ubiquitin ligase, is recruited and activated by 
full-length Pink1.  Once at the mitochondria, Parkin ubiquitinates the Mfns on the 
surface of the mitochondria (612), as well as other OMM proteins (242, 602, 603, 
607, 608, 613).  It has been stated that Parkin may play different roles in various 
cancer types (614).  As with PINK1, PARK2 (the Parkin gene) overexpression in many 
cancers has been linked to induction of apoptosis, increased mitophagy and cell cycle 
arrest (615-617), whereas knockdown is seen to increase mitochondrial 
fragmentation and reduce ATP production (618).  This indicates that activity of Pink1 
and Parkin can play a role in metabolism as well as mitochondrial quality control.  
Parkin has been shown to induce β-catenin ubiquitination and subsequent 
degradation, therefore reducing Wnt/β-catenin signalling (619, 620).  This study by 
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Rawal et al. also showed that downregulation of PARK2 led to excessive Wnt/β-
catenin signalling (619). 
Once the Mfns have been ubiquitinated by Parkin, the fusion process is blocked and 
activates the autophagy machinery (598, 602).  A double membrane autophagosome 
forms surrounding the mitochondria which fuses with lysosomes to form 
autolysosomes and sequester its contents (591, 595, 621, 622).  This process is 
controlled by a group of Atg proteins that can be divided into three groups according 
to their function.  The first are involved in the initiation step such as ULK1.  This is 
followed by nucleation involving proteins such as Beclin 1.  Finally, proteins such as 
the Microtubule-associated protein 1 light chain 3α (MAP1LC3A; LC3), control the 
elongation and closure of the autophagosome (591, 622).   
Nucleoporin p62 (SQSTM1) is an adaptor protein that recognises the ubiquitin on the 
Mfns and subsequently binds LC3 to the ubiquinated proteins ready for degradation 
(598, 622).  LC3 is then cleaved at the C-terminus and binds a 
phosphatidylethanolamine (PE) to produce its mature form found on the 
autophagosome membrane (622).  Accumulation of p62 has been associated with 
increased tumourigenesis (595) and knockdown of SQSTM1 can decrease levels of 
mitophagy (602).  However, autophagy, due to nutrient starvation, increases p62 
degradation and, therefore, reduces its intracellular levels (622).  Specifically, in 
melanoma, autophagy is reduced by knockdown of BECN1, but during starvation 
autophagy and Beclin 1 are upregulated (547, 591, 621).  Cellular energy levels are 
regulated by mammalian targets of rapamycin (mTOR) and it has been shown that 
autophagy can be inhibited via mTOR, due to activation of a number of oncogenes 
such as Ras and Akt (547, 591, 623).  The Wnt/β-catenin pathway is implicated further 
in autophagy as it is known to regulate p62 transcription (622).  During starvation, 
Wnt3a signalling is decreased due to β-catenin being targeted for degradation by LC3 
binding (596).  Conversely, knockdown of MAP1LC3A or BECN1 increases Wnt3a 
activity, indicating that autophagy negatively regulates Wnt3a signalling (595, 624).  
This is done by promoting degradation of Dvl through p62-mediated aggregation of 
ubiquitinated Dvl (595, 596, 622, 624, 625).  Likewise, Wnt/β-catenin signalling 
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downregulates autophagy via TCF4 and siRNA knockdown of β-catenin increases 
numbers of autophagosomes, as measured by increases in LC3-II and p62 in 
colorectal cancers (596).  This suggests that Wnt signalling plays a prominent role in 
the regulation of autophagy. 
 
In this final chapter, the aim is to identify a mechanism of action that enables the 
mitochondria of PTENWT cells to become highly networked with reduced cellular 
metabolism.  Firstly, investigating the genes of mitochondrial dynamics will establish 
if the mitochondrial networking is due to an increase in mitochondrial fusion or a 
defect in mitochondrial fission.  Following this, the mitochondrial membrane 
potential was analysed as this plays an important role in the health and function of 
the mitochondria, directly affecting the mitophagy process.  Finally, the genes of 
mitochondrial quality control and mitophagy were analysed to assess if the reduced 
metabolism is due to a defect in the removal process of damaged mitochondria.   
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 Wnt/-Catenin Increases Mitochondrial Fusion Genes 
In order to investigate the changes in the mitochondrial shape and networking of 
PTENWT cells shown in Chapter 5, it was necessary to investigate the genes of 
mitochondrial dynamics that control the processes of mitochondrial fusion and 
fission.  There are three genes that control fusion, MFN1 and MFN2 on the outer 
mitochondrial membrane (OMM), and OPA1 on the inner mitochondrial membrane 
(570).  There is a clear increase in mitochondrial fusion proteins in PTENWT cells and 
it was within these cells that activation of the Wnt/β-catenin signalling pathway 
caused a reduction in migration and invasion.  This was confirmed in an in vivo tail 
vein metastasis mouse model (see Chapter 4).  Confocal imaging of the fusion genes 
achieved very clear results.  Having been incubated with the Mfn1, Mfn2 or Opa1 
antibodies, a secondary antibody in the far-red channel was used for fluorescence 
imaging (see section 2.3.26.2).  As with all previous imaging, the gain settings were 
kept consistent between controls and Wnt3a overexpression samples.  The results 
are shown in Figure 6.1a.  All three mitochondrial fusion proteins show huge up 
regulation in the Wnt3a samples, indicating an increase in their expression.  This was 
also seen when the cells were analysed by flow cytometry (see section 2.3.15.2).  
Figure 6.1b shows the flow results for Mfn1, Mfn2 and Opa1 and the subsequently 
calculated fold change in fluorescence, compared to control as 1.4, 1.5, and 1.3 fold 
respectively.  The up regulation of the fusion proteins Mfn1, Mfn2 and Opa1 can also 
been seen in total protein samples in Figure 6.2a.  However DNM1L (the Drp1 gene) 
is a mitochondrial fission gene.  Imaging, flow and protein expression of active Drp1 
is not possible as it is in the cytoplasm of the cells and only recruited onto the 
mitochondria when it is needed during mitochondrial fission (273).  Therefore, by 
extracting the mitochondrial protein (see section 2.3.29) and analysing this by 
western blot (see section 2.3.13), both the fusion and fission protein levels at the 
mitochondria can be analysed (see Figure 6.2a).  In order to check the purity of the 
mitochondrial protein extraction, the expression levels of E-cadherin, lamin A/C and 
α-tubulin were also assessed as shown in Figure 6.2a.  E-cadherin is present at the 
adherens junctions (626) and lamin A/C are scaffolding elements of the nuclear 
envelope (627).  Therefore, neither of these markers   
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     a) 
                  
     b) 
   
Figure 6.1: Wnt/β-catenin Signalling Increases Expression of Mitochondrial Fusion Proteins 
in PTENWT Cells 
The fusion genes; MFN1, MFN2 and OPA1 were all analysed using confocal microscopy and 
flow cytometry with the secondary fluorescent antibody AF633. a) Wnt3a-overexpression 
cells were fixed and permeablised before staining with primary antibodies and Far Red 
secondary antibodies before counter staining with Hoechst (blue). Cells were imaged on a 
Zeiss LSM510 META with a 63X oil objective.  Laser power and gain settings remained 
constant between control and Wnt3a, but were adjusted for different antibodies. Scale bar 
= 50 μm. b) Cells were analysed on an Accuri C6 flow cytometer for expression of secondary 
antibody AF633 and fold change in fluorescence calculated. Mean shown ± SD. p = <0.05*. 
N=4. 
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should be present at the mitochondria.  During the extraction process, cytoskeletal 
markers such as tubulin or actin are also removed from the protein preparation.  
Therefore, by comparing the levels of E-cadherin, lamin A/C and α-tubulin in total 
and mitochondrial extracted protein the purity of the mitochondrial protein can be 
assessed.  Figure 6.2a shows that the levels of E-cadherin, lamin A/C and α-tubulin 
are very low in the mitochondrial protein and therefore the preparation is pure.  In 
order to qualitatively assess the loading control for the fusion and fission genes, they 
were compared to Ponceau S staining of the membrane, following transfer.  The 
fusion proteins verify the previously shown results and are all up-regulated in the 
Wnt3a samples and the active fission protein is down regulated.  To verify that this 
effect was not unique to the overexpression cells, the other PTENWT cells lines were 
treated with rWnt3a and the expression levels of Mfn1 are shown in Figure 6.2b.  In 
A375, M202 and Mel501, Mfn1 is upregulated in response to rWnt3a stimulation, 
confirming the results seen in the Wnt3a overexpression cells using total and 
mitochondrial extracted protein.  In order to quantify the increase in expression in 
these cells lines, densitometry was carried out and the relative fold increases were 
calculated at 1.15-fold in the A375 cells, 1.4-fold increase in M202 cells and 1.55-fold 
increase in the rWnt3a stimulated Mel501 cells (see Figure 6.2c).  This data shows 
that activation of Wnt/β-catenin signalling pathway causes increased mitochondrial 
fusion and decreased mitochondrial fission protein expression in PTENWT cells. 
 
It was shown in the previous chapter that, when β-catenin was knocked down in the 
PTENWT cells, there was complete fragmentation of the mitochondria (Figure 5.18a).  
To confirm this, the expression of Mfn1 was measured in the A375 control and Wnt3a 
overexpression cells treated with scrambled and β-catenin siRNA (see section 
2.3.28).  The western blot shown in Figure 6.3 clearly shows a reduction in the 
expression of Mfn1 in the β-catenin siRNA knock down, confirming that   
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a)        
 
b)                 c) 
        
 
Figure 6.2: Wnt/β-catenin Signalling Increases Expression of Mitochondrial Fusion Proteins 
and Reduces Expression of Fission Proteins in PTENWT Cells 
a) Comparing the expression of mitochondrial dynamic proteins in A375 and A375-Wnt3a 
overexpression cells in total and mitochondrial protein lysates.  Levels of E-cadherin and 
lamin A/C were used to assess the purity of the mitochondrial preparation. α-tubulin and 
ponceau s staining were used as loading controls. The mitochondria were extracted from 
6x107 A375 Wnt3a overexpression or control cells. Total protein-30 µg. b) A375, M202 and 
Mel501 cells were stimulated with rWnt3a (50 ng/ml) for 48 hours before cells were lysed 
and BCA for protein concentration was carried out and 30 µg total protein was analysed. c) 
Densitometry was carried out to quantify the increased expression of Mfn1 in rWnt3a 
treated cell lines. Mean shown ± SD. p = <0.05*. All proteins were run on a 12% Bis-Tris gel 
and transferred onto a nitrocellulose membrane.  Blocking and antibody dilutions were 
carried out in a 5% Non-Fat Milk solution. Antibody dilution: Mfn1 - 1:500, Mfn2 – 1:500, 
Opa1 – 1:200, Drp1 – 1:1000, E-cadherin 1:1000, lamin A/C 1:1000. Antibodies were 
incubated overnight before anti-mouse secondary antibody and ECL development. 
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Figure 6.3: Mfn1 Expression Levels are Controlled by β-catenin 
A375 cells were reverse transfected for 72 hours with β-catenin siRNA.  A scrambled control 
siRNA was used as a control. Cells were lysed and BCA for protein concentration was carried 
out. 30 µg of protein was run on a 12% Bis-Tris gel and transferred onto nitrocellulose 
membrane.  Blocking and antibody dilutions were carried out in a 5% Non-Fat Milk solution, 
MFN1 antibody was diluted 1:500 and incubated overnight before anti-mouse secondary 
antibody and ECL development.  α-tubulin was used as a loading control. 
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depletion of β-catenin causes a reduction in Mfn1 protein.  This data indicate that β-
catenin regulates fusion proteins in PTENWT melanoma cells. 
 
It was previously shown that PTEN siRNA (see Figure 5.19) also removed the 
mitochondrial fusion effect from the A375 cells.  This effect is confirmed in a 
reduction of Mfn1 protein expression in A375 cells treated with PTEN siRNA, 
compared to scrambled siRNA control (see Figure 6.4).  The cells were treated with 
carrier or rWnt3a protein and the increase in Mfn1 seen in the rWnt3a treated 
sample supports previous results (see Figure 6.1-6.2).  These results show that the 
presence of PTEN is needed for the up regulation of Mfn1 in cells with activated 
Wnt/β-catenin signalling. 
 
As all the levels of fusion and fission genes are affected by the activation of the 
Wnt/β-catenin pathway and the expression of Mfn1 was reduced by the removal of 
β-catenin, qPCR (see section 2.3.27) was utilised to see if the fusion and fission genes 
are controlled at the transcriptional level by β-catenin.  There was no statistical 
significance in the difference at the mRNA level in any of the four genes measured as 
shown in Figure 6.5.  There are large error bars but, following normalisation to three 
housekeeping genes (β-actin, YWHAZ, UBC), it is possible to conclude that β-catenin 
does not transcriptionally control expression of these mitochondrial dynamics genes. 
 Mitochondrial Fusion Accompanies an Increase in 
Mitochondrial Membrane Potential 
A mitochondrial membrane potential is created when free ions generated from the 
TCA cycle pass through components of the ETC in the mitochondrial membrane (628).  
Fluorescent dyes, such as JC1 and TMRM, can measure the membrane potential as 
they accumulate inside the mitochondria in a manner directly   
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Figure 6.4: Mfn1 Expression levels are Controlled by PTEN 
A375 cells were reverse transfected for 72 hours with PTEN siRNA.  A scrambled control 
siRNA was used as a control. Cells were lysed and BCA for protein concentration was carried 
out. 20 µg of protein was run on a 12% Bis-Tris gel and transferred onto nitrocellulose 
membrane.  Blocking and antibody dilutions were carried out in a 5% Non-Fat Milk solution, 
MFN1 antibody was diluted 1:500 and incubated overnight before anti-mouse secondary 
antibody and ECL development.  α-tubulin was used as a loading control. 
 
 
 
Figure 6.5: Transcriptional Regulation of Mitochondrial Fusion and Fission Genes in A375 
control and Wnt3a Overexpression Cells 
qRT-PCR for MFN1, MFN2, OPA1 and DRP1 in A375 control and Wnt3a overexpression cells. 
mRNA expression levels were normalized based on the expression of three housekeepers, 
Ywhaz, UBC and β-actin.  RNA was extracted using GeneJet and quantified, RT-PCR was 
carried out and 2 μg of cDNA was analysed using SYBR green. N=3. Ns. 
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proportional to the mitochondrial membrane potential (629, 630).  Accumulation 
causes a shift in their fluorescence which can then be analysed by flow cytometry as 
a measure mitochondrial membrane potential and a subsequent indication of 
mitochondrial health, fusion and cellular stress. 
JC1 (5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide; 
Invitrogen) is a green fluorescent monomer but, as it accumulates in the 
mitochondria, it forms red J-aggregates (631).  Therefore, the ratio of green to red, 
when analysed by flow cytometry (see section 2.3.15.4) gives a proportionate 
analysis of the membrane potential.  Figure 6.6a shows a shift in the FL2 (red) channel 
in A375-overexpression cells.  The shift is measured by the percentage of cells in the 
high FL2 gate-R1 and lower FL2 gate-R2.  The A375-Wnt3a overexpression cells show 
a 13% shift from R2 to R1, indicating an increase in membrane potential, which is 
represented, by an increase in J-aggregates forming in the mitochondria.  
TMRM is a methyl ester of tetramethylrhodamine and, like JC1, is a cationic dye that 
accumulates in the mitochondria relative to the mitochondrial membrane potential 
according to the Nernst equation (629, 630).  Figure 6.6b shows the flow cytometry 
staining of TMRM (see section 2.3.15.4) and, as with the JC1 results, the shift in 
fluorescence is represented in the change of percentage in gates R1 and R2.  The 
Wnt3a overexpression cells increase the percentage of cells in R1 from 87 to 98%, 
indicating an increase in membrane potential.  Taken together the data shows using 
two different membrane potential dependent dyes, Wnt/β-catenin signalling in 
PTENWT cells causes an increase in mitochondrial membrane potential. 
 Investigations of Mitophagy Control by Canonical Wnt 
Signalling 
As explained in section 6.1.2, the regulation of mitochondrial quality control is 
governed by two genes called PINK1 and PARK2.  It has previously been shown that 
Pink1 is vital for mitochondrial fusion (603, 609), but along with Parkin, it is also 
implicated in mitophagy and in the prevention of oxidative stress (632, 633).    
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a)       
 
 b)  
 
Figure 6.6: Wnt/β-catenin Increases Mitochondrial Membrane Potential of PTENWT Cells 
Representative images of Flow Cytometry.  A375-Wnt3a overexpression cells were incubated 
with a) 2 μM JC-1 or b) 20 μM TMRM diluted in complete media for 2 hours at 37°C, cells 
were washed in PBS before being resuspended in FACS buffer (PBS +0.01% FCS) and analysed 
on an Accuri C6 flow cytometer. Mean shown ± SD. p = <0.05*. N=3. 
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Therefore, understanding the activity of Pink1 and Parkin in these cells could explain 
the mitochondrial fusion effects and subsequent down regulation of metabolism. 
 
Typically, Pink1 is taken into the mitochondria where Parl cleaves it at the N-terminus 
forming ΔN-Pink1 (602-605).  This removes Pink1 from constitutively activating the 
mitophagy pathway on healthy mitochondria (606).  During selective mitophagy, 
cleavage stops allowing full-length Pink1 to accumulate on the mitochondria where 
it recruits and activates Parkin.  Investigating the protein expression (see section 
2.3.10-2.3.13) of Pink1 in the Wnt3a overexpressing cells revealed two distinct bands 
(see Figure 6.7).  These two isoforms have previously been published as a full length 
Pink1 at 63kDa and ΔN-Pink1 at 53kDa (603) which are formed from cleavage of the 
N-terminus of Pink1 upon entering the mitochondria.  Figure 6.7 shows that the 
control cells have roughly equal expression of both isoforms of Pink1, but the A375-
Wnt3a overexpression cells have increased expression of the full-length isoform and 
reduced levels of the cleaved isoform.  These findings indicated a reduction in Pink1 
cleavage which could be effecting the recruitment of Parkin to the mitochondria in 
the mitophagy pathway. 
 
As Pink1 is vital for recruitment of Parkin, it was important to study the levels of 
Parkin in both total and mitochondrial extracted protein (613).  Figure 6.8a shows 
that there is no difference in the protein levels of Parkin in the Wnt3a overexpression 
cells compared to control. Figure 6.8b shows that, as with total protein, there are no 
differences in the levels of Parkin at the mitochondria, but interestingly there are 
increased levels of β-catenin at the mitochondria in Wnt3a overexpression cells.  It 
has previously been suggested in neurons that Parkin can bind to β-catenin in a 
protective role against excessive Wnt/β-catenin signalling (619), as would be the case 
in the Wnt3a-overexpressing cells where the signalling pathway is constitutively 
active.  Therefore, the potential binding of Parkin to β-  
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Figure 6.7: Wnt/β-catenin Signalling Reduces Pink1 Cleavage 
A375 Wnt3a overexpression or control cells were lysed and BCA for protein concentration 
was carried out and 25 µg total protein was run on a 12% Bis-Tris gel and transferred onto a 
nitrocellulose membrane.  Blocking and antibody dilutions were carried out in a 5% Non-Fat 
Milk solution, anti-Pink1 1:1000, and incubated overnight before anti-rabbit secondary 
antibody and ECL development.  α-tubulin was used as a loading control. Arrows indicate 
sizes of full length Pink1 at 63kDa and ΔN-Pink1 at 53kDa. 
 
 
 
a)                                                               b)     
               
 
Figure 6.8: Total and mitochondrial Parkin Expression in Unaffected by Wnt/β-catenin 
Signalling but β-catenin expression at the Mitochondria is Increased 
a) A375 Wnt3a overexpression or control cells were lysed and BCA for protein concentration 
was carried out and 30 µg total protein was run on a 12% Bis-Tris gel and transferred onto 
nitrocellulose membrane.  Blocking and antibody dilutions were carried out in a 5% Non-Fat 
Milk solution, Parkin 1:1000, and incubated overnight at 4°C before anti-rabbit secondary 
antibody and ECL development.  α-tubulin was used as a loading control. b) The mitochondria 
were extracted from 6x107 A375 Wnt3a overexpression or control cells.  Mitochondrial 
pellets were resuspended in 1X SDS loading buffer.  Concentrations are unknown, Ponceau 
S staining was used for loading comparisons. Proteins were blotted for Parkin at 1:200 and 
β-catenin at 1:1000. 
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catenin in melanoma cells was investigated using co-immunoprecipitation of β-
catenin and Parkin (see section 2.3.30).  The blot shown in Figure 6.9 shows the 
results.  The levels of Parkin were analysed in the 1/150th of total input of protein, 
the two pre-clear stages using Concavolin A (399) beads for non-glycosylated β-
catenin and IgG control for non-specific binding in the IP samples.  Parkin is present 
in all samples, including the IP samples indicating that Parkin does bind β-catenin in 
PTENWT melanoma cells.  The level of binding in the Wnt3a samples is higher than 
that in the control cells indicating that when β-catenin is stabilised, it has higher 
levels of protein binding to Parkin.  As a control for the IP, the samples were all 
blotted for β-catenin as well.  This is shown in the right column of results in Figure 
6.9.  As expected, β-catenin expression was higher in the total input and the IP of the 
Wnt3a samples, this implies that Parkin binds to the cytoplasmic portion of β-catenin 
rather than the adherens junction pool.  Also expected was the lower expression in 
the Wnt3a ConA pre-clear sample, as the Wnt3a samples should have stabilised β-
catenin and therefore will have lower levels of non-glycosylated β-catenin.  These 
controls verify the quality of these results showing that β-catenin binds Parkin and 
that the binding increases in response to Wnt/β-catenin signalling.  
 
As changes to Pink1 cleavage and Parkin binding have been measured, it is necessary 
to investigate if these have any effect on mitophagy, mitochondrial specific 
autophagy.  As explained in section 6.1.2, the Pink1/Parkin pathway maintains 
mitochondrial homeostasis by removing damaged mitochondria through the process 
of autophagosome engulfment (602).  LC3 and p62 are two genes involved in this 
process so their expression levels can indicate levels of autophagy (634). 
LC3 expression was analysed in the A375 Wnt3a-overexpression cells (see Figure 
6.10a).  LC3 (634) is seen in two forms.  LC3I (18kDa) is cytosolic and, when activated, 
is cleaved at the C-terminus to form LC3II (16kDa), which binds to the 
autophagosomes (591, 622).  The control cells only have expression of LC3II,   
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Figure 6.9: Parkin Binds to β-catenin in PTENWT Melanoma Cells 
A375 Wnt3a overexpression or control cells were lysed and BCA for protein concentration 
was carried out. 4 mg of protein was put into a β-catenin IP.  Samples: Total protein diluted 
1:150, pre-clear with ConA beads for non-glycosylated β-catenin and IgG control for non-
specific binding, any unbound protein and IP samples.  All samples were blotted for Parkin 
1:200 and β-catenin 1:1000.  
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indicating that it is constantly activated and autophagosomes are constantly present 
or in the process of forming suggesting that A375 cells are autophagy dependent. 
However, the results for the Wnt3a overexpression cells show much higher levels of 
LC3I.  This suggests that activation of the Wnt/β-catenin signalling pathway may 
inhibit autophagy in the PTENWT melanoma cells. 
As the β-catenin siRNA (see section 2.3.28) experiments have previously been very 
informative and shown that β-catenin is vital in mitochondrial fusion and 
metabolism, the effects of the siRNA knockdown were also investigated in LC3 
expression.  Figure 6.10b shows that the A375-Wnt3a-overexpressing cells lose the 
expression of LC3I when β-catenin is removed from the cells and revert back to the 
autophagy phenotype that highly expresses LC3II.   
Finally, in order to investigate if this effect was specific to the PTENWT cells, the LC3 
expression was analysed in the PTENMut cells.  Figure 6.10c shows the expression in 
A2058 control and Wnt3a-overexpression cells.  The ratio of LC3I to LC3II is equal in 
both cell types, indicating that there is no effect of the Wnt/β-catenin pathway on 
autophagy in these cells.  These results suggest that PTENWT cells have high levels of 
autophagy, where activation of the Wnt/β-catenin signalling pathway can antagonise 
the autophagy pathway in these cells and that β-catenin is necessary for this to occur. 
The autophagy adaptor p62 is responsible for targeting ubiquinated proteins to the 
autophagosomes (602).  Accumulation of p62 is associated with tumourigenesis 
(595) and it is accepted that inhibiting autophagy will cause an accumulation of p62 
(622) and processes such as hypoxia and nutrient starvation, induce p62 degradation 
(288, 622).  The results in section 6.5.1 show that activation of the Wnt/β-catenin 
pathway can block autophagy and this process potentially sends the cells into a 
nutrient poor environment.  It has been shown that p62 can bind and interact with 
the Wnt signalling pathway (see section 6.1.2) and this previous research has led to 
the finding that Wnt/β-catenin downregulates autophagy and represses p62 (596).  
Figure 6.11a confirms these findings in PTENWT melanoma cells.  The Wnt3a-
overexpression cells have a reduced level of p62 when compared   
  
 
 
 
246 
a)                                                                                     b) 
                          
     
  c) 
 
 
Figure 6.10: Wnt/β-catenin Signalling Reduces Autophagy in PTENWT Cells but not in 
PTENMut Cells. 
A375 Wnt3a overexpression or control cells were lysed and BCA for protein concentration 
was carried out and 25 µg total protein was run on a 12% Bis-Tris gel and transferred onto 
nitrocellulose membrane.  Blocking and antibody dilutions were carried out in a 5% Non-Fat 
Milk solution, LC3 1:1000, and incubated overnight before anti-rabbit secondary antibody 
and ECL development.  α-tubulin was used as a loading control. a) Total protein b) Protein 
treated with β-catenin siRNA.  c) A2058 control and Wnt3a overexpression cells. 
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to the control cells and this expression is reversed when β-catenin is removed by 
siRNA (See Figure 6.11b).  These results show that p62 is downregulated by Wnt/β-
catenin signalling and, combined with the findings of LC3, confirms previous findings 
that Wnt/β-catenin signalling reduces autophagy (596) in PTENWT, but not PTENMut 
melanoma cells. 
 β-Catenin Binds Proteins Involved in Cellular Metabolism 
Given β-catenin was found to be present at the mitochondria and it binds to Parkin, 
in addition to the previous findings that β-catenin knockdown affected metabolism 
all suggest that it is a major player in cellular metabolism.  To investigate this further 
we decided to analyse the previously described IP samples (see section 6.4.2) by mass 
spectrometry (MS; see section 2.3.30.1-2.3.30.3).  The data was normalised to non-
specific IgG binding and then compared to either increased or decreased binding 
between the control and the Wnt3a overexpression cells.  These proteins were 
subsequently analysed using PANTHER.  Listed in Table 6.1 are the 5 proteins with 
the highest increase and decrease in binding to β-catenin.  Of these, 3 of the top 5 
proteins with increased binding are linked to metabolism, as are 4 of top 5 proteins 
with decreased binding to β-catenin.  Of specific interest is Microtubule associated 
protein 1B (MAP1B).  This protein had the most reduced level of binding to stabilised 
β-catenin and it is identified as a protein of cellular process.  MAP1B regulates 
microtuble assembly and has been linked to the axonal movement of mitochondria 
and autophagosome formation (635, 636).  MAP1B is a member of the same family 
as LC3 (MAP1LC3A) which has previously been measured to be altered by Wnt/β-
catenin signalling (see Figure 6.10a).  Surprisingly, Parkin was not found in these 
samples, which would have been expected from previous findings (see Figure 6.9).  
However, the results provided much new information about β-catenin binding 
partners.  Figure 6.12a shows the GO Biological Processes of proteins with increased 
binding to β-catenin.  Of these genes, 35% were involved in metabolism.  These 
metabolism genes are listed in Table 8.1 (Appendix).  Of specific interest from this list 
are a number of proteins involved in translation, cell cycle and apoptosis, specifically 
Cytochrome c, which as shown in Figure 4.8, is already known   
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a)                                                                                   b) 
                 
 
Figure 6.11: Wnt/β-catenin Signalling Degrades p62 Expression 
A375 Wnt3a overexpression or control cells were lysed and BCA for protein concentration 
was carried out and 25 µg total protein was run on a 12% Bis-Tris gel and transferred onto 
nitrocellulose membrane.  Blocking and antibody dilutions were carried out in a 5% Non-Fat 
Milk solution, p62 1:1000, and incubated overnight before anti-rabbit secondary antibody 
and ECL development.  α-tubulin was used as a loading control. a) Total protein b) Protein 
treated with β-catenin siRNA.   
 
Table 6.1: Top 5 Proteins with Increased (green) and Decreased (red) Binding to β-catenin 
Mapped 
ID 
Gene Name/Symbol 
 
GO Biological 
Process 
Function 
Q14692 Ribosome biogenesis 
protein BMS1 homolog 
BMS1 
ortholog 
Metabolic Process Nucleobase-containing 
compound metabolic process 
Q9H0A0 N-acetlytransferase 10 Biological Process 
Metabolic Process 
Nucleotide binding 
Q5BKZ1 DBIRD complex subunit Cellular Process DNA binding 
Q9Y678 Coatomer subunit 
gamma-1 
Localisation Vesicle coat protein  
Q9NVP1 ATP-dependent RNA 
helicase DDX18 
DDX18 
ortholog 
Metabolic Process 
Biological 
regulation 
nucleobase-containing 
compound metabolic process 
translation 
regulation of translation 
P46821 Microtubule associated 
protein 1B 
Cellular Process Non-motor microtubule 
binding protein 
P40227 T-complex protein 1 
subunit zeta 
CCT6A 
ortholog 
Metabolic process 
Cellular component 
organisation or 
biogenesis 
Protein folding, protein 
compex assembly, protein 
complex biogenesis 
P09972 Fructose-bisphosphate 
aldolase c 
Apoptotic Process 
Metabolic Process 
Carbohydrate degradation  
glycolysis 
O43175 D-3-phosphoglycerate 
dehydrogenase 
PHGDH 
ortholog 
Metabolic Process Carbohydrate metabolic 
process 
Cellular amino acid 
biosynthetic process 
P52209 6-phosphogluconate 
dehydrogenase, 
decarboxylating 
PGD 
ortholog 
Metabolic Process Pentose phospate shunt 
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to be released in response to Wnt/β-catenin.  The MS analysis also discovered that a 
number of proteins have lower binding to β-catenin when the Wnt/β-catenin 
signalling pathway is activated.  As shown in Figure 6.12b, 42% of proteins with 
reduced binding are involved in metabolism, details of which are in Table 8.2 in the 
Appendix.  As with the proteins with increased binding, the list of proteins with 
reduced binding also has a number of interesting findings, including those involved 
in glycolysis, amino acid metabolism, the ETC and the TCA cycle.  Specifically, there is 
a reduction in Lactate Dehydrogenase A  (LDHA) and Lactate Dehydrogenase B 
(LDHB), supporting the results as shown in Figure 5.6 where a reduction in lactate 
secretion was measured in the PTENWT melanoma cells with active Wnt/β-catenin.  
Table 8.2 also includes ATP-citrate synthase, supporting the reduction in citrate 
synthase activity measured in these cells in Figure 5.5.  These findings show that β-
catenin binds to a number of genes involved in metabolism.  As previously shown in 
Figure 5.18, the removal of β-catenin increased lactate secretion and citrate synthase 
activity, combined with this data, now implicates β-catenin as a key regulator of 
melanoma cell metabolism. 
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a)                   
 
b)                      
 
 
Figure 6.12: Mass Spectrometry Identifies Novel β-catenin Binding Partners in PTENWT 
Melanoma Cells 
A375-Wnt3a overexpression cells used in the β-catenin IP shown in Figure 6.11 were 
analysed by nano-LC-MS/MS on a Thermo Scientific Q Exactive.  Identification and label free 
quantification of peptides was done with MaxQuant 1.5.  Proteins that were significantly 
regulated between conditions were identified using a permutation-based t-test (S1, FDR 5%) 
in Perseus 1.4.1.3. GO-terms were analysed using PANTHER 9.0. a) GO Biological processes 
with increased binding to β-catenin. b) GO Biological processes with reduced binding to β-
catenin.   
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 Discussion 
It was previously shown that activation of the Wnt/β-catenin pathway caused the 
mitochondria of PTENWT melanoma cells to become highly networked, elongated and 
perinuclear with reduced cellular metabolism.  The aim of this chapter was to 
investigate a mechanism that controls this process.  It was found that PTENWT 
melanoma cells have high levels of autophagy providing nutrients for proliferation, 
invasion and migration.  Activation of the Wnt/β-catenin pathway blocks this 
potentially though the binding of β-catenin to Parkin.  This subsequently causes the 
mitochondria to elongate and cluster near the nucleus in a protective manner against 
autophagosome formation and sends the cells into a state of starvation.  This results 
in increased expression of mitochonadrial fusion proteins, an increase in glucose 
intake, potentially as a compensatory mechanism.  This results in the reduced 
OXPHOS, ATP production and glycolysis as previously shown.  
The mitochondria of PTENWT melanoma cells have increased levels of mitochondrial 
fusion proteins in response to active Wnt/β-catenin signalling, as shown by imaging, 
flow cytometry (see Figure 6.1), and western blot (see Figure 6.2).  This includes the 
analysis of mitochondrial fusion proteins Mfn1 and Mfn2 on the OMM and Opa1 on 
the IMM.  This was seen in both total protein and, to a greater extent, in 
mitochondrial extracted protein.  It was also seen in cells with overexpressed Wnt3a, 
to a greater extent to that observed in cells treated with rWnt3a, indicating that 
constitutively active Wnt/β-catenin signalling prolongs and enhances this effect, 
probably due to the increased levels of Wnt3a secretion in the overexpression cells. 
Yoon et al. observed increased size and length of mitochondria of Wnt3a treated 
C2C12 cells (495), potentially implicating Mfns in this model, although the regulators 
of mitochondrial dynamics were never investigated in this study.  In support of the 
findings shown here, including the increased expression of Mfns and the changes to 
mitochondrial shape and location seen in PTENWT melanoma cells in Figure 5.9a, it 
has previously been shown that the overexpression of both MFN1 and MFN2 in COS-
7 and HeLa cells causes mitochondrial perinuclear aggregation (239, 562, 572, 581, 
637) and, in some cell types (U2OS cells), the mitochondria are observed in 
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perinuclear clusters under control conditions (561).  In HeLa and breast cancer cells, 
the increased expression of MFN1 caused the mitochondria to be longer, highly 
branched and interconnected, which is clearly seen in Figure 5.10 (239, 245).  Also, 
knockdown experiments in MEFs resulted in small, cytoplasmically dispersed, 
punctate mitochondria (574, 638), indicating MFN1 plays a specific role in 
mitochondrial elongation (245, 318).  In breast cancer cells, MFN1 knockdown 
increased the tumour cells’ ability to migrate and invade (239).  Likewise, we show 
here, that cells with increased Mfn expression have reduced invasion and migration 
as shown in Figures 4.10 and 4.12.  Overexpression of MFN2 has been seen to 
increase membrane potential, glucose oxidation and inhibit apoptosis (266, 581).  
Whereas, knockdown of MFN2 has been shown to reduce the membrane potential, 
cellular oxygen consumption and glucose oxidation (564, 573), as well as the activity 
of respiratory complexes I and III (581).  The highly fused, perinuclear mitochondria 
of PTENWT melanoma cells have increased membrane potential, compared to their 
controls (see Figure 6.6), measured by two different mitochondrial membrane 
potential-dependent dyes. Increased membrane potential is expected from highly 
fused mitochondria (639) as the fusion process itself is dependent on the 
mitochondrial membrane potential being intact (245, 291).  In a variety of cancers 
including gastric cancer, Mfn2 has been shown to have significantly lower expression 
levels than in normal tissue (580).  However, similar to the results seen in PTENWT 
melanoma cells, the overexpression of MFN2 reduced proliferation, invasion and 
migration, as well as increasing mitochondrial membrane potential and inducing 
apoptosis (580, 640-642), indicating that Mfn2 has an anti-tumour effect and that 
MFN2 may play a direct role in cellular metabolism by affecting OXPHOS (249).  In 
addition, increased Mfn expression and mitochondrial length have been linked to cell 
senescence (643, 644), therefore investigating senescence in future work could give 
more strength to the reduction in proliferation previously seen (see Figure 4.6). 
It has been suggested that increased levels of Mfns only tether the outer 
mitochondrial membrane, causing the mitochondria to cluster, but without the inner 
mitochondrial membrane fusion (239).  This data shows that there is an also 
increased level of Opa1.  Indicating full fusion of the mitochondria (see Figures 6.1-
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6.2).  To enhance these findings, a photoactivated construct such as Mito-PA-GFP 
(Addgene) could be used (645).  This GFP construct increases its fluorescence 100-
fold when activated by 2-photon excitation.  It is transfected into cells with mito-
DsRed and time-lapse imaging is utilised to capture the mitochondrial fusion.  If full 
fusion occurs, the mitochondrial context will mix, gradually diluting the highly 
fluorescent PA-GFP.  However if full fusion does not occur, fluorescence will remain 
high (645).  This option was not chosen in this research as the fusion effects were 
visualised following 48 hours of stimulation.  Therefore, time-lapse imaging would 
not have been possible over this period without photobleaching, which could have 
removed fluorescence results. 
Wnt/β-catenin signalling reduced mitochondrial fission in PTENWT melanoma cells, as 
shown by levels of active Drp1 in extracted mitochondrial proteins.  This further 
verified the results of cell invasion, migration and metastasis shown in Figures 4.10, 
4.12-4.16 and the mitochondrial imaging shown in Figure 5.9a.  It is already known 
that fission is needed to distribute the mitochondria at the leading edge of a tumour 
for movement (239, 554) as explained in section 5.6.  As increased fission is usually 
seen as a sign of severely damaged mitochondria (561) and loss of membrane 
potential is often indicative of cell death (265), these results suggest an increase in 
the health of the mitochondria in response to active Wnt/β-catenin signalling.  Drp1 
has been shown to be upregulated in metastatic lesions and lymph nodes of breast 
cancers (239) and the expression levels were directly proportional to the severity of 
invasiveness and metastasis (239).  In breast cancer samples, the mitochondria were 
found to be more fragmented and expressed lower levels of Mfns (239).  
Unsurprisingly, inhibition of DRP1 leads to elongated, perinuclear mitochondria in 
breast cancer cells (239, 646) with reduced migration and invasion (239) and, in lung 
cancer samples, has been shown to increase apoptosis (565).  This corresponds to 
results shown here in the PTENWT melanoma cells where reduced expression of active 
Drp1 was measured in cells with elongated mitochondria, reduced invasion and 
migration and increased apoptosis. 
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None of the genes of mitochondrial dynamics are controlled at the transcriptional 
level by β-catenin (see Figure 6.5), but siRNA knockdown of β-catenin reduced 
mitofusin levels (see Figure 6.3) indicating that β-catenin plays a vital role in 
mitochondrial dynamics, yet not through de-novo transcription of the MFN genes.  It 
is known that Mfns are degraded by the proteasome (647) following ubiquitination 
by Parkin (606, 608).  However, total and mitochondrial Parkin levels were equal (see 
Figure 6.8a+b), indicating that there is no direct effect of the Wnt/β-catenin pathway 
on Parkin recruitment to the mitochondria.  However, it is possible that activation of 
Wnt/β-catenin signalling could perturb the Pink1/Parkin pathway through an 
alternative mechanism.  Pink1 is taken into the mitochondria and cleaved at the N-
terminus by Parl (603), but in cells with a reduced mitochondrial membrane 
potential, Pink1 is no longer cleaved and, instead, full-length Pink1 accumulates on 
the OMM (605) which subsequently recruits Parkin (604).  It has been shown, that 
the ratio of full-length Pink1 to its cleaved form, ΔN-Pink1, is important and, 
dysregulation of Pink1 cleavage, can lead to a reduced mitochondrial membrane 
potential, an increase in ROS and a disrupted mitochondrial network (603).  In 
PTENWT melanoma cells with activated Wnt/β-catenin signalling, there is an increase 
in the mitochondrial membrane potential (see Figure 6.6) as well as an increase in 
the ratio of full-length Pink1 to ΔN-Pink1 (see Figure 6.7).  It might be possible that 
Pink1 is being aberrantly cleaved and, potentially, Parl is downregulated by Wnt/β-
catenin signalling, although this would need to be directly investigated.  Alternatively, 
it is already known that Parkin can bind to β-catenin in a protective manner against 
excessive Wnt/β-catenin signalling in neuronal cells, protecting the cells from Wnt-
induced apoptosis and cell cycle dysregulation (619).  It is shown here that β-catenin 
is present at the mitochondria and the level is increased when β-catenin is stabilised 
(see Figure 6.8b). It is also shown here, for the first time, that Parkin binds β-catenin 
in melanoma cells.  These results indicate that β-catenin binds to Parkin in the 
cytoplasm of PTENWT melanoma cells.  This is increased as the levels of cytoplasmic, 
stabilised β-catenin increase, potentially affecting the recruitment of Parkin to the 
mitochondria.  In order to investigate this further, co-IP of Parkin and Pink1 would 
inform if their interactions were reduced in Wnt/β-catenin cells and an E3 activity 
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assay could analyse if increased binding of Parkin to β-catenin effects Parkin activity 
(607). 
In order to investigate if the downstream effects of the Pink1/Parkin pathway on 
mitophagy were altered by aberrant Pink1 cleavage or by increased Parkin/β-catenin 
binding, markers of autophagy were investigated.  LC3 (634) is a protein that plays 
an important role in the elongation and closure of the autophagosome.  Its lipidation 
converts it from LC3I to LC3II (591, 621, 622).  Figure 6.10a shows PTENWT melanoma 
cells do not have detectable levels of LC3I.  This phenotype has previously been 
described for cells undergoing autophagy dependency or addiction (541, 599, 623, 
648).  This implies that these cells, require autophagy to recycle cellular components 
to use in the biosynthesis of essential amino acids in order to sustain cell survival, 
metabolism, proliferation and tumourigenesis (541, 547, 599, 621, 623, 648, 649).  
To fully determine this, siRNA knockdown of autophagy proteins Beclin1 or Atg5 
would be needed (541).  The expression of LC3 in Wnt3a activated PTENWT cells shows 
equal expression of LC3I and LC3II showing that autophagy is inhibited by the active 
Wnt/β-catenin pathway.  This removes the source of nutrients from these cells, 
ultimately sending them into a state of starvation as depicted in Figure 6.10a.  In 
support of all of this data, others have shown that, in a state of starvation, levels of 
cAMP increase and subsequently activate PKA, this causes the phosphorylation of 
Drp1 on Ser637 causing the mitochondria of cancer cells to elongate, become 
perinuclear (as shown in Figures 5.9a and 5.10) and have reduced levels of autophagy 
(596, 598, 606).  This suggests that investigation into cAMP expression, PKA activity 
and Drp1 phosphorylation at Ser637 could also confirm autophagy dependency in 
the PTENWT cells.  The mitochondria respond in this manner to protect themselves 
from macroautophagy, as they become too large to fit into the autophagosome.  
Their elongation preserves ATP levels via increased cristae density and, therefore, 
maintains cell viability (242, 598, 606). In addition, the expression of the adaptor 
protein p62, plays an important role in regulating cellular autophagy and it is 
connected to the Wnt/β-catenin pathway though p62-mediated degradation of 
Dishevelled (595, 596, 622, 624, 625).  Its expression is reduced in Wnt3a 
overexpression cells (see Figure 6.10a), supporting the finding that β-catenin 
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stabilisation can inhibit the formation of the autophagososme and the subsequent 
repression of p62 (596), due to degradation during nutrient starvation (622).  As in 
APC driven-colorectal cancers (596), siRNA knockdown of β-catenin reverses the 
Wnt3a-overexpression cells back to their autophagy dependent state.  This increases 
the levels of p62 in cells with activated Wnt/β-catenin signalling (see Figure 6.10b) in 
a transcriptional manner through TCF4 (596), adding to the growing support that β-
catenin is vital in the regulation of mitochondrial related functions.  
To determine if these findings were also dependent on the intact signalling of PTEN, 
siRNA knockdown of the expression was utilised.  PTEN siRNA removed the 
mitochondrial fusion effect and downregulated Mfn1 expression (see Figures 5.20 
and 6.4), showing that the nature of Wnt/β-catenin signalling on the mitochondria is 
PTEN dependent and presumably this is also the case regarding the effects on cellular 
metabolism as the LC3 expression is unaffected by Wnt/β-catenin activation in 
PTENMut melanoma cells, as shown in Figure 6.10c. 
Autophagy addiction is common in cancers with KRas mutations, such as in lung and 
pancreatic cancers and this research has shown for the first time, in melanomas with 
downstream effector mutations such as the BrafV600E or NRas mutations may also be 
dependent on autophagy to sustain their metabolic requirements (541, 547, 594, 
644, 650, 651).  In Ras activated cancers, autophagy is a necessary process for 
mitochondrial metabolic function (599).  When autophagy is inhibited there is an 
accumulation of damaged mitochondria with defective mitochondrial respiration, 
reduced oxygen consumption and reduced glycolysis (242, 541, 547, 594, 599) as 
seen in the PTENWT cells with active Wnt/β-catenin signalling (see Figures 5.1-5.6).  
Instead of managing pyruvate levels for TCA cycle activity, Ras activates LDH to 
increase levels of lactate (599).  In addition to this, Ras activates PDK1, which inhibits 
PDH and therefore the conversion of pyruvate to acetyl-CoA, thereby reducing the 
TCA cycle activity (652).  The Ras activation also makes these cells insensitive to 
glucose levels, by changing the glycolytic requirements of the cells (547, 650).  This 
can be seen in the PTENWT cells in Figure 5.3 where changes in glucose levels have no 
effect on the ECAR.  This would imply that the cells have become dependent upon 
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glutamine for respiration, as has previously been seen in Braf driven lung cancers 
(594).  It has also been shown, that decreased autophagy is known to cause an 
increase in apoptosis and a decrease in proliferation (594, 601), fitting with the data 
shown in Figures 4.6-4.9.  Through multiple pathways, these tumours can reduce 
acetyl-CoA synthesis, leading to a reduction in citrate available for fatty acid synthesis 
(653).  Therefore, in the PTENWT cells it would appear that activation of the Wnt/β-
catenin pathway inhibits autophagy (596), increasing apoptosis and reducing 
proliferation to send the cells into starvation mode.  The autophagy addicted cells 
require the recycling of macromolecules for nutrition, by blocking this pathway the 
cells have no fuel source for mitochondrial metabolism (599).  This then causes the 
large increase in glucose consumption seen in the cells in Figure 5.8.  The reduction 
in autophagy can also explain the reduction in ROS seen in Figure 5.7, as production 
is linked to the formation of the autophagosome (598, 654), and without autophagy 
there is also a reduction in substrates used to produce ROS (594).   
The role of PTEN further ties autophagy addiction to our model of melanoma.  It is 
known that PTEN can induce autophagy through the negative regulations of Akt and 
subsequent inactivation of mTOR (655-657).  During nutrient rich conditions p62 is 
known to bind to Raptor, the regulatory-associated protein of mTOR (622, 658), 
which activates mTORC1 thereby inhibiting autophagy via the PI3K/Akt pathway and 
phosphorylation of S6K1 (547, 591, 598, 623, 659, 660).  Alternatively, deletion of 
PTEN can phosphorylate and activate Akt (661).  Therefore, in PTENMut cells with 
hyperactive PI3K signalling, autophagy addiction is not seen (see Figure 6.10c).  
However, low AMP levels, due to limited nutrient availability, is sensed by AMPK 
which phosphorylates TSC2 and negatively regulates mTOR (547, 662), inducing 
autophagy through to increase the AMP/ATP ratio and prevent metabolic crisis (276, 
547, 663).  Despite this, autophagy addicted Ras-induced tumours do not show 
downregulation of mTOR, indicating that the addiction mechanism must be through 
an mTOR-independent-manner (541) although this is yet to be confirmed in this 
study.  Levels of AMPK and mTORC1 signalling activity would be needed to conclude 
this through the analysis of phosphorylation of S6K1 (656).  This is also surprising as 
AMPK also regulates PGC1-α, the transcriptional activator of NF-E2-related factor 2 
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(Nrf2), a modulator of redox homeostasis (664) and known to interact directly with 
Wnt3a to regulate hepatocyte metabolism (665).  It is also understood that β-
oxidation and the utilization of fatty acids stores is limited through both the inhibition 
of AMPK (666) and activation of Ras/MAPK pathways via PI3K (667) both due to Ras 
activation.  This blocks substrate availability and forces the cells towards an 
autophagy-dependent phenotype (668), in support of the finding that PTENMut cells 
are not autophagy dependent. 
The finding that these effects were attenuated by Wnt/β-catenin signalling also fits 
with a previous study into Salinomycin, a cancer stem cell targeted compound that 
inhibits Wnt/β-catenin signalling (669) and, has more recently, been shown to induce 
mitochondrial fragmentation, mitophagy, decrease the membrane potential and 
reduce cellular ATP levels in prostate and breast cancer (669).  It is believed that it 
does this in a protective manner against excessive apoptosis (669).  In prostate and 
breast cancer, activation of the Wnt/β-catenin signalling pathway is, typically, seen 
as detrimental to patient prognosis and the opposing effects are often seen in 
melanoma (670).  In melanoma, activation of the Wnt/β-catenin signalling pathway 
induces mitochondrial fusion with reduced levels of mitophagy and increased 
membrane potential, findings that are complimentary to the Salinomycin study in 
other cancer cell types. 
It has already been shown how vital β-catenin is to the maintenance and function of 
the cell as a whole and specifically to the mitochondria.  The MS analysis of β-catenin 
binding partners shown in Table 6.1, Figure 6.12 and Appendix 8.1 provides a number 
of interesting new targets for future research, but more importantly also supports 
the findings shown throughout this research.  Specifically, proteins with increased 
binding in response to active Wnt/β-catenin includes cytochrome c which, as shown 
in Figure 4.8, is increased in Wnt3a overexpression cells.  This data also includes 
Insulin-like Growth Factor, which has previously been linked to Mfn2 in diabetes and 
cancer (671) and Chromatin which is linked to β-catenin transcriptional regulation 
(672).  More interesting are the proteins with reduced binding to β-catenin as these 
include a number of metabolism proteins.  These included; LDHA, LDHB, and ATP-
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Citrate Synthase, supporting the reduction in lactate secretion and citrate synthase 
activity measured in these cells (see Figure 5.5-5.6).  In addition, there are a number 
of proteins involved in glycolysis, such as Glucose-6-phosphate and other members 
of the PPP pathway supporting the reduction shown in Figures 5.1-5.2.  This data 
suggests that there are a number of major glycolysis and OXPHOS genes that cannot 
interact with β-catenin when it is not CK-1/GSK3β-phosphorylated or when it is being 
shuttled to the nucleus. This highlights that β-catenin is a potential master regulator 
of metabolism as well as mitochondrial dynamics in PTENWT melanoma cells.  There 
are, also, a number of proteins with reduced binding to stabilised β-catenin that 
provide much scope for future melanoma research.  This includes CDK1 that has been 
linked to p53 function in Melanoma and β-catenin signalling (673, 674), the Ras-
Associated Protein 1 (Rap1) that is linked to Ras/BRAF/ERK activation and integrin-
mediated cell adhesion and migration (675).  In addition, Table 8.2 includes a number 
of proteins that could, possibly, have links to the findings shown throughout this 
research.  For example, there is a reduction in the binding of a number of proteins 
involved in the biosynthesis of amino acids that could be linked to the reduced 
proliferation.  There are, also, leads within this data that will help to further identify 
the mechanism that is controlling the changes seen in the mitochondria of melanoma 
cells.  This includes the Ubiquitin-like modifier-activating enzyme 1 (UBA1) that could 
be linked to the reduction in mitophagy. 
 
Taking this data together, it suggests that PTENWT melanoma cells are autophagy 
dependent and that β-catenin is a master regulator of both metabolism and 
mitochondrial dynamics and its stabilisation in PTENWT cells reduces the 
tumourigenesis of melanoma cells.  The following is a suggested model for Wnt-
activated PTENWT melanoma cells; the PTENWT melanoma cells rely on the process of 
autophagy to produce enough nutrients for cellular survival and growth.  Activating 
the Wnt/β-catenin signalling pathway blocks the autophagy pathway and sends the 
cells into a starvation mode where the mitochondria become highly fused and 
perinuclear to protect them from mitophagy.  Figure 6.13 is a schematic representing 
  
 
 
 
260 
this potential mode of action, it shows In a Wnt ‘off’ situation β-catenin is degraded 
in the cytoplasm.  Mitochondria are readily sequestered by the autophagy pathway 
producing amino acids to drive ATP synthesis and sustain proliferation and other 
cellular activities such as migration.  In a Wnt ‘on’ model, β-catenin is stabilised in 
the cytoplasm allowing it to bind to the mitochondria to promote mitochondrial 
fusion protein activity, probably through binding Parkin and leading to increased 
expression of mitochondrial fusion proteins levels.  The mitochondria elongate and 
become perinuclear evading autophagosome engulfment and sending the cells into 
starvation mode therefore causing an increase of glucose to potentially compensate.  
OXPHOS, ATP synthesis and glycolysis are all reduced likely leading to a reduction in 
cell proliferation and migration.  This highlights a novel tumour suppressor function 
of Wnt/β-catenin signalling in PTENWT melanoma cells. 
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Figure 6.13: Working Model of Wnt-Activation in PTENWT Melanoma Cells 
In a Wnt ‘off’ situation β-catenin is degraded in the cytoplasm.  Mitochondria are readily 
sequestered by the autophagy pathway producing amino acids to drive ATP synthesis and 
sustain proliferation and other cellular activities such as migration.  In a Wnt ‘on’ model, β-
catenin is stabilised in the cytoplasm allowing it to bind to the mitochondria to promote 
mitochondrial fusion protein activity, probably through binding Parkin and leading to 
increased expression of mitochondrial fusion proteins levels.  The mitochondria elongate and 
become perinuclear evading autophagosome engulfment and sending the cells into 
starvation mode therefore causing an increase of glucose to potentially compensate.  
OXPHOS, ATP synthesis and glycolysis are all reduced likely leading to a reduction in cell 
proliferation and migration.  This highlights a novel tumour suppressor function of Wnt/β-
catenin signalling in PTENWT melanoma cells. 
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This project combines three extensively studied areas of research, Wnt/β-catenin 
signalling, melanoma and metabolism, which have all been shown to interact with 
each other individually but, as yet, have not been directly linked together.  It is 
becoming abundantly clear that cancer is a metabolic disease (294) and the data 
presented in this thesis shows that, in melanoma, Wnt/β-catenin signalling which is 
already highly implicated (195), plays an important part in the metabolic alterations 
of the cancer cells.   
Opinions are still mixed on whether stabilisation of β-catenin is beneficial to 
melanoma progression, with some stating that activation of the pathway leads to 
increased proliferation, migration and poor patient outcome (404, 436, 437, 439-
441).  This research, however, agrees with the alternative opinion that activation of 
the Wnt/β-catenin pathway is beneficial for patient prognosis (20, 166, 203, 384, 430, 
442-444).  The data supports previous findings that Wnt/β-catenin signalling 
increases apoptosis (350) and reduces proliferation (203) of melanoma cells, 
potentially inducing a state of oncogenic senescence and possibly even contributing 
to the high levels of treatment resistance seen in melanoma (676).  This data is also 
in support of the previous work on the β-catenin-independent Wnt5a signalling 
pathway that typically has opposing effects on melanoma progression, with higher 
levels of invasion and migration (222, 228, 337, 450, 453, 461).  We have previously 
shown that Wnt5a increased aerobic glycolysis in melanoma cells (196).  Due to this, 
the hypothesis was made that Wnt3a signalling in a β-catenin-dependent manner 
can also affect cellular metabolism in melanoma cells.  This study found that the 
effects of Wnt signalling are context dependent and agrees with others that this 
applies to the cancer type and the genetic background of the tumour (165, 166, 169, 
177, 200, 201, 207, 211, 428).   
In order to characterise the panel of 29 melanoma cell lines, they were investigated 
in respect to two different models of melanoma that are theoretically linked to the 
Wnt/β-catenin signalling pathway.  The phenotype switching model is linked through 
the expression of Wnt pathway genes associated with either the proliferative (MITF 
and TCF4) or invasive (Wnt5a and LEF1) phenotypes (334, 361, 365).  Despite distinct 
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differences in the 3D Matrigel growth (see Figure 3.4) of melanoma cells, it was not 
possible to link these differences to the respective phenotypes, nor was it possible 
to link active Wnt/β-catenin signalling to the regulation of this model.  The second 
model of melanoma progression is that of the tumour initiation/cancer stem cells, 
identified through cell surface expression of markers associated with hematopoietic 
stem cells, development of the neural crest and self-renewal capacity (389-394), such 
as CD271, CD133 and ABCB5.  In this study, it was not possible to identify melanoma 
cells with specific expression of these markers (see Figure 3.9).  However, it has been 
hypothesised that the population of tumour initiating cells could be as small as 2% of 
the total tumour population (357).  Therefore, it would, potentially, be necessary to 
enrich the tumour initiating cell population before these cells could be identified.  
This could be done with the use of stem cell media or an in vitro assay that facilitates 
the separation and isolation of adherent and non-adherent stem cells (409).  
This research did, however, identify different melanoma phenotypes based on the 
genetic background and their response to active Wnt/β-catenin signalling.  
Melanoma cells with a MAPK signalling pathway activating mutation, either in BRAF 
or RAS, but with wildtype PTEN expression (PTENWT) significantly reduced invasion 
(see Figure 4.10), migration (see figure 4.12) and lung metastasis (see Figures 4.13-
15) in response to Wnt/β-catenin signalling.  The opposite was observed for 
melanoma cells that contain both a MAPK signalling activating mutation and a PTEN 
inactivating/reducing mutation (PTENMut), where an increase in invasion, migration 
and the number of lung micrometastasis were observed (see Figure 4.16).  This is in 
support of a published transgenic mouse model of melanoma (142, 143).  In addition, 
Wnt/β-catenin signalling had alternate effects on the shape, location and function of 
the mitochondria in the different genetic backgrounds.  PTENWT cells with active 
Wnt/β-catenin signalling had decreased aerobic glycolysis and OXPHOS, measured 
by the Seahorse XFe96 Extracellular Flux Analyzer and biochemical analysis of lactate 
secretion and citrate synthase activity (see Figures 5.2, 5.5, 5.6).  The mitochondria 
of these cells became elongated and perinuclear (see Figure 5.9a and 5.10), with 
increased expression of mitochondrial fusion markers Mfn1, Mfn2 and Opa1, in 
addition to decreased expression of mitochondrial fission marker Drp1 (see Figures 
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6.1-6.2), all factors indicative of nutrient starvation (598, 606).  As with the invasion 
and migration results, the PTENMut cells had the opposing response to active Wnt/β-
catenin signalling with insignificant trends towards increased aerobic glycolysis and 
OXPHOS.  However, there were no changes observed in the mitochondrial shape or 
location of the PTENMut cells (see Figure 5.9b). 
The research indicated that activation of the Wnt/β-catenin pathway was providing 
an inhibitory effect to cancer cell growth in PTENWT cells.  Analysis of the 
mitochondrial quality control genes indicated that PTENWT cells were autophagy 
addicted (see Figure 6.10a), as shown by the predominant expression of LC3II (541, 
594), but, to fully conclude this, siRNA knockdown of autophagy proteins Beclin1 or 
Atg5 would be needed (541, 677, 678).  Autophagy addiction, has previously, been 
shown for Ras-activated cancers, such as lung and pancreatic cancers.  This research, 
along with that of others (679-683), shows autophagy addiction in melanomas with 
downstream effector mutations such as the BrafV600E or Nras mutations (541, 547, 
594, 644, 650, 651).  The expression of LC3 and p62 were reduced in PTENWT cells 
with active Wnt/β-catenin signalling indicating that stabilised β-catenin inhibits the 
autophagy pathway (see Figures 6.10a and 6.11a), potentially through the increased 
binding to Parkin which has previously been seen in neuronal cells (619), but is shown 
here for the first time in melanoma cells (see Figure 6.9).  This was supported by the 
finding of increased levels of β-catenin at the mitochondria (see Figure 6.8) and full 
length Pink1 (see Figure 6.7).  However, levels of Parkin were unaffected, indicating 
that Pink1-mediated Parkin recruitment is possibly impaired as is, the subsequently 
initiation of mitophagy (633).  
These findings were dependent on β-catenin, as shown by DKK1 inhibition (see 
Figures 5.14-16) and β-catenin siRNA knockdown (see Figures 5.17-18).  The absence 
of β-catenin removed all mitochondrial fusion from the cells, including in the absence 
of a Wnt ligand, as measured by Mitotracker imaging and the expression of Mfn1 
(see Figure 6.3).  In addition, removal of β-catenin from the PTENWT cells reversed 
their metabolism and migratory capacity in response to Wnt/β-catenin signalling (see 
Figure 5.19).  It also reversed the inhibition of autophagy, sending the cells back into 
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an autophagy dependent phenotype with the predominant expression of LC3II (see 
Figure 6.10b).  However, the transcriptional regulation that β-catenin has over cell 
motility, adhesion, differentiation and cell cycle progression, such as Cyclin D1, MYC 
and CD44 (439, 531, 555), must be taken into consideration in siRNA knockdown 
results.  Despite these considerations, these findings indicate that β-catenin plays an 
important role in mitochondrial functions.  To further verify this statement, MS 
analysis revealed that a large number of metabolism proteins increase binding to β-
catenin in response to its stabilisation and an even larger number of metabolism 
related proteins lose their binding, including both glycolysis and OXPHOS proteins 
(see Table 6.1, Figure 6.12 and Appendix 1).  This highlights that β-catenin is 
potentially a master regulator of metabolism, as well as mitochondrial dynamics.   
We have already shown that Wnt5a, can increase aerobic glycolysis in melanoma 
cells via Akt (196) therefore providing cross-talk to the canonical control of 
autophagy and metabolism through mTOR.  However, in the previous study, neither 
the effect on mitochondrial shape and location or the genetic context of the cells 
were investigated.  Given the results seen in this current research with Wnt3a, it 
would be interesting to investigate if the non-canonical signalling was as dependent 
on the genetic context of the tumour.  
The majority of this research has focused on the PTENWT cells that, in the presence 
of activated Wnt/β-catenin signalling, had an inhibitory effect against melanoma 
progression.  However, also shown in this study was the progressive effect that 
Wnt/β-catenin had on PTENMut melanomas.  This data provides the potential for Wnt 
inhibitor treatments in the right genetic context.  Patients would need to be 
stratified, based on both their BRAF and PTEN genetic status.  Those patients that 
had a MAPK activating mutation and an inactivating PTEN mutation may respond to 
treatments that reduce Wnt/β-catenin signalling.  There are many natural inhibitors 
of the Wnt/β-catenin pathway, including DKK proteins that were shown in this study 
to specifically, and successfully, block canonical signalling by competitively binding to 
the LRP5/6 co-receptor (234, 236, 521, 684).  DKK3 has specifically been shown to 
affect apoptosis and proliferation of solid cancers (684).  Secreted frizzled related 
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proteins (SFRP) and Wnt-inhibitory factor 1 (WIF1) could also be utilised to 
manipulate excessive Wnt signalling as they bind directly to the Wnt ligand, blocking 
its binding to receptors (235).  They are both commonly down regulated in tumours 
(173, 234) and, in normal cells, SFRPs act as tumour suppressor genes and, therefore, 
restoration of their expression could be beneficial against tumour progression as has 
already been shown in colon cancer (178).  However, the mechanism by which WIF1 
works is not well understood and it is thought that both SFRPs and WIF1 can also 
bind to β-catenin-catenin-independent Wnts and, therefore, could potentially 
increase melanoma progression as has been shown in glioma tumours (178).  As well 
as these, inhibitors acting upon the FZD receptors such as pertussis toxins could also 
be used (178).  The benefits of these treatments are that they act at the cell 
membrane and, therefore, can alter Wnt signalling even when there are down-
stream mutations (178).  However, as non-canonical Wnts also bind through FZD 
receptors and they are necessary for the maintenance of adult stem cells, inhibition 
of the pathway via the FZD receptors could have detrimental side effects (685).  The 
expression of the Wnt ligands could also be attenuated through the use of small 
molecules or biologicals.  There are antibodies and siRNAs directly targeting the Wnt 
ligands, including Wnt1 in lung, breast and colon cancer (178, 475, 477) and Wnt2 in 
melanoma, lung and mesothelioma (178, 389).   
Small molecule inhibitors of the Wnt pathway have also been intensively developed 
in recent years for use in cancer treatment.  Wnt ligands have also been shown to be 
diminished in prostate (484), breast (686) and head and neck cancers by the 
Porcupine inhibitor which blocks the palmitoylation of Wnts and their subsequent 
secretion (485-487).  β-catenin itself, can also be targeted to prevent transcription 
(687).  Alternatively, inhibiting other aspects of the Wnt/β-catenin pathway has been 
shown to have success in different cancers, including breast and melanoma.  The 
molecular inhibitor XAV939 inhibits Tankyrases 1 and 2, these are members of the 
PARP-family and regulate levels of Axin.  Their inhibition causes levels of Axin to 
increase leading to β-catenin degradation (688, 689).  Likewise, CK1α can be inhibited 
by Pyrvinium (690) or the interaction between β-catenin and TCF (691-693) or the 
CBP (694) can be blocked by small molecular inhibitors.  However, the subsequent 
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lack of β-catenin-regulated transcription must be taken into consideration as adverse 
effects of these treatments.  Each of these treatments would reduce Wnt/β-catenin 
signalling in melanoma and, therefore, in the specific genetic context, would 
potentially be beneficial for melanoma patient prognosis. 
The effects to PTENWT melanoma progression shown here, due to active Wnt/β-
catenin signalling, also seem to be an attractive treatment option for patients with 
the appropriate genetic background.  However, given that activation of the Wnt/β-
catenin pathway is known to induce melanocyte differentiation and initiate 
melanoma formation, in addition to the fact that β-catenin is involved in a number 
of other processes (200), constitutive activation of the Wnt/β-catenin pathway 
would not be a suitable treatment option.  Instead, once a tumour has been 
confirmed as autophagy dependent and as this has been reported for other cancers, 
including prostate and lung cancer, this applies to any cancer type, the inhibition of 
autophagy could be a viable treatment option, as currently being tested in clinical 
trials for a number of cancers (648, 683).  These include the use of Chloroquine in 
lung cancer, which blocks TLR signalling and autolysosomal degradation (695).  
Hydroxychloroquine works through the same mechanism and is, currently, in use in 
the treatment of breast and renal cancers (696).  In addition, Hydroxychloroquine is 
used in combination therapies with Bortezomib in Myeloma causing cell cycle arrest, 
and with the Akt inhibitor MK2206 or the mTOR inhibitor Temsirolimus in melanoma 
(105, 648, 661, 697, 698).  These inhibitor co-therapies act upon the PI3K pathway.  
The data shown in this study indicated that cells with PTENWT were autophagy 
dependent, whereas cells with PTENMut were not.  This implies that, if the PI3K 
pathway were blocked or, indeed, PI3K itself were inhibited, the autophagy addiction 
of PTENWT cells could be blocked and could, potentially, be beneficial for melanoma 
patients.  Due to this, other PI3K targeted treatments should also be suggested as 
potential therapies, including wortmannin, LY294002 and 3-methyladenine (591) 
but, specifically, in the treatment of melanoma, GDC0941 and XL147, which are in 
ongoing clinical trials (698). 
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As both Ras-induced autophagy and hyperactive Wnt/β-catenin signalling are seen in 
a number of different cancers, the treatments detailed above could be considered 
for the future cancer therapy.  In support of the use of these therapies is the finding 
that Wnt/β-catenin signalling had no effect on the mitochondrial structure of 
melanocyte cells and, although, the metabolism of the melanocytes was not 
investigated, this implies that there would be no adverse effects on normal cell 
metabolism.  However, in contrast to this, Sethi et al. described very well the complex 
nature of Wnt signalling in the metabolism of normal cell maintenance and 
development (195).  In addition, Yoon et al. showed that Wnt signalling affected the 
metabolism of normal fibroblasts and myoblasts (495), and Wnt signalling inhibitors 
have been shown to reduce oxidative metabolism in adipocytes (235).  However, as 
previously discussed in Chapter 1, different cells regulate their mitochondria in 
proportion to their energetic demands (245).  Therefore, given that Wnts, both 
canonical and non-canonical play such important roles in the regulation of stem cell 
maintenance, it is easy to assume any alterations to Wnt signalling would also have 
effects on tissue homeostasis.   
In summary, it has been shown here, for the first time, that Ras-activated melanomas 
with wildtype PTEN signalling are autophagy dependent.  I hypothesise that 
activation of the Wnt/β-catenin signalling pathway can block autophagy and send the 
cells into starvation mode (see Figure 6.13), causing glycolysis and OXPHOS to be 
reduced, their mitochondria to elongate, become perinuclear and, subsequently, 
cause a reduction in proliferation, invasion and migration.  The mechanism by which 
the Wnt/β-catenin pathway does this is still unknown.  However, it is possible that 
stabilised β-catenin binds to Parkin, blocking the mitophagy process and allowing 
damaged mitochondria to accumulate in the cells.  This indicates that autophagy 
inhibition could be a potentially viable target for melanoma treatments in a specific 
genetic context.  My opinion is highlighted by this research in that detailed genetic 
profiling of patients is a necessity in order to enable the best, most beneficial 
treatments, for patients with currently incurable, late stage cancers. 
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Table 8.1: Metabolic Proteins with Increased Binding to β-catenin 
Gene ID Mapped ID Gene Name/Symbol GO Biological Process 
HUMAN|Ensembl
=ENSG000000217
76|UniProtKB=O6
0306 
O60306 Intron-binding 
protein aquarius 
AQR  
ortholog 
  
  
DNA replication 
transcription from RNA 
polymerase II promoter 
mRNA splicing, via 
spliceosome 
tRNA metabolic process 
RNA catabolic process 
protein metabolic 
process 
cell cycle 
regulation of 
transcription from RNA 
polymerase II promoter 
    
    
    
    
HUMAN|Ensembl
=ENSG000001440
28|UniProtKB=O7
5643 
O75643 U5 small nuclear 
ribonucleoprotein 
200 kDa helicase 
SNRNP200 
ortholog 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
meiosis 
    
HUMAN|Ensembl
=ENSG000001005
91|UniProtKB=O9
5433 
O95433 Activator of 90 kDa 
heat shock protein 
ATPase homolog 1 
AHSA1 
ortholog 
immune system process 
protein folding 
response to stress 
regulation of catalytic 
activity     
HUMAN|Ensembl
=ENSG000001890
60|UniProtKB=P0
7305 
P07305 Histone H1.0 
H1F0 
ortholog 
nucleobase-containing 
compound metabolic 
process 
cellular process 
chromatin organization 
HUMAN|Ensembl
=ENSG000001242
28|UniProtKB=Q9
6GQ7 
Q96GQ7 Probable ATP-
dependent RNA 
helicase DDX27 
DDX27 
ortholog 
nucleobase-containing 
compound metabolic 
process 
translation 
regulation of translation     
HUMAN|Ensembl
=ENSG000001362
71|UniProtKB=Q9
NY93 
Q9NY93 Probable ATP-
dependent RNA 
helicase DDX56 
DDX56 
ortholog 
nucleobase-containing 
compound metabolic 
process 
translation 
regulation of translation     
HUMAN|Ensembl
=ENSG000001835
Q9Y3A2 Probable U3 small 
nucleolar RNA-
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20|UniProtKB=Q9
Y3A2 
associated protein 
11 
UTP11L 
ortholog 
nucleobase-containing 
compound metabolic 
process 
  
  
    
HUMAN|Ensembl
=ENSG000002153
01|UniProtKB=O0
0571 
O00571 ATP-dependent RNA 
helicase DDX3X 
DDX3X 
ortholog 
nucleobase-containing 
compound metabolic 
process 
translation 
regulation of translation 
HUMAN|Ensembl
=ENSG000001029
78|UniProtKB=P1
9387 
P19387 DNA-directed RNA 
polymerase II 
subunit RPB3 
POLR2C 
ortholog 
transcription from RNA 
polymerase II promoter 
  
  
    
HUMAN|Ensembl
=ENSG000000967
46|UniProtKB=P3
1942 
P31942 Heterogeneous 
nuclear 
ribonucleoprotein 
H3 
HNRNPH3 
ortholog 
mRNA splicing, via 
spliceosome 
  
  
    
HUMAN|Ensembl
=ENSG000001436
21|UniProtKB=Q1
2905 
Q12905 Interleukin 
enhancer-binding 
factor 2 
ILF2 
ortholog 
  
  
  
  
  
  
spermatogenesis 
response to interferon-
gamma 
apoptotic process 
purine nucleobase 
metabolic process 
protein metabolic 
process 
cell cycle 
apoptotic process 
response to stimulus 
RNA localization 
regulation of catalytic 
activity 
    
    
    
    
HUMAN|Ensembl
=ENSG000001321
53|UniProtKB=Q7
L2E3 
Q7L2E3 Putative ATP-
dependent RNA 
helicase DHX30 
DHX30 
ortholog 
mRNA splicing, via 
spliceosome 
  
  
    
HUMAN|Ensembl
=ENSG000001518
93|UniProtKB=Q8
6Y37 
Q86Y37 CDK2-associated and 
cullin domain-
containing protein 1 
CACUL1 
ortholog 
induction of apoptosis 
proteolysis 
mitosis 
induction of apoptosis 
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HUMAN|Ensembl
=ENSG000001192
85|UniProtKB=Q9
H583 
Q9H583 HEAT repeat-
containing protein 1 
HEATR1 
ortholog 
rRNA metabolic process 
  
  
HUMAN|Ensembl
=ENSG000001063
44|UniProtKB=Q9
NW13 
Q9NW13 RNA-binding protein 
28 
RBM28 
ortholog 
  
  
  
  
  
  
  
DNA replication 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
mRNA polyadenylation 
RNA splicing, via 
transesterification 
reactions 
rRNA metabolic process 
protein metabolic 
process 
cell cycle 
neurological system 
process 
ectoderm development 
    
    
    
    
    
HUMAN|Ensembl
=ENSG000001592
17|UniProtKB=Q9
NZI8 
Q9NZI8 Insulin-like growth 
factor 2 mRNA-
binding protein 1 
IGF2BP1 
ortholog 
  
  
  
  
  
  
  
  
induction of apoptosis 
RNA splicing, via 
transesterification 
reactions 
transcription from RNA 
polymerase II promoter 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
protein metabolic 
process 
cell communication 
neurological system 
process 
induction of apoptosis 
intracellular protein 
transport 
nuclear transport 
    
    
    
    
    
    
HUMAN|Ensembl
=ENSG000001259
70|UniProtKB=Q9
UKM9 
Q9UKM9 RNA-binding protein 
Raly 
RALY 
ortholog 
mRNA splicing, via 
spliceosome 
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HUMAN|Ensembl
=ENSG000001531
47|UniProtKB=O6
0264 
O60264 SWI/SNF-related 
matrix-associated 
actin-dependent 
regulator of 
chromatin subfamily 
A member 5 
SMARCA5 
ortholog 
DNA repair 
DNA recombination 
transcription from RNA 
polymerase II promoter 
cellular process 
regulation of 
transcription from RNA 
polymerase II promoter 
chromatin organization 
    
    
HUMAN|Ensembl
=ENSG000000921
99|UniProtKB=P0
7910 
P07910 Heterogeneous 
nuclear 
ribonucleoproteins 
C1/C2 
HNRNPC 
ortholog 
mRNA splicing, via 
spliceosome 
HUMAN|Ensembl
=ENSG000000997
83|UniProtKB=P5
2272 
P52272 Heterogeneous 
nuclear 
ribonucleoprotein M 
HNRNPM 
ortholog 
mRNA splicing, via 
spliceosome 
  
  
    
HUMAN|Ensembl
=ENSG000001084
68|UniProtKB=P8
3916 
P83916 Chromobox protein 
homolog 1 
CBX1 
ortholog 
  
  
  
apoptotic process 
transcription from RNA 
polymerase II promoter 
cellular process 
apoptotic process 
regulation of 
transcription from RNA 
polymerase II promoter 
chromatin organization 
    
    
HUMAN|Ensembl
=ENSG000001134
60|UniProtKB=Q8
TDN6 
Q8TDN6 Ribosome 
biogenesis protein 
BRX1 homolog 
BRIX1 
ortholog 
rRNA metabolic process  
      
HUMAN|Ensembl
=ENSG000001079
37|UniProtKB=Q9
BZE4  
Q9BZE4 Nucleolar GTP-
binding protein 1 
GTPBP4 
ortholog 
translation 
HUMAN|Ensembl
=ENSG000001345
97|UniProtKB=Q9
Y388 
Q9Y388 RNA-binding motif 
protein, X-linked 2 
RBMX2 
ortholog 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
    
  
 
 
 
275 
HUMAN|Ensembl
=ENSG000001308
26|UniProtKB=O6
0832 
O60832 H/ACA 
ribonucleoprotein 
complex subunit 4 
DKC1 
ortholog 
rRNA metabolic process 
cell cycle 
  
    
HUMAN|Ensembl
=ENSG000001155
24|UniProtKB=O7
5533 
O75533 Splicing factor 3B 
subunit 1 
SF3B1 
ortholog 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
    
HUMAN|Ensembl
=ENSG000001011
61|UniProtKB=O9
4906 
O94906 Pre-mRNA-
processing factor 6 
PRPF6 
ortholog 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
ectoderm development 
nervous system 
development 
    
    
HUMAN|Ensembl
=ENSG000001262
67|UniProtKB=P1
4854 
P14854 Cytochrome c 
oxidase subunit 6B1 
COX6B1 
ortholog 
oxidative 
phosphorylation 
respiratory electron 
transport chain 
  
HUMAN|Ensembl
=ENSG000001738
01|UniProtKB=P1
4923 
P14923 Junction plakoglobin 
JUP 
ortholog 
  
  
  
  
  
  
  
  
  
  
  
  
  
female gamete 
generation 
nitrogen compound 
metabolic process 
biosynthetic process 
transcription from RNA 
polymerase II promoter 
cell-cell signaling 
cell adhesion 
pattern specification 
process 
pattern specification 
process 
cellular component 
morphogenesis 
embryo development 
cell differentiation 
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    heart development 
response to stimulus 
protein localization 
regulation of 
transcription from RNA 
polymerase II promoter 
cytoskeleton 
organization 
HUMAN|Ensembl
=ENSG000001052
02|UniProtKB=P2
2087 
P22087 rRNA 2'-O-
methyltransferase 
fibrillarin 
FBL 
ortholog 
rRNA metabolic process  
      
HUMAN|Ensembl
=ENSG000002612
36|UniProtKB=Q1
4137 
Q14137 Ribosome 
biogenesis protein 
BOP1 
BOP1 
ortholog 
rRNA metabolic process 
translation 
  
    
HUMAN|Ensembl
=ENSG000000079
68|UniProtKB=Q1
4209 
Q14209 Transcription factor 
E2F2 
E2F2 
ortholog 
  
transcription from RNA 
polymerase II promoter 
cell cycle 
cell communication 
regulation of 
transcription from RNA 
polymerase II promoter 
    
HUMAN|Ensembl
=ENSG000001742
31|UniProtKB=Q6
P2Q9 
Q6P2Q9 Pre-mRNA-
processing-splicing 
factor 8 
PRPF8 
ortholog 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
    
HUMAN|Ensembl
=ENSG000001349
87|UniProtKB=Q8
NI36 
Q8NI36 WD repeat-
containing protein 
36 
WDR36 
ortholog 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
    
HUMAN|Ensembl
=ENSG000000486
49|UniProtKB=Q9
6T23 
Q96T23 Remodeling and 
spacing factor 1 
RSF1 
ortholog 
induction of apoptosis 
transcription from RNA 
polymerase II promoter 
protein acetylation 
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cell cycle 
induction of apoptosis 
regulation of 
transcription from RNA 
polymerase II promoter 
    
    
HUMAN|Ensembl
=ENSG000001851
29|UniProtKB=Q0
0577 
Q00577 Transcriptional 
activator protein 
Pur-alpha 
PURA 
ortholog 
transcription from RNA 
polymerase II promoter 
      
HUMAN|Ensembl
=ENSG000001358
29|UniProtKB=Q0
8211 
Q08211 ATP-dependent RNA 
helicase A 
DHX9 
ortholog 
mRNA splicing, via 
spliceosome 
HUMAN|Ensembl
=ENSG000001127
39|UniProtKB=Q1
3523 
Q13523 Serine/threonine-
protein kinase PRP4 
homolog 
PRPF4B 
ortholog 
glycogen metabolic 
process 
protein phosphorylation 
mitosis 
cell communication     
HUMAN|Ensembl
=ENSG000001657
33|UniProtKB=Q1
4692 
Q14692 Ribosome 
biogenesis protein 
BMS1 homolog 
BMS1 
ortholog 
nucleobase-containing 
compound metabolic 
process 
      
HUMAN|Ensembl
=ENSG000001153
68|UniProtKB=Q8
IWA0 
Q8IWA0 WD repeat-
containing protein 
75 
WDR75 
ortholog 
  
RNA splicing, via 
transesterification 
reactions 
transcription from RNA 
polymerase II promoter 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
RNA localization 
regulation of catalytic 
activity 
    
    
    
HUMAN|Ensembl
=ENSG000000964
01|UniProtKB=Q9
9459 
Q99459 Cell division cycle 5-
like protein 
CDC5L 
ortholog 
purine nucleobase 
metabolic process 
transcription from RNA 
polymerase II promoter 
rRNA metabolic process 
cellular amino acid 
biosynthetic process 
cell cycle 
    
    
      
  
 
 
 
278 
regulation of 
transcription from RNA 
polymerase II promoter 
HUMAN|Ensembl
=ENSG000001308
10|UniProtKB=Q9
NQ55 
Q9NQ55 Suppressor of SWI4 
1 homolog 
PPAN 
ortholog 
mRNA splicing, via 
spliceosome 
HUMAN|Ensembl
=ENSG000000533
72|UniProtKB=Q9
UKD2 
Q9UKD2 mRNA turnover 
protein 4 homolog 
MRTO4 
ortholog 
translation 
HUMAN|Ensembl
=ENSG000000651
83|UniProtKB=Q9
UNX4 
Q9UNX4 WD repeat-
containing protein 3 
WDR3 
ortholog 
nucleobase-containing 
compound metabolic 
process 
HUMAN|Ensembl
=ENSG000000541
18|UniProtKB=Q9
Y2W1 
Q9Y2W1 Thyroid hormone 
receptor-associated 
protein 3 
THRAP3 
ortholog 
transcription from RNA 
polymerase II promoter 
regulation of 
transcription from RNA 
polymerase II promoter     
HUMAN|Ensembl
=ENSG000000550
44|UniProtKB=Q9
Y2X3 
Q9Y2X3 Nucleolar protein 58 
NOP58 
ortholog 
rRNA metabolic process  
HUMAN|Ensembl
=ENSG000001682
98|UniProtKB=P1
0412 
P10412 Histone H1.4 
HIST1H1E 
ortholog 
nucleobase-containing 
compound metabolic 
process 
cellular process 
chromatin organization 
HUMAN|Ensembl
=ENSG000001680
36|UniProtKB=P3
5222 
P35222 Catenin beta-1 
CTNNB1 
ortholog 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
female gamete 
generation 
immune system process 
apoptotic process 
nitrogen compound 
metabolic process 
biosynthetic process 
transcription from RNA 
polymerase II promoter 
synaptic transmission 
cell proliferation 
cell adhesion 
neurological system 
process 
pattern specification 
process 
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pattern specification 
process 
endoderm development 
cellular component 
morphogenesis 
embryo development 
apoptotic process 
cell differentiation 
skeletal system 
development 
angiogenesis 
nervous system 
development 
heart development 
hemopoiesis 
response to endogenous 
stimulus 
vesicle-mediated 
transport 
protein localization 
regulation of 
transcription from RNA 
polymerase II promoter 
regulation of sequence-
specific DNA binding 
transcription factor 
activity 
cytoskeleton 
organization 
    
    
    
    
    
    
    
    
    
HUMAN|Ensembl
=ENSG000002537
29|UniProtKB=P7
8527 
P78527 DNA-dependent 
protein kinase 
catalytic subunit 
PRKDC 
ortholog 
immune system process 
induction of apoptosis 
DNA repair 
DNA recombination 
protein phosphorylation 
cell cycle 
cell communication 
induction of apoptosis 
response to stress 
chromatin organization 
    
    
      
      
HUMAN|Ensembl
=ENSG000001310
51|UniProtKB=Q1
4498 
Q14498 RNA-binding protein 
39 
RBM39 
ortholog 
DNA replication 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
mRNA polyadenylation 
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      RNA splicing, via 
transesterification 
reactions 
rRNA metabolic process 
protein metabolic 
process 
cell cycle 
neurological system 
process 
ectoderm development 
nervous system 
development 
      
      
HUMAN|Ensembl
=ENSG000001085
92|UniProtKB=Q8
IY81 
Q8IY81 pre-rRNA processing 
protein FTSJ3 
FTSJ3 
ortholog 
rRNA metabolic process  
HUMAN|Ensembl
=ENSG000001889
76|UniProtKB=Q9
Y3T9 
Q9Y3T9 Nucleolar complex 
protein 2 homolog 
NOC2L 
ortholog 
protein metabolic 
process 
protein targeting 
nuclear transport 
HUMAN|Ensembl
=ENSG000001728
09|UniProtKB=P6
3173 
P63173 60S ribosomal 
protein L38 
RPL38 
ortholog 
translation 
HUMAN|Ensembl
=ENSG000001158
16|UniProtKB=Q0
3701 
Q03701 CCAAT/enhancer-
binding protein zeta 
CEBPZ 
ortholog 
transcription from RNA 
polymerase II promoter 
regulation of 
transcription from RNA 
polymerase II promoter 
HUMAN|Ensembl
=ENSG000001115
30|UniProtKB=Q8
6VP6 
Q86VP6 Cullin-associated 
NEDD8-dissociated 
protein 1 
CAND1 
ortholog 
transcription from RNA 
polymerase II promoter 
      
HUMAN|Ensembl
=ENSG000001230
64|UniProtKB=Q8
TDD1 
Q8TDD1 ATP-dependent RNA 
helicase DDX54 
DDX54 
ortholog 
nucleobase-containing 
compound metabolic 
process 
translation 
regulation of translation 
HUMAN|Ensembl
=ENSG000001566
97|UniProtKB=Q9
BVJ6  
Q9BVJ6 U3 small nucleolar 
RNA-associated 
protein 14 homolog 
A 
UTP14A 
ortholog 
nucleobase-containing 
compound metabolic 
process 
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HUMAN|Ensembl
=ENSG000000897
37|UniProtKB=Q9
GZR7 
Q9GZR7 ATP-dependent RNA 
helicase DDX24 
DDX24 
ortholog 
nucleobase-containing 
compound metabolic 
process 
translation 
regulation of translation 
HUMAN|Ensembl
=ENSG000001225
66|UniProtKB=P2
2626 
P22626 Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1 
HNRNPA2B1 
ortholog 
DNA replication 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
mRNA polyadenylation 
RNA splicing, via 
transesterification 
reactions 
rRNA metabolic process 
protein metabolic 
process 
cell cycle 
neurological system 
process 
ectoderm development 
nervous system 
development 
    
    
      
      
      
HUMAN|Ensembl
=ENSG000000670
66|UniProtKB=P2
3497 
P23497 Nuclear autoantigen 
Sp-100 
SP100 
ortholog 
transcription from RNA 
polymerase II promoter 
cell communication 
regulation of 
transcription from RNA 
polymerase II promoter 
chromatin organization 
    
HUMAN|Ensembl
=ENSG000001217
74|UniProtKB=Q0
7666 
Q07666 KH domain-
containing, RNA-
binding, signal 
transduction-
associated protein 1 
KHDRBS1 
ortholog 
  
Ribosome 
biogenesis 
regulatory protein 
homolog 
RRS1 
ortholog 
spermatogenesis 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
nucleobase-containing 
compound metabolic 
process 
    
    
    
HUMAN|Ensembl
=ENSG000001790
41|UniProtKB=Q1
5050 
Q15050 
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HUMAN|Ensembl
=ENSG000001638
11|UniProtKB=Q1
5061 
Q15061 WD repeat-
containing protein 
43 
WDR43 
ortholog 
RNA splicing, via 
transesterification 
reactions 
transcription from RNA 
polymerase II promoter 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
ectoderm development 
RNA localization 
regulation of catalytic 
activity 
    
    
      
      
HUMAN|Ensembl
=ENSG000002486
43|UniProtKB=Q9
6PK6 
Q96PK6 RNA-binding protein 
14 
RBM14 
ortholog 
DNA replication 
RNA splicing, via 
transesterification 
reactions 
transcription from RNA 
polymerase II promoter 
mRNA splicing, via 
spliceosome 
mRNA polyadenylation 
RNA splicing, via 
transesterification 
reactions 
protein metabolic 
process 
cell cycle 
ectoderm development 
nervous system 
development 
    
    
      
      
      
HUMAN|Ensembl
=ENSG000000769
24|UniProtKB=Q9
HCS7  
Q9HCS7 Pre-mRNA-splicing 
factor SYF1 
XAB2 
ortholog 
RNA splicing, via 
transesterification 
reactions 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
ectoderm development 
nervous system 
development 
    
    
HUMAN|Ensembl
=ENSG000000882
Q9NVP1 ATP-dependent RNA 
helicase DDX18 
DDX18 
nucleobase-containing 
compound metabolic 
process 
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05|UniProtKB=Q9
NVP1 
ortholog translation 
regulation of translation 
HUMAN|Ensembl
=ENSG000001201
58|UniProtKB=Q9
Y2P8 
Q9Y2P8 RNA 3'-terminal 
phosphate cyclase-
like protein 
RCL1 
ortholog 
mRNA splicing, via 
spliceosome 
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Table 8.2: Metabolic Proteins with Reduced Binding to β-catenin 
Gene ID Mapped ID Gene Name/Symbol 
GO Biological 
Process 
HUMAN|Ensembl
=ENSG00000010
244|UniProtKB=
O43670  
O43670 Zinc finger protein 207 
ZNF207 
ortholog 
nucleobase-
containing 
compound 
metabolic process  
HUMAN|Ensembl
=ENSG00000125
166|UniProtKB=
P00505 
P00505 Aspartate 
aminotransferase, 
mitochondrial 
GOT2 
ortholog 
cellular amino acid 
metabolic process  
      
HUMAN|Ensembl
=ENSG00000111
640|UniProtKB=
P04406 
P04406 Glyceraldehyde-3-
phosphate 
dehydrogenase 
GAPDH 
ortholog 
glycolysis 
glycolysis 
HUMAN|Ensembl
=ENSG00000163
902|UniProtKB=
P04843 
P04843 Dolichyl-
diphosphooligosacchari
de--protein 
glycosyltransferase 
subunit 1 
RPN1 
ortholog 
translation 
protein 
glycosylation 
HUMAN|Ensembl
=ENSG00000177
600|UniProtKB=
P05387 
P05387 60S acidic ribosomal 
protein P2 
RPLP2 
ortholog 
translation  
HUMAN|Ensembl
=ENSG00000008
018|UniProtKB=
P20618 
P20618 Proteasome subunit 
beta type-1 
PSMB1 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000041
357|UniProtKB=
P25789 
P25789 Proteasome subunit 
alpha type-4 
PSMA4 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000167
004|UniProtKB=
P30101 
P30101 Protein disulfide-
isomerase A3 
PDIA3 
ortholog 
protein folding 
cellular protein 
modification process 
HUMAN|Ensembl
=ENSG00000168
906|UniProtKB=
P31153 
P31153 S-adenosylmethionine 
synthase isoform type-
2 
MAT2A 
ortholog 
cellular amino acid 
metabolic process  
      
HUMAN|Ensembl
=ENSG00000170
606|UniProtKB=
P34932 
P34932 Heat shock 70 kDa 
protein 4 
HSPA4 
ortholog 
immune system 
process 
protein folding 
protein complex 
assembly 
response to stress 
protein complex 
biogenesis 
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HUMAN|Ensembl
=ENSG00000150
753|UniProtKB=
P48643 
P48643 T-complex protein 1 
subunit epsilon 
CCT5 
ortholog 
protein folding 
HUMAN|Ensembl
=ENSG00000100
380|UniProtKB=
P50502 
P50502 Hsc70-interacting 
protein 
ST13 
ortholog 
protein folding 
response to stress 
HUMAN|Ensembl
=ENSG00000065
427|UniProtKB=
Q15046  
Q15046 Lysine--tRNA ligase 
KARS 
ortholog 
translation  
HUMAN|Ensembl
=ENSG00000111
196|UniProtKB=
Q96A72  
Q96A72 Protein mago nashi 
homolog 2 
MAGOHB 
ortholog 
female gamete 
generation 
nucleobase-
containing 
compound 
metabolic process 
sex determination 
RNA localization 
HUMAN|Ensembl
=ENSG00000135
018|UniProtKB=
Q9UMX0  
Q9UMX0 Ubiquilin-1 
UBQLN1 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000134
333|UniProtKB=
P00338 
P00338 L-lactate 
dehydrogenase A chain 
LDHA 
ortholog 
glycolysis 
glycolysis 
tricarboxylic acid 
cycle 
HUMAN|Ensembl
=ENSG00000155
660|UniProtKB=
P13667 
P13667 Protein disulfide-
isomerase A4 
PDIA4 
ortholog 
protein folding 
cellular protein 
modification process 
HUMAN|Ensembl
=ENSG00000130
985|UniProtKB=
P22314 
P22314 Ubiquitin-like modifier-
activating enzyme 1 
UBA1 
ortholog 
coenzyme metabolic 
process 
cellular protein 
modification process 
proteolysis 
cell communication 
intracellular protein 
transport 
nuclear transport 
    
    
HUMAN|Ensembl
=ENSG00000130
741|UniProtKB=
P41091 
P41091 Eukaryotic translation 
initiation factor 2 
subunit 3 
EIF2S3 
ortholog 
translation 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000241
837|UniProtKB=
P48047 
P48047 ATP synthase subunit 
O, mitochondrial 
ATP5O 
ortholog 
coenzyme metabolic 
process 
nucleobase-
containing 
compound 
metabolic process 
cation transport 
HUMAN|Ensembl
=ENSG00000134
P54577 Tyrosine--tRNA ligase, 
cytoplasmic 
YARS 
translation  
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684|UniProtKB=
P54577 
ortholog 
HUMAN|Ensembl
=ENSG00000131
467|UniProtKB=
P61289 
P61289 Proteasome activator 
complex subunit 3 
PSME3 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000067
057|UniProtKB=
Q01813  
Q01813 6-phosphofructokinase 
type C 
PFKP 
ortholog 
glycolysis 
glycolysis 
HUMAN|Ensembl
=ENSG00000104
823|UniProtKB=
Q13011  
Q13011 Delta(3,5)-Delta(2,4)-
dienoyl-CoA 
isomerase, 
mitochondrial 
ECH1 
ortholog 
coenzyme metabolic 
process 
vitamin biosynthetic 
process 
carbohydrate 
metabolic process 
fatty acid beta-
oxidation 
    
HUMAN|Ensembl
=ENSG00000110
958|UniProtKB=
Q15185  
Q15185 Prostaglandin E 
synthase 3 
PTGES3 
ortholog 
protein folding 
protein complex 
assembly 
protein complex 
biogenesis 
HUMAN|Ensembl
=ENSG00000100
836|UniProtKB=
Q86U42  
Q86U42 Polyadenylate-binding 
protein 2 
PABPN1 
ortholog 
mRNA processing 
HUMAN|Ensembl
=ENSG00000107
164|UniProtKB=
Q96I24  
Q96I24 Far upstream element-
binding protein 3 
FUBP3 
ortholog 
induction of 
apoptosis 
RNA splicing, via 
transesterification 
reactions 
transcription from 
RNA polymerase II 
promoter 
mRNA splicing, via 
spliceosome 
RNA splicing, via 
transesterification 
reactions 
protein metabolic 
process 
cell communication 
neurological system 
process 
induction of 
apoptosis 
intracellular protein 
transport 
nuclear transport 
    
    
      
      
      
HUMAN|Ensembl
=ENSG00000143
401|UniProtKB=
Q9BTT0  
Q9BTT0 Acidic leucine-rich 
nuclear 
phosphoprotein 32 
family member E 
ANP32E 
ortholog 
metabolic process 
regulation of 
catalytic activity 
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HUMAN|Ensembl
=ENSG00000108
010|UniProtKB=
O76003  
O76003 Glutaredoxin-3 
GLRX3 
ortholog 
respiratory electron 
transport chain 
sulfur compound 
metabolic process 
response to stress 
HUMAN|Ensembl
=ENSG00000162
813|UniProtKB=
O95861  
O95861 3'(2'),5'-bisphosphate 
nucleotidase 1 
BPNT1 
ortholog 
sulfur compound 
metabolic process 
phospholipid 
metabolic process 
nucleobase-
containing 
compound 
metabolic process 
phospholipid 
metabolic process 
cellular process 
    
    
HUMAN|Ensembl
=ENSG00000121
552|UniProtKB=
P01040 
P01040 Cystatin-A 
CSTA 
ortholog 
proteolysis 
regulation of 
catalytic activity 
HUMAN|Ensembl
=ENSG00000160
213|UniProtKB=
P04080 
P04080 Cystatin-B 
CSTB 
ortholog 
proteolysis 
regulation of 
catalytic activity 
HUMAN|Ensembl
=ENSG00000170
312|UniProtKB=
P06493 
P06493 Cyclin-dependent 
kinase 1 
CDK1 
ortholog 
glycogen metabolic 
process 
protein 
phosphorylation 
mitosis 
cell communication 
HUMAN|Ensembl
=ENSG00000182
199|UniProtKB=
P34897 
P34897 Serine 
hydroxymethyltransfer
ase, mitochondrial 
SHMT2 
ortholog 
nucleobase-
containing 
compound 
metabolic process 
cellular amino acid 
metabolic process 
HUMAN|Ensembl
=ENSG00000072
778|UniProtKB=
P49748 
P49748 Very long-chain 
specific acyl-CoA 
dehydrogenase, 
mitochondrial 
ACADVL 
ortholog 
respiratory electron 
transport chain 
acyl-CoA metabolic 
process 
nitrogen compound 
metabolic process 
fatty acid beta-
oxidation 
acyl-CoA metabolic 
process 
    
HUMAN|Ensembl
=ENSG00000127
314|UniProtKB=
P61224 
P61224 Ras-related protein 
Rap-1b 
RAP1B 
ortholog 
metabolic process 
synaptic 
transmission 
cell adhesion 
neurological system 
process 
intracellular protein 
transport 
receptor-mediated 
endocytosis 
    
  
 
 
 
288 
HUMAN|Ensembl
=ENSG00000103
257|UniProtKB=
Q01650  
Q01650 Large neutral amino 
acids transporter small 
subunit 1 
SLC7A5 
ortholog 
cellular amino acid 
metabolic process 
amino acid transport 
HUMAN|Ensembl
=ENSG00000197
157|UniProtKB=
Q7KZF4  
Q7KZF4 Staphylococcal 
nuclease domain-
containing protein 1 
SND1 
ortholog 
transcription from 
RNA polymerase II 
promoter  
HUMAN|Ensembl
=ENSG00000168
872|UniProtKB=
Q9NUU7  
Q9NUU7 ATP-dependent RNA 
helicase DDX19A 
DDX19A 
ortholog 
nucleobase-
containing 
compound 
metabolic process 
translation 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000134
440|UniProtKB=
O43776  
O43776 Asparagine--tRNA 
ligase, cytoplasmic 
NARS 
ortholog 
translation  
HUMAN|Ensembl
=ENSG00000111
716|UniProtKB=
P07195 
P07195 L-lactate 
dehydrogenase B chain 
LDHB 
ortholog 
glycolysis 
glycolysis 
tricarboxylic acid 
cycle 
HUMAN|Ensembl
=ENSG00000175
592|UniProtKB=
P15407 
P15407 Fos-related antigen 1 
FOSL1 
ortholog 
immune system 
process 
induction of 
apoptosis 
transcription from 
RNA polymerase II 
promoter 
cell cycle 
neurological system 
process 
induction of 
apoptosis 
regulation of 
transcription from 
RNA polymerase II 
promoter 
    
    
      
HUMAN|Ensembl
=ENSG00000120
053|UniProtKB=
P17174 
P17174 Aspartate 
aminotransferase, 
cytoplasmic 
GOT1 
ortholog 
cellular amino acid 
metabolic process  
HUMAN|Ensembl
=ENSG00000125
977|UniProtKB=
P20042 
P20042 Eukaryotic translation 
initiation factor 2 
subunit 2 
EIF2S2 
ortholog 
translation 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000152
234|UniProtKB=
P25705 
P25705 ATP synthase subunit 
alpha, mitochondrial 
ATP5A1 
ortholog 
respiratory electron 
transport chain 
purine nucleobase 
metabolic process 
cation transport 
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HUMAN|Ensembl
=ENSG00000163
918|UniProtKB=
P35249 
P35249 Replication factor C 
subunit 4 
RFC4 
ortholog 
DNA replication 
cell cycle 
HUMAN|Ensembl
=ENSG00000014
641|UniProtKB=
P40925 
P40925 Malate dehydrogenase, 
cytoplasmic 
MDH1 
ortholog 
generation of 
precursor 
metabolites and 
energy 
carbohydrate 
metabolic process 
tricarboxylic acid 
cycle 
HUMAN|Ensembl
=ENSG00000109
332|UniProtKB=
P61077 
P61077 Ubiquitin-conjugating 
enzyme E2 D3 
UBE2D3 
ortholog 
apoptotic process 
cellular protein 
modification process 
apoptotic process 
HUMAN|Ensembl
=ENSG00000184
640|UniProtKB=
Q9UHD8  
Q9UHD8 Septin-9 
ortholog 
metabolic process 
cytokinesis 
mitosis 
HUMAN|Ensembl
=ENSG00000091
164|UniProtKB=
O43396  
O43396 Thioredoxin-like 
protein 1 
TXNL1 
ortholog 
respiratory electron 
transport chain 
sulfur compound 
metabolic process 
cell cycle 
cell communication 
response to stress 
    
HUMAN|Ensembl
=ENSG00000154
473|UniProtKB=
O43684  
O43684 Mitotic checkpoint 
protein BUB3 
BUB3 
ortholog 
nucleobase-
containing 
compound 
metabolic process 
mitosis 
chromosome 
segregation 
RNA localization 
HUMAN|Ensembl
=ENSG00000163
399|UniProtKB=
P05023 
P05023 Sodium/potassium-
transporting ATPase 
subunit alpha-1 
ATP1A1 
ortholog 
metabolic process 
cation transport 
cellular calcium ion 
homeostasis 
HUMAN|Ensembl
=ENSG00000105
220|UniProtKB=
P06744 
P06744 Glucose-6-phosphate 
isomerase 
GPI 
ortholog 
glycolysis 
gluconeogenesis 
glycolysis 
HUMAN|Ensembl
=ENSG00000080
824|UniProtKB=
P07900 
P07900 Heat shock protein HSP 
90-alpha 
HSP90AA1 
ortholog 
protein folding 
response to stress 
HUMAN|Ensembl
=ENSG00000096
384|UniProtKB=
P08238 
P08238 Heat shock protein HSP 
90-beta 
HSP90AB1 
ortholog 
immune system 
process 
protein folding 
response to stress 
HUMAN|Ensembl
=ENSG00000164
111|UniProtKB=
P08758 
P08758 Annexin A5 
ANXA5 
ortholog 
fatty acid metabolic 
process  
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HUMAN|Ensembl
=ENSG00000100
567|UniProtKB=
P25788 
P25788 Proteasome subunit 
alpha type-3 
PSMA3 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000254
772|UniProtKB=
P26641 
P26641 Elongation factor 1-
gamma 
EEF1G 
ortholog 
immune system 
process 
translation 
cell communication 
response to toxic 
substance 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000143
106|UniProtKB=
P28066 
P28066 Proteasome subunit 
alpha type-5 
PSMA5 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000100
804|UniProtKB=
P28074 
P28074 Proteasome subunit 
beta type-5 
PSMB5 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000169
710|UniProtKB=
P49327 
P49327 Fatty acid synthase 
FASN 
ortholog 
cellular amino acid 
metabolic process 
fatty acid 
biosynthetic process 
HUMAN|Ensembl
=ENSG00000178
952|UniProtKB=
P49411 
P49411 Elongation factor Tu, 
mitochondrial 
TUFM 
ortholog 
translation 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000090
861|UniProtKB=
P49588 
P49588 Alanine--tRNA ligase, 
cytoplasmic 
AARS 
ortholog 
tRNA metabolic 
process  
HUMAN|Ensembl
=ENSG00000115
484|UniProtKB=
P50991 
P50991 T-complex protein 1 
subunit delta 
CCT4 
ortholog 
protein folding 
protein complex 
assembly 
protein complex 
biogenesis 
HUMAN|Ensembl
=ENSG00000260
245|UniProtKB=
P53396 
P53396 ATP-citrate synthase 
ACLY 
ortholog 
generation of 
precursor 
metabolites and 
energy 
coenzyme metabolic 
process 
carbohydrate 
metabolic process 
tricarboxylic acid 
cycle 
lipid metabolic 
process 
HUMAN|Ensembl
=ENSG00000124
207|UniProtKB=
P55060 
P55060 Exportin-2 
CSE1L 
ortholog 
metabolic process 
intracellular protein 
transport 
nuclear transport 
HUMAN|Ensembl
=ENSG00000136
Q07065 Cytoskeleton-
associated protein 4 
CKAP4 
DNA replication 
DNA repair 
mitosis 
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026|UniProtKB=
Q07065  
ortholog meiosis 
chromosome 
segregation 
chromatin 
organization 
HUMAN|Ensembl
=ENSG00000187
840|UniProtKB=
Q13541  
Q13541 Eukaryotic translation 
initiation factor 4E-
binding protein 1 
EIF4EBP1 
ortholog 
translation  
HUMAN|Ensembl
=ENSG00000263
344|UniProtKB=
Q15056  
Q15056 Eukaryotic translation 
initiation factor 4H 
EIF4H 
ortholog 
translation 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000143
870|UniProtKB=
Q15084  
Q15084 Protein disulfide-
isomerase A6 
PDIA6 
ortholog 
protein folding 
cellular protein 
modification process 
HUMAN|Ensembl
=ENSG00000262
812|UniProtKB=
Q9Y4L1  
Q9Y4L1 Hypoxia up-regulated 
protein 1 
HYOU1 
ortholog 
protein folding 
protein complex 
assembly 
response to stress 
protein complex 
biogenesis 
HUMAN|Ensembl
=ENSG00000223
639|UniProtKB=
O00299  
O00299 Chloride intracellular 
channel protein 1 
CLIC1 
ortholog 
immune system 
process 
translation 
cell communication 
response to toxic 
substance 
anion transport 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000136
628|UniProtKB=
P07814 
P07814 Bifunctional 
glutamate/proline--
tRNA ligase 
EPRS 
ortholog 
translation  
HUMAN|Ensembl
=ENSG00000160
752|UniProtKB=
P14324 
P14324 Farnesyl 
pyrophosphate 
synthase 
FDPS 
ortholog 
cholesterol 
metabolic process  
HUMAN|Ensembl
=ENSG00000166
825|UniProtKB=
P15144 
P15144 Aminopeptidase N 
ANPEP 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000153
113|UniProtKB=
P20810 
P20810 Calpastatin 
CAST 
ortholog 
proteolysis 
regulation of 
catalytic activity 
HUMAN|Ensembl
=ENSG00000117
592|UniProtKB=
P30041 
P30041 Peroxiredoxin-6 
PRDX6 
ortholog 
metabolic process  
  
 
 
 
292 
HUMAN|Ensembl
=ENSG00000156
261|UniProtKB=
P50990 
P50990 T-complex protein 1 
subunit theta 
CCT8 
ortholog 
protein folding 
protein complex 
assembly 
protein complex 
biogenesis 
HUMAN|Ensembl
=ENSG00000172
531|UniProtKB=
P62136 
P62136 Serine/threonine-
protein phosphatase 
PP1-alpha catalytic 
subunit 
PPP1CA 
ortholog 
immune system 
process 
apoptotic process 
glycogen metabolic 
process 
transcription from 
RNA polymerase II 
promoter 
mRNA processing 
protein 
phosphorylation 
mitosis 
meiosis 
cell communication 
apoptotic process 
response to stress 
regulation of 
carbohydrate 
metabolic process 
regulation of 
nucleobase-
containing 
compound 
metabolic process 
    
    
      
      
HUMAN|Ensembl
=ENSG00000196
262|UniProtKB=
P62937 
P62937 Peptidyl-prolyl cis-
trans isomerase A 
PPIA 
ortholog 
immune system 
process 
protein folding 
intracellular protein 
transport 
nuclear transport 
HUMAN|Ensembl
=ENSG00000135
624|UniProtKB=
Q99832  
Q99832 T-complex protein 1 
subunit eta 
CCT7 
ortholog 
protein folding 
protein complex 
assembly 
protein complex 
biogenesis 
HUMAN|Ensembl
=ENSG00000116
161|UniProtKB=
Q9HB71  
Q9HB71 Calcyclin-binding 
protein 
CACYBP 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000178
896|UniProtKB=
Q9NPD3  
Q9NPD3 Exosome complex 
component RRP41 
EXOSC4 
ortholog 
tRNA metabolic 
process 
RNA catabolic 
process 
rRNA metabolic 
process 
HUMAN|Ensembl
=ENSG00000092
621|UniProtKB=
O43175  
O43175 D-3-phosphoglycerate 
dehydrogenase 
PHGDH 
ortholog 
carbohydrate 
metabolic process 
cellular amino acid 
biosynthetic process 
HUMAN|Ensembl
=ENSG00000110
P06576 ATP synthase subunit 
beta, mitochondrial 
respiratory electron 
transport chain 
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955|UniProtKB=
P06576 
ATP5B 
ortholog 
purine nucleobase 
metabolic process 
cation transport 
HUMAN|Ensembl
=ENSG00000170
445|UniProtKB=
P12081 
P12081 Histidine--tRNA ligase, 
cytoplasmic 
HARS 
ortholog 
translation  
HUMAN|Ensembl
=ENSG00000166
598|UniProtKB=
P14625 
P14625 Endoplasmin 
HSP90B1 
ortholog 
protein folding 
response to stress 
HUMAN|Ensembl
=ENSG00000168
374|UniProtKB=
P18085 
P18085 ADP-ribosylation factor 
4 
ARF4 
ortholog 
metabolic process 
cell communication 
intracellular protein 
transport 
vesicle-mediated 
transport 
HUMAN|Ensembl
=ENSG00000159
335|UniProtKB=
P20962 
P20962 Parathymosin 
PTMS 
ortholog 
nucleobase-
containing 
compound 
metabolic process  
HUMAN|Ensembl
=ENSG00000226
589|UniProtKB=
P26640 
P26640 Valine--tRNA ligase 
VARS 
ortholog 
translation  
HUMAN|Ensembl
=ENSG00000146
731|UniProtKB=
P40227 
P40227 T-complex protein 1 
subunit zeta 
CCT6A 
ortholog 
protein folding 
protein complex 
assembly 
protein complex 
biogenesis 
HUMAN|Ensembl
=ENSG00000142
657|UniProtKB=
P52209 
P52209 6-phosphogluconate 
dehydrogenase, 
decarboxylating 
PGD 
ortholog 
pentose-phosphate 
shunt 
HUMAN|Ensembl
=ENSG00000087
191|UniProtKB=
P62195 
P62195 26S protease 
regulatory subunit 8 
PSMC5 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000088
832|UniProtKB=
P62942 
P62942 Peptidyl-prolyl cis-
trans isomerase 
FKBP1A 
FKBP1A 
ortholog 
cellular protein 
modification process 
cellular process 
HUMAN|Ensembl
=ENSG00000092
010|UniProtKB=
Q06323  
Q06323 Proteasome activator 
complex subunit 1 
PSME1 
ortholog 
proteolysis 
HUMAN|Ensembl
=ENSG00000099
810|UniProtKB=
Q13126  
Q13126 S-methyl-5'-
thioadenosine 
phosphorylase 
MTAP 
ortholog 
purine nucleobase 
metabolic process  
HUMAN|Ensembl
=ENSG00000090
Q13310 Polyadenylate-binding 
protein 4 
PABPC4 
DNA replication 
  
 
 
 
294 
621|UniProtKB=
Q13310  
ortholog RNA splicing, via 
transesterification 
reactions 
transcription from 
RNA polymerase II 
promoter 
mRNA splicing, via 
spliceosome 
mRNA 
polyadenylation 
RNA splicing, via 
transesterification 
reactions 
protein metabolic 
process 
cell cycle 
ectoderm 
development 
nervous system 
development 
HUMAN|Ensembl
=ENSG00000084
623|UniProtKB=
Q13347  
Q13347 Eukaryotic translation 
initiation factor 3 
subunit I 
EIF3I 
ortholog 
translation 
regulation of 
translation 
HUMAN|Ensembl
=ENSG00000038
274|UniProtKB=
Q9NZL9  
Q9NZL9 Methionine 
adenosyltransferase 2 
subunit beta 
MAT2B 
ortholog 
carbohydrate 
metabolic process  
HUMAN|Ensembl
=ENSG00000168
003|UniProtKB=
P08195 
P08195 4F2 cell-surface 
antigen heavy chain 
SLC3A2 
ortholog 
glycogen metabolic 
process  
HUMAN|Ensembl
=ENSG00000132
646|UniProtKB=
P12004 
P12004 Proliferating cell 
nuclear antigen 
PCNA 
ortholog 
DNA replication 
DNA repair 
cell cycle 
regulation of 
catalytic activity 
HUMAN|Ensembl
=ENSG00000198
959|UniProtKB=
P21980 
P21980 Protein-glutamine 
gamma-
glutamyltransferase 2 
TGM2 
ortholog 
cellular protein 
modification process  
HUMAN|Ensembl
=ENSG00000101
444|UniProtKB=
P23526 
P23526 Adenosylhomocysteina
se 
AHCY 
ortholog 
purine nucleobase 
metabolic process  
HUMAN|Ensembl
=ENSG00000138
363|UniProtKB=
P31939 
P31939 Bifunctional purine 
biosynthesis protein 
PURH 
ATIC 
ortholog 
purine nucleobase 
metabolic process  
HUMAN|Ensembl
=ENSG00000167
P35232 Prohibitin 
PHB 
ortholog 
DNA replication 
cell cycle 
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085|UniProtKB=
P35232 
HUMAN|Ensembl
=ENSG00000105
379|UniProtKB=
P38117 
P38117 Electron transfer 
flavoprotein subunit 
beta 
ETFB 
ortholog 
respiratory electron 
transport chain  
HUMAN|Ensembl
=ENSG00000100
983|UniProtKB=
P48637 
P48637 Glutathione synthetase 
GSS 
ortholog 
sulfur compound 
metabolic process  
HUMAN|Ensembl
=ENSG00000004
455|UniProtKB=
P54819 
P54819 Adenylate kinase 2, 
mitochondrial 
AK2 
ortholog 
purine nucleobase 
metabolic process 
pyrimidine 
nucleobase 
metabolic process 
HUMAN|Ensembl
=ENSG00000004
478|UniProtKB=
Q02790  
Q02790 Peptidyl-prolyl cis-
trans isomerase FKBP4 
FKBP4 
ortholog 
cellular protein 
modification process 
cellular process 
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